{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "9fb4d478",
   "metadata": {},
   "source": [
    "# Chapter 6: Planning\n",
    "지능적인 행동은 단순히 즉각적인 입력에 반응하는 것 이상을 포함한다\n",
    "- 예측\n",
    "- 복잡한 태스크를 더 작고 관리가능한 단계로 나누는 능력\n",
    "- 그리고 원하는 결과를 달성하기 위한 전략적 사고\n",
    "\n",
    "플래닝 패턴은 초기 상태에서 목표한 상태로 향하기 위해 액션의 순소를 구성하는 에이전트의 능력이다.\n",
    "\n",
    "## Planning Pattern Overview \n",
    "\n",
    "플래닝 에이전트를 복잡한 목표를 위임할 수 있는 전문가로 생각해야한다. \n",
    "\n",
    "\"팀 오프사이트를 조직해줘\" 라고 요청하면, 무엇(what) -- 목적과 제약사항 -- 을 정의하는 것이지, 어떻게(how)를 정의하지는 않는다. \n",
    "\n",
    "에이전트의 코어 태스크는 목표로 향하는 코스를 자율적으로 설계하는 것이다.\n",
    "\n",
    "1. 초기 상태(예산, 참가자 수, 원하는 날짜)를 이해\n",
    "2. 목표 상태(성공적으로 예약된 오프사이트)를 정함\n",
    "3. 두 상태를 연결하기 위한 최적의 액션 시퀀스를 찾아낸다.\n",
    "\n",
    "계획은 미리 알고 있는 것이 아니다; 요청에 대한 응답에서 생성되는 것이다.\n",
    "\n",
    "Agent의 플래닝 패턴의 특징은 적응력(Adaptability), 예를 들어\n",
    "\n",
    "`미리 선호한 장소가 사용 불가 해졌다면, 에이전트는 단순히 실패하지 않는다`\n",
    "\n",
    "새로운 정보를 받아 들이고, 장애물을 제약 조건으로 새롭게 인식한 다음, 가능한 선택지를 다시 평가하고 새로운 계획을 세운다.\n",
    "\n",
    "\n",
    "유도리와 예측 가능성의 트레이드-오프를 인식하는 것이 중요하다. \n",
    "Dynamic planning이 항상 만능인 솔루션이 아니다. \n",
    "\n",
    "문제의 해결 방법이 잘 이해되어 있고, 반복 가능한 경우, 에이전트를 미리 정해진 고정된 워크플로우로 제한하는 편이 더 효과적이다. \n",
    "에이전트의 자율성을 제한 하는 대신 예측하지 못한 행동에 대한 리스크를 줄이고, 신뢰할 수 있고 일관된 결과를 보장한다.\n",
    "\n",
    "플래닝 에이전트 VS 단순 태스크 실행 에이전트 : 어떻게(how)를 새롭게 발굴해야하는가 VS 이미 알고있는가?\n",
    "\n",
    "# Practical Applications & Use Cases\n",
    "복잡한 일들을 순서 있게 잘 처리할 수 있도록 도와주는 지능적인 설계 방식\n",
    "### 절차적 업무 자동화(procedural task automation)\n",
    "플래닝 패턴이 복잡한 워크플로우 오케스트레션에 사용된다. 새로운 직원 온보딩의 경우, \n",
    "- 시스템 계정 생성\n",
    "- 트레이닝 모듈 할당\n",
    "- 여러 다른 부서 들과 협업 조율\n",
    "에이전트가 이러한 스텝 들을 논리적 순서로 수행하기 위한 계획을 생성하고, 필요한 툴 호출을 하거나 시스템과 상호작용해서 스텝 간의 의존성을 관리한다.\n",
    "\n",
    "### 로보틱스와 자율 주행\n",
    "플래닝 패턴이 상태 공간(state-space)을 탐색하는 근본이다. 목표 상태로 이동하기 위해 경로 또는 액션의 시퀀스를 생성해야 한다.\n",
    "시간 혹은 에너지 소비와 같은 메트릭을 최적화하는 것을 포함하고, 장애물 회피나 교통 규칙 준수 같은 환경적 제약을 고려해야한다\n",
    "\n",
    "### 구조화된 정보 종합(structured information synthesis)\n",
    "리서치 보고서 같은 복잡한 결과물을 생성해야하는 태스크 수행 시, \n",
    "- 정보 수집\n",
    "- 데이터 요약\n",
    "- 컨텐츠 구조화\n",
    "- 반복적 개선\n",
    "같은 명확히 구분된 단계를 포함하는 계획을 세운다.\n",
    "\n",
    "여러 단계를 거치는 태스크 수행 시, 에이전트가\n",
    "- 진단\n",
    "- 솔루션 구현\n",
    "- 상위 단계로 에스컬레이션\n",
    "같은 체계적인 계획을 생성하고 따라야한다.\n",
    "\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7aea61e6",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "1e9f0e69",
   "metadata": {},
   "outputs": [],
   "source": [
    "from __future__ import annotations\n",
    "\n",
    "from typing import List, Dict,TypedDict\n",
    "from typing_extensions import Annotated\n",
    "from dataclasses import dataclass\n",
    "from pydantic import BaseModel, Field\n",
    "\n",
    "from langchain_openai import ChatOpenAI\n",
    "from langchain_core.prompts import ChatPromptTemplate\n",
    "from langchain_core.messages import AnyMessage, AIMessage\n",
    "from langgraph.graph import StateGraph, START, END\n",
    "from langgraph.graph.message import add_messages\n",
    "from langgraph.types import interrupt\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "92603a86",
   "metadata": {},
   "source": [
    "CrewAI의 Agent/Task 메타를 상태로 모델링"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "c7f112a6",
   "metadata": {},
   "outputs": [],
   "source": [
    "@dataclass\n",
    "class AgentSpec:\n",
    "    name: str\n",
    "    role: str\n",
    "    goal: str\n",
    "    backstory: str\n",
    "\n",
    "@dataclass\n",
    "class TaskSpec:\n",
    "    name: str\n",
    "    description: str\n",
    "    expected_output: str\n",
    "\n",
    "\n",
    "class Plan(BaseModel):\n",
    "    steps: List[str] = Field(description=\"정확한 요약을 위한 순차적 단계들 ( 4-6 단계 )\")\n",
    "\n",
    "class Critique(BaseModel):\n",
    "    is_perfect: bool = Field(description=\"초안이 완벽한지 여부 ( `True` 또는 `False` )\")\n",
    "    issues: List[str] = Field(default_factory=list, description=\"문제들, 스타일, 엣지 케이스 등\")\n",
    "    guidance: str = Field(default=\"\", description=\"개선하기 위한 구체적인 지침\")\n",
    "\n",
    "# 그래프 상태를 나타내는 TypedDict ( State-first 접근 방식 )\n",
    "class GraphState(TypedDict):\n",
    "    topic: str\n",
    "    agents: Dict[str, AgentSpec]\n",
    "    tasks: Dict[str, TaskSpec]\n",
    "\n",
    "    need_plan_approval: bool\n",
    "    max_revisions: int\n",
    "    revision_count: int\n",
    "\n",
    "    plan: List[str]\n",
    "    draft: str\n",
    "    critique: Critique | None\n",
    "    report: str\n",
    "\n",
    "    messages: Annotated[List[AnyMessage], add_messages()]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "added52d",
   "metadata": {},
   "source": [
    "LLM"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "ae190cc0",
   "metadata": {},
   "outputs": [],
   "source": [
    "planner_llm = ChatOpenAI(\n",
    "    model=\"qwen3-4b-q4_k_m\",\n",
    "    base_url=\"http://127.0.0.1:8080/v1\",\n",
    "    api_key=\"llama.cpp\",\n",
    "    temperature=0\n",
    ")\n",
    "writer_llm = ChatOpenAI(\n",
    "    model=\"qwen3-4b-q4_k_m\",\n",
    "    base_url=\"http://127.0.0.1:8080/v1\",\n",
    "    api_key=\"llama.cpp\",\n",
    "    temperature=0.2\n",
    ")\n",
    "review_llm = ChatOpenAI(\n",
    "    model=\"qwen3-4b-q4_k_m\",\n",
    "    base_url=\"http://127.0.0.1:8080/v1\",\n",
    "    api_key=\"llama.cpp\",\n",
    "    temperature=0\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "618b4779",
   "metadata": {},
   "source": [
    "Agent별 프롬프트 (역할/목표/백스토리를 system에 )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "14b58209",
   "metadata": {},
   "outputs": [],
   "source": [
    "def make_planner_prompt(agent: AgentSpec) -> ChatPromptTemplate:\n",
    "    return ChatPromptTemplate.from_messages([\n",
    "        (\"system\",\n",
    "         f\"당신은 {agent.name}. 역할: {agent.role}\\n\"\n",
    "         f\"목표: {agent.goal}\\n\"\n",
    "         f\"배경 이야기: {agent.backstory}\\n\"\n",
    "         \"먼저 계획을 세우세요. 출력은 간결하고 실행 가능한 단계(4-6개)여야 합니다.\"),\n",
    "        (\"human\", \"주제: {topic}\")\n",
    "    ])\n",
    "\n",
    "def make_writer_prompt(agent: AgentSpec) -> ChatPromptTemplate:\n",
    "    return ChatPromptTemplate.from_messages([\n",
    "        (\"system\",\n",
    "         f\"당신은 {agent.name}. 역할: {agent.role}\\n\"\n",
    "         f\"목표: {agent.goal}\\n\"\n",
    "         f\"배경 이야기: {agent.backstory}\\n\"\n",
    "         \"명확하게 작성하고 주어진 계획을 따르세요. 약 200단어를 목표로 하세요.\"),\n",
    "        (\"human\", \"주제: {topic}\\n계획:\\n{plan_bullets}\\n\\n최종 요약을 작성하세요.\")\n",
    "    ])\n",
    "\n",
    "def make_revise_prompt(agent: AgentSpec) -> ChatPromptTemplate:\n",
    "    return ChatPromptTemplate.from_messages([\n",
    "        (\"system\",\n",
    "         f\"당신은 {agent.name}. 역할: {agent.role}\\n\"\n",
    "         f\"목표: {agent.goal}\\n\"\n",
    "         f\"배경 이야기: {agent.backstory}\\n\"\n",
    "         \"비판과 계획을 엄격히 따르며 요약을 수정하세요.\"),\n",
    "        (\"human\", \"주제: {topic}\\n계획:\\n{plan_bullets}\\n\\n현재 초안:\\n{draft}\\n\\n비판:\\n{critique}\\n\\n초안을 수정하세요.\")\n",
    "    ])\n",
    "\n",
    "review_prompt = ChatPromptTemplate.from_messages([\n",
    "    (\"system\",\n",
    "     \"당신은 파이써닉하고, 쓸데없는 말을 하지 않는 리뷰어입니다. \"\n",
    "     \"초안이 모든 요구 사항을 충족하는지 확인하세요: 계획을 따르고; 명확하고 간결하며; ~200단어입니다. \"\n",
    "     \"완벽하다면 is_perfect를 true로 설정하세요. 그렇지 않다면 구체적인 문제를 나열하고 지침을 제공하세요.\"),\n",
    "    (\"human\", \"주제: {topic}\\n계획:\\n{plan_bullets}\\n\\n초안:\\n{draft}\")\n",
    "])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7c72ab6a",
   "metadata": {},
   "source": [
    "노드들 (순수 함수: 상태→부분 업데이트 반환)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "903729a9",
   "metadata": {},
   "outputs": [],
   "source": [
    "def plan_node(state: GraphState) -> GraphState:\n",
    "    agent = state[\"agents\"][\"planner\"]\n",
    "    chain = make_planner_prompt(agent) | planner_llm.with_structured_output(Plan)\n",
    "    plan_obj: Plan = chain.invoke({\"topic\": state[\"topic\"]})\n",
    "    steps = plan_obj.steps\n",
    "\n",
    "    if state.get(\"need_plan_approval\", False):\n",
    "        approved_or_feedback = interrupt(\n",
    "            \"계획을 승인 하시겠습니까? 진행하려면 `yes`를 입력하거나 변경을 요청하려면 피드백을 작성하세요.\"\n",
    "        )\n",
    "        if isinstance(approved_or_feedback, str) and approved_or_feedback.lower() != \"yes\":\n",
    "            feedback = approved_or_feedback\n",
    "            replan_chain = ChatPromptTemplate.from_messages([\n",
    "                (\"system\", \"당신은 계획 재작성 전문가입니다. 사용자의 피드백을 바탕으로 계획을 개선하세요.\"),\n",
    "                (\"human\", \"원래 주제: {topic}\\n현재 계획:\\n{cur}\\n\\n피드백:\\n{fb}\\n\\n개선된 계획을 작성하세요.\")\n",
    "            ]) | planner_llm.with_structured_output(Plan)\n",
    "            plan_obj = replan_chain.invoke({\"topic\": state[\"topic\"], \"cur\": \"\\n\".join(steps), \"fb\": feedback})\n",
    "            steps = plan_obj.steps\n",
    "\n",
    "    return {\n",
    "        \"plan\": steps,\n",
    "        \"messages\": [AIMessage(content=f\"(planner) 계획 단계 생성됨\")]\n",
    "    }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "aee6770b",
   "metadata": {},
   "outputs": [],
   "source": [
    "def write_node(state: GraphState) -> GraphState:\n",
    "    agent = state[\"agents\"][\"writer\"]\n",
    "    bullets = \"\\n\".join(f\"- {step}\" for step in state[\"plan\"])\n",
    "    chain = make_writer_prompt(agent) | writer_llm\n",
    "    ai = chain.invoke({\"topic\": state[\"topic\"], \"plan_bullets\": bullets})\n",
    "    return {\n",
    "        \"draft\": ai.content if hasattr(ai, \"content\") else str(ai),\n",
    "        \"messages\": [AIMessage(content=f\"(writer) 초안 작성됨\")]\n",
    "    }\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "bb7ff4a6",
   "metadata": {},
   "outputs": [],
   "source": [
    "def review_node(state: GraphState) -> GraphState:\n",
    "    bullets = \"\\n\".join(f\"- {step}\" for step in state[\"plan\"])\n",
    "    chain = review_prompt | review_llm.with_structured_output(Critique)\n",
    "    critique: Critique = chain.invoke({\n",
    "        \"topic\": state[\"topic\"],\n",
    "        \"plan_bullets\": bullets,\n",
    "        \"draft\": state[\"draft\"]\n",
    "    })\n",
    "    return {\n",
    "        \"critique\": critique,\n",
    "        \"messages\": [AIMessage(content=f\"(reviewer) 초안 검토됨\")]\n",
    "    }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "869bbd34",
   "metadata": {},
   "outputs": [],
   "source": [
    "def revise_node(state: GraphState) -> GraphState:\n",
    "    agent = state[\"agents\"][\"writer\"]\n",
    "    bullets = \"\\n\".join(f\"- {step}\" for step in state[\"plan\"])\n",
    "    critique_str = (\n",
    "        f\"is_perfect: {state['critique'].is_perfect}\\n\"\n",
    "        f\"issues: \" + \", \".join(state['critique'].issues) + \"\\n\"\n",
    "        f\"guidance: {state['critique'].guidance}\"\n",
    "    )\n",
    "    chain = make_revise_prompt(agent) | writer_llm\n",
    "    ai = chain.invoke({\n",
    "        \"topic\": state[\"topic\"],\n",
    "        \"plan_bullets\": bullets,\n",
    "        \"draft\": state[\"draft\"],\n",
    "        \"critique\": critique_str\n",
    "    })\n",
    "    return {\n",
    "        \"draft\": ai.content if hasattr(ai, \"content\") else str(ai),\n",
    "        \"revision_count\": state.get(\"revision_count\", 0) + 1,\n",
    "        \"messages\": [AIMessage(content=f\"(writer) 초안 수정됨\")]\n",
    "    }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "eb0001a7",
   "metadata": {},
   "outputs": [],
   "source": [
    "def format_report_node(state: GraphState) -> GraphState:\n",
    "    plan_sec = \"\\n\".join(f\"- {step}\" for step in state[\"plan\"])\n",
    "    report = (\n",
    "        \"### 계획\\n\"\n",
    "        f\"{plan_sec}\\n\\n\"\n",
    "        \"### 요약\\n\"\n",
    "        f\"{state['draft']}\"\n",
    "    )\n",
    "    return {\"report\": report}"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "95d03101",
   "metadata": {},
   "source": [
    "분기 로직"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "91116d55",
   "metadata": {},
   "outputs": [],
   "source": [
    "def route_after_review(state: GraphState) -> str:\n",
    "    critique: Critique = state[\"critique\"]\n",
    "    if critique.is_perfect:\n",
    "        return \"format\"\n",
    "\n",
    "    if state.get(\"revision_count\", 0) < state.get(\"max_revisions\", 3):\n",
    "        return \"format\" # 한도 초과 시, 초안으로 보고서 작성\n",
    "    return \"revise\"\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ce7d4de7",
   "metadata": {},
   "source": [
    "그래프 구성 "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "5c5ecec0",
   "metadata": {},
   "outputs": [],
   "source": [
    "builder = StateGraph(GraphState)\n",
    "\n",
    "builder.add_node(\"plan\", plan_node)\n",
    "builder.add_node(\"write\", write_node)\n",
    "builder.add_node(\"review\", review_node)\n",
    "builder.add_node(\"revise\", revise_node)\n",
    "builder.add_node(\"format\", format_report_node)\n",
    "\n",
    "builder.add_edge(START, \"plan\")\n",
    "builder.add_edge(\"plan\", \"write\")\n",
    "builder.add_edge(\"write\", \"review\")\n",
    "builder.add_conditional_edges(\"review\", route_after_review, {\n",
    "    \"format\": \"format\",\n",
    "    \"revise\": \"revise\"\n",
    "})\n",
    "builder.add_edge(\"revise\", \"review\")\n",
    "builder.add_edge(\"format\", END)\n",
    "\n",
    "app = builder.compile()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "85d486a6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from IPython.display import Image, display\n",
    "\n",
    "display(Image(app.get_graph().draw_mermaid_png()))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "671e0b01",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "최종 보고서:\n",
      "\n",
      "### 계획\n",
      "- 1. 주제 분석 및 구조 결정: 에이전트 패턴의 정의, 주요 유형(예: 상태 에이전트, 행동 에이전트), 실제 응용 사례 등을 파악하고, 보고서 구조를 결정합니다.\n",
      "- 2. 일일 학습 계획 수립: 매일 3개의 챕터를 집중적으로 공부하고, 각 챕터의 핵심 내용, 예시, 그리고 학습 후 정리 노트를 작성하는 방식을 정합니다.\n",
      "- 3. 학습 자료 확보: 관련 책, 논문, 온라인 자료 등을 수집하여 매일 학습에 활용할 수 있도록 준비합니다.\n",
      "- 4. 정리 및 요약: 매일 학습 후, 해당 챕터의 핵심 내용을 간결하게 요약하고, 정리 노트를 작성하여 이해도를 높입니다.\n",
      "- 5. 주기적 검토 및 피드백: 주간 또는 매주 첫날에 학습 내용을 검토하고, 필요시 추가 학습 또는 수정을 진행합니다.\n",
      "- 6. 보고서 작성 및 정리: 모든 챕터를 학습하고 정리한 후, 보고서를 작성하고, 내용을 체계적으로 정리하여 최종 결과물을 제출합니다.\n",
      "\n",
      "### 요약\n",
      "에이전트 패턴을 매일 3개의 챕터씩 공부하는 방법에 대한 보고서는 구조화된 학습 접근법을 통해 효율적으로 진행할 수 있습니다. 첫 단계에서는 에이전트 패턴의 정의, 주요 유형, 실제 응용 사례 등을 분석하고, 보고서 구조를 결정합니다. 다음으로 일일 학습 계획을 수립하여 매일 3개의 챕터를 집중적으로 공부하고, 핵심 내용, 예시, 정리 노트를 작성합니다. 관련 자료를 확보하고, 매일 학습 후 요약 및 정리 노트를 통해 이해도를 높입니다. 주간 검토를 통해 내용을 정리하고, 필요시 추가 학습을 진행합니다. 마지막으로 모든 챕터를 학습한 후 보고서를 체계적으로 작성하여 결과물을 제출합니다. 이 방법은 지속적인 학습과 정리을 통해 에이전트 패턴에 대한 깊은 이해를 도모합니다.\n"
     ]
    }
   ],
   "source": [
    "topic = \"에이전트 패턴을 매일 세 챕터 씩 공부하는 방법에 대한 보고서 작성\"\n",
    "\n",
    "planner_spec = AgentSpec(\n",
    "    name=\"Planner\",\n",
    "    role=\"전문 계획 수립자\",\n",
    "    goal=\"효과적인 계획을 수립하여 고품질 요약을 작성하는 것\",\n",
    "    backstory=\"다양한 주제에 대한 계획 수립 경험이 풍부한 전문가\"\n",
    ")\n",
    "writer_spec = AgentSpec(\n",
    "    name=\"Writer\",\n",
    "    role=\"숙련된 콘텐츠 작성자\",\n",
    "    goal=\"명확하고 간결한 요약을 작성하는 것\",\n",
    "    backstory=\"다양한 주제에 대한 글쓰기 경험이 풍부한 전문가\"\n",
    ")\n",
    "\n",
    "plan_task = TaskSpec(\n",
    "    name=\"Plan Creation\",\n",
    "    description=f\"주어진 주제 '{topic}'에 대한 실행 가능한 계획을 수립합니다.\",\n",
    "    expected_output=\"4-6단계의 명확한 계획\"\n",
    ")\n",
    "write_task = TaskSpec(\n",
    "    name=\"Draft Writing\",\n",
    "    description=\"수립된 계획을 바탕으로 명확하고 간결한 요약을 작성합니다.\",\n",
    "    expected_output=\"약 200단어의 요약 초안\"\n",
    ")\n",
    "\n",
    "result = app.invoke(\n",
    "    {\n",
    "        \"topic\": topic,\n",
    "        \"agents\": {\n",
    "            \"planner\": planner_spec,\n",
    "            \"writer\": writer_spec\n",
    "        },\n",
    "        \"tasks\": {\n",
    "            \"plan_creation\": plan_task,\n",
    "            \"draft_writing\": write_task\n",
    "        },\n",
    "        \"need_plan_approval\": False,\n",
    "        \"max_revisions\": 2,\n",
    "        \"revision_count\": 0,\n",
    "        \"plan\": [],\n",
    "        \"draft\": \"\",\n",
    "        \"critique\": None,\n",
    "        \"report\": \"\",\n",
    "        \"messages\": []\n",
    "    }\n",
    ")\n",
    "\n",
    "print(\"최종 보고서:\\n\")\n",
    "print(result[\"report\"])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d409276d",
   "metadata": {},
   "source": [
    "# Google DeepResearch\n",
    "\n",
    "사용자가 던진 질문을 단순히 검색하는 게 아니라, 스스로 연구 계획을 세우고 실행하는 시스템이다.  \n",
    "기존의 단일 질의-응답형 검색과 달리, **복잡한 주제를 체계적으로 탐구하고 종합하는 자동 연구 에이전트**이다.\n",
    "\n",
    "## 작동 구조\n",
    "1. 프롬프트 분석 → 사용자의 질문을 세분화해서 multi-point research plan(다항목 연구 계획)을 만든다.\n",
    "2. 계획 검토 단계 → 사용자가 이 계획을 보고 수정하거나 승인할 수 있다. → 사용자와 협업하는 플래닝 시스템이다.\n",
    "3. 반복적 탐색 루프 실행 → 계획이 승인되면 에이전트가 Google 검색을 반복 수행하며, 매 단계마다\n",
    "    - 새로운 쿼리를 동적으로 작성\n",
    "    - **정보의 공백(knowledge gaps)**을 파악\n",
    "    - 데이터 검증(corroboration) 및 불일치 해결(discrepancy resolution)\n",
    "\n",
    "이 과정 전체는 단일 질의-응답이 아닌 **관리된 장기 실행 프로세스(long-running process)**로 운영된다.\n",
    "\n",
    "## 설계적 특징\n",
    "- 비동기(asynchronous) 구조 → 수백 개의 소스를 분석해도 단일 장애에 견딤\n",
    "- 사용자 알림 시스템 → 실행 중 사용자는 이탈(disengage) 가능, 완료 시 통보\n",
    "- 문서 통합 기능 → 사용자가 제공한 개인 문서와 웹 데이터를 함께 분석\n",
    "\n",
    "## 결과물 (Output)\n",
    "- 단순 요약이 아니라 **구조화된 다중 페이지 보고서(structured multi-page report)**\n",
    "- **비판적 평가(critical evaluation)**를 통해 주요 주제 도출\n",
    "- **논리적 섹션(logical sections)**으로 정리된 흐름이 자연스러운 이야기 구조(coherent narrative)  \n",
    "  → 단순 정보 나열이 아니라 주제 간 인과관계와 논리 흐름을 드러냄\n",
    "- 상호작용형 보고서 : 오디오 요약, 차트, 원본 인용 링크 포함\n",
    "- 투명성 보장 : 검색·참조한 모든 출처를 명시 (그림 2 참고)\n",
    "\n",
    "## 핵심 가치\n",
    "수작업으로 데이터를 수집하고 정리하는 과정을 자동화하여,  \n",
    "**더 넓고 깊은 정보 탐색을 빠르게 수행**하고,  \n",
    "사용자가 **전략적 해석과 의사결정에 집중**할 수 있도록 지원한다."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "41b9e805",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Google GenAI SDK는 Google의 생성형 AI 모델(예: Gemini)에 접근하기 위한 클라이언트 라이브러리이며, 이 SDK를 통해 접근하는 서비스에는 일반적으로 무료 등급(Free Tier)이 제공됩니다. 하지만 \"무료 한도\"는 **어떤 방식으로 Google의 GenAI 서비스를 이용하느냐**에 따라 다소 차이가 있습니다.\n",
      "\n",
      "주로 두 가지 주요 접근 방식이 있습니다:\n",
      "\n",
      "1.  **Google AI Studio (이전 MakerSuite) / Gemini API 직접 이용:**\n",
      "    *   이것은 개발자가 빠르게 프로토타이핑하고 앱을 구축할 수 있도록 설계된 서비스입니다.\n",
      "    *   **특징:**\n",
      "        *   별도의 Google Cloud 계정 없이 Google 계정으로 접근 가능합니다.\n",
      "        *   주로 개인 프로젝트, 학습, 소규모 애플리케이션 개발에 적합합니다.\n",
      "        *   **무료 한도:** 일반적으로 **매우 관대한 무료 사용량**을 제공합니다. 이는 보통 월별 또는 분당 특정 수의 요청 및 토큰(입력/출력)으로 측정됩니다. 정확한 수치는 Google의 정책에 따라 변경될 수 있으므로, 항상 최신 정보를 확인해야 합니다.\n",
      "        *   **예시 (과거 또는 일반적인 수준):**\n",
      "            *   특정 모델에 대해 분당 수십 ~ 수백 회의 요청.\n",
      "            *   월별 수십만 ~ 수백만 개의 토큰 사용량.\n",
      "        *   **장점:** 시작하기 매우 쉽고, 비용 걱정 없이 실험하기 좋습니다.\n",
      "        *   **단점:** 엔터프라이즈 기능(고급 보안, VPC 네트워크 통합 등)은 제한적입니다.\n",
      "    *   **공식 문서 확인:** Google AI Studio 또는 Gemini API 문서를 통해 최신 무료 한도를 확인해야 합니다.\n",
      "\n",
      "2.  **Google Cloud Vertex AI 플랫폼을 통한 GenAI 이용:**\n",
      "    *   이것은 기업 및 대규모 프로덕션 환경을 위한 Google Cloud의 통합 ML 플랫폼입니다.\n",
      "    *   **특징:**\n",
      "        *   Google Cloud 프로젝트 내에서 GenAI 모델을 사용합니다.\n",
      "        *   Google Cloud의 강력한 인프라, 보안, 모니터링, 데이터 거버넌스 기능과 통합됩니다.\n",
      "        *   **무료 한도:** Vertex AI의 GenAI 모델(예: Gemini, PaLM 2, Imagen)도 자체적인 \"무료 등급\" 또는 \"무료 사용량\"을 제공합니다. 이는 Google Cloud의 \"Always Free\" 프로그램의 일부로 제공될 수도 있고, GenAI 서비스 자체의 무료 할당량으로 제공될 수도 있습니다.\n",
      "        *   **예시 (Vertex AI GenAI의 일반적인 무료 등급):**\n",
      "            *   **Gemini 모델 (예: `gemini-pro`, `gemini-pro-vision`):** 월별 일정량의 입력 토큰과 출력 토큰 (예: 수십만 개)이 무료로 제공됩니다.\n",
      "            *   **PaLM 2 모델 (예: `text-bison`, `chat-bison`):** 마찬가지로 월별 일정량의 입력/출력 토큰이 무료로 제공됩니다.\n",
      "            *   **Imagen (텍스트-이미지 변환):** 월별 일정량의 이미지 생성 또는 편집 요청이 무료로 제공될 수 있습니다.\n",
      "        *   **장점:** 엔터프라이즈급 기능, 확장성, Google Cloud 생태계와의 완벽한 통합.\n",
      "        *   **단점:** Google Cloud 프로젝트 설정 및 결제 계정 활성화가 필요하며, 무료 한도를 초과하면 표준 요금으로 자동 전환됩니다.\n",
      "    *   **공식 문서 확인:** **Google Cloud의 Vertex AI 가격 책정 페이지**에서 가장 정확하고 최신 정보를 확인할 수 있습니다. 특히 \"Generative AI models\" 섹션을 살펴보세요.\n",
      "\n",
      "### 핵심 요약 및 권장 사항:\n",
      "\n",
      "*   **가장 관대한 무료 등급:** **Google AI Studio / Gemini API**를 통해 GenAI SDK를 사용하는 것이 개발자에게는 가장 쉽고 관대한 무료 한도를 제공합니다. 간단한 프로토타입이나 개인 프로젝트에 적합합니다.\n",
      "*   **엔터프라이즈급 무료 등급:** **Vertex AI**를 통한 GenAI는 Google Cloud의 일부로서, 특정 월별 무료 할당량을 제공하지만, 일반적으로 Google AI Studio보다 엄격할 수 있습니다. 그러나 대규모 프로젝트나 프로덕션 환경으로 나아갈 때 더 적합합니다.\n",
      "*   **무료 한도 초과 시:** 두 경우 모두 무료 한도를 초과하면 표준 유료 요금으로 전환됩니다. Vertex AI의 경우 Google Cloud 결제 계정에 요금이 청구됩니다.\n",
      "*   **항상 공식 문서 확인:** Google의 서비스 약관 및 가격 정책은 변경될 수 있으므로, 항상 Google AI Studio 또는 Google Cloud Vertex AI의 **공식 가격 책정 및 무료 등급 문서**를 직접 확인하는 것이 가장 중요합니다.\n",
      "\n",
      "**추천 링크:**\n",
      "*   **Google Cloud Vertex AI 가격 책정:** [https://cloud.google.com/vertex-ai/pricing?hl=ko](https://cloud.google.com/vertex-ai/pricing?hl=ko) (특히 \"Generative AI\" 부분을 확인하세요)\n",
      "*   **Google AI Studio / Gemini API 문서:** (Google AI Studio 웹사이트나 Gemini API 문서를 참조하세요. 보통 Pricing 또는 Quotas 섹션에 정보가 있습니다.)\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import dotenv\n",
    "from google import genai\n",
    "\n",
    "dotenv.load_dotenv()\n",
    "\n",
    "# The client gets the API key from the environment variable `GEMINI_API_KEY`.\n",
    "client = genai.Client()\n",
    "\n",
    "response = client.models.generate_content(\n",
    "    model=\"gemini-2.5-flash\", contents=\"Google GenAI SDK의 무료 등급: 무료 한도\"\n",
    ")\n",
    "print(response.text)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ee3e6dfc",
   "metadata": {},
   "source": [
    "https://github.com/google-gemini/gemini-fullstack-langgraph-quickstart/tree/main/backend"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e6c4022b",
   "metadata": {},
   "source": [
    "LangGraph 에이전트의 상태 관리를 위한 여러 TypedDict 클래스"
   ]
  },
  {
   "attachments": {
    "image.png": {
     "image/png": "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"
    }
   },
   "cell_type": "markdown",
   "id": "87cefe13",
   "metadata": {},
   "source": [
    "![image.png](attachment:image.png)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "687efe31",
   "metadata": {},
   "outputs": [],
   "source": [
    "from __future__ import annotations\n",
    "\n",
    "\n",
    "from dataclasses import dataclass, field\n",
    "from typing import TypedDict\n",
    "\n",
    "from langgraph.graph import add_messages\n",
    "from typing_extensions import Annotated\n",
    "\n",
    "import operator\n",
    "\n",
    "class OverallState(TypedDict):\n",
    "    messages: Annotated[list, add_messages]\n",
    "    search_query: Annotated[list, operator.add]\n",
    "    web_research_result: Annotated[list, operator.add]\n",
    "    sources_gathered: Annotated[list, operator.add]\n",
    "    initial_search_query_count: int\n",
    "    max_research_loops: int\n",
    "    research_loop_count: int\n",
    "    reasoning_model: str\n",
    "\n",
    "\n",
    "class ReflectionState(TypedDict):\n",
    "    is_sufficient: bool\n",
    "    knowledge_gap: str\n",
    "    follow_up_queries: Annotated[list, operator.add]\n",
    "    research_loop_count: int\n",
    "    number_of_ran_queries: int\n",
    "\n",
    "\n",
    "class Query(TypedDict):\n",
    "    query: str\n",
    "    rationale: str\n",
    "\n",
    "\n",
    "class QueryGenerationState(TypedDict):\n",
    "    search_query: list[Query]\n",
    "\n",
    "\n",
    "class WebSearchState(TypedDict):\n",
    "    search_query: str\n",
    "    id: str\n",
    "\n",
    "\n",
    "@dataclass(kw_only=True)\n",
    "class SearchStateOutput:\n",
    "    running_summary: str = field(default=None) # Final report"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d1e76d74",
   "metadata": {},
   "source": [
    "에이전트의 설정값"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "afbf6a56",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from pydantic import BaseModel, Field\n",
    "from typing import Any, Optional\n",
    "\n",
    "from langchain_core.runnables import RunnableConfig\n",
    "\n",
    "\n",
    "class Configuration(BaseModel):\n",
    "    query_generator_model: str = Field(\n",
    "        default=\"gemini-2.5-flash\",\n",
    "        description=\"에이전트의 쿼리 생성에 사용할 언어 모델의 이름\"\n",
    "    )\n",
    "\n",
    "    reflection_model: str = Field(\n",
    "        default=\"gemini-2.5-flash\",\n",
    "        description=\"에이전트의 반성(평가) 과정에 사용할 언어 모델의 이름\"\n",
    "    )\n",
    "\n",
    "    answer_model: str = Field(\n",
    "        default=\"gemini-2.5-flash\",\n",
    "        description=\"에이전트의 답변 생성에 사용할 언어 모델의 이름\"\n",
    "    )\n",
    "\n",
    "    number_of_initial_queries: int = Field(\n",
    "        default=3,\n",
    "        description=\"생성할 초기 검색 쿼리의 수\"\n",
    "    )\n",
    "\n",
    "    max_research_loops: int = Field(\n",
    "        default=2,\n",
    "        description=\"수행할 최대 연구 루프 수\"\n",
    "    )\n",
    "\n",
    "    @classmethod\n",
    "    def from_runnable_config(\n",
    "        cls, config: Optional[RunnableConfig] = None\n",
    "    ) -> \"Configuration\":\n",
    "\n",
    "        configurable = (\n",
    "            config[\"configurable\"] if config and \"configurable\" in config else {}\n",
    "        )\n",
    "\n",
    "        raw_values: dict[str, Any] = {\n",
    "            name: os.environ.get(name.upper(), configurable.get(name))\n",
    "            for name in cls.model_fields.keys()\n",
    "        }\n",
    "\n",
    "        values = {k: v for k, v in raw_values.items() if v is not None}\n",
    "\n",
    "        return cls(**values)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "ddb60631",
   "metadata": {},
   "outputs": [],
   "source": [
    "from datetime import datetime\n",
    "from typing import Any, Dict, List\n",
    "\n",
    "from langchain_google_genai import ChatGoogleGenerativeAI\n",
    "from langchain_core.messages import AnyMessage, AIMessage, HumanMessage\n",
    "\n",
    "\n",
    "def get_current_date():\n",
    "    return datetime.now().strftime(\"%B %d, %Y\")\n",
    "\n",
    "\n",
    "def get_research_topic(messages: List[AnyMessage]) -> str:\n",
    "    if len(messages) == 1:\n",
    "        research_topic = messages[-1].content\n",
    "    else:\n",
    "        research_topic = \"\"\n",
    "        for message in messages:\n",
    "            if isinstance(message, HumanMessage):\n",
    "                research_topic += f\"User: {message.content}\\n\"\n",
    "            elif isinstance(message, AIMessage):\n",
    "                research_topic += f\"Assistant: {message.content}\\n\"\n",
    "    return research_topic\n",
    "\n",
    "\n",
    "class SearchQueryList(BaseModel):\n",
    "    query: List[str] = Field(\n",
    "        description=\"웹 리서치에 사용할 검색 쿼리 목록\"\n",
    "    )\n",
    "    rationale: str = Field(\n",
    "        description=\"이 쿼리들이 연구 주제와 관련이 있는 이유에 대한 간단한 설명\"\n",
    "    )\n",
    "\n",
    "\n",
    "class Reflection(BaseModel):\n",
    "    is_sufficient: bool = Field(\n",
    "        description=\"제공된 요약이 사용자의 질문에 답하기에 충분한지 여부\"\n",
    "    )\n",
    "    knowledge_gap: str = Field(\n",
    "        description=\"누락되었거나 명확히 해야할 정보에 대한 설명\"\n",
    "    )\n",
    "    follow_up_queries: List[str] = Field(\n",
    "        description=\"지식 격차를 해결하기 위한 후속 쿼리 목록\"\n",
    "    )\n",
    "\n",
    "\n",
    "def generate_query(state: OverallState, config: RunnableConfig) -> QueryGenerationState:\n",
    "    configurable = Configuration.from_runnable_config(config)\n",
    "\n",
    "    if state.get(\"initial_search_query_count\") is None:\n",
    "        state[\"initial_search_query_count\"] = configurable.number_of_initial_queries\n",
    "\n",
    "    llm = ChatGoogleGenerativeAI(\n",
    "        model=configurable.query_generator_model,\n",
    "        temperature=1.0,\n",
    "        max_retries=2,\n",
    "        api_key=os.getenv(\"GEMINI_API_KEY\")\n",
    "    )\n",
    "    structured_llm = llm.with_structured_output(SearchQueryList)\n",
    "\n",
    "    query_writer_instructions = \"\"\"당신의 목표는 정교하고 다양한 웹 검색 쿼리를 생성하는 것입니다. 이 쿼리들은 복잡한 결과를 분석하고, 링크를 따라가며, 정보를 종합할 수 있는 고급 자동화 웹 연구 도구를 위한 것입니다.\n",
    "\n",
    "    지침:\n",
    "    - 항상 단일 검색 쿼리를 선호하되, 원래 질문이 여러 측면이나 요소를 요구하고 하나의 쿼리로는 충분하지 않을 때만 추가 쿼리를 생성하세요.\n",
    "    - 각 쿼리는 원래 질문의 특정한 한 측면에 집중해야 합니다.\n",
    "    - {number_queries}개 이상의 쿼리를 생성하지 마세요.\n",
    "    - 쿼리는 다양해야 하며, 주제가 광범위하면 1개 이상의 쿼리를 생성하세요.\n",
    "    - 유사한 쿼리를 여러 개 생성하지 마세요. 1개면 충분합니다.\n",
    "    - 쿼리는 가장 최신 정보를 수집할 수 있도록 해야 합니다. 현재 날짜는 {current_date}입니다.\n",
    "\n",
    "    형식:\n",
    "    - 다음 두 키를 모두 포함하는 JSON 객체로 응답을 형식화하세요:\n",
    "    - \"rationale\": 이 쿼리들이 관련성이 있는 이유에 대한 간단한 설명\n",
    "    - \"query\": 검색 쿼리 목록\n",
    "\n",
    "    예시:\n",
    "\n",
    "    주제: 작년에 애플 주식과 아이폰 구매자 수 중 어느 것의 수익이 더 많이 증가했는가\n",
    "    ```json\n",
    "    {{\n",
    "        \"rationale\": \"이 비교 성장 질문에 정확히 답하기 위해서는 애플의 주식 성과와 아이폰 판매 지표에 대한 구체적인 데이터 포인트가 필요합니다. 이 쿼리들은 직접 비교를 위해 필요한 정확한 재무 정보를 대상으로 합니다: 회사 수익 동향, 제품별 판매량 수치, 그리고 같은 회계 기간 동안의 주가 움직임.\",\n",
    "        \"query\": [\"Apple total revenue growth fiscal year 2024\", \"iPhone unit sales growth fiscal year 2024\", \"Apple stock price growth fiscal year 2024\"],\n",
    "    }}\n",
    "    ```\n",
    "\n",
    "    맥락: {research_topic}\"\"\"\n",
    "\n",
    "    formatted_prompt = query_writer_instructions.format(\n",
    "        current_date=get_current_date(),\n",
    "        number_queries=state[\"initial_search_query_count\"],\n",
    "        research_topic=get_research_topic(state[\"messages\"])\n",
    "    )\n",
    "    result = structured_llm.invoke(formatted_prompt)\n",
    "    return {\"search_query\": result.query}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "e31899b3",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "\n",
    "from langgraph.types import Send\n",
    "from google.genai import Client\n",
    "\n",
    "\n",
    "genai_client = Client(api_key=os.getenv(\"GEMINI_API_KEY\"))\n",
    "\n",
    "\n",
    "def continue_to_web_research(state: QueryGenerationState):\n",
    "    \"\"\"웹 리서치 노드로 검색 쿼리를 전송하는 헬퍼 함수\n",
    "    \"\"\"\n",
    "\n",
    "    return [\n",
    "        Send(\"web_research\", {\"search_query\": search_query, \"id\": int(idx)})\n",
    "        for idx, search_query in enumerate(state[\"search_query\"])\n",
    "    ]\n",
    "\n",
    "\n",
    "def resolve_urls(urls_to_resolve: List[Any], id: int) -> Dict[str, str]:\n",
    "    \"\"\"URL을 고유한 식별자로 매핑하는 헬퍼 함수    \"\"\"\n",
    "    prefix = f\"https://vertexaisearch.cloud.google.com/id/\"\n",
    "    urls = [site.web.uri for site in urls_to_resolve]\n",
    "\n",
    "    resolved_map = {}\n",
    "    for idx, url in enumerate(urls):\n",
    "        if url not in resolved_map:\n",
    "            resolved_map[url] = f\"{prefix}{id}-{idx}\"\n",
    "\n",
    "    return resolved_map\n",
    "\n",
    "\n",
    "def get_citations(response, resolved_urls_map):\n",
    "    citations = []\n",
    "\n",
    "    if not response or not response.candidates:\n",
    "        return citations\n",
    "\n",
    "    candidate = response.candidates[0]\n",
    "    if (\n",
    "        not hasattr(candidate, \"grounding_metadata\")\n",
    "        or not candidate.grounding_metadata\n",
    "        or not hasattr(candidate.grounding_metadata, \"grounding_supports\")\n",
    "    ):\n",
    "        return citations\n",
    "\n",
    "    for support in candidate.grounding_metadata.grounding_supports:\n",
    "        citation = {}\n",
    "\n",
    "        if not hasattr(support, \"segment\") or support.segment is None:\n",
    "            continue\n",
    "\n",
    "        start_index = (\n",
    "            support.segment.start_index\n",
    "            if support.segment.start_index is not None\n",
    "            else 0\n",
    "        )\n",
    "\n",
    "        if support.segment.end_index is None:\n",
    "            continue\n",
    "\n",
    "        citation[\"start_index\"] = start_index\n",
    "        citation[\"end_index\"] = support.segment.end_index\n",
    "\n",
    "        citation[\"segments\"] = []\n",
    "        if (\n",
    "            hasattr(support, \"grounding_chunk_indices\")\n",
    "            and support.grounding_chunk_indices\n",
    "        ):\n",
    "            for ind in support.grounding_chunk_indices:\n",
    "                try:\n",
    "                    chunk = candidate.grounding_metadata.grounding_chunks[ind]\n",
    "                    resolved_url = resolved_urls_map.get(chunk.web.uri, None)\n",
    "                    citation[\"segments\"].append(\n",
    "                        {\n",
    "                            \"label\": chunk.web.title.split(\".\")[:-1][0],\n",
    "                            \"short_url\": resolved_url,\n",
    "                            \"value\": chunk.web.uri,\n",
    "                        }\n",
    "                    )\n",
    "                except (IndexError, AttributeError, NameError):\n",
    "                    pass\n",
    "        citations.append(citation)\n",
    "    return citations\n",
    "\n",
    "\n",
    "def insert_citation_markers(text, citations_list):\n",
    "    sorted_citations = sorted(\n",
    "        citations_list, key=lambda c: (c[\"end_index\"], c[\"start_index\"]), reverse=True\n",
    "    )\n",
    "\n",
    "    modified_text = text\n",
    "    for citation_info in sorted_citations:\n",
    "        end_idx = citation_info[\"end_index\"]\n",
    "        marker_to_insert = \"\"\n",
    "        for segment in citation_info[\"segments\"]:\n",
    "            marker_to_insert += f\" [{segment['label']}]({segment['short_url']})\"\n",
    "        modified_text = (\n",
    "            modified_text[:end_idx] + marker_to_insert + modified_text[end_idx:]\n",
    "        )\n",
    "\n",
    "    return modified_text\n",
    "\n",
    "\n",
    "\n",
    "def web_research(state: WebSearchState, config: RunnableConfig) -> OverallState:\n",
    "    configurable = Configuration.from_runnable_config(config)\n",
    "\n",
    "    web_searcher_instructions = \"\"\"\"{research_topic}\"에 대한 가장 최신의 신뢰할 수 있는 정보를 수집하기 위해 타겟팅된 Google 검색을 수행하고, 이를 검증 가능한 텍스트 결과물로 종합하세요.\n",
    "\n",
    "    지침:\n",
    "    - 쿼리는 가장 최신 정보를 수집할 수 있도록 해야 합니다. 현재 날짜는 {current_date}입니다.\n",
    "    - 포괄적인 정보를 수집하기 위해 다양하고 여러 번의 검색을 수행하세요.\n",
    "    - 각 특정 정보에 대한 출처를 꼼꼼히 추적하면서 핵심 발견사항을 통합하세요.\n",
    "    - 출력은 검색 결과를 바탕으로 한 잘 작성된 요약 또는 보고서여야 합니다.\n",
    "    - 검색 결과에서 발견된 정보만 포함하고, 어떤 정보도 지어내지 마세요.\n",
    "\n",
    "    연구 주제:\n",
    "    {research_topic}\n",
    "    \"\"\"\n",
    "\n",
    "    formatted_prompt = web_searcher_instructions.format(\n",
    "        current_date=get_current_date(),\n",
    "        research_topic=state[\"search_query\"])\n",
    "\n",
    "    # 제미나이 클라이언트를 langchain 클라이언트 대신 사용 ( 근거 메타데이터 반환 )\n",
    "    response = genai_client.models.generate_content(\n",
    "        model=configurable.query_generator_model,\n",
    "        contents=formatted_prompt,\n",
    "        config={\n",
    "            \"tools\": [{\"google_search\": {}}],\n",
    "            \"temperature\": 0,\n",
    "        },\n",
    "    )\n",
    "\n",
    "    resolved_urls = resolve_urls(\n",
    "        response.candidates[0].grounding_metadata.grounding_chunks, state[\"id\"]\n",
    "    )\n",
    "\n",
    "    citations = get_citations(response, resolved_urls)\n",
    "    modified_text = insert_citation_markers(response.text, citations)\n",
    "    sources_gathered = [item for citation in citations for item in citation[\"segments\"]]\n",
    "\n",
    "    return {\n",
    "        \"sources_gathered\": sources_gathered,\n",
    "        \"search_query\": [state[\"search_query\"]],\n",
    "        \"web_research_result\": [modified_text],\n",
    "    }\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "ec49e478",
   "metadata": {},
   "outputs": [],
   "source": [
    "class Reflection(BaseModel):\n",
    "    is_sufficient: bool = Field(\n",
    "        description=\"제공된 요약이 사용자의 질문에 답하기에 충분한지 여부\"\n",
    "    )\n",
    "    knowledge_gap: str = Field(\n",
    "        description=\"누락되었거나 명확히 해야할 정보에 대한 설명\"\n",
    "    )\n",
    "    follow_up_queries: List[str] = Field(\n",
    "        description=\"지식 격차를 해결하기 위한 후속 쿼리 목록\"\n",
    "    )\n",
    "\n",
    "\n",
    "\n",
    "def reflection(state: OverallState, config: RunnableConfig) -> ReflectionState:\n",
    "    configurable = Configuration.from_runnable_config(config)\n",
    "    state[\"research_loop_count\"] = state.get(\"research_loop_count\", 0) + 1\n",
    "    reasoning_model = state.get(\"reasoning_model\", configurable.reflection_model)\n",
    "\n",
    "    current_date = get_current_date()\n",
    "\n",
    "    reflection_instructions = \"\"\"당신은 \"{research_topic}\"에 대한 요약을 분석하는 전문 연구 보조원입니다.\n",
    "\n",
    "    지침:\n",
    "    - 지식 격차나 더 깊은 탐구가 필요한 영역을 식별하고 후속 쿼리를 생성하세요. (1개 또는 여러 개)\n",
    "    - 제공된 요약이 사용자의 질문에 답하기에 충분하다면, 후속 쿼리를 생성하지 마세요.\n",
    "    - 지식 격차가 있다면, 이해를 확장하는 데 도움이 될 후속 쿼리를 생성하세요.\n",
    "    - 완전히 다루어지지 않은 기술적 세부사항, 구현 사양 또는 새로운 트렌드에 집중하세요.\n",
    "\n",
    "    요구사항:\n",
    "    - 후속 쿼리가 독립적이며 웹 검색에 필요한 맥락을 포함하도록 하세요.\n",
    "\n",
    "    출력 형식:\n",
    "    - 다음의 정확한 키를 가진 JSON 객체로 응답을 형식화하세요:\n",
    "    - \"is_sufficient\": true 또는 false\n",
    "    - \"knowledge_gap\": 누락되었거나 명확히 해야 할 정보를 설명\n",
    "    - \"follow_up_queries\": 이 격차를 해결하기 위한 구체적인 질문 작성\n",
    "\n",
    "    예시:\n",
    "    ```json\n",
    "    {{\n",
    "        \"is_sufficient\": true, // 또는 false\n",
    "        \"knowledge_gap\": \"요약에 성능 지표와 벤치마크에 대한 정보가 부족합니다\", // is_sufficient가 true이면 \"\"\n",
    "        \"follow_up_queries\": [\"[특정 기술]을 평가하는 데 사용되는 일반적인 성능 벤치마크와 지표는 무엇인가요?\"] // is_sufficient가 true이면 []\n",
    "    }}\n",
    "    ```\n",
    "\n",
    "    요약을 신중히 검토하여 지식 격차를 식별하고 후속 쿼리를 생성하세요. 그런 다음 이 JSON 형식에 따라 출력을 생성하세요:\n",
    "\n",
    "    요약:\n",
    "    {summaries}\n",
    "    \"\"\"\n",
    "\n",
    "    formatted_prompt = reflection_instructions.format(\n",
    "        current_date=current_date,\n",
    "        research_topic=get_research_topic(state[\"messages\"]),\n",
    "        summaries=\"\\n\\n---\\n\\n\".join(state[\"web_research_result\"]),\n",
    "    )\n",
    "    llm = ChatGoogleGenerativeAI(\n",
    "        model=reasoning_model,\n",
    "        temperature=1.0,\n",
    "        max_retries=2,\n",
    "        api_key=os.getenv(\"GEMINI_API_KEY\")\n",
    "    )\n",
    "    result = llm.with_structured_output(Reflection).invoke(formatted_prompt)\n",
    "\n",
    "    return {\n",
    "        \"is_sufficient\": result.is_sufficient,\n",
    "        \"knowledge_gap\": result.knowledge_gap,\n",
    "        \"follow_up_queries\": result.follow_up_queries,\n",
    "        \"research_loop_count\": state[\"research_loop_count\"],\n",
    "        \"number_of_ran_queries\": len(state[\"search_query\"])\n",
    "    }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "f3cd96f3",
   "metadata": {},
   "outputs": [],
   "source": [
    "def evaluate_research(\n",
    "    state: ReflectionState,\n",
    "    config: RunnableConfig,\n",
    ") -> OverallState:\n",
    "    configurable = Configuration.from_runnable_config(config)\n",
    "    max_research_loops = (\n",
    "        state.get(\"max_research_loops\")\n",
    "        if state.get(\"max_research_loops\") is not None\n",
    "        else configurable.max_research_loops\n",
    "    )\n",
    "    if state[\"is_sufficient\"] or state[\"research_loop_count\"] >= max_research_loops:\n",
    "        return \"finalize_answer\"\n",
    "    else:\n",
    "        return [\n",
    "            Send(\n",
    "                \"web_research\",\n",
    "                {\n",
    "                    \"search_query\": follow_up_query,\n",
    "                    \"id\": state[\"number_of_ran_queries\"] + int(idx)\n",
    "                },\n",
    "            )\n",
    "            for idx, follow_up_query in enumerate(state[\"follow_up_queries\"])\n",
    "        ]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "8c122947",
   "metadata": {},
   "outputs": [],
   "source": [
    "def finalize_answer(state: OverallState, config: RunnableConfig):\n",
    "    configurable = Configuration.from_runnable_config(config)\n",
    "    reasoning_model = state.get(\"reasoning_model\") or configurable.answer_model\n",
    "\n",
    "    current_date = get_current_date()\n",
    "    answer_instructions = \"\"\"제공된 요약을 바탕으로 사용자의 질문에 대한 고품질 답변을 생성하세요.\n",
    "\n",
    "    지침:\n",
    "    - 현재 날짜는 {current_date}입니다.\n",
    "    - 당신은 다단계 연구 프로세스의 마지막 단계입니다. 마지막 단계라는 것을 언급하지 마세요.\n",
    "    - 이전 단계에서 수집된 모든 정보에 접근할 수 있습니다.\n",
    "    - 사용자의 질문에 접근할 수 있습니다.\n",
    "    - 제공된 요약과 사용자의 질문을 바탕으로 고품질 답변을 생성하세요.\n",
    "    - 요약에서 사용한 출처를 답변에 올바르게 포함하세요. 마크다운 형식을 사용하세요 (예: [apnews](https://vertexaisearch.cloud.google.com/id/1-0)). 이것은 필수입니다.\n",
    "\n",
    "    사용자 맥락:\n",
    "    - {research_topic}\n",
    "\n",
    "    요약:\n",
    "    {summaries}\"\"\"\n",
    "\n",
    "    formatted_prompt = answer_instructions.format(\n",
    "        current_date=current_date,\n",
    "        research_topic=get_research_topic(state[\"messages\"]),\n",
    "        summaries=\"\\n---\\n\\n\".join(state[\"web_research_result\"]),\n",
    "    )\n",
    "\n",
    "    llm = ChatGoogleGenerativeAI(\n",
    "        model=reasoning_model,\n",
    "        temperature=1.0,\n",
    "        max_retries=2,\n",
    "        api_key=os.getenv(\"GEMINI_API_KEY\")\n",
    "    )\n",
    "    result = llm.invoke(formatted_prompt)\n",
    "\n",
    "    unique_sources = []\n",
    "    for source in state[\"sources_gathered\"]:\n",
    "        if source[\"short_url\"] in result.content:\n",
    "            result.content = result.content.replace(\n",
    "                source[\"short_url\"], source[\"value\"]\n",
    "            )\n",
    "            unique_sources.append(source)\n",
    "\n",
    "    return {\n",
    "        \"messages\": [AIMessage(content=result.content)],\n",
    "        \"sources_gathred\": unique_sources,\n",
    "    }\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "86a8ba32",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langgraph.graph import StateGraph\n",
    "from langgraph.graph import START, END\n",
    "\n",
    "\n",
    "builder = StateGraph(OverallState, context_schema=Configuration)\n",
    "\n",
    "builder.add_node(\"generate_query\", generate_query)\n",
    "builder.add_node(\"web_research\", web_research)\n",
    "builder.add_node(\"reflection\", reflection)\n",
    "builder.add_node(\"finalize_answer\", finalize_answer)\n",
    "\n",
    "builder.add_edge(START, \"generate_query\")\n",
    "builder.add_conditional_edges(\n",
    "    \"generate_query\",\n",
    "    continue_to_web_research,\n",
    "    [\"web_research\"]\n",
    ")\n",
    "builder.add_edge(\"web_research\", \"reflection\")\n",
    "builder.add_conditional_edges(\n",
    "    \"reflection\",\n",
    "    evaluate_research,\n",
    "    [\"web_research\", \"finalize_answer\"]\n",
    ")\n",
    "builder.add_edge(\"finalize_answer\", END)\n",
    "\n",
    "app = builder.compile(name=\"web-research-agent\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "2719398d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<IPython.core.display.Image object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from IPython.display import Image, display\n",
    "\n",
    "\n",
    "display(Image(app.get_graph().draw_mermaid_png()))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "20068f79",
   "metadata": {},
   "outputs": [],
   "source": [
    "state = {\n",
    "    # 필수\n",
    "    \"messages\": [HumanMessage(content=\"에이전트 패턴을 매일 세 챕터 씩 공부하는 방법에 대한 보고서 작성\")],\n",
    "    \"initial_search_query_count\": 3,  # 초기 쿼리 개수\n",
    "    \"max_research_loops\": 2,  # 최대 반복 횟수\n",
    "    \"reasoning_model\": \"gemini-2.5-pro\",  # 모델명\n",
    "}\n",
    "result = app.invoke(state)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "2ff3fbdb",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'messages': [HumanMessage(content='에이전트 패턴을 매일 세 챕터 씩 공부하는 방법에 대한 보고서 작성', additional_kwargs={}, response_metadata={}, id='a76d9c27-9fa2-4776-97cd-9e1531cffb7e'),\n",
       "  AIMessage(content='에이전트 패턴 학습을 위한 보고서: 일일 3챕터 스터디 가이드\\n\\n에이전트 패턴을 매일 세 챕터씩 체계적으로 학습하기 위한 보고서입니다. 이 가이드는 기초 개념부터 고급 아키텍처 및 실제 구현까지 단계적으로 구성되어 있으며, 각 단계는 심층적인 이해를 돕기 위한 핵심 주제들로 이루어져 있습니다.\\n\\n### **1단계: AI 에이전트 기초 다지기 (1~2주차)**\\n\\n첫 주에는 AI 에이전트의 기본 원리와 핵심 디자인 패턴을 이해하는 데 중점을 둡니다.\\n\\n*   **1일차 (챕터 1-3): AI 에이전트의 기본**\\n    *   **챕터 1: AI 에이전트의 정의와 유형:** 에이전트의 기본 개념과 자율성, 반응성, 사회성 등 핵심 특징을 학습합니다. 단순 반사 에이전트부터 학습 에이전트까지 다양한 유형을 이해합니다 [brunch](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEt-xQcI2Qpi5icjpwpmSnJx9z8Dfgl_YuHWlCpDkzMe79rSkVqUFpTqEFoRO0MrZzgPFmLPGqpxgM_H-IQnFW8e3NWeCloAQOHIVR1Ew2-CJBc7fWNDc94awjgf4k=) [tistory](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF97Rw0OjI-njUFFQyHTzJMMnIzcxX5UQzgKRttX1QeDbP9RtDkfAJJoCHZ9K3GCEV7LX2d1yxGGKoNc22UfawMsqOO0-9_jAH_UVBuJxNwtUuaJ-OCYy-pupKCaLeCsc0_JA_Se3S-mQ-vJRRpPpGzPY_ARzKwtdSGl6C5ojhnHXlqVie8sE5wPhu4ZZbXNXZB1lNiG-Y7e16K8t-P_w9_YH5TjTfaW5sbSZysKcthGHRd1SikprBkPJo1oQo7-bHsmRc9ryuLv3AptqiF1kZE-9k8FW7JzdhaUI-ulyS8OW1UvvJ66FLwWykmzFvw3y21S8s5NAUz).\\n    *   **챕터 2: 강화 학습(RL)의 원리:** 에이전트가 환경과의 상호작용을 통해 학습하는 핵심 메커니즘인 강화 학습을 배웁니다. 에이전트, 환경, 행동, 보상, 정책 등 주요 구성 요소를 파악합니다 [automationanywhere](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjLNuEZzK_7EzggUgWWQ-6_lb_-Tagr__l82dJJNXjgXY10egg8aT6DQWW-bb2Hgjmy43NMkzJzlIrmttfxHQGe82m6DOQaGYYt9ek1cCwMT67weUGDNTsaSS8DSZSZ7wrvWjhfhY7n9cJmdM0S_--KQb3JScsbEI=).\\n    *   **챕터 3: 에이전트의 핵심 아키텍처:** 에이전트가 정보를 수집하고, 추론하며, 행동을 결정하는 과정을 관리하는 오케스트레이션 레이어의 개념을 학습합니다 [mindscale](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG20oDIU4-5XNo_BNjm6YjFezY69xgICQVT2wMHwwBbjEgmq-i1WMcID97j11OFitbSKG-4nhX03ZwrZ9GpsxRIrZYeIncFk8UVDLuPdirfEKN7QVZ97xwJeiM7H_4hq5HWkjrdB_MoovLHwjVmFeDZe9YvIEhuqU89Klo=) [tistory](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF97Rw0OjI-njUFFQyHTzJMMnIzcxX5UQzgKRttX1QeDbP9RtDkfAJJoCHZ9K3GCEV7LX2d1yxGGKoNc22UfawMsqOO0-9_jAH_UVBuJxNwtUuaJ-OCYy-pupKCaLeCsc0_JA_Se3S-mQ-vJRRpPpGzPY_ARzKwtdSGl6C5ojhnHXlqVie8sE5wPhu4ZZbXNXZB1lNiG-Y7e16K8t-P_w9_YH5TjTfaW5sbSZysKcthGHRd1SikprBkPJo1oQo7-bHsmRc9ryuLv3AptqiF1kZE-9k8FW7JzdhaUI-ulyS8OW1UvvJ66FLwWykmzFvw3y21S8s5NAUz) [tistory](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEswhnU-5NV78DcI8cQaXuJqDr_HET-d5uGP7ibuiBe9GQ2E8LpgBq4OAKozwdMqT-NkulVnxjYWzlgfevE01MYIZqKO00wRgljhb-lRrvzQFcrAPNVc_z-XH2y6Q==) [tistory](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEfUQdoPrhJCeGgUHl4wM4cWJzrf75yD-Rlwpx6gZHsQpnKMy5QukJwHX_mFP0adk8RzvT21uyNYzQcVGsO8E5pLDjp9HYzESttVcAj0lbCDtrkdOXqL_34DBR6KLzn9FRmXC1XnGGgOSbEel2i5Gg6PFzH8HHXr740Dyd5Mv370).\\n\\n*   **2일차 (챕터 4-6): 기본 디자인 패턴**\\n    *   **챕터 4: 도구 사용(Tool Use) 패턴:** 에이전트가 외부 도구(API, 데이터베이스, 검색 엔진 등)를 활용하여 LLM의 한계를 극복하고 실시간 정보에 접근하는 방법을 학습합니다 [automationanywhere](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjLNuEZzK_7EzggUgWWQ-6_lb_-Tagr__l82dJJNXjgXY10egg8aT6DQWW-bb2Hgjmy43NMkzJzlIrmttfxHQGe82m6DOQaGYYt9ek1cCwMT67weUGDNTsaSS8DSZSZ7wrvWjhfhY7n9cJmdM0S_--KQb3JScsbEI=) [google](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEfUQdoPrhJCeGgUHl4wM4cWJzrf75yD-Rlwpx6gZHsQpnKMy5QukJwHX_mFP0adk8RzvT21uyNYzQcVGsO8E5pLDjp9HYzESttVcAj0lbCDtrkdOXqL_34DBR6KLzn9FRmXC1XnGGgOSbEel2i5Gg6PFzH8HHXr740Dyd5Mv37).\\n    *   **챕터 5: 메모리(Memory) 패턴:** 에이전트가 과거의 상호작용을 기억하고 활용하여 문맥을 유지하고 더 정교한 결정을 내리는 단기 및 장기 메모리 메커니즘을 배웁니다 [mindscale](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG20oDIU4-5XNo_BNjm6YjFezY69xgICQVT2wMHwwBbjEgmq-i1WMcID97j11OFitbSKG-4nhX03ZwrZ9GpsxRIrZYeIncFk8UVDLuPdirfEKN7QVZ97xwJeiM7H_4hq5HWkjrdB_MoovLHwjVmFeDZe9YvIEhuqU89Klo=).\\n    *   **챕터 6: 검색 증강 생성(RAG) 패턴:** 에이전트가 외부 지식 베이스를 참조하여 답변의 정확성과 신뢰도를 높이고 환각(Hallucination)을 줄이는 RAG 패턴을 학습합니다.\\n\\n### **2단계: 중급 패턴 및 다중 에이전트 시스템 (3~4주차)**\\n\\n기본 패턴에 대한 이해를 바탕으로, 더 복잡한 문제 해결을 위한 전략과 여러 에이전트 간의 협업을 학습합니다.\\n\\n*   **3일차 (챕터 7-9): 고급 추론 및 계획**\\n    *   **챕터 7: ReAct (Reason + Acting) 패턴:** 에이전트가 추론과 행동을 반복하며 환경과 상호작용하고 지속적으로 학습하는 과정을 심도 있게 다룹니다.\\n    *   **챕터 8: 반성 및 자기 교정(Reflection and Self-Correction) 패턴:** 에이전트가 자신의 결과를 평가하고, 오류를 식별하며, 접근 방식을 스스로 개선하는 메커니즘을 학습합니다 [ibm](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFD9P1Elyt072ROOgIhTm0il6jXajpogsp_n-I8RFs_u7mo6yQVzMGYG5K7UeWMu1620fUsyzsoXcMRaHVAbalJiec8SCODuPztqkOlTGFXa7BarmbCd_RobSKvMJBbvJWJIIAL9kHQltzi8643_vBY_UaP) [hunihub](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH-Y7f2zS5Ttz1mPIRdsCmmMk95igk7cqcqfA-6ooMizsMOpUVDiTQ3AefGz_A_vpodKPQq368NQDHm_dLB57fAIJLKGAzmYCpBCsrsmxyShcUon8cz31oV6c_91H10PA==).\\n    *   **챕터 9: 계획(Planning) 패턴:** 복잡한 작업을 수행하기 위해 에이전트가 상위 목표를 설정하고 체계적인 계획을 수립하여 실행하는 방법을 배웁니다 [automationanywhere](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjLNuEZzK_7EzggUgWWQ-6_lb_-Tagr__l82dJJNXjgXY10egg8aT6DQWW-bb2Hgjmy43NMkzJzlIrmttfxHQGe82m6DOQaGYYt9ek1cCwMT67weUGDNTsaSS8DSZSZ7wrvWjhfhY7n9cJmdM0S_--KQb3JScsbEI=).\\n\\n*   **4일차 (챕터 10-12): 다중 에이전트 시스템(MAS)**\\n    *   **챕터 10: 다중 에이전트 시스템(MAS) 소개:** 단일 에이전트의 한계를 넘어 여러 에이전트가 협력하여 복잡한 문제를 해결하는 MAS의 개념과 장점을 학습합니다 [ibm](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFD9P1Elyt072ROOgIhTm0il6jXajpogsp_n-I8RFs_u7mo6yQVzMGYG5K7UeWMu1620fUsyzsoXcMRaHVAbalJiec8SCODuPztqkOlTGFXa7BarmbCd_RobSKvMJBbvJWJIIAL9kHQltzi8643_vBY_UaP) [google](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEfUQdoPrhJCeGgUHl4wM4cWJzrf75yD-Rlwpx6gZHsQpnKMy5QukJwHX_mFP0adk8RzvT21uyNYzQcVGsO8E5pLDjp9HYzESttVcAj0lbCDtrkdOXqL_34DBR6KLzn9FRmXC1XnGGgOSbEel2i5Gg6PFzH8HHXr740Dyd5Mv37).\\n    *   **챕터 11: MAS의 협업 및 조정 메커니즘:** 에이전트 간의 효과적인 협업을 위한 통신 프로토콜, 시장 기반 조정 등 다양한 조정 메커니즘을 탐구합니다 [ibm](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFD9P1Elyt072ROOgIhTm0il6jXajpogsp_n-I8RFs_u7mo6yQVzMGYG5K7UeWMu1620fUsyzsoXcMRaHVAbalJiec8SCODuPztqkOlTGFXa7BarmbCd_RobSKvMJBbvJWJIIAL9kHQltzi8643_vBY_UaP) [google](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEfUQdoPrhJCeGgUHl4wM4cWJzrf75yD-Rlwpx6gZHsQpnKMy5QukJwHX_mFP0adk8RzvT21uyNYzQcVGsO8E5pLDjp9HYzESttVcAj0lbCDtrkdOXqL_34DBR6KLzn9FRmXC1XnGGgOSbEel2i5Gg6PFzH8HHXr740Dyd5Mv37).\\n    *   **챕터 12: MAS 아키텍처:** 중앙 집중식, 분산형, 계층적 구조 등 다양한 MAS 아키텍처를 학습하고, 특히 복잡한 작업 처리에 유용한 계층적 멀티 에이전트 시스템을 분석합니다 [ibm](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFD9P1Elyt072ROOgIhTm0il6jXajpogsp_n-I8RFs_u7mo6yQVzMGYG5K7UeWMu1620fUsyzsoXcMRaHVAbalJiec8SCODuPztqkOlTGFXa7BarmbCd_RobSKvMJBbvJWJIIAL9kHQltzi8643_vBY_UaP) [google](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEfUQdoPrhJCeGgUHl4wM4cWJzrf75yD-Rlwpx6gZHsQpnKMy5QukJwHX_mFP0adk8RzvT21uyNYzQcVGsO8E5pLDjp9HYzESttVcAj0lbCDtrkdOXqL_34DBR6KLzn9FRmXC1XnGGgOSbEel2i5Gg6PFzH8HHXr740Dyd5Mv37).\\n\\n### **3단계: 시스템 설계 및 실용적 고려사항 (5~6주차)**\\n\\n이론적 지식을 실제 시스템에 적용할 때 필요한 기술적, 윤리적 측면을 학습합니다.\\n\\n*   **5일차 (챕터 13-15): 시스템 전반의 고려사항**\\n    *   **챕터 13: 확장성 및 자원 효율성:** 대규모 동적 프로세스를 지원하기 위한 확장 가능한 인프라와 컴퓨팅 자원 관리의 중요성을 학습합니다.\\n    *   **챕터 14: 보안 및 신뢰:** 제로 트러스트 아키텍처, 역할 기반 접근 제어(IAM), 감사 추적 등 에이전트 시스템의 보안을 확보하는 방법을 배웁니다 [mindscale](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG20oDIU4-5XNo_BNjm6YjFezY69xgICQVT2wMHwwBbjEgmq-i1WMcID97j11OFitbSKG-4nhX03ZwrZ9GpsxRIrZYeIncFk8UVDLuPdirfEKN7QVZ97xwJeiM7H_4hq5HWkjrdB_MoovLHwjVmFeDZe9YvIEhuqU89Klo=) [velog](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFGNhef__7Sx_doaYJxjtH157EIDHqmmwAHPo2PKtgOwBfiHODRFr1LRCCubMNpwL8cWiAHdxj7v77DapdR1t_ILF64cMltMjqjF5kHqs1Q5ANJLSEhm11E1WjjM3Fd6gyeVISV8iBkWiVkTuroxcpvFJAqjMUXNf31NoKqIztqkMRPzs46bd1YHo9n8_eJFqS3WN1ufCsOrju8TL_PMcckKUOt4tB9m0j72mxtA6y1_46pl3b5CDwNw3xL8rJWX0BMCQ==).\\n    *   **챕터 15: 오류 처리 및 통합:** 예상치 못한 상황에 대처하는 능력과 다양한 패턴들을 효과적으로 통합하는 전략을 학습합니다.\\n\\n*   **6일차 (챕터 16-18): 인간-AI 협업 및 최신 동향**\\n    *   **챕터 16: 인간 참여 루프(Human-in-the-Loop) 패턴:** 인간의 피드백을 통해 에이전트의 성능을 개선하고, 의사결정을 감독하는 체계의 중요성을 학습합니다 [brunch](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEt-xQcI2Qpi5icjpwpmSnJx9z8Dfgl_YuHWlCpDkzMe79rSkVqUFpTqEFoRO0MrZzgPFmLPGqpxgM_H-IQnFW8e3NWeCloAQOHIVR1Ew2-CJBc7fWNDc94awjgf4k=) [velog](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFGNhef__7Sx_doaYJxjtH157EIDHqmmwAHPo2PKtgOwBfiHODRFr1LRCCubMNpwL8cWiAHdxj7v77DapdR1t_ILF64cMltMjqjF5kHqs1Q5ANJLSEhm11E1WjjM3Fd6gyeVISV8iBkWiVkTuroxcpvFJAqjMUXNf31NoKqIztqkMRPzs46bd1YHo9n8_eJFqS3WN1ufCsOrju8TL_PMcckKUOt4tB9m0j72mxtA6y1_46pl3b5CDwNw3xL8rJWX0BMCQ==) [tistory](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF97Rw0OjI-njUFFQyHTzJMMnIzcxX5UQzgKRttX1QeDbP9RtDkfAJJoCHZ9K3GCEV7LX2d1yxGGKoNc22UfawMsqOO0-9_jAH_UVBuJxNwtUuaJ-OCYy-pupKCaLeCsc0_JA_Se3S-mQ-vJRRpPpGzPY_ARzKwtdSGl6C5ojhnHXlqVie8sE5wPhu4ZZbXNXZB1lNiG-Y7e16K8t-P_w9_YH5TjTfaW5sbSZysKcthGHRd1SikprBkPJo1oQo7-bHsmRc9ryuLv3AptqiF1kZE-9k8FW7JzdhaUI-ulyS8OW1UvvJ66FLwWykmzFvw3y21S8s5NAUz) [ibm](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGYTmzl5GAbM13enXsXtVYL8NDcHlrbCAWnIf6r1J8ybOkQCus94T-IHu-_TEj62XjXThqtqaQb105PFuS2PX5e1ZvNXia7kUwNRMSIIFvUUnR60lD0HiDSm03MCP3WATYuK4YljYTAOV3tzsxgF8xMJG2leYoAWPI=) [tistory](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEswhnU-5NV78DcI8cQaXuJqDr_HET-d5uGP7ibuiBe9GQ2E8LpgBq4OAKozwdMqT-NkulVnxjYWzlgfevE01MYIZqKO00wRgljhb-lRrvzQFcrAPNVc_z-XH2y6Q==) [tistory](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEfUQdoPrhJCeGgUHl4wM4cWJzrf75yD-Rlwpx6gZHsQpnKMy5QukJwHX_mFP0adk8RzvT21uyNYzQcVGsO8E5pLDjp9HYzESttVcAj0lbCDtrkdOXqL_34DBR6KLzn9FRmXC1XnGGgOSbEel2i5Gg6PFzH8HHXr740Dyd5Mv370).\\n    *   **챕터 17: 동적 적응(Dynamic Adaptation) 패턴:** 전이 학습 등을 사용하여 에이전트가 새로운 환경이나 작업에 빠르게 적응하는 방법을 배웁니다.\\n    *   **챕터 18: 최신 연구 동향:** 다중 에이전트 시스템에서의 심층 강화 학습 적용, 알고리즘 안정성 향상 등 현재 연구되고 있는 최신 기술 동향을 파악합니다.\\n\\n### **4단계: 실습을 통한 심화 학습**\\n\\n이론 학습을 마친 후, 오픈소스 프로젝트와 프레임워크를 활용하여 직접 에이전트를 구현하며 학습 효과를 극대화합니다.\\n\\n*   **이론을 코드로 변환하기:** JADE(Java), PADE(Python), LangGraph와 같은 에이전트 개발 프레임워크를 선택하여 간단한 단일 에이전트 프로젝트부터 시작합니다. 점진적으로 ReAct, RAG, 메모리 등 학습한 패턴들을 적용하며 복잡성을 높여나갑니다 [scribd](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEElCfm1YRwDDCi9kB48cINjYZ91nXxI_B8DdDj5oAhwH7H4xB4n_rFWDT7Yk64zjElW_0y7IrU6dtjRKivapLAyXsRb6DXFYXgHAsPZ9nE6bWRgfiYWp1ZYT-UC3zzlHSAaoBkd6iCm6OojBGrqhLOvRKut6i0qJtezpS4DLmvKTXm6OTGcw==) [projectpro](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE2cs5B7yrop30q6Onb6ICe2Lrb5ATnAMxFWySC2uoBe7AanIaCuTp8sP0RiTxucRqmiZqoMxDlo8MQ2qjFXb8xRMuFx-GrUJynE7lnmP5kRUQjE7kc3RwQlrlqrJCELc1wXnFsfxlH9H54RXqdMrVjV8l9LWnf-Pov8m6e) [medium](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfELnsU3MJZs7MZ5cidjQpU1WG4P4MnxWnTP28uWOZRCXcFkY2XKnnSkMdfaRV1oguLHwmDQcxccs20EBldKp3yifQh8xkmgzb2wxkJo2uU47P5h7E8GNEk49YkXry_ym0hmK3oZxQ4t0xhMBk_f96HddYU8weNWySD5uzJvq29iq6MQeVGj95lC2aCbNionW_T4=) [philschmid](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvE5fF_hSFknYY6AK0PPXy78bDkX0IU3fl5CtJk0roAi0KTMHQdVkcbeX3992WRRCH7OT-7N-KyCz3qTQsGgtApN8ogaiARiTQAj8G1zpz5oSIagjnlQ3Snxv5Q2dpH7o5Qlb2) [machinelearningmastery](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHNQ4x6C8PXZANK15nRwPE57XPthbI0LO9nlzwMafsHRX7QP0C6X4rIm0U6l4oUGMeYW3VsJG8uls_iLJEltUp3H5_Zf6_jdLRcmXFUlwCJXU3KH9o9PNwHVGAHnm__iU9SfZTssOEZnnWdK9wBr-t7r2yK3wjufqKmHXSV4J7m3zQAvD6X) [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFnLH3KPT4HUNc6Dd_50MV_RZ0TnDJWaD15l-atW6yG8JWCXswjZG4jy32iqjp9CPlrRBSjkmI6cnKqbanYlrF7LV1clGv4VWTCfGrQ927o2XZI5O5l9ODJvPKiI-73f62ZJwLCge--a8IxKIxIwUQF6xQsTAuiglDNekyWzaGWbAhZ_1KzEy9Tn9-L1OxZFQ==0) [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFnLH3KPT4HUNc6Dd_50MV_RZ0TnDJWaD15l-atW6yG8JWCXswjZG4jy32iqjp9CPlrRBSjkmI6cnKqbanYlrF7LV1clGv4VWTCfGrQ927o2XZI5O5l9ODJvPKiI-73f62ZJwLCge--a8IxKIxIwUQF6xQsTAuiglDNekyWzaGWbAhZ_1KzEy9Tn9-L1OxZFQ==1).\\n*   **추천 프레임워크 및 프로젝트:**\\n    *   **LangChain & LangGraph:** ReAct, RAG, 메모리 패턴을 구현하기 위한 포괄적인 도구를 제공합니다. 특히 LangGraph는 복잡한 에이전트의 상태와 흐름을 관리하는 데 유용합니다 [langchain](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEYkxrMovSyOd2POoQpnjswQY4VQOozQzDtuytJ4BlE7qWyK_zJJAwMdn-WP8eDv9oBeBEUBvp9csjJrTLNuHciu30iSVE71HaahfszJaQ1_tab6_raG0Tslb1_GMdNoKlMvigC2IigNeRse5GC) [sider](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHft1chmON3YN61Gp_fMGWqOK4FENiwuOyD52nktUTDyjv6iwKqCZ5fzy5IieUDATDcEWb5vqs-m0pfQyscvLZylJpNl3XQWDxFao37fsj5wd2jdqLI9nO0SagCfQ-FuPZGwwQKPRqsPsSZrR39EcSlrj9aSg8xNu1s7xR1ehcCt2aQfPYUOxTIZxPZhC6LRM_dyek=) [coursera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNVchBrhedBr3bgA2PwPleQTdUOyLOJ3uUCO9s6ID_qGQKoctFBFkYFOl4BlP0R7cscc0ybdA8Z1a_OK2QpoFx57XQPF4gXcnrxBDV7HGk56eDwce5QEGVTdIDJD_V6XdJXMUCx6yahz5Im85xE13wqOCEgFNMyKE-0s-k_MsCzK0Zk1yB0CPGbGGV) [hexstream](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFz0RYn1_VeBH_fpYCtrBbJ1KVuUIEhGI5LZFaTelVPOMzVqAe4sMAk-YlUMj2KIgbaXl1fbRZSDcvbvzPk7-BXaYWL-NS81quulbWIrtK0ouBFNeuWRfjNRGpfu0c6QZefDrTJLbMjTLp3z7yU8n97YYPVOhVMwrst1ryH6Ae8H0EXCIVIhf8Q0EroXsWaWBfghv20HiiG1B9DR11WLY7gzqiGsSmErKcg7v4pq42LwMH14q_L6flbT62frrauEJuQtxXlRQ==) [towardsai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFUjXI8B9JbLE9ZzGLB1SJRFPSMizNYcV0t53k1Iq5q64FjiyYK5kjHHCuzdlE1zMlvvkC4Q-l7U90CiR6GZGgc-y5y59wbhB7a23yNQWm1k446vTZS5mY4PeitKRhtx6zzmfpid7BQ_vEVsJPy4Mg6t53KXlNpYREM10qbZxDhoJ9L2LvlL4AMbQ0caSQFfTsfHg==) [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQENfZz-5DmpyrhePjemu3Lk7xHWp_T9uKyQIgMBPj8_sYsduLApyQUisNNDwtrSqsXT_swdjp3BcsQEOJIqeVDi5pDCriBpS4xFNmdJ4wtaWw6FzDUpDjSaqIryTvQ9NHBTfKBfcw==).\\n    *   **AutoGen (Microsoft):** 여러 에이전트 간의 통신과 협업을 중심으로 설계된 프레임워크로, 다중 에이전트 RAG 시스템 구축에 적합합니다 [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHJWvSaHjgCdS6FRp7nW5yE48MzQcem-stBuUxw3WXkzhldH1nshBmyIULE5FAIWIwsRqBvbJ2AYP6NmAwndbI5ZpwIHyBbejqxm2IZeB0g6kmE3J7aibIrmzWtgJ70IHBoUAzO3w==) [hexstream](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFz0RYn1_VeBH_fpYCtrBbJ1KVuUIEhGI5LZFaTelVPOMzVqAe4sMAk-YlUMj2KIgbaXl1fbRZSDcvbvzPk7-BXaYWL-NS81quulbWIrtK0ouBFNeuWRfjNRGpfu0c6QZefDrTJLbMjTLp3z7yU8n97YYPVOhVMwrst1ryH6Ae8H0EXCIVIhf8Q0EroXsWaWBfghv20HiiG1B9DR11WLY7gzqiGsSmErKcg7v4pq42LwMH14q_L6flbT62frrauEJuQtxXlRQ==) [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQENfZz-5DmpyrhePjemu3Lk7xHWp_T9uKyQIgMBPj8_sYsduLApyQUisNNDwtrSqsXT_swdjp3BcsQEOJIqeVDi5pDCriBpS4xFNmdJ4wtaWw6FzDUpDjSaqIryTvQ9NHBTfKBfcw==).\\n    *   **LlamaIndex:** RAG 파이프라인 구축에 특화된 프레임워크로, 데이터 수집부터 검색까지의 과정을 단순화합니다 [github](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHft1chmON3YN61Gp_fMGWqOK4FENiwuOyD52nktUTDyjv6iwKqCZ5fzy5IieUDATDcEWb5vqs-m0pfQyscvLZylJpNl3XQWDxFao37fsj5wd2jdqLI9nO0SagCfQ-FuPZGwwQKPRqsPsSZrR39EcSlrj9aSg8xNu1s7xR1ehcCt2aQfPYUOxTIZxPZhC6LRM_dyek=0) [coursera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNVchBrhedBr3bgA2PwPleQTdUOyLOJ3uUCO9s6ID_qGQKoctFBFkYFOl4BlP0R7cscc0ybdA8Z1a_OK2QpoFx57XQPF4gXcnrxBDV7HGk56eDwce5QEGVTdIDJD_V6XdJXMUCx6yahz5Im85xE13wqOCEgFNMyKE-0s-k_MsCzK0Zk1yB0CPGbGGV) [medium](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHft1chmON3YN61Gp_fMGWqOK4FENiwuOyD52nktUTDyjv6iwKqCZ5fzy5IieUDATDcEWb5vqs-m0pfQyscvLZylJpNl3XQWDxFao37fsj5wd2jdqLI9nO0SagCfQ-FuPZGwwQKPRqsPsSZrR39EcSlrj9aSg8xNu1s7xR1ehcCt2aQfPYUOxTIZxPZhC6LRM_dyek=1).', additional_kwargs={}, response_metadata={}, id='88a28ce9-a824-4559-a3d9-ee4383ebb595')],\n",
       " 'search_query': ['에이전트 패턴 학습 효과적인 전략',\n",
       "  '매일 3챕터 공부 습관화 유지 방법',\n",
       "  '에이전트 패턴 학습 효과적인 전략',\n",
       "  '매일 3챕터 공부 습관화 유지 방법',\n",
       "  '에이전트 패턴의 이론적 학습을 실제 코딩 프로젝트와 통합하기 위한 단계별 가이드는 무엇인가요?',\n",
       "  'AI 에이전트 패턴을 효과적으로 학습하기 위한 추천 학습 순서나 커리큘럼은 무엇이며, 각 패턴별 학습에 적절한 시간 배분은 어떻게 되나요?',\n",
       "  'ReAct, RAG, 메모리 패턴과 같은 특정 AI 에이전트 패턴을 깊이 있게 이해하고 구현하는 데 도움이 되는 최고의 오픈소스 프로젝트, 튜토리얼, 실습 플랫폼은 무엇인가요?'],\n",
       " 'web_research_result': [\"에이전트 패턴 학습의 효과적인 전략은 단일 에이전트의 자율성 및 추론 능력 강화부터 다중 에이전트 시스템의 협업 및 분산 학습에 이르기까지 다양한 접근 방식을 포함하며, 최신 연구 동향은 이러한 전략들의 고도화에 초점을 맞추고 있습니다. 현재(2025년 11월)를 기준으로 가장 최신의 신뢰할 수 있는 정보들을 종합하여 다음과 같은 핵심 전략들을 도출할 수 있습니다.\\n\\n**1. 다중 에이전트 시스템(Multi-Agent Systems, MAS)을 통한 협업 및 분산 학습**\\n다중 에이전트 시스템은 복잡한 문제를 해결하는 데 있어 단일 에이전트보다 뛰어난 성능을 보이는 경향이 있습니다. 이는 에이전트들이 정보를 공유하고, 전문화된 기술을 활용하며, 협력적으로 문제를 해결하기 때문입니다.\\n\\n*   **지속적인 학습 및 적응:** MAS는 통합 학습 기능을 통해 지속적으로 학습하고 적응하며 스스로 개선할 수 있습니다. 여기에는 데이터 프라이버시와 운영 경계를 유지하면서 통찰력과 모델 개선 사항을 공유하는 '분산 학습'이 포함됩니다.\\n*   **강화 학습:** 에이전트들은 비즈니스 결과 및 핵심 성과 지표(KPI)에 기반한 보상 신호를 통해 의사결정 정책을 최적화합니다.\\n*   **협업 필터링:** 유사한 작업을 처리하는 다른 에이전트들의 경험과 결정을 통해 학습하여 전체적인 개선을 가속화합니다.\\n*   **조정 메커니즘:** 시장 기반 조정(에이전트가 역량에 따라 작업에 '입찰')과 표준화된 통신 프로토콜은 효과적인 협업을 위해  [ibm](https://vertexaisearch.cloud.google.com/id/0-0) [google](https://vertexaisearch.cloud.google.com/id/0-1)중요합니다.\\n*   **아키텍처:** MAS는 중앙 집중식, 분산형, 계층적 구조 등 다양한 아키텍처로 작동할 수 있으며, 특히 계층적 멀티 에이전트 시스템은 상위 관리자 에이전트가 전체 계획을 수립하고 하위 전문가 에이전트가 특정 작업을 수행하는 방식으로 [ibm](https://vertexaisearch.cloud.google.com/id/0-0) [google](https://vertexaisearch.cloud.google.com/id/0-1) 복잡한 작업을 처리합니다.\\n*   **최신 연구 동향:** 적대적 환경에서의 학습 방법, 심층 강화 학습 알고리즘의 MAS 적용, 알고리즘의 안정성 및 효율성 향상에 초점을 맞추고 있습니다.\\n\\n**2. 강화 학습(Reinforcement Learning, RL) 기반의 패턴 인식 및 [automationanywhere](https://vertexaisearch.cloud.google.com/id/0-2) 의사결정**\\n강화 학습은 에이전트가 환경과 상호작용하며 시행착오를 통해 보상을 최대화하는 최적의 행동 전략을 학습하는 방법론입니다.\\n\\n*   **핵심 구성 요소:** 에이전트, 환경, 행동, 상태, 보상, 정책, 가치 함수 등이 있습니다.\\n*   **학습 과정:** 에이전트는 환경의 상 [automationanywhere](https://vertexaisearch.cloud.google.com/id/0-2)태를 관찰하고 행동을 선택하며, 그 결과로 환경으로부터 새로운 상태 정보와 보상을 받아 학습하고 최적의 행동 전략을 개발합니다.\\n*   **주요 알고리즘:** Q-Learning, Deep Q-Network (DQN), Policy Gradient Methods, Actor-Critic 등이 있으며, 특히  [automationanywhere](https://vertexaisearch.cloud.google.com/id/0-2)비동기식 강화 학습(Actor-Critic)은 분산 시스템에서 효율적이고 안정적인 학습을 가능하게 하여 다중 에이전트 문제에 유용합니다.\\n*   **도전 과제:** 학습 속도, 높은 계산 비용, 새로운 환경으로의 일반화, 그리고 윤리적 문제 고려가 중요한 도전 과제입니다.\\n\\n**3. AI 에이전트 디 [automationanywhere](https://vertexaisearch.cloud.google.com/id/0-2)자인 패턴 및 학습 전략**\\nAI 에이전트는 단순한 명령 수행을 넘어 자율적으로 판단하고 행동하며, 경험을 통해 학습하고 적응하는 방향으로 발전하고 있습니다.\\n\\n*   **계획 패턴(Planning Pattern):** 에이전트가 복잡한 작업을 수행하기 위해 상위 수준의 목표와 전략을 포함한 체계적인 계획을 수립하고 실행합니다.\\n*    [automationanywhere](https://vertexaisearch.cloud.google.com/id/0-2) [google](https://vertexaisearch.cloud.google.com/id/0-1)**도구 사용 패턴(Tool Use Pattern):** 에이전트가 외부 도구(API, 데이터베이스, 검색 엔진, 코드 실행기 등)를 활용하여 LLM의 지식 및 능력 한계를 극복하고 실시간 정보 접근 및 복잡한 계산을 수행합니다.\\n*   **ReAct (Reasoning + Acting) 패턴:** 에이전트가 추론(Reasoning)하고 행동(Acting)하는 과정을 반복하며 환경과 상호작용하면서 지속적으로 학습하고 개선됩니다.\\n*   **반성 및 자기 교정 패턴(Reflection and Self-Correction Pattern):** 에이전트가 자신의 능력과 한계를 평가하고, 지식 격차를 식별하며, 결과를 자체 평가하여 접근 [ibm](https://vertexaisearch.cloud.google.com/id/0-0) [hunihub](https://vertexaisearch.cloud.google.com/id/0-3) 방식을 조정하고 개선합니다.\\n*   **검색 증강 생성(Retrieval-Augmented Generation, RAG) 패턴:** LLM이 답변을 생성하기 전에 외부 지식 베이스에서 관련 최신 정보를 검색하고 이를 참고하여 더 정확하고 신뢰성 높은 답변을 생성함으로써 환각(Hallucination) 현상을 줄입니다.\\n*   **메모리 패턴(Memory Patt [mindscale](https://vertexaisearch.cloud.google.com/id/0-4)ern):** 에이전트가 과거의 상호작용 이력, 화면 상태, 사용자 입력 등을 저장하고 재활용하여 단기적인 문맥 유지와 장기적인 정교한 의사결정을 가능하게 합니다. 벡터 기반 메모리 구조와 파라메트릭 메모리를 결합한 하이브리드 방식이 주목받고 있습니다.\\n*   **동적 적응 패턴(Dynamic Adaptation Pattern):** 고급 전이 학습을 사용하여 관련 이전 경험에 따라 새로운 도메인에 빠르게 적응합니다.\\n*   **인간 참여 루프 패턴(Human-in [brunch](https://vertexaisearch.cloud.google.com/id/0-5) [velog](https://vertexaisearch.cloud.google.com/id/0-6) [tistory](https://vertexaisearch.cloud.google.com/id/0-7) [ibm](https://vertexaisearch.cloud.google.com/id/0-8) [tistory](https://vertexaisearch.cloud.google.com/id/0-9) [tistory](https://vertexaisearch.cloud.google.com/id/0-10)-the-Loop Pattern):** 인간의 피드백을 통해 에이전트의 행동과 결정을 개선하고 학습에 활용하는 체계가 중요합니다.\\n*   **오케스트레이션 레이어:** 에이전트가 정보를 수집하고, 내부 추론을 수행하 [mindscale](https://vertexaisearch.cloud.google.com/id/0-4) [tistory](https://vertexaisearch.cloud.google.com/id/0-7) [tistory](https://vertexaisearch.cloud.google.com/id/0-9) [tistory](https://vertexaisearch.cloud.google.com/id/0-10)며, 다음 행동 또는 결정을 내리는 과정을 관리하는 핵심 요소입니다.\\n\\n**4. 시스템 전반의 고려 사항**\\n에이전트 패턴 학습의 효과를 극대화하기 위해서는 시스템 전반의 고려 사항이 필수적입니다.\\n\\n*   **확장성:** 장기적으로 실행되는 동적 기업 프로세스를 위해 높은 확장성을 갖춘 인프라가 필요합니다.\\n*   **보안 및 신뢰:** AI 에이전트의 권한 및 역할 설정, ID 및 액세스 관리(IAM) 시 [mindscale](https://vertexaisearch.cloud.google.com/id/0-4) [velog](https://vertexaisearch.cloud.google.com/id/0-6)스템과의 통합, 제로 트러스트 아키텍처 적용, 평판 시스템을 통한 에이전트 검증 등이 중요합니다. 모든 에이전트 동작 및 결정에 대한 감사 추적 모니터링도 필수적입니다.\\n*   **자원 효율성:** 컴퓨팅 및 메모리 요구 사항을 고려해야 합니다.\\n*   **오류 처리:** 예상치 못한 상황 및 경계 케이스를 관리하는 능력이 중요합니다.\\n*   **통합:** 서로 다른 패턴들이 효과적으로 함께 작동할 수 있도록 통합하는 것이 중요합니다.\\n\\n결론적으로, 에이전트 패턴 학습의 효과적인 전략은 단일 에이전트의 지능을 향상시키는 다양한 디 [brunch](https://vertexaisearch.cloud.google.com/id/0-5) [tistory](https://vertexaisearch.cloud.google.com/id/0-7)자인 패턴과 함께, 여러 에이전트가 협력하고 분산 학습을 수행하는 다중 에이전트 시스템의 구축을 포함합니다. 강화 학습은 이러한 에이전트들이 환경과 상호작용하며 최적의 행동을 학습하는 핵심 메커니즘으로 작용하며, 최신 동향은 자율성, 적응성, 그리고 인간-AI 협업 모델의 진화를 강조하고 있습니다.  [tistory](https://vertexaisearch.cloud.google.com/id/0-9)[explainx](https://vertexaisearch.cloud.google.com/id/0-13) [explainx](https://vertexaisearch.cloud.google.com/id/0-13) [explainx](https://vertexaisearch.cloud.google.com/id/0-13) [automationanywhere](https://vertexaisearch.cloud.google.c [aisparkup](https://vertexaisearch.cloud.google.com/id/0-11) [goover](https://vertexaisearch.cloud.google.com/id/0-12) [explainx](https://vertexaisearch.cloud.google.com/id/0-13) [modulabs](https://vertexaisearch.cloud.google.com/id/0-14)om/id/0-2) [automationanywhere](https://vertexaisearch.cloud.google.com/id/0-2) [automationanywhere](https://vertexaisearch.cloud.google.com/id/0-2) [google](https://vertexaisearch.cloud.google.com/ [hunihub](https://vertexaisearch.cloud.google.com/id/0-3) [explainx](https://vertexaisearch.cloud.google.com/id/0-13) [wishket](https://vertexaisearch.cloud.google.com/id/0-15)id/0-1) [tistory](https://vertexaisearch.cloud.google.com/id/0-20) [explainx](https://vertexaisearch.cloud.google.com/id/0-13) [modulabs](https://vertexaisearch.cloud.google.com/id/0-14) [tistory](https://vertexaisearch.cloud.google.com/id/0-20) [dfinite](https://verte [aisparkup](https://vertexaisearch.cloud.google.com/id/0-11) [explainx](https://vertexaisearch.cloud.google.com/id/0-13) [brunch](https://vertexaisearch.cloud.google.com/id/0-16) [modulabs](https://vertexaisearch.cloud.google.com/id/0-14) [wishket](https://vertexaisearch.cloud.google.com/id/0-15) [slashpage](https://vertexaisearch.cloud.google.com/id/0-17)xaisearch.cloud.google.com/id/0-18) [slashpage](https://vertexaisearch.cloud.google.com/id/0-17) [aisparkup](https://vertexaisearch.cloud.google.com/id/0-11) [slashpage](https://vertexaisearch.cloud.google [hunihub](https://vertexaisearch.cloud.google.com/id/0-3) [explainx](https://vertexaisearch.cloud.google.com/id/0-13) [modulabs](https://vertexaisearch.cloud.google.com/id/0-14) [slashpage](https://vertexaisearch.cloud.google.com/id/0-17).com/id/0-17) [enhans](https://vertexaisearch.cloud.google.com/id/0-19) [dfinite](https://vertexaisearch.cloud.google.com/id/0-18) [brunch](https://vertexaisearch.cloud.google.com/id/0-16) [enhans](https://vertexaisearch.cloud.google.com/id/0-19) [s [aisparkup](https://vertexaisearch.cloud.google.com/id/0-11) [explainx](https://vertexaisearch.cloud.google.com/id/0-13) [slashpage](https://vertexaisearch.cloud.google.com/id/0-17)lashpage](https://vertexaisearch.cloud.google.com/id/0-17) [goover](https://vertexaisearch.cloud.google.com/id/0-12) [brunch](https://vertexaisearch.cloud.google.com/id/0-16) [slashpage](https://vertexaisearch.cloud.google.com/id/0-17)\",\n",
       "  '매일 3챕터 공부 습관을 효과적으로 유지하기 위해서는 명확한 목표 설정, 체계적인 루틴 구축, 동기 부여 전략, 그리고 어려움 극복 방안을 종합적으로 활용하는 것이 중요합니다. 다음은 최신 정보를 바탕으로 한 구체적인 유지 방법입니다.\\n\\n**1. 명확하고 구체적인 목표 설정 및 관리**\\n매일 3챕터 공부라는 목표를 달성하기 위해서는 단순히 \"열심히 공부해야지\"와 같은 막연한 생각보다는 구체적이고 측정 가능한 목표를 세워야 합니다.\\n\\n*   **SMART 목표 설정:** 목표는 구체적(Specific), 측정 가능(Measurable), 달성 가능(Achievable), 관련성(Relevant), 시간 제한(Time-bound)이 있어야 합니다. 예를 들어, \"3개월 안에 토익 800점을 얻겠다\"와 같이 명확한 목표를 설정하는 것이 효과적입니다.\\n*   **작은 목표로 나누기:** 큰 목표를 \"매일 3챕터 읽기\"와 같이 작은 단계로 나누면 성취감을 느끼기 쉽고, 꾸준함을 유지하는 데 도움이 됩니다.\\n*   **목표의 이유 명확화:** 왜 이 목표를 이루고 싶은지 스스로 명확히 인식하고, 목표 달성 시의 모습을 자주 상상하며  [tistory](https://vertexaisearch.cloud.google.com/id/1-0) [tistory](https://vertexaisearch.cloud.google.com/id/1-1) [tistory](https://vertexaisearch.cloud.google.com/id/1-2) [tistory](https://vertexaisearch.cloud.google.com/id/1-3) [pagecall](https://vertexaisearch.cloud.google.com/id/1-4)동기를 부여해야 합니다.\\n\\n**2. 체계적인 루틴 및 환경 구축**\\n공부 습관은 의지력에만 의존하기보다, 자동화된 루틴과 최적화된 환경을 통해 자연스럽게 형성됩니다.\\n\\n*   **규칙적인 스케줄:** 매일 같은 시간에 공부하는 습관을 들이면 뇌가 그 시간에 집중할 준비를 하게 됩니다. 기상 시간과 수면 시간을 고정하여 하루의 리듬을 일정하게 유지하는 것이 중요합니다.\\n*   **고정된 공부 장소:** 공부할 때는 방해 요소를 최소화할 수 있는 조용한 공간을 찾고, 스마트폰은 멀리 두는 것이 좋습니다. 집에서 공부할 경우 책상 위에 필요한 것만 두고, 타이머  [tistory](https://vertexaisearch.cloud.google.com/id/1-2) [comingsoonkorea](https://vertexaisearch.cloud.google.com/id/1-5)앱 등을 활용할 수 있습니다.\\n*   **공부 시작 신호 만들기:** 물 한 잔 마시기, 책상 정리, 타이머 설정 등 공부 시작 전의 행동을 고정하면 뇌가 \\'이제 공부할 시간\\'이라는 신호로 인식하여 자연스럽게 집중 모드로 전환됩니다.\\n*   **포모도로 기법 활용:** 25분 공부 후 5분 휴식과 같이 짧은 집중 시간 단위로 계획을 짜면 피로  [tistory](https://vertexaisearch.cloud.google.com/id/1-6) [reddit](https://vertexaisearch.cloud.google.com/id/1-7) [sangseek](https://vertexaisearch.cloud.google.com/id/1-8) [tistory](https://vertexaisearch.cloud.google.com/id/1-3) [pagecall](https://vertexaisearch.cloud.google.com/id/1-4)누적을 줄이고 집중력 유지가 가능합니다.\\n\\n**3. 동기 부여 및 보상 전략**\\n공부를 지속하기 위해서는 동기 부여를 유지하고, 작은 성과에 대한 보상을 통해 긍정적인 경험을 쌓는 것이 중요합니다.\\n\\n*   **작은 성공 경험 기록:** 공부한 내용을 체크리스트나 달력에 표시하여 시각적으로 성취감을 느끼고, 자신의 발전을 확인하며 동기를 강화할 [tistory](https://vertexaisearch.cloud.google.com/id/1-0) [tistory](https://vertexaisearch.cloud.google.com/id/1-9) [tistory](https://vertexaisearch.cloud.google.com/id/1-2) [pagecall](https://vertexaisearch.cloud.google.com/id/1-4) 수 있습니다.\\n*   **자기 보상 시스템:** 목표를 달성했을 때 잠시 휴식을 취하거나, 좋아하는 활동을 하는 등 스스로에게 작은 보상을 주는 것이 꾸준함을 유지하는 데 효과적입니다.\\n*   **긍정적인 마인드셋:** 완벽한 하루보다 \\'성공한 흐름\\'을 만드는 데 집중하고, 하루 계획을 다 지키지 못했더라도 좌절하지 않고 계속  [brunch](https://vertexaisearch.cloud.google.com/id/1-10) [tistory](https://vertexaisearch.cloud.google.com/id/1-11) [tistory](https://vertexaisearch.cloud.google.com/id/1-3) [network-rich](https://vertexaisearch.cloud.google.com/id/1-12)이어가는 태도가 중요합니다.\\n\\n**4. 어려움 극복 및 지속성 유지**\\n공부 습관을 유지하는 과정에서 슬럼프나 어려움이 발생할 수 있습니다. 이때 효과적으로 대처하는 전략이 필요합니다.\\n\\n*   **실패 복귀 루틴:** 하루 공부를 못했을 경우 다음 날은 10분만이라 [tistory](https://vertexaisearch.cloud.google.com/id/1-6) [reddit](https://vertexaisearch.cloud.google.com/id/1-7) [tistory](https://vertexaisearch.cloud.google.com/id/1-13) [tistory](https://vertexaisearch.cloud.google.com/id/1-14) [tistory](https://vertexaisearch.cloud.google.com/id/1-3) [tistory](https://vertexaisearch.cloud.google.com/id/1-15)도 책상에 앉는 것처럼, 실패했을 때 어떻게 복귀할지를 미리 정해두는 것이 습관 유지에 핵심이 됩니다.\\n*   **점진적인 공부량 증가:** 처음부터 너무 많은 양을 목표로 하기보다, 매일 10분이라도 좋으니  [tistory](https://vertexaisearch.cloud.google.com/id/1-14)짧게라도 규칙적으로 공부하는 습관을 들이고 점차 시간을 늘려가는 것이 중요합니다.\\n*   **복습의 중요성:** 효율적인 학습을 위해서는 평소에 복습하는 습관을 가져야 합니다. 공부한 직후 3분 동안 스스로에게 퀴즈를 내보는 짧은 피드백 루틴은 기억력 향상에 도움이 됩니다.\\n*   **스트레스 관리:** [tistory](https://vertexaisearch.cloud.google.com/id/1-6) [brunch](https://vertexaisearch.cloud.google.com/id/1-10) [tistory](https://vertexaisearch.cloud.google.com/id/1-13) [sangseek](https://vertexaisearch.cloud.google.com/id/1-8) [tistory](https://vertexaisearch.cloud.google.com/id/1-2) [tistory](https://vertexaisearch.cloud.google.com/id/1-3) [samwell](https://vertexaisearch.cloud.google.com/id/1-16) [21erick](https://vertexaisearch.cloud.google.com/id/1-17) 스트레스가 많을 때는 명상, 산책, 가벼운 운동 등으로 마음을 안정시키고, 무리하지 않고 잠시 휴식을 갖는 것이 오히려 공부 지속에 도움이 됩니다.\\n\\n**5. 효율적인 학습 기술 활용**\\n공부 습관 자체의 [tistory](https://vertexaisearch.cloud.google.com/id/1-13) 유지 외에도, 학습의 효율성을 높이는 기술을 활용하면 3챕터 공부를 더욱 수월하게 만들 수 있습니다.\\n\\n*   **\\'가르치듯이\\' 공부하기:** 누군가에게 개념을 설명하는 과정에서 본인의 이해가 부족한 부분이 자연스럽게 드러나며, 학습 효과를 높일 수 있습니다.\\n*   **요약 및 개요 작성:** 일정 분량의 공부를 마친 후 한 문장 또는 한 문단으로 요약하는 과정은 지식을 종합하고 분석하는 능력을 길러줍니다.\\n*   **자투리 시간 활용:** 평상시 자투리 [tistory](https://vertexaisearch.cloud.google.com/id/1-18) [tistory](https://vertexaisearch.cloud.google.com/id/1-11) [network-rich](https://vertexaisearch.cloud.google.com/id/1-12) 시간을 활용하여 간단한 예습 및 복습, 과제 구상 등을 할 수 있습니다.\\n\\n이러한 전략들을 통해 \\'매일 3챕터 공부\\'라는 목표를 꾸준히 실천하고, 장기적인 학습 습관으로 정착시킬 수 있습니다. [qyndora](https://vertexaisearch.cloud.google.com/id/1-24) [tistory](https://v [sangseek](https://vertexaisearch.cloud.google.com/id/1-8) [tistory](https://vertexaisearch.cloud.google.com/id/1-14) [comingsoonkorea](https://vertexaisearch.cloud.google.com/id/1-5) [tistory](https://vertexaisearch.cloud.google.com/id/1-19)ertexaisearch.cloud.google.com/id/1-3) [kiu](https://vertexaisearch.cloud.google.com/id/1-23) [kiu](https://vertexaisearch.cloud.google.com/id/1-23) [samwell](https://vertexaisearch.cloud.google.com/id/ [tistory](https://vertexaisearch.cloud.google.com/id/1-0) [tistory](https://vertexaisearch.cloud.google.com/id/1-9) [sangseek](https://vertexaisearch.cloud.google.com/id/1-8) [tistory](https://vertexaisearch.cloud.google.com/id/1-1) [tistory](https://vertexaisearch.cloud.google.com/id/1-20) [tistory](https://vertexaisearch.cloud.google.com/id/1-2) [tistory](https://vertexaisearch.cloud.google.com/id/1-3) [pagecall](https://vertexaisearch.cloud.google.com/id/1-4)1-16) [21erick](https://vertexaisearch.cloud.google.com/id/1-17) [sangseek](https://vertexaisearch.cloud.google.com/id/1-8) [network-rich](https://vertexaisearch.cloud.google.com/id/1-12) [kiu](https://vertexais [tistory](https://vertexaisearch.cloud.google.com/id/1-0) [tistory](https://vertexaisearch.cloud.google.com/id/1-14) [tistory](https://vertexaisearch.cloud.google.com/id/1-3)earch.cloud.google.com/id/1-23) [sangseek](https://vertexaisearch.cloud.google.com/id/1-8) [tistory](https://vertexaisearch.cloud.google.com/id/1-20) [youtube](https://vertexaisearch.cloud.google.com/id/1-22) [network-rich [sangseek](https://vertexaisearch.cloud.google.com/id/1-8) [tistory](https://vertexaisearch.cloud.google.com/id/1-20) [tistory](https://vertexaisearch.cloud.google.com/id/1-2) [imfreelife](https://vertexaisearch.cloud.google.com/id/1-21) [pagecall](https://vertexaisearch.cloud.google.com/id/1-4)](https://vertexaisearch.cloud.google.com/id/1-12) [tistory](https://vertexaisearch.cloud.google.com/id/1-0) [sangseek](https://vertexaisearch.cloud.google.com/id/1-8) [tistory](https://vertexaisearch.cloud.google.com/id/1 [tistory](https://vertexaisearch.cloud.google.com/id/1-0) [tistory](https://vertexaisearch.cloud.google.com/id/1-14)-20)',\n",
       "  '에이전트 패턴의 이론적 학습을 실제 코딩 프로젝트와 통합하기 위한 단계별 가이드는 다음과 같습니다.\\n\\n**1. 에이전트 지향 프로그래밍(AOP) 및 에이전트 설계 패턴의 기본 이해**\\n\\n*   **이론적 이해:** 에이전트 지향 프로그래밍(AOP)은 객체 지향 프로그래밍과 달리 자율 에이전트를 현대 애플리케이션의 핵심에 둡니다. 에이전트는 환경을 인지하고, 독립적인 결정을 내리며, 목표 달성을 위해 적극적으로 협력할 [smythos](https://vertexaisearch.cloud.google.com/id/4-0) [smythos](https://vertexaisearch.cloud.google.com/id/4-1) 수 있는 지능형 소프트웨어 엔티티입니다. 에이전트의 핵심 특징은 자율성, 능동성, 사회성, 반응성입니다. 에이전트의 상태는 신념(beliefs), 결정(decisions), 능력(capabilities), 의무(obligations)와 같은 구성 요소로 이루어진 \\'정신 상태(mental state)\\'로 구성됩니다.\\n*   **주요 에이전트 설계 패턴:**\\n    *   **ReAct 패턴 (Reason and Act):** 에이전트가 추론(정보 분석 및 격차 식별), 행동(도구 실행 또는 쿼리), 관찰(결과 평가 및 다음 단계 결정) 단계를 번갈아 수행하는 명시적인 추론 루프를 구성합니다.\\n    *   **반영(Reflection) 패턴:** 에이전트가 자신의 출력을 비판하고 반복적으로 개선하는 피드백 루프를 도입합니다. 이는 자체 수정 루프를 사용하여 정확도를 높이고 더 스마트하고 신뢰할 수 있는 결정을 내립니다.\\n    *   **계획(Planning) 패턴:** 에이전트가 실행 전에 복잡한 작업을 구조화된 로드맵으로 분해합니다. 이는 요구 사항을 분석하고, 하위 작업 간의 종속성을 식별하며, 논리적 순서로 작업을 배열합니다.\\n    *   **도구 사용(Tool Use) 패턴:** 에이전트가 외부 시스템과 상호 작용하기 위해 함수를 [smythos](https://vertexaisearch.cloud.google.com/id/4-0) [wikipedia](https://vertexaisearch.cloud.google.com/id/4-2) [medium](https://vertexaisearch.cloud.google.com/id/4-3) [smythos](https://vertexaisearch.cloud.google.com/id/4-1) 활용하여 정보를 수집하거나, 작업을 수행하거나, 데이터를 조작할 수 있도록 합니다.\\n    *   **다중 에이전트(Multi-Agent) 협업 패턴:** 여러 에이전트가 복잡한 작업을 공동으로 수행하도록 조정하는 데 중점을 둡니다. 이는 에이전트 전문화 및 병렬 처리를 활용합니다.\\n    *   **프롬프트 체이닝(Prompt Chaining):** 하나의 LLM 호출의 출력이 다음 LLM 호출의 입력으로 순차적으로 전달되어 작업을 고정된 단계 시퀀스로 분해합니다.\\n    *   **라우팅(Routing) 또는 핸드오프(Handoff):** [scribd](https://vertexaisearch.cloud.google.com/id/4-4) [machinelearningmastery](https://vertexaisearch.cloud.google.com/id/4-5) [medium](https://vertexaisearch.cloud.google.com/id/4-6) 특정 작업에 가장 적합한 에이전트 또는 워크플로로 요청을 지능적으로 전달합니다.\\n    *   **병렬화(Parallelization):** 여러 LLM 호출을 동시에 실행하여 작업을 가속화하거나 다양한 관점을 탐색합니다.\\n\\n**2. 적절한 에이전트 프레임워크 또는 언어 선택**\\n\\n*   **JADE (Java Agent Development Framework):** FIPA(Foundation for Intelligent Physical Agents)를 준수하는 플랫폼으로, 다중 에이전트 시스템 구축 및 [scribd](https://vertexaisearch.cloud.google.com/id/4-4) [projectpro](https://vertexaisearch.cloud.google.com/id/4-7) [medium](https://vertexaisearch.cloud.google.com/id/4-8) [philschmid](https://vertexaisearch.cloud.google.com/id/4-9) [machinelearningmastery](https://vertexaisearch.cloud.google.com/id/4-5) [youtube](https://vertexaisearch.cloud.google.com/id/4-10) [youtube](https://vertexaisearch.cloud.google.com/id/4-11) 관리를 위한 포괄적인 도구 모음을 제공합니다. Java 기반 아키텍처는 원활한 에이전트 통신, 수명 주기 관리 및 분산 컴퓨팅 기능을 가능하게 합니다.\\n*   **AgentSpeak (Jason):** 논리 프로그래밍 및 BDI(Belief-Desire-Intention) 아키텍처를 기반으로 하는 에이전트 지향 프로그래밍 언어입니다. 복잡한 추론 및 의사 결정 기능이 필요한 시나리오에 탁월합니다.\\n*   **PADE (Python Agent DEvelopment fram [medium](https://vertexaisearch.cloud.google.com/id/4-12) [projectpro](https://vertexaisearch.cloud.google.com/id/4-7) [medium](https://vertexaisearch.cloud.google.com/id/4-8) [philschmid](https://vertexaisearch.cloud.google.com/id/4-9) [machinelearningmastery](https://vertexaisearch.cloud.google.com/id/4-5)ework):** Python 애호가를 위한 현대적이고 접근하기 쉬운 에이전트 지향 프로그래밍 진입점입니다. FIPA 및 ACL(Agent Communication Language) 표준을 준수하며 Python의 광범위한 생태계를 활용합니다.\\n*   **Langgraph:** 다중 에이전트 아키텍처와 밀접하게 관련된 아키텍처로, 에이전트 통신, 에이전트 상태 관리 및 에이전트 조정을 위한 강력한 추상화 도구를 제 [scribd](https://vertexaisearch.cloud.google.com/id/4-4) [medium](https://vertexaisearch.cloud.google.com/id/4-12) [medium](https://vertexaisearch.cloud.google.com/id/4-8) [philschmid](https://vertexaisearch.cloud.google.com/id/4-9) [medium](https://vertexaisearch.cloud.google.com/id/4-6)공합니다.\\n*   **OpenAI Agents SDK:** OpenAI 모델을 사용하여 에이전트를 구축하고, 추론 및 행동 루프를 코드에 적용하는 데 도움을 줍니다.\\n\\n**3. 간단한 프로젝트와 단일 에이전트로 시작**\\n\\n*   가장 간단한 솔루션부터 시작하고 점진적으로 복잡성을 추가하는 것이 중요합니다. 문제 해결에 필요한 정확한 단계를 알고 있다면 고정된 워크플로 또는 간단한 스크립트가 에이전트보다 더 효율적일 수 있습 [scribd](https://vertexaisearch.cloud.google.com/id/4-4) [medium](https://vertexaisearch.cloud.google.com/id/4-12) [mongodb](https://vertexaisearch.cloud.google.com/id/4-13) [projectpro](https://vertexaisearch.cloud.google.com/id/4-7) [medium](https://vertexaisearch.cloud.google.com/id/4-8) [philschmid](https://vertexaisearch.cloud.google.com/id/4-9)니다.\\n*   단일 에이전트 시스템은 여러 LLM 호출을 조정하여 들어오는 요청을 처리하는 하나의 조정된 논리 흐름을 특징으로 합니다.\\n\\n**4. 핵심 에이전트 기능 구현**\\n\\n*   **에이전트의 \\'정신 상태\\' 정의:** 에이전트의 신념 시스템은 환경에 대한 이해를 나타내는 기초입니다. 에이전트는 센서와 다른 에이전트와의 통신을 통해 환경과 상호 작용하면서 이러한 신 [philschmid](https://vertexaisearch.cloud.google.com/id/4-9) [youtube](https://vertexaisearch.cloud.google.com/id/4-14) [anthropic](https://vertexaisearch.cloud.google.com/id/4-15)념을 업데이트합니다.\\n*   **도구 사용:** 에이전트는 외부 시스템과 상호 작용하기 위한 다양한 도구에 접근할 수 있으며, 필요에 따라 적절한 도구를 동적으로 선택합니다.\\n*   **추론 및 계획:** 에이전트는 LLM을 활용하여 워크플로 실행을 관리하고 결정을 내립니다. 워크플로가 완료되었음을 인식하고 필 [philschmid](https://vertexaisearch.cloud.google.com/id/4-9) [youtube](https://vertexaisearch.cloud.google.com/id/4-14)요할 경우 자신의 행동을 사전에 수정할 수 있습니다.\\n*   **통신:** 에이전트 프로그램에는 다른 에이전트와 통신하기 위한 기본 요소가 포함됩니다.\\n\\n**5. 에이전트 설계 패턴 점진적으로 적용**\\n\\n*   **ReAct 패턴 구현:** 에이전트가 \"생각하고, 행동 [philschmid](https://vertexaisearch.cloud.google.com/id/4-9) [youtube](https://vertexaisearch.cloud.google.com/id/4-14) [anthropic](https://vertexaisearch.cloud.google.com/id/4-15)하고, 관찰하는\" 루프를 따르도록 합니다. 이는 에이전트가 다음 작업을 수행할 방법을 추론하고, 사용 가능한 도구를 사 [smythos](https://vertexaisearch.cloud.google.com/id/4-0) [wikipedia](https://vertexaisearch.cloud.google.com/id/4-2) [smythos](https://vertexaisearch.cloud.google.com/id/4-1)용하여 행동하며, 결과를 관찰하고, 문제가 해결될 때까지 반복하도록 합니다.\\n*   **반영 패턴 도입:** 에이전트가 자신의 출력을 비판하고 반복적으로 개선하도록 합니다. 이는 초기 LLM이 응답을 생성한 다음, 두 번째 LLM 단계(또는 다른 프롬프트를 가진 동일한 LLM)가 평가자 역할을 하여 초기 출력을 비판하고, 이 피드백을 다시 LLM에 제공하여 개선된 출력을 생성하도록 합니다.\\n*   **계획 패턴 적용:** 복잡한 작업을 계획, 코딩, 테스트, 문서화와 같은 하위 작업으로 분해합니다.\\n*   **다중 에이전트 협업:** 콘텐츠 생성, 일정 관리, 분석 등과 같은 마케팅 워크플로를 위해 여러 에이전트를 조정합니다.\\n*   **다른 패턴:** 프롬프트 [smythos](https://vertexaisearch.cloud.google.com/id/4-0) [wikipedia](https://vertexaisearch.cloud.google.com/id/4-2) [smythos](https://vertexaisearch.cloud.google.com/id/4-1) 체이닝, 라우팅, 병렬화와 같은 패턴을 필요에 따라 통합합니다.\\n\\n**6. 개발 및 평가를 위한 모범 사례**\\n\\n*   **명확한 지침 및 프롬프트:** 모호성을 줄이고 에이전트의 의사 결정을 개선하기 위해 명확한 지침을 사용합니다. 에이전트가 필요한 도구와 컨텍스트만 제공하고, 모순된 지침이나 주의를 산만하게 하는 정보를 피합니다.\\n*   **로깅 및 관찰 가능성:** 각 사용자 요청, 에이전트 계획 및 도구 호출에 대한 자세한 로깅을 구현합니다.\\n*   ** [smythos](https://vertexaisearch.cloud.google.com/id/4-0) [wikipedia](https://vertexaisearch.cloud.google.com/id/4-2) [smythos](https://vertexaisearch.cloud.google.com/id/4-1)오류 처리 및 대체 논리:** 도구 또는 LLM 오류에 대비하여 계획합니다. 재시도 전략, 대체 논리 또는 고급 기능이 실패할 경우 더 간단한 대체 체인을 포함합니다.\\n*   **반복적인 프롬프트 엔지니어링 및 테스트:** 시간이 지남에 따라 프롬프트 및 체인 논리를 개선할 것으로 예상합니다. 각 변경 사항을 버전 관리하여 롤백하거나 버전 간 성능을 비교할 수 있도록 합니다.\\n*   **단순하게 시작하고 점진적으로 복잡성 추가:** 가장 간단한 솔루션부터 시작하고, 포괄적인 평가를 통해 최적화하며, 더 간단한 솔 [smythos](https://vertexaisearch.cloud.google.com/id/4-1)루션이 부족할 때만 다단계 에이전트 시스템을 추가합니다.\\n\\n**실제 적용 사례**\\n\\n*   **자율 주행 차량:** 센서 데이터를 처리하고, 장애물을 감지하며, 실시간으로 탐색 및 의사 결정을 처리하는 여러 전문 에이전트를 배포합니다.\\n*   **스마트 그리드 관리:** 에너지 자원 에이전트가 서로 통신하여 스마트 그리드 내에서 공급/수요 균형의 합의점에 도달합니다.\\n*   **전자 상거래 개인화: [medium](https://vertexaisearch.cloud.google.com/id/4-3)** 사용자 행동에 따라 항목을 추천하는 에이전트를 활용합니다.\\n*   **지능형 튜터링 시스템:** 개인화된 학습 경험을 제공하기 위해 여러 전문 에이전트를 배포합니다.\\n*   **로봇 공학:** 변화하는 생산 요구 사항에 적응하는 제조 로봇이나 위험한 환경에서 즉각적인 결정을 내릴 수 있 [medium](https://vertexaisearch.cloud.google.com/id/4-6)는 수색 및 구조 로봇에 적용됩니다.\\n*   **코드 생성 및 디버깅:** 에이전트가 테스트 결과를 피드백으로  [openai](https://vertexaisearch.cloud.google.com/id/4-16) [databricks](https://vertexaisearch.cloud.google.com/id/4-17) [mongodb](https://vertexaisearch.cloud.google.com/id/4-13) [philschmid](https://vertexaisearch.cloud.google.com/id/4-9) [anthropic](https://vertexaisearch.cloud.google.com/id/4-15) [machinelearningmastery](https://vertexaisearch.cloud.google.com/id/4-5)사용하여 솔루션을 반복하고, 복잡한 코딩 작업을 계획, 코딩, 테스트, 문서화와 같은 하위 작업으로 분해합니다. [philschmid](https://vertexaisearch.cloud.google.com/id/4-9) [anthropic](https://vertexaisearch.cloud.google.com/id/4-15) [machinelearningmastery](https://vertexaisearch.cloud.google.com/id/4-5) [smythos](https://vertexaisearch.cl [databricks](https://vertexaisearch.cloud.google.com/id/4-17) [philschmid](https://vertexaisearch.cloud.google.com/id/4-9) [anthropic](https://vertexaisearch.cloud.google.com/id/4-15) [machinelearningmastery](https://vertexaisearch.cloud.google.com/id/4-5)oud.google.com/id/4-1) [smythos](https://vertexaisearch.cloud.google.com/id/4-1) [medium](https://vertexaisearch.cloud.google.com/id/4-3) [medium](https://vertexaisearc [databricks](https://vertexaisearch.cloud.google.com/id/4-17) [mongodb](https://vertexaisearch.cloud.google.com/id/4-13)h.cloud.google.com/id/4-3) [smythos](htt [smythos](https://vertexaisearch.cloud.google.com/id/4-1) [openai](https://vertexaisearch.cloud.google.com/id/4-16) [medium](https://vertexaisearch.cloud.google.com/id/4-8) [anthropic](https://vertexaisearch.cloud.google.com/id/4-15)ps://vertexaisearch.cloud.google.com/id/4-0) [smythos](https://vertexaisearch.cloud.google.com/id/4-0) [medium](https://vertexaisearch.cloud.google.com/id/4-3) [smythos](https://vertexaisearch.cloud.google.com/id/4-1) [anthropic](https://vertexaisearch.cloud.google.com/id/4-15) [databrick [smythos](https://vertexaisearch.cloud.google.com/id/4-1)s](https://vertexaisearch.cloud.google.com/id/4-17) [anthropic](https://vertexaisearch.cloud.google.com/id/4-15) [machinelearningmastery](https://vertexaisearch.cloud.google.com/id/4-5) [databricks] [openai](https://vertexaisearch.cloud.google.com/id/4-16) [medium](https://vertexaisearch.cloud.google.com/id/4-8) [anthropic](https://vertexaisearch.cloud.google.com/id/4-15)(https://vertexaisearch.cloud.google.com/id/4-17) [databricks](https://vertexaisearch.cloud.google.com/id/4-17) [databricks](https://vertexaisearch.cloud.google.com/id/4-17) [openai](https://vertexaisearch.cloud.google.com/id/4-16) [databricks](h [openai](https://vertexaisearch.cloud.google.com/id/4-16) [medium](https://vertexaisearch.cloud.google.com/id/4-8) [anthropic](https://vertexaisearch.cloud.google.com/id/4-15)ttps://vertexaisearch.cloud.google.com/id/4-17) [openai](https://vertexaisearch.cloud.google.com/id/4-16) [databricks](https: [wikipedia](https://vertexaisearch.cloud.google.com/id/4-2) [medium](https://vertexaisearch.cloud.google.com/id/4-3)//vertexaisearch.cloud.google.com/id/4-17) [philschmid]( [scribd](https://vertexaisearch.cloud.google.com/id/4-4) [databricks](https://vertexaisearch.cloud.google.com/id/4-17) [philschmid](https://vertexaisearch.cloud.google.com/id/4-9) [anthropic](https://vertexaisearch.cloud.google.com/id/4-15) [machinelearningmastery](https://vertexaisearch.cloud.google.com/id/4-5)https://vertexaisearch.cloud.google.com/id/4-9) [anthropic](https://vertexaisearch.cloud.google.com/id/4-15) [machinelearningmastery](https://vertexaisearch.cloud.google.com/id/4-5) [philschmid](https://vertexaisearch.cloud.google.com/id/4-9) [youtube](https://vertexaisearch.cloud.google.com/id/4-14) [anthropic](https://vertexaisear [scribd](https://vertexaisearch.cloud.google.com/id/4-4) [machinelearningmastery](https://vertexaisearch.cloud.google.com/id/4-5) [medium](https://vertexaisearch.cloud.google.com/id/4-6)ch.cloud.google.com/id/4-15) [medium](https://vertexaisearch.cloud.google.com/id/4-12) [projectpro](https://vertexaisearch.cloud.google.com/id/4-7) [medium](https://vertexaisearch.cloud.google.com/id/4-8) [projectpro](https://vertexaisearch.cloud.google.com/id/4-7) [philschmid](https://vertexaisearch.cloud.google.com/id/4-9) [machinelearningmastery](https://vertexaisearch.cloud.google.com/id/4- [scribd](https://vertexaisearch.cloud.google.com/id/4-4) [projectpro](https://vertexaisearch.cloud.google.com/id/4-7) [medium](https://vertexaisearch.cloud.google.com/id/4-8) [philschmid](https://vertexaisearch.cloud.google.com/id/4-9) [machinelearningmastery](https://vertexaisearch.cloud.google.com/id/4-5) [youtube](https://vertexaisearch.cloud.google.com/id/4-10) [youtube](https://vertexaisearch.cloud.google.com/id/4-11)5)',\n",
       "  'AI 에이전트 패턴을 효과적으로 학습하기 위한 추천 학습 순서와 각 패턴별 적절한 시간 배분은 학습자의 사전 지식과 목표에 따라 달라질 수 있지만, 일반적으로 기초부터 심화까지 단계적으로 접근하는 것이 효과적입니다. 최신 정보를 바탕으로 한 추천 학습 순서와 시간 배분은 다음과 같습니다.\\n\\n**AI 에이전트 패턴 학습 추천 커리큘럼 및 시간 배분**\\n\\n**1. AI 에이전트 기초 및 핵심 구성 요소 이해 (예상 학습 시간: 1~2주)**\\nAI 에이전트 학습의 첫 단계는 에이전트의 기본 개념과 작동 원리를 이해하는 것입니다.\\n*   **AI 에이전트 정의 및 유형:** 단순 반사 에이전트, 모델 기반 반사 에이전트, 목표 기반 에이전트, 유틸리티 기반 에이전트, 학습 에이전트, 계층적 에이전트 등 다양한 에이전트 유형을 학습합니다.\\n*   **핵심 구성 요소:** 인식(Perception) 및 데이터 입력, 지식 표현(Knowledge Representation), 추론(Reasoning) 및 의사 결정, 학습(Learning) 및 적응성(Adaptability), 커뮤니케이션 및 상호 작용과 같은 AI 에이전트 아키텍처의 주요 구성 요소를 이해합니다.\\n*   **워크플로우 이해:** 전통적인 워크플로우(정해진 순서, 고정 규칙)와 AI 에이전트 워크플로우(계획-실행-피드백-조정)의 차이를 비교하며 에이전트의 지능적이고 유연한 작업 수행 방식을 배웁니다.\\n*   **선수 지식:** Python 및 객체 지향 프로그래밍(OOP)에 대한 탄탄한 이해가 필요하며, 머신러닝(지도 학습, 비지도 학습, 강화 학습)의 기본 개념을 아는 것이 도움이 됩니다.\\n\\n**2. 기본 AI 에이전트 디자인 패턴 학습 (예상 학습 시간: 1~2주)**\\n기초를 다진 후에는 AI 에이전트의 핵심적인 디자인 패턴을 학습하여 에이전트가 자율적으로 문제를 해결하는 방식을 이해합니다.\\n\\n*   **반 [skimai](https://vertexaisearch.cloud.google.com/id/5-0) [getguru](https://vertexaisearch.cloud.google.com/id/5-1) [tistory](https://vertexaisearch.cloud.google.com/id/5-2)사 패턴 (Reflection Pattern):** AI가 자신의 출력을 검토하고 오류를 찾아 수정하는 자기 평가(Self-Evaluation) 방식을 학습합니다. 이를 통해 에이전트가 점진적으로 더 나은 답변을 생성하도록 합니다.\\n    *   *시간 배분:* 3~5일\\n*   **도구 사용 패턴 (Tool Use Pattern):** AI 에이전트가 외부 도구(API, 검색 엔진, 데이터베이스, 계산기 등)를 활용하여 자신의 기본 기능을 넘어서는 복잡한 작업을 수행하는 능력을 학습합니다.\\n    *   *시간 배분:* 4~7일\\n\\n**3. 중급 AI 에이전트 [skimai](https://vertexaisearch.cloud.google.com/id/5-0) [getguru](https://vertexaisearch.cloud.google.com/id/5-1) [tistory](https://vertexaisearch.cloud.google.com/id/5-2) [youtube](https://vertexaisearch.cloud.google.com/id/5-3) 디자인 패턴 학습 (예상 학습 시간: 2~3주)**\\n더 복잡한 문제 해결을 위한 에이전트의 전략적 사고 방식을 다룹니다.\\n\\n*   **계획 패턴 (Planning Pattern):** AI가 문제를 한 번에 해결하는 것이 아니라, 문제를 세분화하고 계획을 세워 해결하는 방식을 학습합니다. 이는 큰 작업을 더 작고 관리 가능한 단위로 나누고, 각 하위 작업에 적합한 모델을 배정하는 것을 포함합니다.\\n    *   *시간 배분:* 1주\\n*   **학습 및 적응성 (Learni [dacon](https://vertexaisearch.cloud.google.com/id/5-4)ng & Adaptability):** 에이전트가 경험을 통해 지속적으로 발전하고 모델을 갱신하며 변화하는 환경에 유연하게 대처하는 방법을 심층적으로 학습합니다. 강화 학습(Reinforcement Learning) 개념이 중요하게 다루어집니다.\\n    *   *시간 배분:* 1~2주\\n\\n**4. 고급 AI 에이전트 디자인 패턴 및 아키텍처 (예상 학습 시간: 2~4주)**\\n여러 에이전트가 협력하거나 특정 고 [tldv](https://vertexaisearch.cloud.google.com/id/5-5) [skimai](https://vertexaisearch.cloud.google.com/id/5-0) [getguru](https://vertexaisearch.cloud.google.com/id/5-1)급 시나리오에 최적화된 패턴을 학습합니다.\\n\\n*   **다중 에이전트 협업/시스템 (Multi-Agent Collaboration/System):** 여러 AI 에이전트가 각자의 역할을 수행하며 협업하여 복잡한 문제를 해결하는 방식을 학습합니다.\\n    *   *시간 배분:* 1~2주\\n*   **하이브리드 아키텍처:** 규칙 기반 시스템과 머신러닝 기반 에이전트를 결합하는 등 다양한 에이전트 유형과 패턴을 통합하는 방법을 학습합니다.\\n    *   *시간 배분:* 3~5일\\n*   **특정 고급 패턴 (ReACT, CodeACT, Agentic RAG 등):** ReACT, CodeACT, Tool Use, Self-Reflection/Reflexion, Multi-Agent Workflow, Agentic RAG와 같은 주요 AI 에이전트 디자인 패턴의 핵심 개념, 작동 방식, 장단점 및 구체적인 적용 사례를 심층적으로 분석합니다.\\n    *   *시간 배분:* 각 패턴별 3~7일 (학습 깊이에 따라 조절)\\n\\n**5. 실습 및  [baruninfo](https://vertexaisearch.cloud.google.com/id/5-6) [modulabs](https://vertexaisearch.cloud.google.com/id/5-7) [brunch](https://vertexaisearch.cloud.google.com/id/5-8)프로젝트 (예상 학습 시간: 2~4주)**\\n이론 학습 후에는 실제 프로젝트를 통해 배운 지식을 적용하고 심화하는 과정이 필수적입니다.\\n\\n*   **프레임워크 활용:** LangChain, LangGraph, Crew AI, Google ADK 등 AI 에이전트 개발 프레임워크를 사용하여 실습 프로젝트를 진행합니다.\\n*   **배포 및 유지 관리:** AI 에이전트의 배포, 테스트, 유지 관리에 대한 실질적인 지식을 습득합니다.\\n*   **윤리 및 안전:** AI 에이전트 개발 시 고려해야 할 윤리적, 법적 [tistory](https://vertexaisearch.cloud.google.com/id/5-9) [modulabs](https://vertexaisearch.cloud.google.com/id/5-7) [brunch](https://vertexaisearch.cloud.google.com/id/5-8) [wishket](https://vertexaisearch.cloud.google.com/id/5-10) 고려사항, 보안 및 프라이버시 문제, 안전 및 윤리적 정렬에 대해 학습합니다.\\n\\n**총 학습 기간:** 위 커리큘럼은 약 8주에서 18주가 소요될 수 있으며, 이는 학습자의 배경 지식, 학습 속도, 각 주제에 대한 심층 학습 정도에 따라 유동적으로 조절될 수 있습니다. Udemy의 \"AI 에이전트: LangGraph로 자율 AI 에이전트 개발\"과 같은 중급 과정은 3시간 분량의 주문형 비디오를 제공하며, Microsoft Learn의 \"AI 에이전트 개발 소개\" 모듈은 약 15분으로 짧은 개요를 제공합니다. DACON의 \"AI 에이전트 첫걸음\" 과정은 3시간 8단계로 구성되어 있습니다. \"Agentic Design Patterns: 지능형 에이전트 시대를 위한 설계 패턴 가이드\"와 같은 전문 서적은 424페이지에 달하며 실습 기반 학습을 강조합니다.\\n\\n효과적인 학습을 위해서는 이론 학습과 함께 실제 코드를 작성하고 다양한 프레임워크를 경험해보는 실습 위주의 접근 방식이 중요합니다. [pytorch](https://vertexaisearch.cloud.googl [baruninfo](https://vertexaisearch.cloud.google.com/id/5-6) [modulabs](https://vertexaisearch.cloud.google.com/id/5-7) [wishket](https://vertexaisearch.cloud.google.com/id/5-10)e.com/id/5-12) [dacon](https://vertexaisearch.cloud.google.com/id/5-4) [microsoft](https://vertexaisearch.cloud.google.com/id/5-13) [tldv](https://vertexaisearch.cloud.google.com/id/5-5) [tistory](https://vertexaisearch.cloud.google.com/id/5-2) [youtube](https://vertexaisearch.cloud.google.com/id/5-3) [tldv](https://vertexaisearch.cloud.googl [skimai](https://vertexaisearch.cloud.google.com/id/5-0) [getguru](https://vertexaisearch.cloud.google.com/id/5-1) [tistory](https://vertexaisearch.cloud.google.com/id/5-2) [clickup](https://vertexaisearch.cloud.google.com/id/5-11)e.com/id/5-5) [pytorch](https://vertexaisearch.cloud.google.com/id/5-12) [brunch](https://vertexaisearch.cloud.google.com/id/5-8) [getguru](https://vertexaisearch.cloud.google.com/id/5-1) [tistory](https://vertexaisearch.cloud.google.com/id/5-2) [baruninfo](https://vertexaisearch.cloud.google.com/id/5-6) [tistory](https://vertexaisearch.cloud.google.com/id/5-9) [modulabs](https://vertexaisearch.cloud.google.com/id/5-7) [wishket](https://vertexaisearch.cloud.google.com/id/5-10) [youtube](https://vertexaisearch.cloud.google.com/id/5-3)',\n",
       "  'AI 에이전트 패턴(ReAct, RAG, 메모리 패턴)을 깊이 있게 이해하고 구현하는 데 도움이 되는 최고의 오픈소스 프로젝트, 튜토리얼 및 실습 플랫폼은 다음과 같습니다.\\n\\n**주요 프레임워크 및 라이브러리**\\n\\n1.  **LangChain 및 LangGraph**\\n    *   **설명:** LangChain은 ReAct, RAG 및 메모리 패턴을 포함한 다양한 LLM 기반 애플리케이션을 구축하기 위한 포괄적인 프레임워크입니다. LangGraph는 LangChain 생태계 내에서 에이전트의 추론 및 행동 루프를 명시적으로 정의하는 데 중점을 둔 전문 프레임워크입니다. 이는 복잡한 다단계 워크플로우와 상태 관리에 특히 유용합니다.\\n    *   **ReAct:** LangGraph는 ReAct(Reason + Act) 로직을 내장하여 LLM이 행동하기 전에 \"생각\"하도록 하여 추론 추적 및 작업별 작업을 단계별로 생성함으로써 성능을 향상시킵니다.\\n    *   **RAG:** LangChain은 문서 로더, 텍스트 분할기, 임베딩, 벡터 저장소 및 검색기를 포함한 RAG 구현을 위한 모듈식 구성 요소를 제공합니다.\\n    *   **메모리:** LangGraph의 `MemorySaver` 클래스는 체크포인터를 사용하여 에이전트에 단기 메모리를 추가하는 실용적인 방법을 제공하여 대화 기록을 유지하고 에이전트 동작을 디버깅하는 데 중요합니다.\\n    *   **튜토리얼/프로젝트:**\\n  [langchain](https://vertexaisearch.cloud.google.com/id/6-0) [sider](https://vertexaisearch.cloud.google.com/id/6-1) [coursera](https://vertexaisearch.cloud.google.com/id/6-2) [hexstream](https://vertexaisearch.cloud.google.com/id/6-3) [towardsai](https://vertexaisearch.cloud.google.com/id/6-4) [youtube](https://vertexaisearch.cloud.google.com/id/6-5)       *   **공식 LangChain 튜토리얼:** 핵심 개념, RAG 및 에이전트 구축을 위한 최신 모범 사례를 다룹니다.\\n        *   **\"Building Agentic RAG with LangGraph\"**: LangGraph를 사용하여 지능형 RAG 시스템을 구축하는 방법을 설명합니다.\\n        *   **\"Using LangChain ReAct Agents for Answ [medium](https://vertexaisearch.cloud.google.com/id/6-6) [medium](https://vertexaisearch.cloud.google.com/id/6-7) [hexstream](https://vertexaisearch.cloud.google.com/id/6-3)ering Multi-hop Questions in RAG Systems\"**: LangChain의 ReAct 에이전트 구현을 사용하여 다단계 질문에 답하는 방법을 보여줍니다.\\n        *   **\"How to add short-term memory to LangGraph ReAct agent\" (YouTube):** Lang [sider](https://vertexaisearch.cloud.google.com/id/6-1)Graph의 `MemorySaver` 클래스를 사용하여 ReAct 에이전트에 메모리를 추가하는 방법을 보여주는 실습 튜토리얼입니다.\\n\\n2.  **AutoGen (Microsoft)**\\n    *   **설명:** AutoGen은 확장 가능한 에이전트 시스템, 에이전트 간 통신 및 오케스트레이션을 위해 설계된 Microsoft의 오픈소스 다중 에이전트 프레임워크입니다.\\n    *   **RAG 및 메모리:** AutoGen은 `Memory` 프로토콜을 제공하며 `ListMemory [youtube](https://vertexaisearch.cloud.google.com/id/6-8) [hexstream](https://vertexaisearch.cloud.google.com/id/6-3) [youtube](https://vertexaisearch.cloud.google.com/id/6-5)` 및 `ChromaDBVectorMemory`와 같은 구현 예시를 통해 RAG 패턴 및 대화 컨텍스트를 위한 유용한 사실 저장소를 유지할 수 있습니다.\\n    *   **튜토리얼/프로젝트:**\\n        *   **\"Multi-agent RAG with AutoGen: Build locally with Gran [sider](https://vertexaisearch.cloud.google.com/id/6-1)ite\" (IBM):** AutoGen을 사용하여 에이전트 RAG를 로컬에서 구현하는 방법을 보여주는 튜토리얼입니다.\\n        *   **\"How I Use AutoGen With Retrieval Augmented Generation (RAG)\"**: Aut [medium](https://vertexaisearch.cloud.google.com/id/6-9)oGen으로 RAG를 사용하는 방법에 대한 단계별 가이드입니다.\\n        *   **\"Inside AutoGen: Chapter 6 — Memory\"**: AutoGen의 메모리 메커니즘에 대한 심층적인 이해를 제공합니다.\\n    *   **Microsoft Agent Framework:** AutoGen과 Semantic Kernel의 아이디어를 통합한 후속 오픈소 [medium](https://vertexaisearch.cloud.google.com/id/6-6)스 개발 키트입니다.\\n\\n3.  **LlamaIndex**\\n    *   **설명:** LlamaIndex는 RAG 파이프라인을 구축하기 위한 오픈소스 프레임워크로, 데이터 수집, 인덱싱, 쿼리 및 검색을 단순화하여 LLM이 특정 정보에 대해 추론할 수 있도록 합니다.\\n    *   **ReAct 및 메모리:** LlamaIndex는 쿼리 엔진 도구를 사용하는 ReAct 에이전트를 지원하며, 벡터 메모리, 구성 가능한 메모 [youtube](https://vertexaisearch.cloud.google.com/id/6-8)리, 상황별 메모리 등 다양한 메모리 유형을 제공합니다.\\n    *   **튜토리얼/프로젝트:**\\n        *   **\"LlamaIndex: The Complete Guide from Beginner to Advanced RAG Applications\"**: LlamaIndex의 RAG 기능에 중점을 둔 포괄적인 튜토리얼입니다.\\n        *   **\"ReAct Agent with Query Engine (RAG) Tool [github](https://vertexaisearch.cloud.google.com/id/6-10) [coursera](https://vertexaisearch.cloud.google.com/id/6-2) [medium](https://vertexaisearch.cloud.google.com/id/6-11)s\" (LlamaIndex 문서):** LlamaIndex에서 ReAct 에이전트를 설정하는 방법을 보여줍니다.\\n        *   **\"Advanced RAG Techniques with LlamaIndex\" (YouTube):** RAG 구현을 위한 고급 기술을 탐구합니다.\\n\\n**오픈소스 프로젝트 및 플랫폼**\\n\\n*   **Auto-GPT:** 자율적인 목표 실행 루프, 플러그인을 통한 도구 및 API 사용, 파일 및 웹 상호 작용, Redis 또는  [github](https://vertexaisearch.cloud.google.com/id/6-10) [stackademic](https://vertexaisearch.cloud.google.com/id/6-12)Pinecone과 같은 도구를 통한 메모리 기능을 갖춘 초기 바이럴 오픈소스 자율 에이전트입니다.\\n*   **AgentGPT:** 브라우저에서 직접 자율 에이전트를 구축하고 실행할 수 있는 사용하기 쉬운 웹 기반 인터페이스를 제공하며, 메모리 및 도구 구성 기능을 포함합니다.\\n*   **CrewAI:** 정의된 역할, 책임 및 협업을 통해 다중 에이전트 팀을 오케스트레이션하는 데 중점을 둡니다. LangChain 및 도구 [ibm](https://vertexaisearch.cloud.google.com/id/6-13)와 쉽게 통합되며 에이전트 간에 공유 메모리를 지원합니다.\\n*   **RAGFlow:** 신뢰할 수 있는 인용 및 다중 모드 처리를 제공하는 엔터프라이즈급 RAG 엔진으로, 복잡한 문서를 처리하도록 설계되었습니다.\\n*   **Mem0 / Letta (이전 MemGPT):** Mem0는  [plainenglish](https://vertexaisearch.cloud.google.com/id/6-14)이전 상호 작용에 적응할 수 있는 자체 개선 메모리 계층이며, Letta는 LLM 에이전트에 장기 메모리 및 도구 사용을 추가합니다.\\n*   **FlowithOS:** 계획, 도구 오케스트레이션 및 퍼스트 파티 메모리를 결합한 캔버스 우선 에이전트 플 [stackademic](https://vertexaisearch.cloud.google.com/id/6-12)랫폼으로, \"Knowledge Garden\"을 통해 구조화된 지식 검색을 지원합니다.\\n*   **Sim AI:** 복잡한 에이전트 워크플로우를 간단한 드래그 앤 드롭 시각적 블록으로 변환하는 시각적 AI 에이전트 구축 플랫폼입니다.\\n*   **Tra [microsoft](https://vertexaisearch.cloud.google.com/id/6-15)nsformer Lab:** 로컬에서 실행되는 오픈소스 애플리케이션으로, 드래그 앤 드롭 인터페이스를 통해 로컬 RAG 빌더를 포함한 LLM 및 Diffusion 엔지니어링을 위한 기능을 제공합니다.\\n*   **Awesome LLM Apps (GitHub):** OpenAI, Anthropic, Gemini 및 오픈소스 모델을 사용하는 AI 에이전트 및 RAG를 포함한 LLM 앱 컬렉션으로, 메모리 패턴에 대한 튜토리얼도 제공합니다.\\n\\n**추천 튜토리얼 및 실습 플 [medium](https://vertexaisearch.cloud.google.com/id/6-16) [meilisearch](https://vertexaisearch.cloud.google.com/id/6-17) [youtube](https://vertexaisearch.cloud.google.com/id/6-18)랫폼**\\n\\n*   **Coursera의 \"Building AI Agents and Agentic Workflows Specialization\" (IBM):** LangGraph를 사용하여 메모리, 반복, 조건부 로직 및 에이전트 RAG를 지원하는 에이전트 AI 시스템을 구축하는 방법을 배울 수 있습니다. 또한 CrewAI를 사용한 다중 에이전트 시스템 및 ReAct 아키텍처를 다루며 실습 랩을 포함합니다.\\n*   **\"T [llamaindex](https://vertexaisearch.cloud.google.com/id/6-19) [medium](https://vertexaisearch.cloud.google.com/id/6-16)op 5 RAG (Retrieval Augmented Generation) Tutorials: A Comprehensive Guide\"**: RAG에 대한 5가지 최고의 튜토리얼을 탐색하며, 초보자에게 적합한 \"Introduction to Retrieval Augmented Generation (RAG) — Guided Project\"를 포함합니다.\\n*   **Udemy 및 [medium](https://vertexaisearch.cloud.google.com/id/6-16) Free Code Camp:** RAG 구현을 위한 단계별 튜토리얼을 제공하며, 일부는 LangChain 및 임베딩과 같은 고급 기술을 다룹니다.\\n*   **YouTube 채널:** Jeff Heaton, Krishna Naik, Rok Benko와 같은 채널은 LangChain 에이 [llamaindex](https://vertexaisearch.cloud.google.com/id/6-19)전트, RAG, 메모리 구현에 대한 실습 코딩 튜토리얼을 제공합니다.\\n\\n이러한 리소스는 ReAct, RAG 및 메모리 패턴과 같은 AI 에이전트 패턴을 깊이 이해하고 구현하는 데 필요한 최신 정보와 실습 기회를 제공합니다. [youtube](https://vertexaisearch.cloud.google.com/id/6-18) [youtube](https://vertexaisearch.cloud.google.com/id/6-8) [youtube](https://vertexaisearch.cloud.google.com/id/6-22) [youtube](https://vertexaisearch.cloud.google.com/id/6-29) [youtube](https://vertexaisearch.cloud.google.com/id/6-18) [youtube](https://vertexaisearch.cloud.google.com/id/6-30) [obot](https://v [wedge](https://vertexaisearch.cloud.google.com/id/6-20)ertexaisearch.cloud.google.com/id/6-28) [medium](https://vertexaisearch.cloud.google.com/id/6-9) [coursera](https://vertexaisearch.cloud.google.com/id/6-2) [github](https://vertexaisearch.cloud.google.com/id/6-27) [towar [wedge](https://vertexaisearch.cloud.google.com/id/6-20) [medium](https://vertexaisearch.cloud.google.com/id/6-21)dsai](https://vertexaisearch.cloud.google.com/id/6-23) [medium](https://vertexaisearch.cloud.google.com/id/6-24) [towardsai](https://vertexaisearch.cloud.google.com/id/6-23) [medium](https://vertexaisearch.cloud.google.com/id/6-24) [skywork](h [wedge](https://vertexaisearch.cloud.google.com/id/6-20) [coursera](https://vertexaisearch.cloud.google.com/id/6-2) [medium](https://vertexaisearch.cloud.google.com/id/6-11)ttps://vertexaisearch.cloud.google.com/id/6-26) [hackernoon](https://vertexaisearch.cloud.google.com/id/6-25) [youtube](https://vertexaisearch.cloud.google.com/id/6-22) [towardsai](https://vertexaisearch.cloud.google.com/id/6-23) [medium](https://vertexaisearch.cloud.google.com/id/6-24)'],\n",
       " 'sources_gathered': [{'label': 'ibm',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFD9P1Elyt072ROOgIhTm0il6jXajpogsp_n-I8RFs_u7mo6yQVzMGYG5K7UeWMu1620fUsyzsoXcMRaHVAbalJiec8SCODuPztqkOlTGFXa7BarmbCd_RobSKvMJBbvJWJIIAL9kHQltzi8643_vBY_UaP'},\n",
       "  {'label': 'google',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEfUQdoPrhJCeGgUHl4wM4cWJzrf75yD-Rlwpx6gZHsQpnKMy5QukJwHX_mFP0adk8RzvT21uyNYzQcVGsO8E5pLDjp9HYzESttVcAj0lbCDtrkdOXqL_34DBR6KLzn9FRmXC1XnGGgOSbEel2i5Gg6PFzH8HHXr740Dyd5Mv37'},\n",
       "  {'label': 'ibm',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFD9P1Elyt072ROOgIhTm0il6jXajpogsp_n-I8RFs_u7mo6yQVzMGYG5K7UeWMu1620fUsyzsoXcMRaHVAbalJiec8SCODuPztqkOlTGFXa7BarmbCd_RobSKvMJBbvJWJIIAL9kHQltzi8643_vBY_UaP'},\n",
       "  {'label': 'google',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEfUQdoPrhJCeGgUHl4wM4cWJzrf75yD-Rlwpx6gZHsQpnKMy5QukJwHX_mFP0adk8RzvT21uyNYzQcVGsO8E5pLDjp9HYzESttVcAj0lbCDtrkdOXqL_34DBR6KLzn9FRmXC1XnGGgOSbEel2i5Gg6PFzH8HHXr740Dyd5Mv37'},\n",
       "  {'label': 'automationanywhere',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjLNuEZzK_7EzggUgWWQ-6_lb_-Tagr__l82dJJNXjgXY10egg8aT6DQWW-bb2Hgjmy43NMkzJzlIrmttfxHQGe82m6DOQaGYYt9ek1cCwMT67weUGDNTsaSS8DSZSZ7wrvWjhfhY7n9cJmdM0S_--KQb3JScsbEI='},\n",
       "  {'label': 'automationanywhere',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjLNuEZzK_7EzggUgWWQ-6_lb_-Tagr__l82dJJNXjgXY10egg8aT6DQWW-bb2Hgjmy43NMkzJzlIrmttfxHQGe82m6DOQaGYYt9ek1cCwMT67weUGDNTsaSS8DSZSZ7wrvWjhfhY7n9cJmdM0S_--KQb3JScsbEI='},\n",
       "  {'label': 'automationanywhere',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjLNuEZzK_7EzggUgWWQ-6_lb_-Tagr__l82dJJNXjgXY10egg8aT6DQWW-bb2Hgjmy43NMkzJzlIrmttfxHQGe82m6DOQaGYYt9ek1cCwMT67weUGDNTsaSS8DSZSZ7wrvWjhfhY7n9cJmdM0S_--KQb3JScsbEI='},\n",
       "  {'label': 'automationanywhere',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjLNuEZzK_7EzggUgWWQ-6_lb_-Tagr__l82dJJNXjgXY10egg8aT6DQWW-bb2Hgjmy43NMkzJzlIrmttfxHQGe82m6DOQaGYYt9ek1cCwMT67weUGDNTsaSS8DSZSZ7wrvWjhfhY7n9cJmdM0S_--KQb3JScsbEI='},\n",
       "  {'label': 'automationanywhere',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjLNuEZzK_7EzggUgWWQ-6_lb_-Tagr__l82dJJNXjgXY10egg8aT6DQWW-bb2Hgjmy43NMkzJzlIrmttfxHQGe82m6DOQaGYYt9ek1cCwMT67weUGDNTsaSS8DSZSZ7wrvWjhfhY7n9cJmdM0S_--KQb3JScsbEI='},\n",
       "  {'label': 'google',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEfUQdoPrhJCeGgUHl4wM4cWJzrf75yD-Rlwpx6gZHsQpnKMy5QukJwHX_mFP0adk8RzvT21uyNYzQcVGsO8E5pLDjp9HYzESttVcAj0lbCDtrkdOXqL_34DBR6KLzn9FRmXC1XnGGgOSbEel2i5Gg6PFzH8HHXr740Dyd5Mv37'},\n",
       "  {'label': 'ibm',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFD9P1Elyt072ROOgIhTm0il6jXajpogsp_n-I8RFs_u7mo6yQVzMGYG5K7UeWMu1620fUsyzsoXcMRaHVAbalJiec8SCODuPztqkOlTGFXa7BarmbCd_RobSKvMJBbvJWJIIAL9kHQltzi8643_vBY_UaP'},\n",
       "  {'label': 'hunihub',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH-Y7f2zS5Ttz1mPIRdsCmmMk95igk7cqcqfA-6ooMizsMOpUVDiTQ3AefGz_A_vpodKPQq368NQDHm_dLB57fAIJLKGAzmYCpBCsrsmxyShcUon8cz31oV6c_91H10PA=='},\n",
       "  {'label': 'mindscale',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG20oDIU4-5XNo_BNjm6YjFezY69xgICQVT2wMHwwBbjEgmq-i1WMcID97j11OFitbSKG-4nhX03ZwrZ9GpsxRIrZYeIncFk8UVDLuPdirfEKN7QVZ97xwJeiM7H_4hq5HWkjrdB_MoovLHwjVmFeDZe9YvIEhuqU89Klo='},\n",
       "  {'label': 'brunch',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEt-xQcI2Qpi5icjpwpmSnJx9z8Dfgl_YuHWlCpDkzMe79rSkVqUFpTqEFoRO0MrZzgPFmLPGqpxgM_H-IQnFW8e3NWeCloAQOHIVR1Ew2-CJBc7fWNDc94awjgf4k='},\n",
       "  {'label': 'velog',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFGNhef__7Sx_doaYJxjtH157EIDHqmmwAHPo2PKtgOwBfiHODRFr1LRCCubMNpwL8cWiAHdxj7v77DapdR1t_ILF64cMltMjqjF5kHqs1Q5ANJLSEhm11E1WjjM3Fd6gyeVISV8iBkWiVkTuroxcpvFJAqjMUXNf31NoKqIztqkMRPzs46bd1YHo9n8_eJFqS3WN1ufCsOrju8TL_PMcckKUOt4tB9m0j72mxtA6y1_46pl3b5CDwNw3xL8rJWX0BMCQ=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF97Rw0OjI-njUFFQyHTzJMMnIzcxX5UQzgKRttX1QeDbP9RtDkfAJJoCHZ9K3GCEV7LX2d1yxGGKoNc22UfawMsqOO0-9_jAH_UVBuJxNwtUuaJ-OCYy-pupKCaLeCsc0_JA_Se3S-mQ-vJRRpPpGzPY_ARzKwtdSGl6C5ojhnHXlqVie8sE5wPhu4ZZbXNXZB1lNiG-Y7e16K8t-P_w9_YH5TjTfaW5sbSZysKcthGHRd1SikprBkPJo1oQo7-bHsmRc9ryuLv3AptqiF1kZE-9k8FW7JzdhaUI-ulyS8OW1UvvJ66FLwWykmzFvw3y21S8s5NAUz'},\n",
       "  {'label': 'ibm',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGYTmzl5GAbM13enXsXtVYL8NDcHlrbCAWnIf6r1J8ybOkQCus94T-IHu-_TEj62XjXThqtqaQb105PFuS2PX5e1ZvNXia7kUwNRMSIIFvUUnR60lD0HiDSm03MCP3WATYuK4YljYTAOV3tzsxgF8xMJG2leYoAWPI='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEswhnU-5NV78DcI8cQaXuJqDr_HET-d5uGP7ibuiBe9GQ2E8LpgBq4OAKozwdMqT-NkulVnxjYWzlgfevE01MYIZqKO00wRgljhb-lRrvzQFcrAPNVc_z-XH2y6Q=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQECw4lQdeGarZ-6cv99c3rvnkMHahvE9G8BsHNpsVr2pVcIxNmJB_0_yBTdYFrXKYrz9I6Rrs-VlIq4NBGR99J5q2CRpVMkwbH9qcsfzx60NtyGx5ZnpbW5EGGV'},\n",
       "  {'label': 'mindscale',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG20oDIU4-5XNo_BNjm6YjFezY69xgICQVT2wMHwwBbjEgmq-i1WMcID97j11OFitbSKG-4nhX03ZwrZ9GpsxRIrZYeIncFk8UVDLuPdirfEKN7QVZ97xwJeiM7H_4hq5HWkjrdB_MoovLHwjVmFeDZe9YvIEhuqU89Klo='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF97Rw0OjI-njUFFQyHTzJMMnIzcxX5UQzgKRttX1QeDbP9RtDkfAJJoCHZ9K3GCEV7LX2d1yxGGKoNc22UfawMsqOO0-9_jAH_UVBuJxNwtUuaJ-OCYy-pupKCaLeCsc0_JA_Se3S-mQ-vJRRpPpGzPY_ARzKwtdSGl6C5ojhnHXlqVie8sE5wPhu4ZZbXNXZB1lNiG-Y7e16K8t-P_w9_YH5TjTfaW5sbSZysKcthGHRd1SikprBkPJo1oQo7-bHsmRc9ryuLv3AptqiF1kZE-9k8FW7JzdhaUI-ulyS8OW1UvvJ66FLwWykmzFvw3y21S8s5NAUz'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEswhnU-5NV78DcI8cQaXuJqDr_HET-d5uGP7ibuiBe9GQ2E8LpgBq4OAKozwdMqT-NkulVnxjYWzlgfevE01MYIZqKO00wRgljhb-lRrvzQFcrAPNVc_z-XH2y6Q=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQECw4lQdeGarZ-6cv99c3rvnkMHahvE9G8BsHNpsVr2pVcIxNmJB_0_yBTdYFrXKYrz9I6Rrs-VlIq4NBGR99J5q2CRpVMkwbH9qcsfzx60NtyGx5ZnpbW5EGGV'},\n",
       "  {'label': 'mindscale',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG20oDIU4-5XNo_BNjm6YjFezY69xgICQVT2wMHwwBbjEgmq-i1WMcID97j11OFitbSKG-4nhX03ZwrZ9GpsxRIrZYeIncFk8UVDLuPdirfEKN7QVZ97xwJeiM7H_4hq5HWkjrdB_MoovLHwjVmFeDZe9YvIEhuqU89Klo='},\n",
       "  {'label': 'velog',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFGNhef__7Sx_doaYJxjtH157EIDHqmmwAHPo2PKtgOwBfiHODRFr1LRCCubMNpwL8cWiAHdxj7v77DapdR1t_ILF64cMltMjqjF5kHqs1Q5ANJLSEhm11E1WjjM3Fd6gyeVISV8iBkWiVkTuroxcpvFJAqjMUXNf31NoKqIztqkMRPzs46bd1YHo9n8_eJFqS3WN1ufCsOrju8TL_PMcckKUOt4tB9m0j72mxtA6y1_46pl3b5CDwNw3xL8rJWX0BMCQ=='},\n",
       "  {'label': 'brunch',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEt-xQcI2Qpi5icjpwpmSnJx9z8Dfgl_YuHWlCpDkzMe79rSkVqUFpTqEFoRO0MrZzgPFmLPGqpxgM_H-IQnFW8e3NWeCloAQOHIVR1Ew2-CJBc7fWNDc94awjgf4k='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF97Rw0OjI-njUFFQyHTzJMMnIzcxX5UQzgKRttX1QeDbP9RtDkfAJJoCHZ9K3GCEV7LX2d1yxGGKoNc22UfawMsqOO0-9_jAH_UVBuJxNwtUuaJ-OCYy-pupKCaLeCsc0_JA_Se3S-mQ-vJRRpPpGzPY_ARzKwtdSGl6C5ojhnHXlqVie8sE5wPhu4ZZbXNXZB1lNiG-Y7e16K8t-P_w9_YH5TjTfaW5sbSZysKcthGHRd1SikprBkPJo1oQo7-bHsmRc9ryuLv3AptqiF1kZE-9k8FW7JzdhaUI-ulyS8OW1UvvJ66FLwWykmzFvw3y21S8s5NAUz'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEswhnU-5NV78DcI8cQaXuJqDr_HET-d5uGP7ibuiBe9GQ2E8LpgBq4OAKozwdMqT-NkulVnxjYWzlgfevE01MYIZqKO00wRgljhb-lRrvzQFcrAPNVc_z-XH2y6Q=='},\n",
       "  {'label': 'aisparkup',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-11',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEKi-IVj7JwDz8FX2lhg6iItc9bJOI1PXvdoHCxJ2aSXy6YJPb1KmqLPXtoRSrqzccaVafMf0cBsxitVkp8ieUmPMwut28gJLggLpcXDjgoiJDKOnbAB8F9KSg1'},\n",
       "  {'label': 'goover',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEEo5MfCoPfMk5I-5MmMb7cwPmUEHW0xuso5w8HEzEnHEWwy2NSWKpOGTaiFWSEc5bZvBvEqXq-GzDU0Oi2S_UpINjSyGtCNe4_YJaIEPLQAVzB2I7T3ZIdTiJga_s1yV5DlPet0SV-X_-oNtARXGc9OkOjLwnG0ZAAYZC8bqowyTgbDV4Ugqh4QyYPrPY0ithToynd8ODngJkTqKuO9hjN'},\n",
       "  {'label': 'explainx',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpn0AJ3EybD1_DF2S0VHZBGKdajK90JE53BmdCz7EA0I8CgCP6_1nKzykaPv0e9jGi2R05RsFfYjIJsI6PiKGKwGOkKn-peS459WjQe95bKoOT3nM9adh7-CKeRSwWgYYuAUF6CofVsyhnDxBuc7u0fgjBM88vCyITDA=='},\n",
       "  {'label': 'modulabs',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFK_JLMJIKUyVqcFKEqNCTpJVuNYx1uE5x5eT3hBjBb_NJPjKD_wOny2BmufY8KpPD1Tc6LwcwdwF0AP3tsa-4RnozmG0dzNRLUJl49BVBy5imJdmja79zxCwdx7y6URcjBFaiX7-d9chpj9eT7xME='},\n",
       "  {'label': 'hunihub',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH-Y7f2zS5Ttz1mPIRdsCmmMk95igk7cqcqfA-6ooMizsMOpUVDiTQ3AefGz_A_vpodKPQq368NQDHm_dLB57fAIJLKGAzmYCpBCsrsmxyShcUon8cz31oV6c_91H10PA=='},\n",
       "  {'label': 'explainx',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpn0AJ3EybD1_DF2S0VHZBGKdajK90JE53BmdCz7EA0I8CgCP6_1nKzykaPv0e9jGi2R05RsFfYjIJsI6PiKGKwGOkKn-peS459WjQe95bKoOT3nM9adh7-CKeRSwWgYYuAUF6CofVsyhnDxBuc7u0fgjBM88vCyITDA=='},\n",
       "  {'label': 'wishket',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFuoH5w0Mmbyp1-gTvxFpvuUcgiRoaza2uiYkGAwnynAhGJDdGj2sQ6dvYzyglfY3IM9d1hhVrCeJurtMTcR2IoBR7DZL11Hidq7c8UHR08CGZ9QcekLk9PmgYBFJ8s5PsEivNJoZGFkOY='},\n",
       "  {'label': 'aisparkup',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-11',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEKi-IVj7JwDz8FX2lhg6iItc9bJOI1PXvdoHCxJ2aSXy6YJPb1KmqLPXtoRSrqzccaVafMf0cBsxitVkp8ieUmPMwut28gJLggLpcXDjgoiJDKOnbAB8F9KSg1'},\n",
       "  {'label': 'explainx',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpn0AJ3EybD1_DF2S0VHZBGKdajK90JE53BmdCz7EA0I8CgCP6_1nKzykaPv0e9jGi2R05RsFfYjIJsI6PiKGKwGOkKn-peS459WjQe95bKoOT3nM9adh7-CKeRSwWgYYuAUF6CofVsyhnDxBuc7u0fgjBM88vCyITDA=='},\n",
       "  {'label': 'brunch',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-16',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGeExjRKN8HFnS9EhcEOyFargZCXcleCAIdWnx81C_rg6Gp8_MjnvPSk1Ss9IaIot_-y1he1wOE7cUxwNMByducLW7C5aOkr9B0so83Ni1ljEZ-lIGL8ytrXp7iynM='},\n",
       "  {'label': 'modulabs',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFK_JLMJIKUyVqcFKEqNCTpJVuNYx1uE5x5eT3hBjBb_NJPjKD_wOny2BmufY8KpPD1Tc6LwcwdwF0AP3tsa-4RnozmG0dzNRLUJl49BVBy5imJdmja79zxCwdx7y6URcjBFaiX7-d9chpj9eT7xME='},\n",
       "  {'label': 'wishket',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFuoH5w0Mmbyp1-gTvxFpvuUcgiRoaza2uiYkGAwnynAhGJDdGj2sQ6dvYzyglfY3IM9d1hhVrCeJurtMTcR2IoBR7DZL11Hidq7c8UHR08CGZ9QcekLk9PmgYBFJ8s5PsEivNJoZGFkOY='},\n",
       "  {'label': 'slashpage',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHZbr_rd63DlKVAlJWlstyPXzyY3S8GF8bQgzl9E42YsrbgNjGcYEyLf8WogN8fWcvVDhjTGlNfqm1nuIlsfSHnU0Y1B3QI0o4djWQRa6RbiwmoCK3V82OzGkWIqWk3Zv1IvSVrVAhSW4BzViJml8JZn9Ljl_DnhA=='},\n",
       "  {'label': 'hunihub',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH-Y7f2zS5Ttz1mPIRdsCmmMk95igk7cqcqfA-6ooMizsMOpUVDiTQ3AefGz_A_vpodKPQq368NQDHm_dLB57fAIJLKGAzmYCpBCsrsmxyShcUon8cz31oV6c_91H10PA=='},\n",
       "  {'label': 'explainx',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpn0AJ3EybD1_DF2S0VHZBGKdajK90JE53BmdCz7EA0I8CgCP6_1nKzykaPv0e9jGi2R05RsFfYjIJsI6PiKGKwGOkKn-peS459WjQe95bKoOT3nM9adh7-CKeRSwWgYYuAUF6CofVsyhnDxBuc7u0fgjBM88vCyITDA=='},\n",
       "  {'label': 'modulabs',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFK_JLMJIKUyVqcFKEqNCTpJVuNYx1uE5x5eT3hBjBb_NJPjKD_wOny2BmufY8KpPD1Tc6LwcwdwF0AP3tsa-4RnozmG0dzNRLUJl49BVBy5imJdmja79zxCwdx7y6URcjBFaiX7-d9chpj9eT7xME='},\n",
       "  {'label': 'slashpage',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHZbr_rd63DlKVAlJWlstyPXzyY3S8GF8bQgzl9E42YsrbgNjGcYEyLf8WogN8fWcvVDhjTGlNfqm1nuIlsfSHnU0Y1B3QI0o4djWQRa6RbiwmoCK3V82OzGkWIqWk3Zv1IvSVrVAhSW4BzViJml8JZn9Ljl_DnhA=='},\n",
       "  {'label': 'aisparkup',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-11',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEKi-IVj7JwDz8FX2lhg6iItc9bJOI1PXvdoHCxJ2aSXy6YJPb1KmqLPXtoRSrqzccaVafMf0cBsxitVkp8ieUmPMwut28gJLggLpcXDjgoiJDKOnbAB8F9KSg1'},\n",
       "  {'label': 'explainx',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpn0AJ3EybD1_DF2S0VHZBGKdajK90JE53BmdCz7EA0I8CgCP6_1nKzykaPv0e9jGi2R05RsFfYjIJsI6PiKGKwGOkKn-peS459WjQe95bKoOT3nM9adh7-CKeRSwWgYYuAUF6CofVsyhnDxBuc7u0fgjBM88vCyITDA=='},\n",
       "  {'label': 'slashpage',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHZbr_rd63DlKVAlJWlstyPXzyY3S8GF8bQgzl9E42YsrbgNjGcYEyLf8WogN8fWcvVDhjTGlNfqm1nuIlsfSHnU0Y1B3QI0o4djWQRa6RbiwmoCK3V82OzGkWIqWk3Zv1IvSVrVAhSW4BzViJml8JZn9Ljl_DnhA=='},\n",
       "  {'label': 'goover',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEEo5MfCoPfMk5I-5MmMb7cwPmUEHW0xuso5w8HEzEnHEWwy2NSWKpOGTaiFWSEc5bZvBvEqXq-GzDU0Oi2S_UpINjSyGtCNe4_YJaIEPLQAVzB2I7T3ZIdTiJga_s1yV5DlPet0SV-X_-oNtARXGc9OkOjLwnG0ZAAYZC8bqowyTgbDV4Ugqh4QyYPrPY0ithToynd8ODngJkTqKuO9hjN'},\n",
       "  {'label': 'brunch',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-16',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGeExjRKN8HFnS9EhcEOyFargZCXcleCAIdWnx81C_rg6Gp8_MjnvPSk1Ss9IaIot_-y1he1wOE7cUxwNMByducLW7C5aOkr9B0so83Ni1ljEZ-lIGL8ytrXp7iynM='},\n",
       "  {'label': 'slashpage',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHZbr_rd63DlKVAlJWlstyPXzyY3S8GF8bQgzl9E42YsrbgNjGcYEyLf8WogN8fWcvVDhjTGlNfqm1nuIlsfSHnU0Y1B3QI0o4djWQRa6RbiwmoCK3V82OzGkWIqWk3Zv1IvSVrVAhSW4BzViJml8JZn9Ljl_DnhA=='},\n",
       "  {'label': 'dfinite',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-18',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHTvnqrsCXjoy6QWqAqNG3MnXQ3thTaW62K9R9LkAqemmaSlBV6AzOngHmkQ8u0BTpFuNmrXdB8USkeohzcVAPxoT7etmsxlCrAY905LkejNJb21War6S83dALL-ctPj-uWhXzcre9eOH8sco_k8Rl2WffSMv_ZhhtV'},\n",
       "  {'label': 'brunch',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-16',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGeExjRKN8HFnS9EhcEOyFargZCXcleCAIdWnx81C_rg6Gp8_MjnvPSk1Ss9IaIot_-y1he1wOE7cUxwNMByducLW7C5aOkr9B0so83Ni1ljEZ-lIGL8ytrXp7iynM='},\n",
       "  {'label': 'enhans',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-19',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDp_xjBvOEzxJyyofgUtgcqaASLGP9Cp2YxGp2v78fuvBwPVCVRUFGWFyXKtu929fq9b6U8jrhXwtMdILtvnfQoBJ85gP4eJb5uetqGshqKmDKRaZpwFlqrNK4uMv8lqbcYwhijGPS15lZCIiZFEjOdPIGS-fMQrtm-5kUId85Zus5SAm4Yay82Ts='},\n",
       "  {'label': 'slashpage',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHZbr_rd63DlKVAlJWlstyPXzyY3S8GF8bQgzl9E42YsrbgNjGcYEyLf8WogN8fWcvVDhjTGlNfqm1nuIlsfSHnU0Y1B3QI0o4djWQRa6RbiwmoCK3V82OzGkWIqWk3Zv1IvSVrVAhSW4BzViJml8JZn9Ljl_DnhA=='},\n",
       "  {'label': 'enhans',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-19',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDp_xjBvOEzxJyyofgUtgcqaASLGP9Cp2YxGp2v78fuvBwPVCVRUFGWFyXKtu929fq9b6U8jrhXwtMdILtvnfQoBJ85gP4eJb5uetqGshqKmDKRaZpwFlqrNK4uMv8lqbcYwhijGPS15lZCIiZFEjOdPIGS-fMQrtm-5kUId85Zus5SAm4Yay82Ts='},\n",
       "  {'label': 'aisparkup',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-11',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEKi-IVj7JwDz8FX2lhg6iItc9bJOI1PXvdoHCxJ2aSXy6YJPb1KmqLPXtoRSrqzccaVafMf0cBsxitVkp8ieUmPMwut28gJLggLpcXDjgoiJDKOnbAB8F9KSg1'},\n",
       "  {'label': 'slashpage',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHZbr_rd63DlKVAlJWlstyPXzyY3S8GF8bQgzl9E42YsrbgNjGcYEyLf8WogN8fWcvVDhjTGlNfqm1nuIlsfSHnU0Y1B3QI0o4djWQRa6RbiwmoCK3V82OzGkWIqWk3Zv1IvSVrVAhSW4BzViJml8JZn9Ljl_DnhA=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-20',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEOGkgxt1mgP2LwdScWVn_G_tddKGx_wE_eCpJJ0hY_bLx-Auv-vj6vPX6FllcHThvn0T7LYZRp-mKh4PbITCBgW6D_rWlvnujt3dCL-A3gcEkWXXZ3eFddWjtieg=='},\n",
       "  {'label': 'dfinite',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-18',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHTvnqrsCXjoy6QWqAqNG3MnXQ3thTaW62K9R9LkAqemmaSlBV6AzOngHmkQ8u0BTpFuNmrXdB8USkeohzcVAPxoT7etmsxlCrAY905LkejNJb21War6S83dALL-ctPj-uWhXzcre9eOH8sco_k8Rl2WffSMv_ZhhtV'},\n",
       "  {'label': 'slashpage',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHZbr_rd63DlKVAlJWlstyPXzyY3S8GF8bQgzl9E42YsrbgNjGcYEyLf8WogN8fWcvVDhjTGlNfqm1nuIlsfSHnU0Y1B3QI0o4djWQRa6RbiwmoCK3V82OzGkWIqWk3Zv1IvSVrVAhSW4BzViJml8JZn9Ljl_DnhA=='},\n",
       "  {'label': 'modulabs',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFK_JLMJIKUyVqcFKEqNCTpJVuNYx1uE5x5eT3hBjBb_NJPjKD_wOny2BmufY8KpPD1Tc6LwcwdwF0AP3tsa-4RnozmG0dzNRLUJl49BVBy5imJdmja79zxCwdx7y6URcjBFaiX7-d9chpj9eT7xME='},\n",
       "  {'label': 'automationanywhere',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjLNuEZzK_7EzggUgWWQ-6_lb_-Tagr__l82dJJNXjgXY10egg8aT6DQWW-bb2Hgjmy43NMkzJzlIrmttfxHQGe82m6DOQaGYYt9ek1cCwMT67weUGDNTsaSS8DSZSZ7wrvWjhfhY7n9cJmdM0S_--KQb3JScsbEI='},\n",
       "  {'label': 'google',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEfUQdoPrhJCeGgUHl4wM4cWJzrf75yD-Rlwpx6gZHsQpnKMy5QukJwHX_mFP0adk8RzvT21uyNYzQcVGsO8E5pLDjp9HYzESttVcAj0lbCDtrkdOXqL_34DBR6KLzn9FRmXC1XnGGgOSbEel2i5Gg6PFzH8HHXr740Dyd5Mv37'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-20',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEOGkgxt1mgP2LwdScWVn_G_tddKGx_wE_eCpJJ0hY_bLx-Auv-vj6vPX6FllcHThvn0T7LYZRp-mKh4PbITCBgW6D_rWlvnujt3dCL-A3gcEkWXXZ3eFddWjtieg=='},\n",
       "  {'label': 'explainx',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpn0AJ3EybD1_DF2S0VHZBGKdajK90JE53BmdCz7EA0I8CgCP6_1nKzykaPv0e9jGi2R05RsFfYjIJsI6PiKGKwGOkKn-peS459WjQe95bKoOT3nM9adh7-CKeRSwWgYYuAUF6CofVsyhnDxBuc7u0fgjBM88vCyITDA=='},\n",
       "  {'label': 'automationanywhere',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjLNuEZzK_7EzggUgWWQ-6_lb_-Tagr__l82dJJNXjgXY10egg8aT6DQWW-bb2Hgjmy43NMkzJzlIrmttfxHQGe82m6DOQaGYYt9ek1cCwMT67weUGDNTsaSS8DSZSZ7wrvWjhfhY7n9cJmdM0S_--KQb3JScsbEI='},\n",
       "  {'label': 'automationanywhere',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjLNuEZzK_7EzggUgWWQ-6_lb_-Tagr__l82dJJNXjgXY10egg8aT6DQWW-bb2Hgjmy43NMkzJzlIrmttfxHQGe82m6DOQaGYYt9ek1cCwMT67weUGDNTsaSS8DSZSZ7wrvWjhfhY7n9cJmdM0S_--KQb3JScsbEI='},\n",
       "  {'label': 'explainx',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpn0AJ3EybD1_DF2S0VHZBGKdajK90JE53BmdCz7EA0I8CgCP6_1nKzykaPv0e9jGi2R05RsFfYjIJsI6PiKGKwGOkKn-peS459WjQe95bKoOT3nM9adh7-CKeRSwWgYYuAUF6CofVsyhnDxBuc7u0fgjBM88vCyITDA=='},\n",
       "  {'label': 'explainx',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpn0AJ3EybD1_DF2S0VHZBGKdajK90JE53BmdCz7EA0I8CgCP6_1nKzykaPv0e9jGi2R05RsFfYjIJsI6PiKGKwGOkKn-peS459WjQe95bKoOT3nM9adh7-CKeRSwWgYYuAUF6CofVsyhnDxBuc7u0fgjBM88vCyITDA=='},\n",
       "  {'label': 'explainx',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpn0AJ3EybD1_DF2S0VHZBGKdajK90JE53BmdCz7EA0I8CgCP6_1nKzykaPv0e9jGi2R05RsFfYjIJsI6PiKGKwGOkKn-peS459WjQe95bKoOT3nM9adh7-CKeRSwWgYYuAUF6CofVsyhnDxBuc7u0fgjBM88vCyITDA=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGTdUKRsUmw52ia1bc8otOws8QO3e_BHmrzI5bZ8JLlCkuuC1dIPyY3r7YToqlUxqcF_ExSRkF5ba7MYUa8HxKSHcMv95qzbpVTRDCnodPqsMj_HbpF8Lj1qpAY0v1'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFcA91ZliKDqFdV4RD9mlDi79oMcV3ACKm6i8Srdk3QM_xxwz9n2Wx3XeVG56Pcm1yQ2J_09ct3BtVssG_-piGZ2Q_QVczzxt77Zf1ZpjDxGGWSuhkPQUyg4-iKdg=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXIupUVDwCpwutsR5gTHP3knhqgeqx1-UjZ-rtnMAAQYRavNMfBgR84EJxV_whrCGpDL34Tx-mW_PlB7U9r51ra9oSM_tpgAyFY8onVZYgfwH-h7Ovln2YUJFgBtf-4ycv7LCtjvqfp3pRh3ahsYtCrraLiwLTyh-O2_H-NXUS5smQc28N--AWtZnpMSMfg8Gu1e4DddCncVsWohgtSFxGXWoE0ZB9AMaPQfun2DgF'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQELK1O9YQHKog-EQq7MRcD1iJhsGiuyXnceQ9LqtStjIR6R0mOM-x3fUGC3-PCR14mXyMoCN2gmjc1i3BAMAwXhf7sNgPMi30GQEUYvGyGCeEQxD8tcVzehheEzqiMkklnyA12U8LxL4LR3gttJ2qFfjKk60GhOard-y1eOH32kGY5ocaidpEVAko-vSiorOJUhJk3yYDWD1VCQpokQ9k0k3sspHusOBhInbrb0ZsSAB20d9TrFDQi6rokJKH6XMx508XdNsFynAjEYHUMSY14orLhC9BWD4_qGU_2itIAGCf5oiXLL8BlpMZIoDbp0oshakgL9-UxmoGLocycMp2Cw6JOybd2lBx3bebne540AyQZcuEYEDrv1xViwhfc='},\n",
       "  {'label': 'pagecall',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHdKDQfUHaG8gV_EeQTJss3HgpLbiG3Sew8zpnB626wm0NAkDVambLc1_qiBBxSG96dqTED6_lPPEllq9YxtASdLxsrG1cFmpPvRlx35ML7TpM41s-hIq3ivKdf-VSksyVRKctBBkFql6GDt24wBUwaikOms2v5m_iwdK4dcstoNXSA2BXiwt8kIozAF_iG6nSIJjV_SgKtj7-aIrOymX57Z2Nv30JyZhJwcB103z-oEyj-87FPWv50C9y-elQPrCUp_bths-kYQrYS3HbBd75WY_rc931AkQXTwomVB6ChZ8zSZhiXM3fzg-uUJmxWEJIIsrAmMI0cwxABtX4_KIUw-Ybu_x0wiPQjrMRDTbq5rWvUYabbIQ=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXIupUVDwCpwutsR5gTHP3knhqgeqx1-UjZ-rtnMAAQYRavNMfBgR84EJxV_whrCGpDL34Tx-mW_PlB7U9r51ra9oSM_tpgAyFY8onVZYgfwH-h7Ovln2YUJFgBtf-4ycv7LCtjvqfp3pRh3ahsYtCrraLiwLTyh-O2_H-NXUS5smQc28N--AWtZnpMSMfg8Gu1e4DddCncVsWohgtSFxGXWoE0ZB9AMaPQfun2DgF'},\n",
       "  {'label': 'comingsoonkorea',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEKCayQbbGGF-Y7fWRv8WKvVjNNxCh5o3Mo4CHqekpUOGnirH0VqO4AMTOV3iYdjRq4GljqPIkCNqi2tJ4IpDOqIImonWVsO0mLvKVfbuZpssxf_F3ZJzJCIE09dP3Xve8Q9-YXgq4rauDIZ1b1CoCqgUyeyyEh1rK8YNDRbTfqW2x7uSMaxSF06fFCoWXGyWnHFstpaWhgXizhxMDJsYWnY3U='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH7hnmrwYZceto8qJ4TihtSk0xxPbahISABCsPnnW2CQee_2OXcyyzTDLGJg0bM_IbNYA-9ueizkitVYnXO24U751indrczbN7AjzGri4Tx8N7_FqVLkHPqrg=='},\n",
       "  {'label': 'reddit',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFM769A2fA0Q0mK991ByRJmOVMnFOjG4TR-bHO-iI9xJ3Ui90lHafHQjJj65T2pBLt_1jiicraxZxuF1sEErzeK3RbgfGgE-axYDvYnya1_pPt7aTXT2HPCdA22iAZEGq8Us-qClJ40IvJYf-8WG80GncN9OErLtHeZzMlWU0ZKvRhA5SgkUgXfngGMAxiO6LbNNJ5-ao-sWpgttQtjKTNAcD3Sdd1e6bg='},\n",
       "  {'label': 'sangseek',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHDxOD7V44CGHv-roI34fWPMqY7-y82TgYUrFdsmcTQUvtMr9DyAn0p_k2ZG3YGZpSceOAjFh6DqWyJb5ALTnz1avCAkbk4kE0sOV4qzOn9dbyZt32OJyWW2CiNzBEUDrN0kw=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQELK1O9YQHKog-EQq7MRcD1iJhsGiuyXnceQ9LqtStjIR6R0mOM-x3fUGC3-PCR14mXyMoCN2gmjc1i3BAMAwXhf7sNgPMi30GQEUYvGyGCeEQxD8tcVzehheEzqiMkklnyA12U8LxL4LR3gttJ2qFfjKk60GhOard-y1eOH32kGY5ocaidpEVAko-vSiorOJUhJk3yYDWD1VCQpokQ9k0k3sspHusOBhInbrb0ZsSAB20d9TrFDQi6rokJKH6XMx508XdNsFynAjEYHUMSY14orLhC9BWD4_qGU_2itIAGCf5oiXLL8BlpMZIoDbp0oshakgL9-UxmoGLocycMp2Cw6JOybd2lBx3bebne540AyQZcuEYEDrv1xViwhfc='},\n",
       "  {'label': 'pagecall',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHdKDQfUHaG8gV_EeQTJss3HgpLbiG3Sew8zpnB626wm0NAkDVambLc1_qiBBxSG96dqTED6_lPPEllq9YxtASdLxsrG1cFmpPvRlx35ML7TpM41s-hIq3ivKdf-VSksyVRKctBBkFql6GDt24wBUwaikOms2v5m_iwdK4dcstoNXSA2BXiwt8kIozAF_iG6nSIJjV_SgKtj7-aIrOymX57Z2Nv30JyZhJwcB103z-oEyj-87FPWv50C9y-elQPrCUp_bths-kYQrYS3HbBd75WY_rc931AkQXTwomVB6ChZ8zSZhiXM3fzg-uUJmxWEJIIsrAmMI0cwxABtX4_KIUw-Ybu_x0wiPQjrMRDTbq5rWvUYabbIQ=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGTdUKRsUmw52ia1bc8otOws8QO3e_BHmrzI5bZ8JLlCkuuC1dIPyY3r7YToqlUxqcF_ExSRkF5ba7MYUa8HxKSHcMv95qzbpVTRDCnodPqsMj_HbpF8Lj1qpAY0v1'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHWOtsajkREb927NuNy449F4Yag206cU-yCPOtOKEHk6SbHzTUzXLKUW-510gCYnRmaKRWl9rtcS_XyJ-c86xvXmFYTeH03BE1cSpyZGPVTl0rWJBw9eo9sMBBAZjZ0tEEwXC9K0sX_hYVAm4z1_M0q08LUnlwRB0X2dsFVT9DjjkDYDpFOXW8f_cN-vtEASMavB_8wbJkWcDE3OsGI4iP8oCA4Ndd30PBIXQPhpWvWig=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXIupUVDwCpwutsR5gTHP3knhqgeqx1-UjZ-rtnMAAQYRavNMfBgR84EJxV_whrCGpDL34Tx-mW_PlB7U9r51ra9oSM_tpgAyFY8onVZYgfwH-h7Ovln2YUJFgBtf-4ycv7LCtjvqfp3pRh3ahsYtCrraLiwLTyh-O2_H-NXUS5smQc28N--AWtZnpMSMfg8Gu1e4DddCncVsWohgtSFxGXWoE0ZB9AMaPQfun2DgF'},\n",
       "  {'label': 'pagecall',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHdKDQfUHaG8gV_EeQTJss3HgpLbiG3Sew8zpnB626wm0NAkDVambLc1_qiBBxSG96dqTED6_lPPEllq9YxtASdLxsrG1cFmpPvRlx35ML7TpM41s-hIq3ivKdf-VSksyVRKctBBkFql6GDt24wBUwaikOms2v5m_iwdK4dcstoNXSA2BXiwt8kIozAF_iG6nSIJjV_SgKtj7-aIrOymX57Z2Nv30JyZhJwcB103z-oEyj-87FPWv50C9y-elQPrCUp_bths-kYQrYS3HbBd75WY_rc931AkQXTwomVB6ChZ8zSZhiXM3fzg-uUJmxWEJIIsrAmMI0cwxABtX4_KIUw-Ybu_x0wiPQjrMRDTbq5rWvUYabbIQ=='},\n",
       "  {'label': 'brunch',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEMduSUz5SRNcXofn4mcICNkWNWbdsGMwBUVZlbHR9cFxncnS4jw1noCcwhWp6yaM7_Of4OCIJUzTyJEsJ6mKkcrBfASazA0kaLGlyN1xPZNbQAsq0uMJN6iiY1EQ=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-11',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFSk6wPaXFkVPP6V1GuAPp_oHow85BqxB_x4cawO4p6ZLRaNXzy_2lp0IrRHLkCraNqw494oYVa5KyLkexyhphSOixN5oUk4-ZKM8DvIESRrA5GHr-yJ8Sr5d_slndt'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQELK1O9YQHKog-EQq7MRcD1iJhsGiuyXnceQ9LqtStjIR6R0mOM-x3fUGC3-PCR14mXyMoCN2gmjc1i3BAMAwXhf7sNgPMi30GQEUYvGyGCeEQxD8tcVzehheEzqiMkklnyA12U8LxL4LR3gttJ2qFfjKk60GhOard-y1eOH32kGY5ocaidpEVAko-vSiorOJUhJk3yYDWD1VCQpokQ9k0k3sspHusOBhInbrb0ZsSAB20d9TrFDQi6rokJKH6XMx508XdNsFynAjEYHUMSY14orLhC9BWD4_qGU_2itIAGCf5oiXLL8BlpMZIoDbp0oshakgL9-UxmoGLocycMp2Cw6JOybd2lBx3bebne540AyQZcuEYEDrv1xViwhfc='},\n",
       "  {'label': 'network-rich',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFa4nUNKjgYCz48_Q43O96NtPCmjcyUEhR31txdyK_ITV5__w4oiFktkm_0H2WYtfCwPiwccWWOQ7nXCkf4d-RZ0YxH2gzm7XVZ-XPH0HO0UgjGnd-F5aIjXXp28nyPYhSX00dqMCxteXrj13-Dp2mtFyj7'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH7hnmrwYZceto8qJ4TihtSk0xxPbahISABCsPnnW2CQee_2OXcyyzTDLGJg0bM_IbNYA-9ueizkitVYnXO24U751indrczbN7AjzGri4Tx8N7_FqVLkHPqrg=='},\n",
       "  {'label': 'reddit',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFM769A2fA0Q0mK991ByRJmOVMnFOjG4TR-bHO-iI9xJ3Ui90lHafHQjJj65T2pBLt_1jiicraxZxuF1sEErzeK3RbgfGgE-axYDvYnya1_pPt7aTXT2HPCdA22iAZEGq8Us-qClJ40IvJYf-8WG80GncN9OErLtHeZzMlWU0ZKvRhA5SgkUgXfngGMAxiO6LbNNJ5-ao-sWpgttQtjKTNAcD3Sdd1e6bg='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGbn_NwF8NVW6lIjYJeo8gPZgi_BYAEWlIg5jNoQrVVsxyrA7XYTdNuvPvHE1_EYU4dpUzjneedtYvN-b09xz8vTvJlIuslyptk5m_ri9s5LKBDjrok1OxzswT1BqZMsLryf8rY81fn2jxCehv8yGFwoncKzmRtfMnW3iUJZy8aIirSb1VwzWU86etqCBcQOfJAqmu0lJnLpw9nlmK10tWuf4dIycV9uoiN7A6VkY7gDL_1ilJQuSL9Utotx8ymuKU0nKDl0g7nY6LCZ6I9UKhERmB0mDDIKGj4IKzu19tmc6J5bw8='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGPXoRZRoEQyt-3v9RjKkX1qwqGPR1u5JTW3c3D3DDIVQelGBgv4QDLQSkL2WdJ8f1xyt5w1G-ElWhMWa6NAaF9HXmpgng8zKq8stk1RBlEjh9HRrIhLqp399_Jbzsh'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQELK1O9YQHKog-EQq7MRcD1iJhsGiuyXnceQ9LqtStjIR6R0mOM-x3fUGC3-PCR14mXyMoCN2gmjc1i3BAMAwXhf7sNgPMi30GQEUYvGyGCeEQxD8tcVzehheEzqiMkklnyA12U8LxL4LR3gttJ2qFfjKk60GhOard-y1eOH32kGY5ocaidpEVAko-vSiorOJUhJk3yYDWD1VCQpokQ9k0k3sspHusOBhInbrb0ZsSAB20d9TrFDQi6rokJKH6XMx508XdNsFynAjEYHUMSY14orLhC9BWD4_qGU_2itIAGCf5oiXLL8BlpMZIoDbp0oshakgL9-UxmoGLocycMp2Cw6JOybd2lBx3bebne540AyQZcuEYEDrv1xViwhfc='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGA9J-U6moSrMYiIvi9IRUyxBiwdyq1sGvkW1mke8pRTHteHnSGryQ7U9DYxbt0zepVuKlnppELOlxM7exT5B--at58U4zXnvXnQQeTUBctbo44rfT7UhN-bJzqtE1B'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGPXoRZRoEQyt-3v9RjKkX1qwqGPR1u5JTW3c3D3DDIVQelGBgv4QDLQSkL2WdJ8f1xyt5w1G-ElWhMWa6NAaF9HXmpgng8zKq8stk1RBlEjh9HRrIhLqp399_Jbzsh'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH7hnmrwYZceto8qJ4TihtSk0xxPbahISABCsPnnW2CQee_2OXcyyzTDLGJg0bM_IbNYA-9ueizkitVYnXO24U751indrczbN7AjzGri4Tx8N7_FqVLkHPqrg=='},\n",
       "  {'label': 'brunch',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEMduSUz5SRNcXofn4mcICNkWNWbdsGMwBUVZlbHR9cFxncnS4jw1noCcwhWp6yaM7_Of4OCIJUzTyJEsJ6mKkcrBfASazA0kaLGlyN1xPZNbQAsq0uMJN6iiY1EQ=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGbn_NwF8NVW6lIjYJeo8gPZgi_BYAEWlIg5jNoQrVVsxyrA7XYTdNuvPvHE1_EYU4dpUzjneedtYvN-b09xz8vTvJlIuslyptk5m_ri9s5LKBDjrok1OxzswT1BqZMsLryf8rY81fn2jxCehv8yGFwoncKzmRtfMnW3iUJZy8aIirSb1VwzWU86etqCBcQOfJAqmu0lJnLpw9nlmK10tWuf4dIycV9uoiN7A6VkY7gDL_1ilJQuSL9Utotx8ymuKU0nKDl0g7nY6LCZ6I9UKhERmB0mDDIKGj4IKzu19tmc6J5bw8='},\n",
       "  {'label': 'sangseek',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHDxOD7V44CGHv-roI34fWPMqY7-y82TgYUrFdsmcTQUvtMr9DyAn0p_k2ZG3YGZpSceOAjFh6DqWyJb5ALTnz1avCAkbk4kE0sOV4qzOn9dbyZt32OJyWW2CiNzBEUDrN0kw=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXIupUVDwCpwutsR5gTHP3knhqgeqx1-UjZ-rtnMAAQYRavNMfBgR84EJxV_whrCGpDL34Tx-mW_PlB7U9r51ra9oSM_tpgAyFY8onVZYgfwH-h7Ovln2YUJFgBtf-4ycv7LCtjvqfp3pRh3ahsYtCrraLiwLTyh-O2_H-NXUS5smQc28N--AWtZnpMSMfg8Gu1e4DddCncVsWohgtSFxGXWoE0ZB9AMaPQfun2DgF'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQELK1O9YQHKog-EQq7MRcD1iJhsGiuyXnceQ9LqtStjIR6R0mOM-x3fUGC3-PCR14mXyMoCN2gmjc1i3BAMAwXhf7sNgPMi30GQEUYvGyGCeEQxD8tcVzehheEzqiMkklnyA12U8LxL4LR3gttJ2qFfjKk60GhOard-y1eOH32kGY5ocaidpEVAko-vSiorOJUhJk3yYDWD1VCQpokQ9k0k3sspHusOBhInbrb0ZsSAB20d9TrFDQi6rokJKH6XMx508XdNsFynAjEYHUMSY14orLhC9BWD4_qGU_2itIAGCf5oiXLL8BlpMZIoDbp0oshakgL9-UxmoGLocycMp2Cw6JOybd2lBx3bebne540AyQZcuEYEDrv1xViwhfc='},\n",
       "  {'label': 'samwell',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-16',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZm1qKSaZ8QnYVNEqo61z-S-ucu1iu_YXwXbNsKFO_eCQKPE4yqzd3eg2lIPSy_tX0uQ7RtiJb6XicXc96abO8w4hc66M6eGN_0MX7InFyQg0yKTgLhL_d4Kk36NdZosJQCV9jlX54YdG2AF3223z93xSWS47X2VW-0sUq'},\n",
       "  {'label': '21erick',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF-QbihUYvSj_jHySd_VzH5_LRbLgdpBMSb6b6jI00rIMWfI5VQlfVvZbdNcN_fhDwSbmmDSJ1Doo3K9IqYoMpCHDRgbmNOrdpz4L5E9FD8ghwCyBp2LsB6mDD_fA=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGbn_NwF8NVW6lIjYJeo8gPZgi_BYAEWlIg5jNoQrVVsxyrA7XYTdNuvPvHE1_EYU4dpUzjneedtYvN-b09xz8vTvJlIuslyptk5m_ri9s5LKBDjrok1OxzswT1BqZMsLryf8rY81fn2jxCehv8yGFwoncKzmRtfMnW3iUJZy8aIirSb1VwzWU86etqCBcQOfJAqmu0lJnLpw9nlmK10tWuf4dIycV9uoiN7A6VkY7gDL_1ilJQuSL9Utotx8ymuKU0nKDl0g7nY6LCZ6I9UKhERmB0mDDIKGj4IKzu19tmc6J5bw8='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-18',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG8A3r1245GGKYieayAEs8nDXR1eOrwscEaje0dZbrNhTZ-Ub9BfCC-FdiPAG9rwrmVwV-7KeE-ks4du8hahI8tx0vxmcpOjjpadKRBKceqTuw2NGyWMV7ppE3v-Zs3'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-11',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFSk6wPaXFkVPP6V1GuAPp_oHow85BqxB_x4cawO4p6ZLRaNXzy_2lp0IrRHLkCraNqw494oYVa5KyLkexyhphSOixN5oUk4-ZKM8DvIESRrA5GHr-yJ8Sr5d_slndt'},\n",
       "  {'label': 'network-rich',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFa4nUNKjgYCz48_Q43O96NtPCmjcyUEhR31txdyK_ITV5__w4oiFktkm_0H2WYtfCwPiwccWWOQ7nXCkf4d-RZ0YxH2gzm7XVZ-XPH0HO0UgjGnd-F5aIjXXp28nyPYhSX00dqMCxteXrj13-Dp2mtFyj7'},\n",
       "  {'label': 'sangseek',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHDxOD7V44CGHv-roI34fWPMqY7-y82TgYUrFdsmcTQUvtMr9DyAn0p_k2ZG3YGZpSceOAjFh6DqWyJb5ALTnz1avCAkbk4kE0sOV4qzOn9dbyZt32OJyWW2CiNzBEUDrN0kw=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGPXoRZRoEQyt-3v9RjKkX1qwqGPR1u5JTW3c3D3DDIVQelGBgv4QDLQSkL2WdJ8f1xyt5w1G-ElWhMWa6NAaF9HXmpgng8zKq8stk1RBlEjh9HRrIhLqp399_Jbzsh'},\n",
       "  {'label': 'comingsoonkorea',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEKCayQbbGGF-Y7fWRv8WKvVjNNxCh5o3Mo4CHqekpUOGnirH0VqO4AMTOV3iYdjRq4GljqPIkCNqi2tJ4IpDOqIImonWVsO0mLvKVfbuZpssxf_F3ZJzJCIE09dP3Xve8Q9-YXgq4rauDIZ1b1CoCqgUyeyyEh1rK8YNDRbTfqW2x7uSMaxSF06fFCoWXGyWnHFstpaWhgXizhxMDJsYWnY3U='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-19',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEIlvRIW4tIQJqtQ5OXm0Rmcs2NfRfkpa6pFMg8wr8_lTlhFU8kM4y8qCe7AjuEePo4MgmNU0spOFWPZQyDZHtqwtQIbPbrbKX6VxtxrcLeOSQ7zkIHJTm6jgc_'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGTdUKRsUmw52ia1bc8otOws8QO3e_BHmrzI5bZ8JLlCkuuC1dIPyY3r7YToqlUxqcF_ExSRkF5ba7MYUa8HxKSHcMv95qzbpVTRDCnodPqsMj_HbpF8Lj1qpAY0v1'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHWOtsajkREb927NuNy449F4Yag206cU-yCPOtOKEHk6SbHzTUzXLKUW-510gCYnRmaKRWl9rtcS_XyJ-c86xvXmFYTeH03BE1cSpyZGPVTl0rWJBw9eo9sMBBAZjZ0tEEwXC9K0sX_hYVAm4z1_M0q08LUnlwRB0X2dsFVT9DjjkDYDpFOXW8f_cN-vtEASMavB_8wbJkWcDE3OsGI4iP8oCA4Ndd30PBIXQPhpWvWig=='},\n",
       "  {'label': 'sangseek',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHDxOD7V44CGHv-roI34fWPMqY7-y82TgYUrFdsmcTQUvtMr9DyAn0p_k2ZG3YGZpSceOAjFh6DqWyJb5ALTnz1avCAkbk4kE0sOV4qzOn9dbyZt32OJyWW2CiNzBEUDrN0kw=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFcA91ZliKDqFdV4RD9mlDi79oMcV3ACKm6i8Srdk3QM_xxwz9n2Wx3XeVG56Pcm1yQ2J_09ct3BtVssG_-piGZ2Q_QVczzxt77Zf1ZpjDxGGWSuhkPQUyg4-iKdg=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-20',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGJTZkHo5a0dslZtwzXyTE9RlcFMchEAh196AYvbGR7F9huCK01b07--09vztJn4qa56gXxTVNsTiclpaZT6A9bY-V7GdF_oFUM0Cqs7gdlQgpTB4w61wGDQyE='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXIupUVDwCpwutsR5gTHP3knhqgeqx1-UjZ-rtnMAAQYRavNMfBgR84EJxV_whrCGpDL34Tx-mW_PlB7U9r51ra9oSM_tpgAyFY8onVZYgfwH-h7Ovln2YUJFgBtf-4ycv7LCtjvqfp3pRh3ahsYtCrraLiwLTyh-O2_H-NXUS5smQc28N--AWtZnpMSMfg8Gu1e4DddCncVsWohgtSFxGXWoE0ZB9AMaPQfun2DgF'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQELK1O9YQHKog-EQq7MRcD1iJhsGiuyXnceQ9LqtStjIR6R0mOM-x3fUGC3-PCR14mXyMoCN2gmjc1i3BAMAwXhf7sNgPMi30GQEUYvGyGCeEQxD8tcVzehheEzqiMkklnyA12U8LxL4LR3gttJ2qFfjKk60GhOard-y1eOH32kGY5ocaidpEVAko-vSiorOJUhJk3yYDWD1VCQpokQ9k0k3sspHusOBhInbrb0ZsSAB20d9TrFDQi6rokJKH6XMx508XdNsFynAjEYHUMSY14orLhC9BWD4_qGU_2itIAGCf5oiXLL8BlpMZIoDbp0oshakgL9-UxmoGLocycMp2Cw6JOybd2lBx3bebne540AyQZcuEYEDrv1xViwhfc='},\n",
       "  {'label': 'pagecall',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHdKDQfUHaG8gV_EeQTJss3HgpLbiG3Sew8zpnB626wm0NAkDVambLc1_qiBBxSG96dqTED6_lPPEllq9YxtASdLxsrG1cFmpPvRlx35ML7TpM41s-hIq3ivKdf-VSksyVRKctBBkFql6GDt24wBUwaikOms2v5m_iwdK4dcstoNXSA2BXiwt8kIozAF_iG6nSIJjV_SgKtj7-aIrOymX57Z2Nv30JyZhJwcB103z-oEyj-87FPWv50C9y-elQPrCUp_bths-kYQrYS3HbBd75WY_rc931AkQXTwomVB6ChZ8zSZhiXM3fzg-uUJmxWEJIIsrAmMI0cwxABtX4_KIUw-Ybu_x0wiPQjrMRDTbq5rWvUYabbIQ=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGTdUKRsUmw52ia1bc8otOws8QO3e_BHmrzI5bZ8JLlCkuuC1dIPyY3r7YToqlUxqcF_ExSRkF5ba7MYUa8HxKSHcMv95qzbpVTRDCnodPqsMj_HbpF8Lj1qpAY0v1'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGPXoRZRoEQyt-3v9RjKkX1qwqGPR1u5JTW3c3D3DDIVQelGBgv4QDLQSkL2WdJ8f1xyt5w1G-ElWhMWa6NAaF9HXmpgng8zKq8stk1RBlEjh9HRrIhLqp399_Jbzsh'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQELK1O9YQHKog-EQq7MRcD1iJhsGiuyXnceQ9LqtStjIR6R0mOM-x3fUGC3-PCR14mXyMoCN2gmjc1i3BAMAwXhf7sNgPMi30GQEUYvGyGCeEQxD8tcVzehheEzqiMkklnyA12U8LxL4LR3gttJ2qFfjKk60GhOard-y1eOH32kGY5ocaidpEVAko-vSiorOJUhJk3yYDWD1VCQpokQ9k0k3sspHusOBhInbrb0ZsSAB20d9TrFDQi6rokJKH6XMx508XdNsFynAjEYHUMSY14orLhC9BWD4_qGU_2itIAGCf5oiXLL8BlpMZIoDbp0oshakgL9-UxmoGLocycMp2Cw6JOybd2lBx3bebne540AyQZcuEYEDrv1xViwhfc='},\n",
       "  {'label': 'sangseek',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHDxOD7V44CGHv-roI34fWPMqY7-y82TgYUrFdsmcTQUvtMr9DyAn0p_k2ZG3YGZpSceOAjFh6DqWyJb5ALTnz1avCAkbk4kE0sOV4qzOn9dbyZt32OJyWW2CiNzBEUDrN0kw=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-20',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGJTZkHo5a0dslZtwzXyTE9RlcFMchEAh196AYvbGR7F9huCK01b07--09vztJn4qa56gXxTVNsTiclpaZT6A9bY-V7GdF_oFUM0Cqs7gdlQgpTB4w61wGDQyE='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXIupUVDwCpwutsR5gTHP3knhqgeqx1-UjZ-rtnMAAQYRavNMfBgR84EJxV_whrCGpDL34Tx-mW_PlB7U9r51ra9oSM_tpgAyFY8onVZYgfwH-h7Ovln2YUJFgBtf-4ycv7LCtjvqfp3pRh3ahsYtCrraLiwLTyh-O2_H-NXUS5smQc28N--AWtZnpMSMfg8Gu1e4DddCncVsWohgtSFxGXWoE0ZB9AMaPQfun2DgF'},\n",
       "  {'label': 'imfreelife',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-21',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFqq-92cQDvMrxHfxRk9F3QzoLvWvtwbiAuIedJJVU0mXbyQ_0vla-jbqStKSg66KcB5YzYkD6jDFAoVkJAwgG9N214ieJar-lBvgY8KOzI8-zjma278RalRJi0yWM5YlFqTPrbA-ldTsWyWMklvHXIb7vaYQUqU4t3uzSaRQVu7jWQ4xpl-NFVdj9cdfb8K32E94Sr_u9Wt7X0bOtY7vkVQmu57D2IwdXd-Sc1Lnnps7cfhzqKGDdKvW6Kjq3UvW55I1CHw3ZhICUYKX-SD92rX9_aohAY5DvqwVnZll-p8QuAj788EliAL14='},\n",
       "  {'label': 'pagecall',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHdKDQfUHaG8gV_EeQTJss3HgpLbiG3Sew8zpnB626wm0NAkDVambLc1_qiBBxSG96dqTED6_lPPEllq9YxtASdLxsrG1cFmpPvRlx35ML7TpM41s-hIq3ivKdf-VSksyVRKctBBkFql6GDt24wBUwaikOms2v5m_iwdK4dcstoNXSA2BXiwt8kIozAF_iG6nSIJjV_SgKtj7-aIrOymX57Z2Nv30JyZhJwcB103z-oEyj-87FPWv50C9y-elQPrCUp_bths-kYQrYS3HbBd75WY_rc931AkQXTwomVB6ChZ8zSZhiXM3fzg-uUJmxWEJIIsrAmMI0cwxABtX4_KIUw-Ybu_x0wiPQjrMRDTbq5rWvUYabbIQ=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGTdUKRsUmw52ia1bc8otOws8QO3e_BHmrzI5bZ8JLlCkuuC1dIPyY3r7YToqlUxqcF_ExSRkF5ba7MYUa8HxKSHcMv95qzbpVTRDCnodPqsMj_HbpF8Lj1qpAY0v1'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGPXoRZRoEQyt-3v9RjKkX1qwqGPR1u5JTW3c3D3DDIVQelGBgv4QDLQSkL2WdJ8f1xyt5w1G-ElWhMWa6NAaF9HXmpgng8zKq8stk1RBlEjh9HRrIhLqp399_Jbzsh'},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGTdUKRsUmw52ia1bc8otOws8QO3e_BHmrzI5bZ8JLlCkuuC1dIPyY3r7YToqlUxqcF_ExSRkF5ba7MYUa8HxKSHcMv95qzbpVTRDCnodPqsMj_HbpF8Lj1qpAY0v1'},\n",
       "  {'label': 'sangseek',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHDxOD7V44CGHv-roI34fWPMqY7-y82TgYUrFdsmcTQUvtMr9DyAn0p_k2ZG3YGZpSceOAjFh6DqWyJb5ALTnz1avCAkbk4kE0sOV4qzOn9dbyZt32OJyWW2CiNzBEUDrN0kw=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-20',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGJTZkHo5a0dslZtwzXyTE9RlcFMchEAh196AYvbGR7F9huCK01b07--09vztJn4qa56gXxTVNsTiclpaZT6A9bY-V7GdF_oFUM0Cqs7gdlQgpTB4w61wGDQyE='},\n",
       "  {'label': 'network-rich',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFa4nUNKjgYCz48_Q43O96NtPCmjcyUEhR31txdyK_ITV5__w4oiFktkm_0H2WYtfCwPiwccWWOQ7nXCkf4d-RZ0YxH2gzm7XVZ-XPH0HO0UgjGnd-F5aIjXXp28nyPYhSX00dqMCxteXrj13-Dp2mtFyj7'},\n",
       "  {'label': 'sangseek',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHDxOD7V44CGHv-roI34fWPMqY7-y82TgYUrFdsmcTQUvtMr9DyAn0p_k2ZG3YGZpSceOAjFh6DqWyJb5ALTnz1avCAkbk4kE0sOV4qzOn9dbyZt32OJyWW2CiNzBEUDrN0kw=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-20',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGJTZkHo5a0dslZtwzXyTE9RlcFMchEAh196AYvbGR7F9huCK01b07--09vztJn4qa56gXxTVNsTiclpaZT6A9bY-V7GdF_oFUM0Cqs7gdlQgpTB4w61wGDQyE='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-22',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHoUIJ8pXgL1u5zegbv-sTVrNik-C-sTvBl9WKbR8N1qXHOSMBAQ8q0UA9xfgI3w1-7OZGk0w-VCdAHefxCik5PH7ZuM7sC1wpwfnUcwB7f3SM9yGgv2NfFiPQr3J-zTeeYxAiH0r8='},\n",
       "  {'label': 'kiu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-23',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE2BLw3k36KHa_ciuhKktpiTRtT8i2Xr_Z2Uk48Tre8j-zwHWs4DPxmu1Ku6mq9N6nN0vnzlgUlp6MxFiDx4fqhsx2EZ4RrZkNr9gL-KSBJqP_V8dk-KywkTgWow2WEQQk1MdeKnxiPBm2Akjs='},\n",
       "  {'label': 'network-rich',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFa4nUNKjgYCz48_Q43O96NtPCmjcyUEhR31txdyK_ITV5__w4oiFktkm_0H2WYtfCwPiwccWWOQ7nXCkf4d-RZ0YxH2gzm7XVZ-XPH0HO0UgjGnd-F5aIjXXp28nyPYhSX00dqMCxteXrj13-Dp2mtFyj7'},\n",
       "  {'label': 'sangseek',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHDxOD7V44CGHv-roI34fWPMqY7-y82TgYUrFdsmcTQUvtMr9DyAn0p_k2ZG3YGZpSceOAjFh6DqWyJb5ALTnz1avCAkbk4kE0sOV4qzOn9dbyZt32OJyWW2CiNzBEUDrN0kw=='},\n",
       "  {'label': '21erick',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF-QbihUYvSj_jHySd_VzH5_LRbLgdpBMSb6b6jI00rIMWfI5VQlfVvZbdNcN_fhDwSbmmDSJ1Doo3K9IqYoMpCHDRgbmNOrdpz4L5E9FD8ghwCyBp2LsB6mDD_fA=='},\n",
       "  {'label': 'kiu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-23',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE2BLw3k36KHa_ciuhKktpiTRtT8i2Xr_Z2Uk48Tre8j-zwHWs4DPxmu1Ku6mq9N6nN0vnzlgUlp6MxFiDx4fqhsx2EZ4RrZkNr9gL-KSBJqP_V8dk-KywkTgWow2WEQQk1MdeKnxiPBm2Akjs='},\n",
       "  {'label': 'samwell',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-16',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZm1qKSaZ8QnYVNEqo61z-S-ucu1iu_YXwXbNsKFO_eCQKPE4yqzd3eg2lIPSy_tX0uQ7RtiJb6XicXc96abO8w4hc66M6eGN_0MX7InFyQg0yKTgLhL_d4Kk36NdZosJQCV9jlX54YdG2AF3223z93xSWS47X2VW-0sUq'},\n",
       "  {'label': 'kiu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-23',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE2BLw3k36KHa_ciuhKktpiTRtT8i2Xr_Z2Uk48Tre8j-zwHWs4DPxmu1Ku6mq9N6nN0vnzlgUlp6MxFiDx4fqhsx2EZ4RrZkNr9gL-KSBJqP_V8dk-KywkTgWow2WEQQk1MdeKnxiPBm2Akjs='},\n",
       "  {'label': 'qyndora',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-24',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEl-tDWunPUPjMInzDcvxMjzM-L1aPAs2Zd3pqntxObwYjpDHKacX-CLkcsJ8c8Qhj0NoP7IOxqz98gOUjMq97V5PNoX3bqZqYFegfEiremvbLO5xXeENWE6zdG1TWj5TIygH-ZukojnxbadwV9_vVZMe9qEgvVKBh8RwPhtVLJ0LOKT9_Y2segyBnscnV0LHiW9vMunnO0Ee_8IGksCslfPaPmIfhIdkyKIoYmqnOs1pGBGMgUBsgD8-Wz7x4tBR_eKyp9BdRuGBcLFNkqqyFvelFH87W7ilL4ZSTJZ9DdBKUYqAb5A82P44aFC_i_jTzLwXc7PymnWtoGO7R1YMD6dgQ_C2l2U40CihFlyka0A82x9HfhZXEmmdn4Wz0='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQELK1O9YQHKog-EQq7MRcD1iJhsGiuyXnceQ9LqtStjIR6R0mOM-x3fUGC3-PCR14mXyMoCN2gmjc1i3BAMAwXhf7sNgPMi30GQEUYvGyGCeEQxD8tcVzehheEzqiMkklnyA12U8LxL4LR3gttJ2qFfjKk60GhOard-y1eOH32kGY5ocaidpEVAko-vSiorOJUhJk3yYDWD1VCQpokQ9k0k3sspHusOBhInbrb0ZsSAB20d9TrFDQi6rokJKH6XMx508XdNsFynAjEYHUMSY14orLhC9BWD4_qGU_2itIAGCf5oiXLL8BlpMZIoDbp0oshakgL9-UxmoGLocycMp2Cw6JOybd2lBx3bebne540AyQZcuEYEDrv1xViwhfc='},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQENV4Kzm58IYkUHFdIHObuQmS1qqTMBNV57Bp1hNKUH6AerzlCO9ouxCQCczpanebKRW4r2JrR-9QuEb5rEOhsVdKv3e_DKPxR0bW9a0Unj71Ca5e0iG5GQX-PsiOnwggDCMmkbsR39byiiORO6iPhgchn_GPq4O8S7tdfcN4SC7ZB4WZ2LiaQrLXgHVsQy2z8='},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFnLH3KPT4HUNc6Dd_50MV_RZ0TnDJWaD15l-atW6yG8JWCXswjZG4jy32iqjp9CPlrRBSjkmI6cnKqbanYlrF7LV1clGv4VWTCfGrQ927o2XZI5O5l9ODJvPKiI-73f62ZJwLCge--a8IxKIxIwUQF6xQsTAuiglDNekyWzaGWbAhZ_1KzEy9Tn9-L1OxZFQ=='},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQENV4Kzm58IYkUHFdIHObuQmS1qqTMBNV57Bp1hNKUH6AerzlCO9ouxCQCczpanebKRW4r2JrR-9QuEb5rEOhsVdKv3e_DKPxR0bW9a0Unj71Ca5e0iG5GQX-PsiOnwggDCMmkbsR39byiiORO6iPhgchn_GPq4O8S7tdfcN4SC7ZB4WZ2LiaQrLXgHVsQy2z8='},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXjFmz-eZzTpMCsO9egUS9kcW0xjp7qGY9pZhHOEwJX44Cj8_eNdWP1ZX5xhtPJsSWYjmKscWFQ-KltE2v4OWVPK4PCfdQozEqzFGCL-NlFp01lmtWjdvix9oBLvtSnHwrKIkGXDajlaw05g9RQvc8HiRR'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNSIfxgHceqCwAneLQbIZ3n5K1lQ4Er93ziDKX8w7CoO8JN3KgdIle68lzlQnQzCXibpRdCNA-H9o-8T-NR6NsjSQAEGlPGZYm5UJb2R1WLrGr7_MbnALNu8o7BvVmIKYGexyOoZWBC667dYLmD7nws5WRH-4KJfEpK_PMm3UO03mCPVIyl7lZjDGq_VJ84Vgz3ZZeCqt5frMScH_25bteeQCI0WGg7vkDz1FIrrLZ'},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFnLH3KPT4HUNc6Dd_50MV_RZ0TnDJWaD15l-atW6yG8JWCXswjZG4jy32iqjp9CPlrRBSjkmI6cnKqbanYlrF7LV1clGv4VWTCfGrQ927o2XZI5O5l9ODJvPKiI-73f62ZJwLCge--a8IxKIxIwUQF6xQsTAuiglDNekyWzaGWbAhZ_1KzEy9Tn9-L1OxZFQ=='},\n",
       "  {'label': 'scribd',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEElCfm1YRwDDCi9kB48cINjYZ91nXxI_B8DdDj5oAhwH7H4xB4n_rFWDT7Yk64zjElW_0y7IrU6dtjRKivapLAyXsRb6DXFYXgHAsPZ9nE6bWRgfiYWp1ZYT-UC3zzlHSAaoBkd6iCm6OojBGrqhLOvRKut6i0qJtezpS4DLmvKTXm6OTGcw=='},\n",
       "  {'label': 'machinelearningmastery',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHNQ4x6C8PXZANK15nRwPE57XPthbI0LO9nlzwMafsHRX7QP0C6X4rIm0U6l4oUGMeYW3VsJG8uls_iLJEltUp3H5_Zf6_jdLRcmXFUlwCJXU3KH9o9PNwHVGAHnm__iU9SfZTssOEZnnWdK9wBr-t7r2yK3wjufqKmHXSV4J7m3zQAvD6X'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH6qb6tuVSjisXsKM4v1orF8_8rTsaMuhwHWPEhqax1rzWL27Z_BxxFB8-2gLW2JIuTgfr4CkKJxbUylthWvLtpWHPJzd-Fr6DTrQEjKGcGyTasZm0FUkfLqBVKohaaFgCn7odLylygwELgAxxMwuIjn_gOV3lF2klh0Qy6AyRsgSsaMwcih95y4kyDMuNpYsQ8vilQgKC_jy8cmJBejLC4T5UWqHhW3gT5Q2SoiCxY5ode'},\n",
       "  {'label': 'scribd',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEElCfm1YRwDDCi9kB48cINjYZ91nXxI_B8DdDj5oAhwH7H4xB4n_rFWDT7Yk64zjElW_0y7IrU6dtjRKivapLAyXsRb6DXFYXgHAsPZ9nE6bWRgfiYWp1ZYT-UC3zzlHSAaoBkd6iCm6OojBGrqhLOvRKut6i0qJtezpS4DLmvKTXm6OTGcw=='},\n",
       "  {'label': 'projectpro',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE2cs5B7yrop30q6Onb6ICe2Lrb5ATnAMxFWySC2uoBe7AanIaCuTp8sP0RiTxucRqmiZqoMxDlo8MQ2qjFXb8xRMuFx-GrUJynE7lnmP5kRUQjE7kc3RwQlrlqrJCELc1wXnFsfxlH9H54RXqdMrVjV8l9LWnf-Pov8m6e'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfELnsU3MJZs7MZ5cidjQpU1WG4P4MnxWnTP28uWOZRCXcFkY2XKnnSkMdfaRV1oguLHwmDQcxccs20EBldKp3yifQh8xkmgzb2wxkJo2uU47P5h7E8GNEk49YkXry_ym0hmK3oZxQ4t0xhMBk_f96HddYU8weNWySD5uzJvq29iq6MQeVGj95lC2aCbNionW_T4='},\n",
       "  {'label': 'philschmid',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvE5fF_hSFknYY6AK0PPXy78bDkX0IU3fl5CtJk0roAi0KTMHQdVkcbeX3992WRRCH7OT-7N-KyCz3qTQsGgtApN8ogaiARiTQAj8G1zpz5oSIagjnlQ3Snxv5Q2dpH7o5Qlb2'},\n",
       "  {'label': 'machinelearningmastery',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHNQ4x6C8PXZANK15nRwPE57XPthbI0LO9nlzwMafsHRX7QP0C6X4rIm0U6l4oUGMeYW3VsJG8uls_iLJEltUp3H5_Zf6_jdLRcmXFUlwCJXU3KH9o9PNwHVGAHnm__iU9SfZTssOEZnnWdK9wBr-t7r2yK3wjufqKmHXSV4J7m3zQAvD6X'},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHDy7cDMPgcuwXeHikVNeAKdjzDkbUNq3uIVftmtvqN285-x5aGMONEZoJAgVpqtt2w3kz_LoRhLH8y6-qnBHP8hxpyNgWsDVvHLlRNHOmJDZyd3c8XnZq7DUyxBLTnrTMuoIyN8qE='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-11',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHqi76Tghm10nzEoYp9GqbFh5FnNOgqKj05R-QWX6lNqdOT3oe8ICivHRK5D0m49QV79OaQJZbjxOtVWjQcVASaEeaG831MruqPzwFlgUSDQ7zh6VeqoOqzhzbnWGaMisiOSHFVaWc='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE34VHbeK73R253rtrtfWhefSUfuZRf7WOvP1Y3t14E7jm5BGYRkb4rvp45y4puWlK4DDkPWekIdlUL1VWSFYDaELn9ttkehvK_kkvqE23WlhLc4eOZWhpmGXZK7y4teCIlreRRojwhNyLJ8Ubs1cA5VlCFfvnbW8BqReSauubK'},\n",
       "  {'label': 'projectpro',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE2cs5B7yrop30q6Onb6ICe2Lrb5ATnAMxFWySC2uoBe7AanIaCuTp8sP0RiTxucRqmiZqoMxDlo8MQ2qjFXb8xRMuFx-GrUJynE7lnmP5kRUQjE7kc3RwQlrlqrJCELc1wXnFsfxlH9H54RXqdMrVjV8l9LWnf-Pov8m6e'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfELnsU3MJZs7MZ5cidjQpU1WG4P4MnxWnTP28uWOZRCXcFkY2XKnnSkMdfaRV1oguLHwmDQcxccs20EBldKp3yifQh8xkmgzb2wxkJo2uU47P5h7E8GNEk49YkXry_ym0hmK3oZxQ4t0xhMBk_f96HddYU8weNWySD5uzJvq29iq6MQeVGj95lC2aCbNionW_T4='},\n",
       "  {'label': 'philschmid',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvE5fF_hSFknYY6AK0PPXy78bDkX0IU3fl5CtJk0roAi0KTMHQdVkcbeX3992WRRCH7OT-7N-KyCz3qTQsGgtApN8ogaiARiTQAj8G1zpz5oSIagjnlQ3Snxv5Q2dpH7o5Qlb2'},\n",
       "  {'label': 'machinelearningmastery',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHNQ4x6C8PXZANK15nRwPE57XPthbI0LO9nlzwMafsHRX7QP0C6X4rIm0U6l4oUGMeYW3VsJG8uls_iLJEltUp3H5_Zf6_jdLRcmXFUlwCJXU3KH9o9PNwHVGAHnm__iU9SfZTssOEZnnWdK9wBr-t7r2yK3wjufqKmHXSV4J7m3zQAvD6X'},\n",
       "  {'label': 'scribd',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEElCfm1YRwDDCi9kB48cINjYZ91nXxI_B8DdDj5oAhwH7H4xB4n_rFWDT7Yk64zjElW_0y7IrU6dtjRKivapLAyXsRb6DXFYXgHAsPZ9nE6bWRgfiYWp1ZYT-UC3zzlHSAaoBkd6iCm6OojBGrqhLOvRKut6i0qJtezpS4DLmvKTXm6OTGcw=='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE34VHbeK73R253rtrtfWhefSUfuZRf7WOvP1Y3t14E7jm5BGYRkb4rvp45y4puWlK4DDkPWekIdlUL1VWSFYDaELn9ttkehvK_kkvqE23WlhLc4eOZWhpmGXZK7y4teCIlreRRojwhNyLJ8Ubs1cA5VlCFfvnbW8BqReSauubK'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfELnsU3MJZs7MZ5cidjQpU1WG4P4MnxWnTP28uWOZRCXcFkY2XKnnSkMdfaRV1oguLHwmDQcxccs20EBldKp3yifQh8xkmgzb2wxkJo2uU47P5h7E8GNEk49YkXry_ym0hmK3oZxQ4t0xhMBk_f96HddYU8weNWySD5uzJvq29iq6MQeVGj95lC2aCbNionW_T4='},\n",
       "  {'label': 'philschmid',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvE5fF_hSFknYY6AK0PPXy78bDkX0IU3fl5CtJk0roAi0KTMHQdVkcbeX3992WRRCH7OT-7N-KyCz3qTQsGgtApN8ogaiARiTQAj8G1zpz5oSIagjnlQ3Snxv5Q2dpH7o5Qlb2'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH6qb6tuVSjisXsKM4v1orF8_8rTsaMuhwHWPEhqax1rzWL27Z_BxxFB8-2gLW2JIuTgfr4CkKJxbUylthWvLtpWHPJzd-Fr6DTrQEjKGcGyTasZm0FUkfLqBVKohaaFgCn7odLylygwELgAxxMwuIjn_gOV3lF2klh0Qy6AyRsgSsaMwcih95y4kyDMuNpYsQ8vilQgKC_jy8cmJBejLC4T5UWqHhW3gT5Q2SoiCxY5ode'},\n",
       "  {'label': 'scribd',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEElCfm1YRwDDCi9kB48cINjYZ91nXxI_B8DdDj5oAhwH7H4xB4n_rFWDT7Yk64zjElW_0y7IrU6dtjRKivapLAyXsRb6DXFYXgHAsPZ9nE6bWRgfiYWp1ZYT-UC3zzlHSAaoBkd6iCm6OojBGrqhLOvRKut6i0qJtezpS4DLmvKTXm6OTGcw=='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE34VHbeK73R253rtrtfWhefSUfuZRf7WOvP1Y3t14E7jm5BGYRkb4rvp45y4puWlK4DDkPWekIdlUL1VWSFYDaELn9ttkehvK_kkvqE23WlhLc4eOZWhpmGXZK7y4teCIlreRRojwhNyLJ8Ubs1cA5VlCFfvnbW8BqReSauubK'},\n",
       "  {'label': 'mongodb',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEa7F0uZ126TDPmMyC8gjU-Enojmstx1IFc_9mMEo89rwVxayuaZR8pS87gjmoW8YWbbouw2LCpUhhGsCkmUqyP2Ip1xqIa5XM0m2fCL6YswsD8Nfwy6YzqrHsp0aenCUhQCK-kP-yKdOsrRFNnHFf-_seaQ_F6g-H_aDgy6e7iAHOAABIZKZpiCSXh'},\n",
       "  {'label': 'projectpro',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE2cs5B7yrop30q6Onb6ICe2Lrb5ATnAMxFWySC2uoBe7AanIaCuTp8sP0RiTxucRqmiZqoMxDlo8MQ2qjFXb8xRMuFx-GrUJynE7lnmP5kRUQjE7kc3RwQlrlqrJCELc1wXnFsfxlH9H54RXqdMrVjV8l9LWnf-Pov8m6e'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfELnsU3MJZs7MZ5cidjQpU1WG4P4MnxWnTP28uWOZRCXcFkY2XKnnSkMdfaRV1oguLHwmDQcxccs20EBldKp3yifQh8xkmgzb2wxkJo2uU47P5h7E8GNEk49YkXry_ym0hmK3oZxQ4t0xhMBk_f96HddYU8weNWySD5uzJvq29iq6MQeVGj95lC2aCbNionW_T4='},\n",
       "  {'label': 'philschmid',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvE5fF_hSFknYY6AK0PPXy78bDkX0IU3fl5CtJk0roAi0KTMHQdVkcbeX3992WRRCH7OT-7N-KyCz3qTQsGgtApN8ogaiARiTQAj8G1zpz5oSIagjnlQ3Snxv5Q2dpH7o5Qlb2'},\n",
       "  {'label': 'philschmid',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvE5fF_hSFknYY6AK0PPXy78bDkX0IU3fl5CtJk0roAi0KTMHQdVkcbeX3992WRRCH7OT-7N-KyCz3qTQsGgtApN8ogaiARiTQAj8G1zpz5oSIagjnlQ3Snxv5Q2dpH7o5Qlb2'},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHHWkOshfznUWDFLGiiWFKRlA82itqxXpJKnj0W26xkVvyU258X-YpW0rKcbjAcsNA9Je-jbwkYvvxamiPVNxTcOZgWIrNM_drpbR-7ByoDlDOlzB3n14LvQorEpSUDj8lmsO3dGvI='},\n",
       "  {'label': 'anthropic',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEiUS25WrTXB7MXBjLgNbqfuj7AhMQgoerCwMGkDIGe5k2GbfnFJLlRWZTGeGOUufVTsDYLb4APfyrQVNetdc25-LMtW1yWpqNmzjOuKNqBqauewNuyMEFXcbw9kE_DMqKOY6edwhKgWomFvpWczF_b4y0cnC-30Q=='},\n",
       "  {'label': 'philschmid',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvE5fF_hSFknYY6AK0PPXy78bDkX0IU3fl5CtJk0roAi0KTMHQdVkcbeX3992WRRCH7OT-7N-KyCz3qTQsGgtApN8ogaiARiTQAj8G1zpz5oSIagjnlQ3Snxv5Q2dpH7o5Qlb2'},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHHWkOshfznUWDFLGiiWFKRlA82itqxXpJKnj0W26xkVvyU258X-YpW0rKcbjAcsNA9Je-jbwkYvvxamiPVNxTcOZgWIrNM_drpbR-7ByoDlDOlzB3n14LvQorEpSUDj8lmsO3dGvI='},\n",
       "  {'label': 'philschmid',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvE5fF_hSFknYY6AK0PPXy78bDkX0IU3fl5CtJk0roAi0KTMHQdVkcbeX3992WRRCH7OT-7N-KyCz3qTQsGgtApN8ogaiARiTQAj8G1zpz5oSIagjnlQ3Snxv5Q2dpH7o5Qlb2'},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHHWkOshfznUWDFLGiiWFKRlA82itqxXpJKnj0W26xkVvyU258X-YpW0rKcbjAcsNA9Je-jbwkYvvxamiPVNxTcOZgWIrNM_drpbR-7ByoDlDOlzB3n14LvQorEpSUDj8lmsO3dGvI='},\n",
       "  {'label': 'anthropic',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEiUS25WrTXB7MXBjLgNbqfuj7AhMQgoerCwMGkDIGe5k2GbfnFJLlRWZTGeGOUufVTsDYLb4APfyrQVNetdc25-LMtW1yWpqNmzjOuKNqBqauewNuyMEFXcbw9kE_DMqKOY6edwhKgWomFvpWczF_b4y0cnC-30Q=='},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQENV4Kzm58IYkUHFdIHObuQmS1qqTMBNV57Bp1hNKUH6AerzlCO9ouxCQCczpanebKRW4r2JrR-9QuEb5rEOhsVdKv3e_DKPxR0bW9a0Unj71Ca5e0iG5GQX-PsiOnwggDCMmkbsR39byiiORO6iPhgchn_GPq4O8S7tdfcN4SC7ZB4WZ2LiaQrLXgHVsQy2z8='},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXjFmz-eZzTpMCsO9egUS9kcW0xjp7qGY9pZhHOEwJX44Cj8_eNdWP1ZX5xhtPJsSWYjmKscWFQ-KltE2v4OWVPK4PCfdQozEqzFGCL-NlFp01lmtWjdvix9oBLvtSnHwrKIkGXDajlaw05g9RQvc8HiRR'},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFnLH3KPT4HUNc6Dd_50MV_RZ0TnDJWaD15l-atW6yG8JWCXswjZG4jy32iqjp9CPlrRBSjkmI6cnKqbanYlrF7LV1clGv4VWTCfGrQ927o2XZI5O5l9ODJvPKiI-73f62ZJwLCge--a8IxKIxIwUQF6xQsTAuiglDNekyWzaGWbAhZ_1KzEy9Tn9-L1OxZFQ=='},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQENV4Kzm58IYkUHFdIHObuQmS1qqTMBNV57Bp1hNKUH6AerzlCO9ouxCQCczpanebKRW4r2JrR-9QuEb5rEOhsVdKv3e_DKPxR0bW9a0Unj71Ca5e0iG5GQX-PsiOnwggDCMmkbsR39byiiORO6iPhgchn_GPq4O8S7tdfcN4SC7ZB4WZ2LiaQrLXgHVsQy2z8='},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXjFmz-eZzTpMCsO9egUS9kcW0xjp7qGY9pZhHOEwJX44Cj8_eNdWP1ZX5xhtPJsSWYjmKscWFQ-KltE2v4OWVPK4PCfdQozEqzFGCL-NlFp01lmtWjdvix9oBLvtSnHwrKIkGXDajlaw05g9RQvc8HiRR'},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFnLH3KPT4HUNc6Dd_50MV_RZ0TnDJWaD15l-atW6yG8JWCXswjZG4jy32iqjp9CPlrRBSjkmI6cnKqbanYlrF7LV1clGv4VWTCfGrQ927o2XZI5O5l9ODJvPKiI-73f62ZJwLCge--a8IxKIxIwUQF6xQsTAuiglDNekyWzaGWbAhZ_1KzEy9Tn9-L1OxZFQ=='},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQENV4Kzm58IYkUHFdIHObuQmS1qqTMBNV57Bp1hNKUH6AerzlCO9ouxCQCczpanebKRW4r2JrR-9QuEb5rEOhsVdKv3e_DKPxR0bW9a0Unj71Ca5e0iG5GQX-PsiOnwggDCMmkbsR39byiiORO6iPhgchn_GPq4O8S7tdfcN4SC7ZB4WZ2LiaQrLXgHVsQy2z8='},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXjFmz-eZzTpMCsO9egUS9kcW0xjp7qGY9pZhHOEwJX44Cj8_eNdWP1ZX5xhtPJsSWYjmKscWFQ-KltE2v4OWVPK4PCfdQozEqzFGCL-NlFp01lmtWjdvix9oBLvtSnHwrKIkGXDajlaw05g9RQvc8HiRR'},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFnLH3KPT4HUNc6Dd_50MV_RZ0TnDJWaD15l-atW6yG8JWCXswjZG4jy32iqjp9CPlrRBSjkmI6cnKqbanYlrF7LV1clGv4VWTCfGrQ927o2XZI5O5l9ODJvPKiI-73f62ZJwLCge--a8IxKIxIwUQF6xQsTAuiglDNekyWzaGWbAhZ_1KzEy9Tn9-L1OxZFQ=='},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFnLH3KPT4HUNc6Dd_50MV_RZ0TnDJWaD15l-atW6yG8JWCXswjZG4jy32iqjp9CPlrRBSjkmI6cnKqbanYlrF7LV1clGv4VWTCfGrQ927o2XZI5O5l9ODJvPKiI-73f62ZJwLCge--a8IxKIxIwUQF6xQsTAuiglDNekyWzaGWbAhZ_1KzEy9Tn9-L1OxZFQ=='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNSIfxgHceqCwAneLQbIZ3n5K1lQ4Er93ziDKX8w7CoO8JN3KgdIle68lzlQnQzCXibpRdCNA-H9o-8T-NR6NsjSQAEGlPGZYm5UJb2R1WLrGr7_MbnALNu8o7BvVmIKYGexyOoZWBC667dYLmD7nws5WRH-4KJfEpK_PMm3UO03mCPVIyl7lZjDGq_VJ84Vgz3ZZeCqt5frMScH_25bteeQCI0WGg7vkDz1FIrrLZ'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH6qb6tuVSjisXsKM4v1orF8_8rTsaMuhwHWPEhqax1rzWL27Z_BxxFB8-2gLW2JIuTgfr4CkKJxbUylthWvLtpWHPJzd-Fr6DTrQEjKGcGyTasZm0FUkfLqBVKohaaFgCn7odLylygwELgAxxMwuIjn_gOV3lF2klh0Qy6AyRsgSsaMwcih95y4kyDMuNpYsQ8vilQgKC_jy8cmJBejLC4T5UWqHhW3gT5Q2SoiCxY5ode'},\n",
       "  {'label': 'openai',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-16',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGiKeNFuwW7RuxYXxnuDwScUA82pLriBH-lBgTwMw5stxQcvic4W3fsPWCXWzxiXyQNEJJt6SyaiDsL73uHnpM5uP0718KTKUtqAY-iYIvCQ6y6ce9IOxpxnI5R9tlpZPZmBh4MjxTxbNDCMb-WLkl6a2TnoW4QdhkqGtI5rRvFMRpGhuojI_XcZtDiCIJRk13y_5v65cfkXA=='},\n",
       "  {'label': 'databricks',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQjOzzXP9xdf37qLCSppLQAAOfVr-5nQkxL3HNna__36fipOz1kFiVYBsw3ir6ZSBctph40EOHbdP21VsL3HDGujGuPHljK3Pu-nIzfJohN6qDXI1_F1iYopAs6aERPSQKBTaYljVKfKrXIG-ZG3zaenhBe4ye0bLj8r7O-4-t-HMDMEGb7h_ifQvpVPkQ'},\n",
       "  {'label': 'mongodb',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEa7F0uZ126TDPmMyC8gjU-Enojmstx1IFc_9mMEo89rwVxayuaZR8pS87gjmoW8YWbbouw2LCpUhhGsCkmUqyP2Ip1xqIa5XM0m2fCL6YswsD8Nfwy6YzqrHsp0aenCUhQCK-kP-yKdOsrRFNnHFf-_seaQ_F6g-H_aDgy6e7iAHOAABIZKZpiCSXh'},\n",
       "  {'label': 'philschmid',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvE5fF_hSFknYY6AK0PPXy78bDkX0IU3fl5CtJk0roAi0KTMHQdVkcbeX3992WRRCH7OT-7N-KyCz3qTQsGgtApN8ogaiARiTQAj8G1zpz5oSIagjnlQ3Snxv5Q2dpH7o5Qlb2'},\n",
       "  {'label': 'anthropic',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEiUS25WrTXB7MXBjLgNbqfuj7AhMQgoerCwMGkDIGe5k2GbfnFJLlRWZTGeGOUufVTsDYLb4APfyrQVNetdc25-LMtW1yWpqNmzjOuKNqBqauewNuyMEFXcbw9kE_DMqKOY6edwhKgWomFvpWczF_b4y0cnC-30Q=='},\n",
       "  {'label': 'machinelearningmastery',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHNQ4x6C8PXZANK15nRwPE57XPthbI0LO9nlzwMafsHRX7QP0C6X4rIm0U6l4oUGMeYW3VsJG8uls_iLJEltUp3H5_Zf6_jdLRcmXFUlwCJXU3KH9o9PNwHVGAHnm__iU9SfZTssOEZnnWdK9wBr-t7r2yK3wjufqKmHXSV4J7m3zQAvD6X'},\n",
       "  {'label': 'databricks',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQjOzzXP9xdf37qLCSppLQAAOfVr-5nQkxL3HNna__36fipOz1kFiVYBsw3ir6ZSBctph40EOHbdP21VsL3HDGujGuPHljK3Pu-nIzfJohN6qDXI1_F1iYopAs6aERPSQKBTaYljVKfKrXIG-ZG3zaenhBe4ye0bLj8r7O-4-t-HMDMEGb7h_ifQvpVPkQ'},\n",
       "  {'label': 'philschmid',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvE5fF_hSFknYY6AK0PPXy78bDkX0IU3fl5CtJk0roAi0KTMHQdVkcbeX3992WRRCH7OT-7N-KyCz3qTQsGgtApN8ogaiARiTQAj8G1zpz5oSIagjnlQ3Snxv5Q2dpH7o5Qlb2'},\n",
       "  {'label': 'anthropic',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEiUS25WrTXB7MXBjLgNbqfuj7AhMQgoerCwMGkDIGe5k2GbfnFJLlRWZTGeGOUufVTsDYLb4APfyrQVNetdc25-LMtW1yWpqNmzjOuKNqBqauewNuyMEFXcbw9kE_DMqKOY6edwhKgWomFvpWczF_b4y0cnC-30Q=='},\n",
       "  {'label': 'machinelearningmastery',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHNQ4x6C8PXZANK15nRwPE57XPthbI0LO9nlzwMafsHRX7QP0C6X4rIm0U6l4oUGMeYW3VsJG8uls_iLJEltUp3H5_Zf6_jdLRcmXFUlwCJXU3KH9o9PNwHVGAHnm__iU9SfZTssOEZnnWdK9wBr-t7r2yK3wjufqKmHXSV4J7m3zQAvD6X'},\n",
       "  {'label': 'databricks',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQjOzzXP9xdf37qLCSppLQAAOfVr-5nQkxL3HNna__36fipOz1kFiVYBsw3ir6ZSBctph40EOHbdP21VsL3HDGujGuPHljK3Pu-nIzfJohN6qDXI1_F1iYopAs6aERPSQKBTaYljVKfKrXIG-ZG3zaenhBe4ye0bLj8r7O-4-t-HMDMEGb7h_ifQvpVPkQ'},\n",
       "  {'label': 'mongodb',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEa7F0uZ126TDPmMyC8gjU-Enojmstx1IFc_9mMEo89rwVxayuaZR8pS87gjmoW8YWbbouw2LCpUhhGsCkmUqyP2Ip1xqIa5XM0m2fCL6YswsD8Nfwy6YzqrHsp0aenCUhQCK-kP-yKdOsrRFNnHFf-_seaQ_F6g-H_aDgy6e7iAHOAABIZKZpiCSXh'},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFnLH3KPT4HUNc6Dd_50MV_RZ0TnDJWaD15l-atW6yG8JWCXswjZG4jy32iqjp9CPlrRBSjkmI6cnKqbanYlrF7LV1clGv4VWTCfGrQ927o2XZI5O5l9ODJvPKiI-73f62ZJwLCge--a8IxKIxIwUQF6xQsTAuiglDNekyWzaGWbAhZ_1KzEy9Tn9-L1OxZFQ=='},\n",
       "  {'label': 'openai',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-16',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGiKeNFuwW7RuxYXxnuDwScUA82pLriBH-lBgTwMw5stxQcvic4W3fsPWCXWzxiXyQNEJJt6SyaiDsL73uHnpM5uP0718KTKUtqAY-iYIvCQ6y6ce9IOxpxnI5R9tlpZPZmBh4MjxTxbNDCMb-WLkl6a2TnoW4QdhkqGtI5rRvFMRpGhuojI_XcZtDiCIJRk13y_5v65cfkXA=='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfELnsU3MJZs7MZ5cidjQpU1WG4P4MnxWnTP28uWOZRCXcFkY2XKnnSkMdfaRV1oguLHwmDQcxccs20EBldKp3yifQh8xkmgzb2wxkJo2uU47P5h7E8GNEk49YkXry_ym0hmK3oZxQ4t0xhMBk_f96HddYU8weNWySD5uzJvq29iq6MQeVGj95lC2aCbNionW_T4='},\n",
       "  {'label': 'anthropic',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEiUS25WrTXB7MXBjLgNbqfuj7AhMQgoerCwMGkDIGe5k2GbfnFJLlRWZTGeGOUufVTsDYLb4APfyrQVNetdc25-LMtW1yWpqNmzjOuKNqBqauewNuyMEFXcbw9kE_DMqKOY6edwhKgWomFvpWczF_b4y0cnC-30Q=='},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFnLH3KPT4HUNc6Dd_50MV_RZ0TnDJWaD15l-atW6yG8JWCXswjZG4jy32iqjp9CPlrRBSjkmI6cnKqbanYlrF7LV1clGv4VWTCfGrQ927o2XZI5O5l9ODJvPKiI-73f62ZJwLCge--a8IxKIxIwUQF6xQsTAuiglDNekyWzaGWbAhZ_1KzEy9Tn9-L1OxZFQ=='},\n",
       "  {'label': 'openai',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-16',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGiKeNFuwW7RuxYXxnuDwScUA82pLriBH-lBgTwMw5stxQcvic4W3fsPWCXWzxiXyQNEJJt6SyaiDsL73uHnpM5uP0718KTKUtqAY-iYIvCQ6y6ce9IOxpxnI5R9tlpZPZmBh4MjxTxbNDCMb-WLkl6a2TnoW4QdhkqGtI5rRvFMRpGhuojI_XcZtDiCIJRk13y_5v65cfkXA=='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfELnsU3MJZs7MZ5cidjQpU1WG4P4MnxWnTP28uWOZRCXcFkY2XKnnSkMdfaRV1oguLHwmDQcxccs20EBldKp3yifQh8xkmgzb2wxkJo2uU47P5h7E8GNEk49YkXry_ym0hmK3oZxQ4t0xhMBk_f96HddYU8weNWySD5uzJvq29iq6MQeVGj95lC2aCbNionW_T4='},\n",
       "  {'label': 'anthropic',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEiUS25WrTXB7MXBjLgNbqfuj7AhMQgoerCwMGkDIGe5k2GbfnFJLlRWZTGeGOUufVTsDYLb4APfyrQVNetdc25-LMtW1yWpqNmzjOuKNqBqauewNuyMEFXcbw9kE_DMqKOY6edwhKgWomFvpWczF_b4y0cnC-30Q=='},\n",
       "  {'label': 'openai',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-16',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGiKeNFuwW7RuxYXxnuDwScUA82pLriBH-lBgTwMw5stxQcvic4W3fsPWCXWzxiXyQNEJJt6SyaiDsL73uHnpM5uP0718KTKUtqAY-iYIvCQ6y6ce9IOxpxnI5R9tlpZPZmBh4MjxTxbNDCMb-WLkl6a2TnoW4QdhkqGtI5rRvFMRpGhuojI_XcZtDiCIJRk13y_5v65cfkXA=='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfELnsU3MJZs7MZ5cidjQpU1WG4P4MnxWnTP28uWOZRCXcFkY2XKnnSkMdfaRV1oguLHwmDQcxccs20EBldKp3yifQh8xkmgzb2wxkJo2uU47P5h7E8GNEk49YkXry_ym0hmK3oZxQ4t0xhMBk_f96HddYU8weNWySD5uzJvq29iq6MQeVGj95lC2aCbNionW_T4='},\n",
       "  {'label': 'anthropic',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEiUS25WrTXB7MXBjLgNbqfuj7AhMQgoerCwMGkDIGe5k2GbfnFJLlRWZTGeGOUufVTsDYLb4APfyrQVNetdc25-LMtW1yWpqNmzjOuKNqBqauewNuyMEFXcbw9kE_DMqKOY6edwhKgWomFvpWczF_b4y0cnC-30Q=='},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXjFmz-eZzTpMCsO9egUS9kcW0xjp7qGY9pZhHOEwJX44Cj8_eNdWP1ZX5xhtPJsSWYjmKscWFQ-KltE2v4OWVPK4PCfdQozEqzFGCL-NlFp01lmtWjdvix9oBLvtSnHwrKIkGXDajlaw05g9RQvc8HiRR'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNSIfxgHceqCwAneLQbIZ3n5K1lQ4Er93ziDKX8w7CoO8JN3KgdIle68lzlQnQzCXibpRdCNA-H9o-8T-NR6NsjSQAEGlPGZYm5UJb2R1WLrGr7_MbnALNu8o7BvVmIKYGexyOoZWBC667dYLmD7nws5WRH-4KJfEpK_PMm3UO03mCPVIyl7lZjDGq_VJ84Vgz3ZZeCqt5frMScH_25bteeQCI0WGg7vkDz1FIrrLZ'},\n",
       "  {'label': 'scribd',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEElCfm1YRwDDCi9kB48cINjYZ91nXxI_B8DdDj5oAhwH7H4xB4n_rFWDT7Yk64zjElW_0y7IrU6dtjRKivapLAyXsRb6DXFYXgHAsPZ9nE6bWRgfiYWp1ZYT-UC3zzlHSAaoBkd6iCm6OojBGrqhLOvRKut6i0qJtezpS4DLmvKTXm6OTGcw=='},\n",
       "  {'label': 'databricks',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQjOzzXP9xdf37qLCSppLQAAOfVr-5nQkxL3HNna__36fipOz1kFiVYBsw3ir6ZSBctph40EOHbdP21VsL3HDGujGuPHljK3Pu-nIzfJohN6qDXI1_F1iYopAs6aERPSQKBTaYljVKfKrXIG-ZG3zaenhBe4ye0bLj8r7O-4-t-HMDMEGb7h_ifQvpVPkQ'},\n",
       "  {'label': 'philschmid',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvE5fF_hSFknYY6AK0PPXy78bDkX0IU3fl5CtJk0roAi0KTMHQdVkcbeX3992WRRCH7OT-7N-KyCz3qTQsGgtApN8ogaiARiTQAj8G1zpz5oSIagjnlQ3Snxv5Q2dpH7o5Qlb2'},\n",
       "  {'label': 'anthropic',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEiUS25WrTXB7MXBjLgNbqfuj7AhMQgoerCwMGkDIGe5k2GbfnFJLlRWZTGeGOUufVTsDYLb4APfyrQVNetdc25-LMtW1yWpqNmzjOuKNqBqauewNuyMEFXcbw9kE_DMqKOY6edwhKgWomFvpWczF_b4y0cnC-30Q=='},\n",
       "  {'label': 'machinelearningmastery',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHNQ4x6C8PXZANK15nRwPE57XPthbI0LO9nlzwMafsHRX7QP0C6X4rIm0U6l4oUGMeYW3VsJG8uls_iLJEltUp3H5_Zf6_jdLRcmXFUlwCJXU3KH9o9PNwHVGAHnm__iU9SfZTssOEZnnWdK9wBr-t7r2yK3wjufqKmHXSV4J7m3zQAvD6X'},\n",
       "  {'label': 'scribd',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEElCfm1YRwDDCi9kB48cINjYZ91nXxI_B8DdDj5oAhwH7H4xB4n_rFWDT7Yk64zjElW_0y7IrU6dtjRKivapLAyXsRb6DXFYXgHAsPZ9nE6bWRgfiYWp1ZYT-UC3zzlHSAaoBkd6iCm6OojBGrqhLOvRKut6i0qJtezpS4DLmvKTXm6OTGcw=='},\n",
       "  {'label': 'machinelearningmastery',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHNQ4x6C8PXZANK15nRwPE57XPthbI0LO9nlzwMafsHRX7QP0C6X4rIm0U6l4oUGMeYW3VsJG8uls_iLJEltUp3H5_Zf6_jdLRcmXFUlwCJXU3KH9o9PNwHVGAHnm__iU9SfZTssOEZnnWdK9wBr-t7r2yK3wjufqKmHXSV4J7m3zQAvD6X'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH6qb6tuVSjisXsKM4v1orF8_8rTsaMuhwHWPEhqax1rzWL27Z_BxxFB8-2gLW2JIuTgfr4CkKJxbUylthWvLtpWHPJzd-Fr6DTrQEjKGcGyTasZm0FUkfLqBVKohaaFgCn7odLylygwELgAxxMwuIjn_gOV3lF2klh0Qy6AyRsgSsaMwcih95y4kyDMuNpYsQ8vilQgKC_jy8cmJBejLC4T5UWqHhW3gT5Q2SoiCxY5ode'},\n",
       "  {'label': 'scribd',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEElCfm1YRwDDCi9kB48cINjYZ91nXxI_B8DdDj5oAhwH7H4xB4n_rFWDT7Yk64zjElW_0y7IrU6dtjRKivapLAyXsRb6DXFYXgHAsPZ9nE6bWRgfiYWp1ZYT-UC3zzlHSAaoBkd6iCm6OojBGrqhLOvRKut6i0qJtezpS4DLmvKTXm6OTGcw=='},\n",
       "  {'label': 'projectpro',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE2cs5B7yrop30q6Onb6ICe2Lrb5ATnAMxFWySC2uoBe7AanIaCuTp8sP0RiTxucRqmiZqoMxDlo8MQ2qjFXb8xRMuFx-GrUJynE7lnmP5kRUQjE7kc3RwQlrlqrJCELc1wXnFsfxlH9H54RXqdMrVjV8l9LWnf-Pov8m6e'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfELnsU3MJZs7MZ5cidjQpU1WG4P4MnxWnTP28uWOZRCXcFkY2XKnnSkMdfaRV1oguLHwmDQcxccs20EBldKp3yifQh8xkmgzb2wxkJo2uU47P5h7E8GNEk49YkXry_ym0hmK3oZxQ4t0xhMBk_f96HddYU8weNWySD5uzJvq29iq6MQeVGj95lC2aCbNionW_T4='},\n",
       "  {'label': 'philschmid',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvE5fF_hSFknYY6AK0PPXy78bDkX0IU3fl5CtJk0roAi0KTMHQdVkcbeX3992WRRCH7OT-7N-KyCz3qTQsGgtApN8ogaiARiTQAj8G1zpz5oSIagjnlQ3Snxv5Q2dpH7o5Qlb2'},\n",
       "  {'label': 'machinelearningmastery',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHNQ4x6C8PXZANK15nRwPE57XPthbI0LO9nlzwMafsHRX7QP0C6X4rIm0U6l4oUGMeYW3VsJG8uls_iLJEltUp3H5_Zf6_jdLRcmXFUlwCJXU3KH9o9PNwHVGAHnm__iU9SfZTssOEZnnWdK9wBr-t7r2yK3wjufqKmHXSV4J7m3zQAvD6X'},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHDy7cDMPgcuwXeHikVNeAKdjzDkbUNq3uIVftmtvqN285-x5aGMONEZoJAgVpqtt2w3kz_LoRhLH8y6-qnBHP8hxpyNgWsDVvHLlRNHOmJDZyd3c8XnZq7DUyxBLTnrTMuoIyN8qE='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-11',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHqi76Tghm10nzEoYp9GqbFh5FnNOgqKj05R-QWX6lNqdOT3oe8ICivHRK5D0m49QV79OaQJZbjxOtVWjQcVASaEeaG831MruqPzwFlgUSDQ7zh6VeqoOqzhzbnWGaMisiOSHFVaWc='},\n",
       "  {'label': 'projectpro',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE2cs5B7yrop30q6Onb6ICe2Lrb5ATnAMxFWySC2uoBe7AanIaCuTp8sP0RiTxucRqmiZqoMxDlo8MQ2qjFXb8xRMuFx-GrUJynE7lnmP5kRUQjE7kc3RwQlrlqrJCELc1wXnFsfxlH9H54RXqdMrVjV8l9LWnf-Pov8m6e'},\n",
       "  {'label': 'philschmid',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvE5fF_hSFknYY6AK0PPXy78bDkX0IU3fl5CtJk0roAi0KTMHQdVkcbeX3992WRRCH7OT-7N-KyCz3qTQsGgtApN8ogaiARiTQAj8G1zpz5oSIagjnlQ3Snxv5Q2dpH7o5Qlb2'},\n",
       "  {'label': 'machinelearningmastery',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHNQ4x6C8PXZANK15nRwPE57XPthbI0LO9nlzwMafsHRX7QP0C6X4rIm0U6l4oUGMeYW3VsJG8uls_iLJEltUp3H5_Zf6_jdLRcmXFUlwCJXU3KH9o9PNwHVGAHnm__iU9SfZTssOEZnnWdK9wBr-t7r2yK3wjufqKmHXSV4J7m3zQAvD6X'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE34VHbeK73R253rtrtfWhefSUfuZRf7WOvP1Y3t14E7jm5BGYRkb4rvp45y4puWlK4DDkPWekIdlUL1VWSFYDaELn9ttkehvK_kkvqE23WlhLc4eOZWhpmGXZK7y4teCIlreRRojwhNyLJ8Ubs1cA5VlCFfvnbW8BqReSauubK'},\n",
       "  {'label': 'projectpro',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE2cs5B7yrop30q6Onb6ICe2Lrb5ATnAMxFWySC2uoBe7AanIaCuTp8sP0RiTxucRqmiZqoMxDlo8MQ2qjFXb8xRMuFx-GrUJynE7lnmP5kRUQjE7kc3RwQlrlqrJCELc1wXnFsfxlH9H54RXqdMrVjV8l9LWnf-Pov8m6e'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDfELnsU3MJZs7MZ5cidjQpU1WG4P4MnxWnTP28uWOZRCXcFkY2XKnnSkMdfaRV1oguLHwmDQcxccs20EBldKp3yifQh8xkmgzb2wxkJo2uU47P5h7E8GNEk49YkXry_ym0hmK3oZxQ4t0xhMBk_f96HddYU8weNWySD5uzJvq29iq6MQeVGj95lC2aCbNionW_T4='},\n",
       "  {'label': 'philschmid',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvE5fF_hSFknYY6AK0PPXy78bDkX0IU3fl5CtJk0roAi0KTMHQdVkcbeX3992WRRCH7OT-7N-KyCz3qTQsGgtApN8ogaiARiTQAj8G1zpz5oSIagjnlQ3Snxv5Q2dpH7o5Qlb2'},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHHWkOshfznUWDFLGiiWFKRlA82itqxXpJKnj0W26xkVvyU258X-YpW0rKcbjAcsNA9Je-jbwkYvvxamiPVNxTcOZgWIrNM_drpbR-7ByoDlDOlzB3n14LvQorEpSUDj8lmsO3dGvI='},\n",
       "  {'label': 'anthropic',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEiUS25WrTXB7MXBjLgNbqfuj7AhMQgoerCwMGkDIGe5k2GbfnFJLlRWZTGeGOUufVTsDYLb4APfyrQVNetdc25-LMtW1yWpqNmzjOuKNqBqauewNuyMEFXcbw9kE_DMqKOY6edwhKgWomFvpWczF_b4y0cnC-30Q=='},\n",
       "  {'label': 'openai',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-16',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGiKeNFuwW7RuxYXxnuDwScUA82pLriBH-lBgTwMw5stxQcvic4W3fsPWCXWzxiXyQNEJJt6SyaiDsL73uHnpM5uP0718KTKUtqAY-iYIvCQ6y6ce9IOxpxnI5R9tlpZPZmBh4MjxTxbNDCMb-WLkl6a2TnoW4QdhkqGtI5rRvFMRpGhuojI_XcZtDiCIJRk13y_5v65cfkXA=='},\n",
       "  {'label': 'databricks',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQjOzzXP9xdf37qLCSppLQAAOfVr-5nQkxL3HNna__36fipOz1kFiVYBsw3ir6ZSBctph40EOHbdP21VsL3HDGujGuPHljK3Pu-nIzfJohN6qDXI1_F1iYopAs6aERPSQKBTaYljVKfKrXIG-ZG3zaenhBe4ye0bLj8r7O-4-t-HMDMEGb7h_ifQvpVPkQ'},\n",
       "  {'label': 'philschmid',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvE5fF_hSFknYY6AK0PPXy78bDkX0IU3fl5CtJk0roAi0KTMHQdVkcbeX3992WRRCH7OT-7N-KyCz3qTQsGgtApN8ogaiARiTQAj8G1zpz5oSIagjnlQ3Snxv5Q2dpH7o5Qlb2'},\n",
       "  {'label': 'anthropic',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEiUS25WrTXB7MXBjLgNbqfuj7AhMQgoerCwMGkDIGe5k2GbfnFJLlRWZTGeGOUufVTsDYLb4APfyrQVNetdc25-LMtW1yWpqNmzjOuKNqBqauewNuyMEFXcbw9kE_DMqKOY6edwhKgWomFvpWczF_b4y0cnC-30Q=='},\n",
       "  {'label': 'machinelearningmastery',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHNQ4x6C8PXZANK15nRwPE57XPthbI0LO9nlzwMafsHRX7QP0C6X4rIm0U6l4oUGMeYW3VsJG8uls_iLJEltUp3H5_Zf6_jdLRcmXFUlwCJXU3KH9o9PNwHVGAHnm__iU9SfZTssOEZnnWdK9wBr-t7r2yK3wjufqKmHXSV4J7m3zQAvD6X'},\n",
       "  {'label': 'openai',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-16',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGiKeNFuwW7RuxYXxnuDwScUA82pLriBH-lBgTwMw5stxQcvic4W3fsPWCXWzxiXyQNEJJt6SyaiDsL73uHnpM5uP0718KTKUtqAY-iYIvCQ6y6ce9IOxpxnI5R9tlpZPZmBh4MjxTxbNDCMb-WLkl6a2TnoW4QdhkqGtI5rRvFMRpGhuojI_XcZtDiCIJRk13y_5v65cfkXA=='},\n",
       "  {'label': 'databricks',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQjOzzXP9xdf37qLCSppLQAAOfVr-5nQkxL3HNna__36fipOz1kFiVYBsw3ir6ZSBctph40EOHbdP21VsL3HDGujGuPHljK3Pu-nIzfJohN6qDXI1_F1iYopAs6aERPSQKBTaYljVKfKrXIG-ZG3zaenhBe4ye0bLj8r7O-4-t-HMDMEGb7h_ifQvpVPkQ'},\n",
       "  {'label': 'databricks',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQjOzzXP9xdf37qLCSppLQAAOfVr-5nQkxL3HNna__36fipOz1kFiVYBsw3ir6ZSBctph40EOHbdP21VsL3HDGujGuPHljK3Pu-nIzfJohN6qDXI1_F1iYopAs6aERPSQKBTaYljVKfKrXIG-ZG3zaenhBe4ye0bLj8r7O-4-t-HMDMEGb7h_ifQvpVPkQ'},\n",
       "  {'label': 'databricks',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQjOzzXP9xdf37qLCSppLQAAOfVr-5nQkxL3HNna__36fipOz1kFiVYBsw3ir6ZSBctph40EOHbdP21VsL3HDGujGuPHljK3Pu-nIzfJohN6qDXI1_F1iYopAs6aERPSQKBTaYljVKfKrXIG-ZG3zaenhBe4ye0bLj8r7O-4-t-HMDMEGb7h_ifQvpVPkQ'},\n",
       "  {'label': 'databricks',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQjOzzXP9xdf37qLCSppLQAAOfVr-5nQkxL3HNna__36fipOz1kFiVYBsw3ir6ZSBctph40EOHbdP21VsL3HDGujGuPHljK3Pu-nIzfJohN6qDXI1_F1iYopAs6aERPSQKBTaYljVKfKrXIG-ZG3zaenhBe4ye0bLj8r7O-4-t-HMDMEGb7h_ifQvpVPkQ'},\n",
       "  {'label': 'databricks',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQjOzzXP9xdf37qLCSppLQAAOfVr-5nQkxL3HNna__36fipOz1kFiVYBsw3ir6ZSBctph40EOHbdP21VsL3HDGujGuPHljK3Pu-nIzfJohN6qDXI1_F1iYopAs6aERPSQKBTaYljVKfKrXIG-ZG3zaenhBe4ye0bLj8r7O-4-t-HMDMEGb7h_ifQvpVPkQ'},\n",
       "  {'label': 'anthropic',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEiUS25WrTXB7MXBjLgNbqfuj7AhMQgoerCwMGkDIGe5k2GbfnFJLlRWZTGeGOUufVTsDYLb4APfyrQVNetdc25-LMtW1yWpqNmzjOuKNqBqauewNuyMEFXcbw9kE_DMqKOY6edwhKgWomFvpWczF_b4y0cnC-30Q=='},\n",
       "  {'label': 'machinelearningmastery',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHNQ4x6C8PXZANK15nRwPE57XPthbI0LO9nlzwMafsHRX7QP0C6X4rIm0U6l4oUGMeYW3VsJG8uls_iLJEltUp3H5_Zf6_jdLRcmXFUlwCJXU3KH9o9PNwHVGAHnm__iU9SfZTssOEZnnWdK9wBr-t7r2yK3wjufqKmHXSV4J7m3zQAvD6X'},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQENV4Kzm58IYkUHFdIHObuQmS1qqTMBNV57Bp1hNKUH6AerzlCO9ouxCQCczpanebKRW4r2JrR-9QuEb5rEOhsVdKv3e_DKPxR0bW9a0Unj71Ca5e0iG5GQX-PsiOnwggDCMmkbsR39byiiORO6iPhgchn_GPq4O8S7tdfcN4SC7ZB4WZ2LiaQrLXgHVsQy2z8='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNSIfxgHceqCwAneLQbIZ3n5K1lQ4Er93ziDKX8w7CoO8JN3KgdIle68lzlQnQzCXibpRdCNA-H9o-8T-NR6NsjSQAEGlPGZYm5UJb2R1WLrGr7_MbnALNu8o7BvVmIKYGexyOoZWBC667dYLmD7nws5WRH-4KJfEpK_PMm3UO03mCPVIyl7lZjDGq_VJ84Vgz3ZZeCqt5frMScH_25bteeQCI0WGg7vkDz1FIrrLZ'},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFnLH3KPT4HUNc6Dd_50MV_RZ0TnDJWaD15l-atW6yG8JWCXswjZG4jy32iqjp9CPlrRBSjkmI6cnKqbanYlrF7LV1clGv4VWTCfGrQ927o2XZI5O5l9ODJvPKiI-73f62ZJwLCge--a8IxKIxIwUQF6xQsTAuiglDNekyWzaGWbAhZ_1KzEy9Tn9-L1OxZFQ=='},\n",
       "  {'label': 'anthropic',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEiUS25WrTXB7MXBjLgNbqfuj7AhMQgoerCwMGkDIGe5k2GbfnFJLlRWZTGeGOUufVTsDYLb4APfyrQVNetdc25-LMtW1yWpqNmzjOuKNqBqauewNuyMEFXcbw9kE_DMqKOY6edwhKgWomFvpWczF_b4y0cnC-30Q=='},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQENV4Kzm58IYkUHFdIHObuQmS1qqTMBNV57Bp1hNKUH6AerzlCO9ouxCQCczpanebKRW4r2JrR-9QuEb5rEOhsVdKv3e_DKPxR0bW9a0Unj71Ca5e0iG5GQX-PsiOnwggDCMmkbsR39byiiORO6iPhgchn_GPq4O8S7tdfcN4SC7ZB4WZ2LiaQrLXgHVsQy2z8='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNSIfxgHceqCwAneLQbIZ3n5K1lQ4Er93ziDKX8w7CoO8JN3KgdIle68lzlQnQzCXibpRdCNA-H9o-8T-NR6NsjSQAEGlPGZYm5UJb2R1WLrGr7_MbnALNu8o7BvVmIKYGexyOoZWBC667dYLmD7nws5WRH-4KJfEpK_PMm3UO03mCPVIyl7lZjDGq_VJ84Vgz3ZZeCqt5frMScH_25bteeQCI0WGg7vkDz1FIrrLZ'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNSIfxgHceqCwAneLQbIZ3n5K1lQ4Er93ziDKX8w7CoO8JN3KgdIle68lzlQnQzCXibpRdCNA-H9o-8T-NR6NsjSQAEGlPGZYm5UJb2R1WLrGr7_MbnALNu8o7BvVmIKYGexyOoZWBC667dYLmD7nws5WRH-4KJfEpK_PMm3UO03mCPVIyl7lZjDGq_VJ84Vgz3ZZeCqt5frMScH_25bteeQCI0WGg7vkDz1FIrrLZ'},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFnLH3KPT4HUNc6Dd_50MV_RZ0TnDJWaD15l-atW6yG8JWCXswjZG4jy32iqjp9CPlrRBSjkmI6cnKqbanYlrF7LV1clGv4VWTCfGrQ927o2XZI5O5l9ODJvPKiI-73f62ZJwLCge--a8IxKIxIwUQF6xQsTAuiglDNekyWzaGWbAhZ_1KzEy9Tn9-L1OxZFQ=='},\n",
       "  {'label': 'smythos',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFnLH3KPT4HUNc6Dd_50MV_RZ0TnDJWaD15l-atW6yG8JWCXswjZG4jy32iqjp9CPlrRBSjkmI6cnKqbanYlrF7LV1clGv4VWTCfGrQ927o2XZI5O5l9ODJvPKiI-73f62ZJwLCge--a8IxKIxIwUQF6xQsTAuiglDNekyWzaGWbAhZ_1KzEy9Tn9-L1OxZFQ=='},\n",
       "  {'label': 'philschmid',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHvE5fF_hSFknYY6AK0PPXy78bDkX0IU3fl5CtJk0roAi0KTMHQdVkcbeX3992WRRCH7OT-7N-KyCz3qTQsGgtApN8ogaiARiTQAj8G1zpz5oSIagjnlQ3Snxv5Q2dpH7o5Qlb2'},\n",
       "  {'label': 'anthropic',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEiUS25WrTXB7MXBjLgNbqfuj7AhMQgoerCwMGkDIGe5k2GbfnFJLlRWZTGeGOUufVTsDYLb4APfyrQVNetdc25-LMtW1yWpqNmzjOuKNqBqauewNuyMEFXcbw9kE_DMqKOY6edwhKgWomFvpWczF_b4y0cnC-30Q=='},\n",
       "  {'label': 'machinelearningmastery',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/4-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHNQ4x6C8PXZANK15nRwPE57XPthbI0LO9nlzwMafsHRX7QP0C6X4rIm0U6l4oUGMeYW3VsJG8uls_iLJEltUp3H5_Zf6_jdLRcmXFUlwCJXU3KH9o9PNwHVGAHnm__iU9SfZTssOEZnnWdK9wBr-t7r2yK3wjufqKmHXSV4J7m3zQAvD6X'},\n",
       "  {'label': 'skimai',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHVWFi3ZwMVTgzNM4uHIqqUX4tq_nGRiO4ouhbIoZOdERWZ7ahGfnKHKvG11ZjZrD3u8FU0Qiir150BOfJ7lMT60-Ao1EsrOw4HBczq2x-QXsdPbKLdYM9uyqN--4dttsJRPwXJW44hsW2qQsFLVk2TUGI3n8WhVbEFVx8JOsUhzqYHqYMObZM5KMedGpEAgTyM0DARTsbKfhbBmXIy0n3KGLhcS6dPihOnBL9_c08cSMXFnv8LhuvxSADlhqH_n-gzo3Zqj1TCje6Q1rSaYwjV-jphhkUZ9VuxfDBXYy_16Ih4AgjW9a-SzDxzROcikHL1Y4cqZfMT2eYpicvZKuNmaEFdQR-irGfLyX0xHrA='},\n",
       "  {'label': 'getguru',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF7LOt4XWNi7KnSs0BD8Pz9ZsLnkfC1ZIKu6sdCiPr_W3MtsQIvwN5j7sUlVqZdL8UgSVESZYyDqYoPo3rvFN-6LDJ8A_VJNLJctI0q4vTpzjTO_UjtVA7U1GbHaQJUzkH4trwAjz9peXKDkNvpJfdl7SxI4m0='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG0O_FlNCB-AdyM1naOaegJ0A-55eT7HrU9MIrY6d4hvVZXjeK9YNuErhDpi4i8HqUQIWOE3DOIhkYbSqYEU8duBboDRhT1p6UZn1aMfYUvD82DfrLW_QMKfFqT'},\n",
       "  {'label': 'skimai',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHVWFi3ZwMVTgzNM4uHIqqUX4tq_nGRiO4ouhbIoZOdERWZ7ahGfnKHKvG11ZjZrD3u8FU0Qiir150BOfJ7lMT60-Ao1EsrOw4HBczq2x-QXsdPbKLdYM9uyqN--4dttsJRPwXJW44hsW2qQsFLVk2TUGI3n8WhVbEFVx8JOsUhzqYHqYMObZM5KMedGpEAgTyM0DARTsbKfhbBmXIy0n3KGLhcS6dPihOnBL9_c08cSMXFnv8LhuvxSADlhqH_n-gzo3Zqj1TCje6Q1rSaYwjV-jphhkUZ9VuxfDBXYy_16Ih4AgjW9a-SzDxzROcikHL1Y4cqZfMT2eYpicvZKuNmaEFdQR-irGfLyX0xHrA='},\n",
       "  {'label': 'getguru',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF7LOt4XWNi7KnSs0BD8Pz9ZsLnkfC1ZIKu6sdCiPr_W3MtsQIvwN5j7sUlVqZdL8UgSVESZYyDqYoPo3rvFN-6LDJ8A_VJNLJctI0q4vTpzjTO_UjtVA7U1GbHaQJUzkH4trwAjz9peXKDkNvpJfdl7SxI4m0='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG0O_FlNCB-AdyM1naOaegJ0A-55eT7HrU9MIrY6d4hvVZXjeK9YNuErhDpi4i8HqUQIWOE3DOIhkYbSqYEU8duBboDRhT1p6UZn1aMfYUvD82DfrLW_QMKfFqT'},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEX1abAWRFTrbDlXytBczAaZUft3ba5FTmeNPyPIVa1QsdWZxL_FLgiZabDzuWIuxSmN13X1OnEs1nhvsoZ9ABpS0xih1pTXB76lvXRHppQYROECqYDYUMPu8w5Q77fC4CEf0xM-A=='},\n",
       "  {'label': 'dacon',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE3-fLRULo4L0cAFMSptROxGXwe3AMzeBaw0-xg4BVgljiaxbrRCTwTn4FjnCpDnLbHEGvJQPyjA-awWCvVzSrb25KomSynCCw28rhOVC20nKAe'},\n",
       "  {'label': 'tldv',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE4ix65-HhQH-M3cGSCwJh6_c53LOpA8KqoigrnLkn4KwkDlF0tW7BOZ5yb9_w7la-SSX2W8lJINxiWyq13vXLP1Rwn04LEXZgOm17V6IdHyQ3M3weGSyG325DWG2uAVu7gZA=='},\n",
       "  {'label': 'skimai',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHVWFi3ZwMVTgzNM4uHIqqUX4tq_nGRiO4ouhbIoZOdERWZ7ahGfnKHKvG11ZjZrD3u8FU0Qiir150BOfJ7lMT60-Ao1EsrOw4HBczq2x-QXsdPbKLdYM9uyqN--4dttsJRPwXJW44hsW2qQsFLVk2TUGI3n8WhVbEFVx8JOsUhzqYHqYMObZM5KMedGpEAgTyM0DARTsbKfhbBmXIy0n3KGLhcS6dPihOnBL9_c08cSMXFnv8LhuvxSADlhqH_n-gzo3Zqj1TCje6Q1rSaYwjV-jphhkUZ9VuxfDBXYy_16Ih4AgjW9a-SzDxzROcikHL1Y4cqZfMT2eYpicvZKuNmaEFdQR-irGfLyX0xHrA='},\n",
       "  {'label': 'getguru',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF7LOt4XWNi7KnSs0BD8Pz9ZsLnkfC1ZIKu6sdCiPr_W3MtsQIvwN5j7sUlVqZdL8UgSVESZYyDqYoPo3rvFN-6LDJ8A_VJNLJctI0q4vTpzjTO_UjtVA7U1GbHaQJUzkH4trwAjz9peXKDkNvpJfdl7SxI4m0='},\n",
       "  {'label': 'baruninfo',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFt1GiTIrIESvkhhsTRXELYHE-fFaeo-JKJRKBRoG0ORDQ_Luv2oLTUXzXgdgll3IqZT-HJqK8zz8X5aSqVHRptXyRxLiXE2wD5tiP1C5-eN06aMgo='},\n",
       "  {'label': 'modulabs',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHdfTRG6f5FrKvs5lYfC5tKm6NcyshSG3U4zSeYNZ8xlfyPyYN7bt217w5Vy6dvSE7xCnDbC-WrYXJ3ezkT3i-9tbaO1k6QKp55nhFsLrQU4gHQnoZAnh_2d6qjK7XcxDNyqyO3UIbokVI-H1w='},\n",
       "  {'label': 'brunch',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFWe7oYVpN1BCv1pevgDdSotuY0GWBvMRUKb_nvXTnpBoBQUARXiVB2BwMzWGWAqtzWe2usXmb2CAwigKvoWUp7c5m1l5nQ6XKK7ho5Ari7w_JW51SjABT2fLNT-w=='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFn28C64e8zjAVYRd_nKCvu0hePvgjvJQa9mB-mQFo2WznmpjwlnTRaqqp2z6csWyzfK4OWkStDASjVpSKrNZPwekb70JzpTFNGZWn5xHJYdhCZ3rdV53POTYBG'},\n",
       "  {'label': 'modulabs',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHdfTRG6f5FrKvs5lYfC5tKm6NcyshSG3U4zSeYNZ8xlfyPyYN7bt217w5Vy6dvSE7xCnDbC-WrYXJ3ezkT3i-9tbaO1k6QKp55nhFsLrQU4gHQnoZAnh_2d6qjK7XcxDNyqyO3UIbokVI-H1w='},\n",
       "  {'label': 'brunch',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFWe7oYVpN1BCv1pevgDdSotuY0GWBvMRUKb_nvXTnpBoBQUARXiVB2BwMzWGWAqtzWe2usXmb2CAwigKvoWUp7c5m1l5nQ6XKK7ho5Ari7w_JW51SjABT2fLNT-w=='},\n",
       "  {'label': 'wishket',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFUVtaNTt3AmGUwbeDDqY1TXWs7vmv4NcDDOtWoJI-oxyr8Wjr41X75PqdQGoF4y0YeYSoTDfVHB5FhSWYBnWcAo--7YVbgqinclGh4PKkFF1I3Jy9mbd0wHPmP2Fh3hqXSjPOWkVm24Q=='},\n",
       "  {'label': 'baruninfo',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFt1GiTIrIESvkhhsTRXELYHE-fFaeo-JKJRKBRoG0ORDQ_Luv2oLTUXzXgdgll3IqZT-HJqK8zz8X5aSqVHRptXyRxLiXE2wD5tiP1C5-eN06aMgo='},\n",
       "  {'label': 'modulabs',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHdfTRG6f5FrKvs5lYfC5tKm6NcyshSG3U4zSeYNZ8xlfyPyYN7bt217w5Vy6dvSE7xCnDbC-WrYXJ3ezkT3i-9tbaO1k6QKp55nhFsLrQU4gHQnoZAnh_2d6qjK7XcxDNyqyO3UIbokVI-H1w='},\n",
       "  {'label': 'wishket',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFUVtaNTt3AmGUwbeDDqY1TXWs7vmv4NcDDOtWoJI-oxyr8Wjr41X75PqdQGoF4y0YeYSoTDfVHB5FhSWYBnWcAo--7YVbgqinclGh4PKkFF1I3Jy9mbd0wHPmP2Fh3hqXSjPOWkVm24Q=='},\n",
       "  {'label': 'skimai',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHVWFi3ZwMVTgzNM4uHIqqUX4tq_nGRiO4ouhbIoZOdERWZ7ahGfnKHKvG11ZjZrD3u8FU0Qiir150BOfJ7lMT60-Ao1EsrOw4HBczq2x-QXsdPbKLdYM9uyqN--4dttsJRPwXJW44hsW2qQsFLVk2TUGI3n8WhVbEFVx8JOsUhzqYHqYMObZM5KMedGpEAgTyM0DARTsbKfhbBmXIy0n3KGLhcS6dPihOnBL9_c08cSMXFnv8LhuvxSADlhqH_n-gzo3Zqj1TCje6Q1rSaYwjV-jphhkUZ9VuxfDBXYy_16Ih4AgjW9a-SzDxzROcikHL1Y4cqZfMT2eYpicvZKuNmaEFdQR-irGfLyX0xHrA='},\n",
       "  {'label': 'getguru',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF7LOt4XWNi7KnSs0BD8Pz9ZsLnkfC1ZIKu6sdCiPr_W3MtsQIvwN5j7sUlVqZdL8UgSVESZYyDqYoPo3rvFN-6LDJ8A_VJNLJctI0q4vTpzjTO_UjtVA7U1GbHaQJUzkH4trwAjz9peXKDkNvpJfdl7SxI4m0='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG0O_FlNCB-AdyM1naOaegJ0A-55eT7HrU9MIrY6d4hvVZXjeK9YNuErhDpi4i8HqUQIWOE3DOIhkYbSqYEU8duBboDRhT1p6UZn1aMfYUvD82DfrLW_QMKfFqT'},\n",
       "  {'label': 'clickup',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-11',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEp8GcNV0n-wxqKDqzDklArQms1eW5zDPjGQzmpTAQIesd_d_UpBnfGejA5G2oaUXKDO4jR02o2eoTGJ4S7iCnLNp8QWNFNVV-obcZnL0gEOcTFIoeyAF5UTfQkl42wYBaq0_7460hzkK3rdrx2tf4C-x0='},\n",
       "  {'label': 'baruninfo',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFt1GiTIrIESvkhhsTRXELYHE-fFaeo-JKJRKBRoG0ORDQ_Luv2oLTUXzXgdgll3IqZT-HJqK8zz8X5aSqVHRptXyRxLiXE2wD5tiP1C5-eN06aMgo='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFn28C64e8zjAVYRd_nKCvu0hePvgjvJQa9mB-mQFo2WznmpjwlnTRaqqp2z6csWyzfK4OWkStDASjVpSKrNZPwekb70JzpTFNGZWn5xHJYdhCZ3rdV53POTYBG'},\n",
       "  {'label': 'modulabs',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHdfTRG6f5FrKvs5lYfC5tKm6NcyshSG3U4zSeYNZ8xlfyPyYN7bt217w5Vy6dvSE7xCnDbC-WrYXJ3ezkT3i-9tbaO1k6QKp55nhFsLrQU4gHQnoZAnh_2d6qjK7XcxDNyqyO3UIbokVI-H1w='},\n",
       "  {'label': 'wishket',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFUVtaNTt3AmGUwbeDDqY1TXWs7vmv4NcDDOtWoJI-oxyr8Wjr41X75PqdQGoF4y0YeYSoTDfVHB5FhSWYBnWcAo--7YVbgqinclGh4PKkFF1I3Jy9mbd0wHPmP2Fh3hqXSjPOWkVm24Q=='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEX1abAWRFTrbDlXytBczAaZUft3ba5FTmeNPyPIVa1QsdWZxL_FLgiZabDzuWIuxSmN13X1OnEs1nhvsoZ9ABpS0xih1pTXB76lvXRHppQYROECqYDYUMPu8w5Q77fC4CEf0xM-A=='},\n",
       "  {'label': 'getguru',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF7LOt4XWNi7KnSs0BD8Pz9ZsLnkfC1ZIKu6sdCiPr_W3MtsQIvwN5j7sUlVqZdL8UgSVESZYyDqYoPo3rvFN-6LDJ8A_VJNLJctI0q4vTpzjTO_UjtVA7U1GbHaQJUzkH4trwAjz9peXKDkNvpJfdl7SxI4m0='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG0O_FlNCB-AdyM1naOaegJ0A-55eT7HrU9MIrY6d4hvVZXjeK9YNuErhDpi4i8HqUQIWOE3DOIhkYbSqYEU8duBboDRhT1p6UZn1aMfYUvD82DfrLW_QMKfFqT'},\n",
       "  {'label': 'brunch',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFWe7oYVpN1BCv1pevgDdSotuY0GWBvMRUKb_nvXTnpBoBQUARXiVB2BwMzWGWAqtzWe2usXmb2CAwigKvoWUp7c5m1l5nQ6XKK7ho5Ari7w_JW51SjABT2fLNT-w=='},\n",
       "  {'label': 'tldv',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE4ix65-HhQH-M3cGSCwJh6_c53LOpA8KqoigrnLkn4KwkDlF0tW7BOZ5yb9_w7la-SSX2W8lJINxiWyq13vXLP1Rwn04LEXZgOm17V6IdHyQ3M3weGSyG325DWG2uAVu7gZA=='},\n",
       "  {'label': 'pytorch',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEWRzyhj0fWHwAQ5yB_aF8fiXcMQSzs8kVD_ts4ZRBkHaosrUH7fNvDI3Wk84Pyp099aUcqNxT8jeTTjoq2BQ3T_ZCcE-P1Evx3Y3Cyr7JFCVBxsSATrgI6p3YbBup2uF6HanwaLYG8fSli90EJYyoazpISc1LWE_3tIEHdkqQppgPqJD4='},\n",
       "  {'label': 'tistory',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG0O_FlNCB-AdyM1naOaegJ0A-55eT7HrU9MIrY6d4hvVZXjeK9YNuErhDpi4i8HqUQIWOE3DOIhkYbSqYEU8duBboDRhT1p6UZn1aMfYUvD82DfrLW_QMKfFqT'},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEX1abAWRFTrbDlXytBczAaZUft3ba5FTmeNPyPIVa1QsdWZxL_FLgiZabDzuWIuxSmN13X1OnEs1nhvsoZ9ABpS0xih1pTXB76lvXRHppQYROECqYDYUMPu8w5Q77fC4CEf0xM-A=='},\n",
       "  {'label': 'tldv',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE4ix65-HhQH-M3cGSCwJh6_c53LOpA8KqoigrnLkn4KwkDlF0tW7BOZ5yb9_w7la-SSX2W8lJINxiWyq13vXLP1Rwn04LEXZgOm17V6IdHyQ3M3weGSyG325DWG2uAVu7gZA=='},\n",
       "  {'label': 'microsoft',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGift334YxZd4zQo1QXrro093WmwdM8HU4YSj1MaWm3H_QfMziaGrgthzVejytEalaK04kw0D0WJO9zUT7JRUp0hq-S2w8f2uJ7Kq7ba19o95jykycyQlPomESlTyqAzuUQ8hZ1NeUgy_tZJM8IdtR8eBnbLimOZ-wksYWqAQnm-zMirA8unaME22DFpg=='},\n",
       "  {'label': 'dacon',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE3-fLRULo4L0cAFMSptROxGXwe3AMzeBaw0-xg4BVgljiaxbrRCTwTn4FjnCpDnLbHEGvJQPyjA-awWCvVzSrb25KomSynCCw28rhOVC20nKAe'},\n",
       "  {'label': 'pytorch',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/5-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEWRzyhj0fWHwAQ5yB_aF8fiXcMQSzs8kVD_ts4ZRBkHaosrUH7fNvDI3Wk84Pyp099aUcqNxT8jeTTjoq2BQ3T_ZCcE-P1Evx3Y3Cyr7JFCVBxsSATrgI6p3YbBup2uF6HanwaLYG8fSli90EJYyoazpISc1LWE_3tIEHdkqQppgPqJD4='},\n",
       "  {'label': 'langchain',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEYkxrMovSyOd2POoQpnjswQY4VQOozQzDtuytJ4BlE7qWyK_zJJAwMdn-WP8eDv9oBeBEUBvp9csjJrTLNuHciu30iSVE71HaahfszJaQ1_tab6_raG0Tslb1_GMdNoKlMvigC2IigNeRse5GC'},\n",
       "  {'label': 'sider',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHft1chmON3YN61Gp_fMGWqOK4FENiwuOyD52nktUTDyjv6iwKqCZ5fzy5IieUDATDcEWb5vqs-m0pfQyscvLZylJpNl3XQWDxFao37fsj5wd2jdqLI9nO0SagCfQ-FuPZGwwQKPRqsPsSZrR39EcSlrj9aSg8xNu1s7xR1ehcCt2aQfPYUOxTIZxPZhC6LRM_dyek='},\n",
       "  {'label': 'coursera',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNVchBrhedBr3bgA2PwPleQTdUOyLOJ3uUCO9s6ID_qGQKoctFBFkYFOl4BlP0R7cscc0ybdA8Z1a_OK2QpoFx57XQPF4gXcnrxBDV7HGk56eDwce5QEGVTdIDJD_V6XdJXMUCx6yahz5Im85xE13wqOCEgFNMyKE-0s-k_MsCzK0Zk1yB0CPGbGGV'},\n",
       "  {'label': 'hexstream',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFz0RYn1_VeBH_fpYCtrBbJ1KVuUIEhGI5LZFaTelVPOMzVqAe4sMAk-YlUMj2KIgbaXl1fbRZSDcvbvzPk7-BXaYWL-NS81quulbWIrtK0ouBFNeuWRfjNRGpfu0c6QZefDrTJLbMjTLp3z7yU8n97YYPVOhVMwrst1ryH6Ae8H0EXCIVIhf8Q0EroXsWaWBfghv20HiiG1B9DR11WLY7gzqiGsSmErKcg7v4pq42LwMH14q_L6flbT62frrauEJuQtxXlRQ=='},\n",
       "  {'label': 'towardsai',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFUjXI8B9JbLE9ZzGLB1SJRFPSMizNYcV0t53k1Iq5q64FjiyYK5kjHHCuzdlE1zMlvvkC4Q-l7U90CiR6GZGgc-y5y59wbhB7a23yNQWm1k446vTZS5mY4PeitKRhtx6zzmfpid7BQ_vEVsJPy4Mg6t53KXlNpYREM10qbZxDhoJ9L2LvlL4AMbQ0caSQFfTsfHg=='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQENfZz-5DmpyrhePjemu3Lk7xHWp_T9uKyQIgMBPj8_sYsduLApyQUisNNDwtrSqsXT_swdjp3BcsQEOJIqeVDi5pDCriBpS4xFNmdJ4wtaWw6FzDUpDjSaqIryTvQ9NHBTfKBfcw=='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHdYDEJ735rePgzVIJr5KgclSNsQ26KwBDaZjuHPhO6Y8RQ7E9ZC9WKw7FO9CCieQuCWa7NZf9LR1V5D2g23sauXY7VX5OcNbOspB0lyXPTfzF2Vze2QTz5k4anYCOhSt8dxL5Zbgio64CfMQ9MOFoh1MVvjuzo2bKOqLlanJc3og6UYvuYqFOLLWjEG-f5Rep8d38IWMaZvmXgqyNGQCJVzJeHdbVHQBo2YPSrkKZiS1vfTK8='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHMXG8OfjKaQKlCjAcHgkVLaU8tzItBc8rOxPKrdxGHpm84yqUQp1kyT5yk-lKFgaYkFSC8E44Bu6Nxl-UGO27XRzfOKrGkHgRl_St6oBgdIl2y2SgrMImkEG8z2l4xYc1rZtyRKp3onOszSwLlkgUrQhaNucp1WNsGk6sczZhwPkKfdXBpgVw6GvOGbI7ISX9Bfs7__3OqEMOGkIl-Ap7s_wUcYmyCB3oW6Q=='},\n",
       "  {'label': 'hexstream',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFz0RYn1_VeBH_fpYCtrBbJ1KVuUIEhGI5LZFaTelVPOMzVqAe4sMAk-YlUMj2KIgbaXl1fbRZSDcvbvzPk7-BXaYWL-NS81quulbWIrtK0ouBFNeuWRfjNRGpfu0c6QZefDrTJLbMjTLp3z7yU8n97YYPVOhVMwrst1ryH6Ae8H0EXCIVIhf8Q0EroXsWaWBfghv20HiiG1B9DR11WLY7gzqiGsSmErKcg7v4pq42LwMH14q_L6flbT62frrauEJuQtxXlRQ=='},\n",
       "  {'label': 'sider',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHft1chmON3YN61Gp_fMGWqOK4FENiwuOyD52nktUTDyjv6iwKqCZ5fzy5IieUDATDcEWb5vqs-m0pfQyscvLZylJpNl3XQWDxFao37fsj5wd2jdqLI9nO0SagCfQ-FuPZGwwQKPRqsPsSZrR39EcSlrj9aSg8xNu1s7xR1ehcCt2aQfPYUOxTIZxPZhC6LRM_dyek='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHJWvSaHjgCdS6FRp7nW5yE48MzQcem-stBuUxw3WXkzhldH1nshBmyIULE5FAIWIwsRqBvbJ2AYP6NmAwndbI5ZpwIHyBbejqxm2IZeB0g6kmE3J7aibIrmzWtgJ70IHBoUAzO3w=='},\n",
       "  {'label': 'hexstream',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFz0RYn1_VeBH_fpYCtrBbJ1KVuUIEhGI5LZFaTelVPOMzVqAe4sMAk-YlUMj2KIgbaXl1fbRZSDcvbvzPk7-BXaYWL-NS81quulbWIrtK0ouBFNeuWRfjNRGpfu0c6QZefDrTJLbMjTLp3z7yU8n97YYPVOhVMwrst1ryH6Ae8H0EXCIVIhf8Q0EroXsWaWBfghv20HiiG1B9DR11WLY7gzqiGsSmErKcg7v4pq42LwMH14q_L6flbT62frrauEJuQtxXlRQ=='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQENfZz-5DmpyrhePjemu3Lk7xHWp_T9uKyQIgMBPj8_sYsduLApyQUisNNDwtrSqsXT_swdjp3BcsQEOJIqeVDi5pDCriBpS4xFNmdJ4wtaWw6FzDUpDjSaqIryTvQ9NHBTfKBfcw=='},\n",
       "  {'label': 'sider',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHft1chmON3YN61Gp_fMGWqOK4FENiwuOyD52nktUTDyjv6iwKqCZ5fzy5IieUDATDcEWb5vqs-m0pfQyscvLZylJpNl3XQWDxFao37fsj5wd2jdqLI9nO0SagCfQ-FuPZGwwQKPRqsPsSZrR39EcSlrj9aSg8xNu1s7xR1ehcCt2aQfPYUOxTIZxPZhC6LRM_dyek='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHORNJ0cwQZyk32XkfnqWp5gQkDwQwf7gpTaGBgpgHrZxaPlb9OESB3iG_pW8nxTivTPRGCylXNi5E1vNZKhmqUOQlWupCuSDvXbJICJQA-XLp1zwvBMxGPhi20keK_xBLuU3xzsnAVsU1biB5MeDbfAVva_AbdYIoz1XBhJvhOe14TbUbJLe-PxD_mFHNNgjvtiex9y1rcUz0o0nfsrOEOW-j0J6i1f3rfmZ4yF64='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHdYDEJ735rePgzVIJr5KgclSNsQ26KwBDaZjuHPhO6Y8RQ7E9ZC9WKw7FO9CCieQuCWa7NZf9LR1V5D2g23sauXY7VX5OcNbOspB0lyXPTfzF2Vze2QTz5k4anYCOhSt8dxL5Zbgio64CfMQ9MOFoh1MVvjuzo2bKOqLlanJc3og6UYvuYqFOLLWjEG-f5Rep8d38IWMaZvmXgqyNGQCJVzJeHdbVHQBo2YPSrkKZiS1vfTK8='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHJWvSaHjgCdS6FRp7nW5yE48MzQcem-stBuUxw3WXkzhldH1nshBmyIULE5FAIWIwsRqBvbJ2AYP6NmAwndbI5ZpwIHyBbejqxm2IZeB0g6kmE3J7aibIrmzWtgJ70IHBoUAzO3w=='},\n",
       "  {'label': 'github',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGS2PTfPvMcj35qygSFRx3D6Goh6OHWCTujkrBlWNPd3RoKCELgtep3q26OB5S0Of326wSMJhQ2JC-2xAsqsZK36JkAXn1EQAvh36UsiSlcKtKvCdUhIm6syB6RTEmrkAAk7O-zu-XO_qJBZV5UBQhLp_Ajp9EvRrRrtkObriKHR9menFhqXCq1Ofi7GlWpg4ug'},\n",
       "  {'label': 'coursera',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNVchBrhedBr3bgA2PwPleQTdUOyLOJ3uUCO9s6ID_qGQKoctFBFkYFOl4BlP0R7cscc0ybdA8Z1a_OK2QpoFx57XQPF4gXcnrxBDV7HGk56eDwce5QEGVTdIDJD_V6XdJXMUCx6yahz5Im85xE13wqOCEgFNMyKE-0s-k_MsCzK0Zk1yB0CPGbGGV'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-11',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEU5ZCGF1Ggg01BquF1yA063vgCw7XbJBMs8TTaxKI_jwF4uXusBEE-u_sqXlR4e5SPrKUYQdbXq9_Z0VsZN9YUe6-Se-biCya7OzjZJa4tdvw0VgZf_05DcE3r5s193pS9QUKDcbiQUDqybSh6WtBOJb_GyoTG3ieOQveqrmOG1BUyGn-s4pwgFXsgLb7h7yHwVxghoTV_-E9ZOl9BY-Q='},\n",
       "  {'label': 'github',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGS2PTfPvMcj35qygSFRx3D6Goh6OHWCTujkrBlWNPd3RoKCELgtep3q26OB5S0Of326wSMJhQ2JC-2xAsqsZK36JkAXn1EQAvh36UsiSlcKtKvCdUhIm6syB6RTEmrkAAk7O-zu-XO_qJBZV5UBQhLp_Ajp9EvRrRrtkObriKHR9menFhqXCq1Ofi7GlWpg4ug'},\n",
       "  {'label': 'stackademic',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHZ7nGSyGoai3e9xt2TuMq82IVd3f7ep6SWqCU0DrpLFYhUTXyfaXrfSu1B9Cp9cp4zElnpY3ib4lib-DOkjR_A0QxVs5_dIyisktRyqL-QgzxBFx-M8PiE7tBKsDGm6VZ3AfsXYBTlQZeALpF7qdBJY9US5VRgJDZpGEbziYqoTX_KSg=='},\n",
       "  {'label': 'ibm',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-13',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEXDuyHMUlEINoqmFgV_tfjYp7lsOXzs98g1sTF74aWQ0k6fr1JjSat0PuW3imtazU9D8se6b1cbocQuM2Q0pE5rOfT32JkmyYvPfU5ny3FYraG040NmQTjYX7LpzV1ntEW7pi-PMc6pufh0bDGvgUxR9cgWpqOZDvj2Yueug=='},\n",
       "  {'label': 'plainenglish',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-14',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFYKE1XGK5wFbILrCjQ3pxliuJMj_NnvJBH2qXQ8Twy_-ZcQMZoEaa1O-4PaDK54Mqft-V7-4JRqyH2MA1nXqyCdOWVB5ZVlwKxuk0vDEmlSHP6-qG5kN53RG43QRxGg-RJxf8asPtH9LednylvmIpIOUYCl1XD0pRKh3dkuj8xWkZmrtEhoP0loed-_DsOYBWN9yCDupPw'},\n",
       "  {'label': 'stackademic',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-12',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHZ7nGSyGoai3e9xt2TuMq82IVd3f7ep6SWqCU0DrpLFYhUTXyfaXrfSu1B9Cp9cp4zElnpY3ib4lib-DOkjR_A0QxVs5_dIyisktRyqL-QgzxBFx-M8PiE7tBKsDGm6VZ3AfsXYBTlQZeALpF7qdBJY9US5VRgJDZpGEbziYqoTX_KSg=='},\n",
       "  {'label': 'microsoft',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-15',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHh9jNcSl7nw0iis2mY9Qb23nf7VydU0tsbu2tnJ2V7gR_VxGbmpZtiBANHpZodt2mtGbHmXLgQJmJRX5XZ6eXjGhArVct_VccTj7MQ6o5PdL-KHPmkP83TsPUeTTJGetCmRlJ5BaN63eEe2VcJHgp8SizZa6u9TstIN5HcnxQnf2yt5_p_6Bh-uMQYkgQ='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-16',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGDXodss3RbRYpQGgfmp0_BAK3YfPXGuzAcSyRFnR1O5crLteZWtcDGgbL7wjiBtsRzbjynVEiyCsU_OwbhTZlPJGqE8ZbKVZ1UMPd8I88H1Bmg0PDeAwhAFvL0Ipw8t2ifJK_wOD1pW-aGdyx9ZVGUC04WvQ-1hcn-ggYBu38xxHPXZ57P4OFM2Thly0kxqhKzocPm6VFXpkvWJKobIdo55sy6x_-Qq0qzT9eF'},\n",
       "  {'label': 'meilisearch',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-17',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGG0apwxWZBgyLunPive4SAlxWTduk1ZVtcWRN84GI0-qHIM9etkEVoB_L2IY9FUKgXgK7AgJxqHuLiHjwZx7hm28-TGGdGgYI7ANXUnjJ5iCbS8YarNo2CiCaCj7UliRSOjpxCTtn3oto='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-18',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHL804_HMi-1LVTtqD1sPNbZi3ltJjuZ7U_W7U_bynpEftzeq0kPV8b1gdl-W0SuHE9Uxi4VrVjgZFQLBXaA7_gNK_107ZMTy-sDzu-SPXE88dK0NjNace41zp0GaduMIdwtr10rg=='},\n",
       "  {'label': 'llamaindex',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-19',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGk52Dv_btvDSxF7SUsgUUtGiI19EEaYMhSfe3LAWfMzSMyIN_s5w0gF9WQVK32mAnBIocdd4oKZFNwBILtglaDNyG2iUJXVYpyW4offxtNASnikJgrT8LB-KiJ6h9WK94YLefKMfafp0mFKuWKYCk2s1Yqz8SVnMNdgcvJMzGdczfj0UdBF1kJZ3wXVOczxQ=='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-16',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGDXodss3RbRYpQGgfmp0_BAK3YfPXGuzAcSyRFnR1O5crLteZWtcDGgbL7wjiBtsRzbjynVEiyCsU_OwbhTZlPJGqE8ZbKVZ1UMPd8I88H1Bmg0PDeAwhAFvL0Ipw8t2ifJK_wOD1pW-aGdyx9ZVGUC04WvQ-1hcn-ggYBu38xxHPXZ57P4OFM2Thly0kxqhKzocPm6VFXpkvWJKobIdo55sy6x_-Qq0qzT9eF'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-16',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGDXodss3RbRYpQGgfmp0_BAK3YfPXGuzAcSyRFnR1O5crLteZWtcDGgbL7wjiBtsRzbjynVEiyCsU_OwbhTZlPJGqE8ZbKVZ1UMPd8I88H1Bmg0PDeAwhAFvL0Ipw8t2ifJK_wOD1pW-aGdyx9ZVGUC04WvQ-1hcn-ggYBu38xxHPXZ57P4OFM2Thly0kxqhKzocPm6VFXpkvWJKobIdo55sy6x_-Qq0qzT9eF'},\n",
       "  {'label': 'llamaindex',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-19',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGk52Dv_btvDSxF7SUsgUUtGiI19EEaYMhSfe3LAWfMzSMyIN_s5w0gF9WQVK32mAnBIocdd4oKZFNwBILtglaDNyG2iUJXVYpyW4offxtNASnikJgrT8LB-KiJ6h9WK94YLefKMfafp0mFKuWKYCk2s1Yqz8SVnMNdgcvJMzGdczfj0UdBF1kJZ3wXVOczxQ=='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-18',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHL804_HMi-1LVTtqD1sPNbZi3ltJjuZ7U_W7U_bynpEftzeq0kPV8b1gdl-W0SuHE9Uxi4VrVjgZFQLBXaA7_gNK_107ZMTy-sDzu-SPXE88dK0NjNace41zp0GaduMIdwtr10rg=='},\n",
       "  {'label': 'wedge',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-20',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE6Mo-v_MDd7YH8BrWc-q9eSgcSva_-rdAUBXzbFanDsUGEuTS2GTfkTX5WfTfv9f__S9kCJQB2dq9_SQU0jS-GktKm6Vak_KBbwJ6yPL7Vu6uyzqmeDR-VtYeKkPclS1m1S6ZYU_9b5JBh4QyLY6_WjXLhGuMXQoHHHtyVZbZDTDH4E1l7aUAjau2W1rlDpIs='},\n",
       "  {'label': 'wedge',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-20',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE6Mo-v_MDd7YH8BrWc-q9eSgcSva_-rdAUBXzbFanDsUGEuTS2GTfkTX5WfTfv9f__S9kCJQB2dq9_SQU0jS-GktKm6Vak_KBbwJ6yPL7Vu6uyzqmeDR-VtYeKkPclS1m1S6ZYU_9b5JBh4QyLY6_WjXLhGuMXQoHHHtyVZbZDTDH4E1l7aUAjau2W1rlDpIs='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-21',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEKiRO5UEpG6ijcRbuGsEpESJMz_uMYRJF7Jgjrq9EBi4iQJKzQDOve0ijmBEUro1okqc8D3YK5GUDrsnEgBY2spVWqIrkMrXg7UT40gIkaqcF_O5XuaesDE62Ed7YRimMOvIZegsADdHiqNbZhgaBNp_BEpn1FIxqhIPSD2oIDH_lLQKEauWWeyvWKdSyFCl93FYO4aihM_3_Qlapvhylb7rOi'},\n",
       "  {'label': 'wedge',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-20',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE6Mo-v_MDd7YH8BrWc-q9eSgcSva_-rdAUBXzbFanDsUGEuTS2GTfkTX5WfTfv9f__S9kCJQB2dq9_SQU0jS-GktKm6Vak_KBbwJ6yPL7Vu6uyzqmeDR-VtYeKkPclS1m1S6ZYU_9b5JBh4QyLY6_WjXLhGuMXQoHHHtyVZbZDTDH4E1l7aUAjau2W1rlDpIs='},\n",
       "  {'label': 'coursera',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNVchBrhedBr3bgA2PwPleQTdUOyLOJ3uUCO9s6ID_qGQKoctFBFkYFOl4BlP0R7cscc0ybdA8Z1a_OK2QpoFx57XQPF4gXcnrxBDV7HGk56eDwce5QEGVTdIDJD_V6XdJXMUCx6yahz5Im85xE13wqOCEgFNMyKE-0s-k_MsCzK0Zk1yB0CPGbGGV'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-11',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEU5ZCGF1Ggg01BquF1yA063vgCw7XbJBMs8TTaxKI_jwF4uXusBEE-u_sqXlR4e5SPrKUYQdbXq9_Z0VsZN9YUe6-Se-biCya7OzjZJa4tdvw0VgZf_05DcE3r5s193pS9QUKDcbiQUDqybSh6WtBOJb_GyoTG3ieOQveqrmOG1BUyGn-s4pwgFXsgLb7h7yHwVxghoTV_-E9ZOl9BY-Q='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-22',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHIjaspwNGtfpgrEFtwtJLl29L2nPHnHCZ5R-irsAaH85-nNr2p3RfFLrsyl9OKG3Sup7OfBAh1CHJGj1yN4HnmNoqhmXvoOWOzoe9u_7jfboZBQIB-N2pnSNdg_w387Wo-WzfCOQ=='},\n",
       "  {'label': 'towardsai',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-23',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGXC4n94xRyO3bXizDmL0k6IQ9yqlXK9vAb2QbUfBc1aGij_2f3NvLDgDl22phNS_ppzWYDnvGdGbiMiWFt2v5XGRD2-gkJUxnh6RrZU9HJxslAqQF5VsFGmZyjWkAjvWA_w3sqTKyRHax7XE8Exnlpy7D6IFTMuNAbTpNopZEFs315UfXuPcNGFidvmUPJi3C7aRXvR6qvFJTAX3l-YZ-sUWc='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-24',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEp3of_VhhPJFfVBQQj6yDqgLp-tz4HTZM-TxL4OCsqFxcWu94-Qz-ZHYoW-CLO1GeaYHhwXkskBnU5l8vyhx81uvZib8SDhLXLHtNdX2oxEN7MLfouLTVcV25NX3Uywp2kYEHzeC1-SO0o7I_1CEN_q-pecBVI3tngpUzF0wLCFGToazVaKnOXnqXGmjIxBKJQtBp8M_yddU4='},\n",
       "  {'label': 'hackernoon',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-25',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHKz1v_KbysFm2BwRoGrvQU9Hg-YM0UyuUvmUlGn3BNDW5lMYQQaxQKfYOq69IdvCWePlQNlwRVxs_Ywtle3SfgNzDrd9OsRSC_9XQxzh1sXaouQ1jioIOIeNqlw3w29wzbTVkDIx6WEs2NaMk5NH1PrApoccFwF43OeUr36t7HJLnmkV6VvZ4AcMnvPAY='},\n",
       "  {'label': 'skywork',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-26',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEPQHIn_9WJSht5_Sw0JV7qrwB_2GzXNI93R-DOTJeOLOwv6YACczjcdITQZCNaFq3LXRa7wsGdNeVM_WKfAICjANja8-valfiJaEUZebpHiXKoKHOygJNauP9pUPebdZLJ6Ncz2O4tsP7vpJmtsLeV-wv3sJw5rvpFhNFCCoqczI2sAfs17xGo4ZMKmWbtRhkcn3RjPXO_UaPE2A=='},\n",
       "  {'label': 'towardsai',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-23',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGXC4n94xRyO3bXizDmL0k6IQ9yqlXK9vAb2QbUfBc1aGij_2f3NvLDgDl22phNS_ppzWYDnvGdGbiMiWFt2v5XGRD2-gkJUxnh6RrZU9HJxslAqQF5VsFGmZyjWkAjvWA_w3sqTKyRHax7XE8Exnlpy7D6IFTMuNAbTpNopZEFs315UfXuPcNGFidvmUPJi3C7aRXvR6qvFJTAX3l-YZ-sUWc='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-24',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEp3of_VhhPJFfVBQQj6yDqgLp-tz4HTZM-TxL4OCsqFxcWu94-Qz-ZHYoW-CLO1GeaYHhwXkskBnU5l8vyhx81uvZib8SDhLXLHtNdX2oxEN7MLfouLTVcV25NX3Uywp2kYEHzeC1-SO0o7I_1CEN_q-pecBVI3tngpUzF0wLCFGToazVaKnOXnqXGmjIxBKJQtBp8M_yddU4='},\n",
       "  {'label': 'towardsai',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-23',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGXC4n94xRyO3bXizDmL0k6IQ9yqlXK9vAb2QbUfBc1aGij_2f3NvLDgDl22phNS_ppzWYDnvGdGbiMiWFt2v5XGRD2-gkJUxnh6RrZU9HJxslAqQF5VsFGmZyjWkAjvWA_w3sqTKyRHax7XE8Exnlpy7D6IFTMuNAbTpNopZEFs315UfXuPcNGFidvmUPJi3C7aRXvR6qvFJTAX3l-YZ-sUWc='},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-24',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEp3of_VhhPJFfVBQQj6yDqgLp-tz4HTZM-TxL4OCsqFxcWu94-Qz-ZHYoW-CLO1GeaYHhwXkskBnU5l8vyhx81uvZib8SDhLXLHtNdX2oxEN7MLfouLTVcV25NX3Uywp2kYEHzeC1-SO0o7I_1CEN_q-pecBVI3tngpUzF0wLCFGToazVaKnOXnqXGmjIxBKJQtBp8M_yddU4='},\n",
       "  {'label': 'github',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-27',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFccf5xamIcgXsan4TTU6y2sJL_fx2dNunRYMxGuY8_Q67yiYEyqqg5ON0qY7lraTZkzzf_4KLiAmCiRiJ1rvXuL6WwwEuNZAHswnphHwwSYbwnTjfSagUqJ65m11x2SznJNHi68SiwIjQU'},\n",
       "  {'label': 'coursera',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNVchBrhedBr3bgA2PwPleQTdUOyLOJ3uUCO9s6ID_qGQKoctFBFkYFOl4BlP0R7cscc0ybdA8Z1a_OK2QpoFx57XQPF4gXcnrxBDV7HGk56eDwce5QEGVTdIDJD_V6XdJXMUCx6yahz5Im85xE13wqOCEgFNMyKE-0s-k_MsCzK0Zk1yB0CPGbGGV'},\n",
       "  {'label': 'medium',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHORNJ0cwQZyk32XkfnqWp5gQkDwQwf7gpTaGBgpgHrZxaPlb9OESB3iG_pW8nxTivTPRGCylXNi5E1vNZKhmqUOQlWupCuSDvXbJICJQA-XLp1zwvBMxGPhi20keK_xBLuU3xzsnAVsU1biB5MeDbfAVva_AbdYIoz1XBhJvhOe14TbUbJLe-PxD_mFHNNgjvtiex9y1rcUz0o0nfsrOEOW-j0J6i1f3rfmZ4yF64='},\n",
       "  {'label': 'obot',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-28',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHDGcD60wBtrLy2ILY3DEmvobqG-VfwOT3EUWNoNSUkMNL0LZEnpli01RoDvS74pRi9UYPi2J46H6hQ37MB8xn7TUUPxU0Mj8cJmTpJFbTq0TwjIPYGEJYXCybItsJTMcZlrIVwWG_ZeioFSvHnKvYYNw=='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHJWvSaHjgCdS6FRp7nW5yE48MzQcem-stBuUxw3WXkzhldH1nshBmyIULE5FAIWIwsRqBvbJ2AYP6NmAwndbI5ZpwIHyBbejqxm2IZeB0g6kmE3J7aibIrmzWtgJ70IHBoUAzO3w=='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-22',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHIjaspwNGtfpgrEFtwtJLl29L2nPHnHCZ5R-irsAaH85-nNr2p3RfFLrsyl9OKG3Sup7OfBAh1CHJGj1yN4HnmNoqhmXvoOWOzoe9u_7jfboZBQIB-N2pnSNdg_w387Wo-WzfCOQ=='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-29',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGrxALy2bH5z7WYwC_jzfIRQWXYEE-qntJpEo_S6G4zTMX8Nw-NoRe_P0zbgqbPCVQVQCtax_-EHY7HQ5HugU1jmKn21a18lPFFzLADyT2VxsqOpkFcHFJxjaFmwD0D97Og2wUt1Q=='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-18',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHL804_HMi-1LVTtqD1sPNbZi3ltJjuZ7U_W7U_bynpEftzeq0kPV8b1gdl-W0SuHE9Uxi4VrVjgZFQLBXaA7_gNK_107ZMTy-sDzu-SPXE88dK0NjNace41zp0GaduMIdwtr10rg=='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/6-30',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEyN5adQ24HI7loCpMrfB3h1wFgL1KYgGEAIeKbWYgUoeRD865cUUvfvM2as8z821Y1hbvvPALG51s0G5HG_jbK0zo6-FvuaFglt9MdxXsSwr9iptd3PmIFVwvQE_0lcAsC85Vtxw=='}],\n",
       " 'initial_search_query_count': 3,\n",
       " 'max_research_loops': 2,\n",
       " 'research_loop_count': 2,\n",
       " 'reasoning_model': 'gemini-2.5-pro'}"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "result"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "535643fe",
   "metadata": {},
   "source": [
    "# OpenAI Deep Research API\n",
    "\n",
    "단순 Q&A가 아니라, **현실 세계의 출처를 기반으로 스스로 추론·계획·종합**하여\n",
    "**구조화되고 인용이 포함된 보고서**를 만들어내는 **프로그래밍 가능(Programmatic)한 연구 에이전트 API**.\n",
    "\n",
    "## 작동 구조\n",
    "1. **고수준 질의 입력** → 모델이 질의를 **하위 질문(sub-questions)**으로 자동 분해\n",
    "2. **계획 실행** → 내장 도구로 **웹 검색(web search)** 수행, 증거(출처) 수집\n",
    "3. **분석·종합** → 사실 검증 및 상충 정보 조정, **인용 포함** 최종 보고서 생성\n",
    "4. **프로그램적 제어** → `client.responses.create`로 **전 과정에 직접 접근**(모델/프롬프트/도구 지정)\n",
    "\n",
    "> 모델 예시(작성 시점):  \n",
    "> - 고품질 종합: `o3-deep-research-2025-06-26`  \n",
    "> - 저지연: `o4-mini-deep-research-2025-06-26`\n",
    "\n",
    "## 설계적 특징\n",
    "- **Agentic Planning**: 질의를 스스로 쪼개고, 필요한 검색/검증 단계를 **계획-실행**  \n",
    "- **투명성(Transparency)**: 결과뿐 아니라 **중간 단계(추론 요약, 실행 쿼리, 실행 코드)**를 노출  \n",
    "- **확장성(Extensibility)**: **MCP(Model Context Protocol)**로 사내 지식베이스/내부 데이터와 연결  \n",
    "- **도구 기반 실행**: 필수 `web_search_preview`, 선택 `code_interpreter` 및 커스텀 MCP 도구 추가 가능\n",
    "\n",
    "## 결과물 (Output)\n",
    "- **구조화된 보고서(structured final report)**: 섹션화/표/차트 가능\n",
    "- **인라인 인용(citation-rich)**: 본문 내 출처 스팬에 **메타데이터 링크** 연결\n",
    "- **일관된 내러티브(coherent narrative)**: 논리적 섹션으로 주제를 전개하고 근거를 배치\n",
    "- **중간 산출물 접근**: 추론 요약, 실제 검색 쿼리, 코드 실행 내역을 **프로그래밍적으로 조회**\n",
    "\n",
    "## 핵심 가치\n",
    "- **시간 단축**: 수시간 걸릴 수작업 리서치를 자동화  \n",
    "- **신뢰성**: **검증 가능한 인용**과 **중간 단계 노출**로 감사/디버깅/재현성 강화  \n",
    "- **현업 적합성**: 전략/투자/정책 의사결정을 뒷받침하는 **데이터 기반 보고서** 생성  \n",
    "- **사내 데이터 융합**: MCP로 **공개 웹+내부 정보**를 결합한 심층 리서치 가능"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "305ec0b7",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import base64\n",
    "from openai import AzureOpenAI\n",
    "\n",
    "endpoint = os.getenv(\"ENDPOINT_URL\")\n",
    "deployment = os.getenv(\"DEPLOYMENT_NAME\")\n",
    "api_key = os.getenv(\"API_KEY\")\n",
    "\n",
    "client = AzureOpenAI(\n",
    "    azure_endpoint=endpoint,\n",
    "    api_key=api_key,\n",
    "    api_version=\"2025-04-01-preview\",\n",
    ")\n",
    "\n",
    "system_message = \"\"\"You are a professional researcher preparing a structured, data-driven report.\n",
    "Focus on data-rich insights, use reliable sources, and include inline citations.\n",
    "\"\"\"\n",
    "user_query = \"Research the economic impact of semaglutide on global healthcare systems.\"\n",
    "\n",
    "\n",
    "chat_prompt = []\n",
    "\n",
    "# Include speech result if speech is enabled\n",
    "messages = chat_prompt\n",
    "\n",
    "response = client.responses.create(\n",
    "    model=deployment,\n",
    "    input=[\n",
    "        {\n",
    "            \"role\": \"developer\",\n",
    "            \"content\": [{\"type\": \"input_text\", \"text\": system_message}]\n",
    "        },\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": [{\"type\": \"input_text\", \"text\": user_query}]\n",
    "        }\n",
    "    ],\n",
    "    reasoning={\"summary\": \"auto\"},\n",
    "    tools=[{\"type\": \"web_search_preview\"}]\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "b59132f9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ Saved JSON : outputs/gemini_response_20251107-151042.json\n",
      "✅ Saved text : outputs/gemini_response_20251107-151042.txt\n",
      "✅ Saved usage: outputs/gemini_response_20251107-151042_usage.json\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "import json\n",
    "import warnings\n",
    "from pathlib import Path\n",
    "from datetime import datetime\n",
    "\n",
    "def save_response(response, outdir=\"outputs\", prefix=\"response\"):\n",
    "    \"\"\"\n",
    "    OpenAI Responses API 응답을 파일로 저장합니다.\n",
    "    - {prefix}_{YYYYmmdd-HHMMSS}.json : 전체 원시 응답\n",
    "    - {prefix}_{YYYYmmdd-HHMMSS}.txt  : 생성 텍스트만\n",
    "    - {prefix}_{YYYYmmdd-HHMMSS}_usage.json : 토큰 사용량 등 요약\n",
    "    \"\"\"\n",
    "    ts = datetime.now().strftime(\"%Y%m%d-%H%M%S\")\n",
    "    out = Path(outdir)\n",
    "    out.mkdir(parents=True, exist_ok=True)\n",
    "\n",
    "    json_path = out / f\"{prefix}_{ts}.json\"\n",
    "    txt_path  = out / f\"{prefix}_{ts}.txt\"\n",
    "    usage_path = out / f\"{prefix}_{ts}_usage.json\"\n",
    "\n",
    "    # --- 1) 전체 응답 저장 (경고 없이, 임의 객체도 안전 직렬화) ---\n",
    "    with warnings.catch_warnings():\n",
    "        warnings.filterwarnings(\"ignore\", message=\"Pydantic serializer warnings:\")\n",
    "        try:\n",
    "            # Pydantic 모델이 보장되는 SDK(v1+) 경로\n",
    "            json_str = response.model_dump_json(\n",
    "                indent=2,\n",
    "                ensure_ascii=False,\n",
    "                warnings=False,\n",
    "                serialize_as_any=True,  # web_search 등 임의 타입 그대로 직렬화\n",
    "            )\n",
    "        except Exception:\n",
    "            # 구버전/타입 불일치 대비: dict로 변환 후 json.dumps\n",
    "            try:\n",
    "                payload = response.model_dump(warnings=False, serialize_as_any=True)\n",
    "            except Exception:\n",
    "                # 마지막 안전망: __dict__ 또는 그대로 json.dumps 시도\n",
    "                payload = getattr(response, \"__dict__\", response)\n",
    "            json_str = json.dumps(payload, ensure_ascii=False, indent=2, default=str)\n",
    "\n",
    "    json_path.write_text(json_str, encoding=\"utf-8\")\n",
    "\n",
    "    # --- 2) 생성 텍스트만 추출해서 저장 ---\n",
    "    # responses API일 경우 response.output_text 가 가장 간단\n",
    "    generated_text = getattr(response, \"output_text\", None)\n",
    "\n",
    "    if generated_text is None:\n",
    "        # 구조가 다를 수 있어 방어적으로 content 트래버스\n",
    "        generated_text = \"\"\n",
    "        try:\n",
    "            payload = json.loads(json_str)  # 위에서 저장한 직렬화 결과 재활용\n",
    "            # output -> list[ {content: [ {type, text}, ... ]}, ... ]\n",
    "            output_items = payload.get(\"output\", []) if isinstance(payload, dict) else []\n",
    "            parts = []\n",
    "            for item in output_items:\n",
    "                for c in item.get(\"content\", []):\n",
    "                    # responses 규격: type=output_text | text\n",
    "                    if isinstance(c, dict) and (\"text\" in c):\n",
    "                        parts.append(c[\"text\"])\n",
    "            generated_text = \"\\n\".join(parts).strip()\n",
    "        except Exception:\n",
    "            pass\n",
    "\n",
    "    txt_path.write_text(generated_text or \"\", encoding=\"utf-8\")\n",
    "\n",
    "    # --- 3) usage 요약 저장 (있을 때만) ---\n",
    "    usage_obj = getattr(response, \"usage\", None)\n",
    "    usage_payload = None\n",
    "    if usage_obj is not None:\n",
    "        try:\n",
    "            # pydantic 모델일 수 있음\n",
    "            usage_payload = getattr(usage_obj, \"model_dump\", lambda **_: usage_obj)(warnings=False, serialize_as_any=True)\n",
    "        except Exception:\n",
    "            usage_payload = getattr(usage_obj, \"__dict__\", None) or usage_obj\n",
    "\n",
    "    if usage_payload is None:\n",
    "        # 직렬화된 전체 JSON에서 usage 키를 찾아 저장\n",
    "        try:\n",
    "            usage_payload = json.loads(json_str).get(\"usage\")\n",
    "        except Exception:\n",
    "            usage_payload = None\n",
    "\n",
    "    if usage_payload is not None:\n",
    "        usage_path.write_text(json.dumps(usage_payload, ensure_ascii=False, indent=2, default=str), encoding=\"utf-8\")\n",
    "\n",
    "    print(f\"✅ Saved JSON : {json_path}\")\n",
    "    print(f\"✅ Saved text : {txt_path}\")\n",
    "    if usage_payload is not None:\n",
    "        print(f\"✅ Saved usage: {usage_path}\")\n",
    "\n",
    "\n",
    "save_response(response, outdir=\"outputs\", prefix=\"gemini_response\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "96ff2f20",
   "metadata": {},
   "source": [
    "### final report"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "07ebef80",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "# Economic Impact of Semaglutide on Global Healthcare Systems\n",
      "\n",
      "## Background: Semaglutide’s Rise and Global Health Context  \n",
      "Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes, now also approved at higher doses for obesity management. It has demonstrated unprecedented efficacy in weight loss, with clinical trials showing average body weight reductions of 12–16% over ~68 weeks ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=for%20a%20maximum%20of%20two,The%202019%20Health%20Survey%20for)) ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=with%20its%20weight,influencers%20and%20public%20figures%20touting)). This dual utility in diabetes control and obesity treatment addresses two major public health challenges. Globally, diabetes and obesity impose enormous economic burdens: annual healthcare spending on diabetes soared from **$232 billion in 2007 to $966 billion in 2021** ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=The%20economic%20burden%20of%20type,1RA%29%20semaglutide)), and the world’s economic cost of high BMI is projected to reach **$4.32 trillion per year by 2035** (nearly 3% of global GDP) if current trends continue ([www.bmj.com](https://www.bmj.com/content/380/bmj.p523#:~:text=BMJ%20www,gross%20domestic%20product%E2%80%94annually%20by%202035)). In this context, semaglutide’s notable health benefits have driven explosive demand worldwide – but also raised pressing questions about costs, affordability, and value for healthcare systems.\n",
      "\n",
      "## Surging Demand and Expenditures  \n",
      "The advent of semaglutide (branded as Ozempic for diabetes and Wegovy for obesity) has triggered a **skyrocketing surge in spending on GLP-1 drugs**. In the United States alone, spending on GLP-1 receptor agonists climbed to an estimated **$71.7 billion in 2023**, a **500% increase** since 2018 ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=medications%2C%20initially%20developed%20to%20manage,Approved)) ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=practice%20and%20consumer%20spending,levels%20with%20minimal%20side%20effects)). This surge is largely driven by semaglutide-based medications and similar agents like tirzepatide, reflecting both medical innovation and intense consumer demand (amplified by social media hype and off-label weight loss use) ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=The%20popularity%20of%20GLP,government%E2%80%99s)) ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=the%20market,1%20RAs%20and)). Ozempic’s spending grew from just **$0.4 billion in 2018 to $26.4 billion in 2023** in the U.S., while newer products like Wegovy and Mounjaro rapidly captured market share ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=Data%20from%20Symphony%20Health%2C%20analyzed,billion%2C%20as%20newer%20drugs%20dominated)). \n",
      "\n",
      "The **unit prices of semaglutide therapies are high**, contributing to this expenditure growth. Typical list prices exceed **$900–$1,300 per month** – for example, Wegovy’s list price is about **$1,349 for a 4-week supply**, and Ozempic about **$968 per pen** (one month’s dose) ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=Cost%20Barrier%20GLP,high%20costs%2C%20some%20economists%20argue)). Such costs translate to over $10,000 per patient annually at list price. Many health insurers cover semaglutide for diabetes, but coverage for obesity is inconsistent (only ~40% of U.S. private plans covered Wegovy for weight loss as of 2023) ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=supply,This%20disparity%20exacerbates%20healthcare)). Consequently, a significant share of patients pay out-of-pocket, underscoring how **semaglutide’s expense can strain personal finances and insurer budgets alike**. Even in public systems, the drug’s cost is substantial; for instance, the UK’s NHS has confidential discounted pricing for Wegovy, but its list price is ~£176 for four weekly 2.4 mg injections ([pharmaphorum.com](https://pharmaphorum.com/news/wegovy-finally-reaches-uk-limited-quantities#:~:text=Wegovy%20finally%20reaches%20the%20UK%2C,although%2C%20one)). Overall, the rapid uptake of semaglutide is **fast becoming a multi-billion-dollar line item** in health expenditures across high-income countries.\n",
      "\n",
      "## Budgetary Impact and Cost Pressures  \n",
      "Health economists warn that broad uptake of semaglutide could **strain healthcare budgets** without careful prioritization or price negotiation. The sheer number of eligible patients is enormous – more than 1 billion adults worldwide have obesity (BMI ≥30) ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=list%20of%20keyboard%20shortcuts%20Wealthier,broad%20range%20of%20cardiometabolic%20conditions)), including an estimated 42% of U.S. adults and 28% of English adults ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=less%20and%20reducing%20their%20overall,a%20new%20line%20of%20pharmaceutical)). If even a fraction of these individuals were to use costly GLP-1 therapy long-term, drug spending would balloon. One projection noted that if **about half of U.S. adults with obesity used GLP-1 medications, annual costs could reach $411 billion by 2031**, a figure that would **far exceed current Medicare or private payer drug budgets** ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=spending%20in%20sectors%20like%20fitness%2C,Challenges%20and%20Controversies)). In fact, early analyses by the U.S. Congressional Budget Office estimated that expanding Medicare coverage to anti-obesity drugs would add tens of billions in new spending over a decade ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=disease%20progression%20outweighed%20treatment%20costs,Limitations)). These forecasts have led many payers and governments to approach semaglutide coverage cautiously – targeting the highest-risk patients to maximize impact per dollar. For example, several European countries have limited reimbursement to those with severe obesity and comorbidities, and England’s NICE recommends Wegovy only for adults with **BMI ≥35 plus a weight-related illness (or ≥30 in exceptional cases), for a maximum of two years** under specialist supervision ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=semaglutide%20,clinical%20trial%2C%20a%20randomised%20double)) ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=list%20price%20of%20semaglutide%202,A)). This targeting aims to ensure that the **hefty upfront costs** are justified by substantial health gains in those patients.\n",
      "\n",
      "Another aspect of budget impact is **the markup between manufacturing cost and price**. Studies suggest semaglutide is relatively inexpensive to produce – a recent analysis in *JAMA Network Open* estimated that **a month’s supply of semaglutide could be manufactured for under $5** ([www.cnbc.com](https://www.cnbc.com/2024/03/27/novo-nordisk-ozempic-can-be-made-for-less-than-5-a-month-study.html#:~:text=Novo%20Nordisk%27s%20Ozempic%20can%20be,month%27s%20supply%20of%20the%20treatment)). Yet the U.S. list price for Ozempic is around **$935–$1,000 per month** ([www.cnbc.com](https://www.cnbc.com/2024/03/27/novo-nordisk-ozempic-can-be-made-for-less-than-5-a-month-study.html#:~:text=Novo%20Nordisk%27s%20list%20price%20for,manufactured%20for%20prices%20far%20below)), implying a **markup on the order of tens of thousands of percent**. Such pricing has made semaglutide a blockbuster revenue source for Novo Nordisk, but it also means payers are footing extremely high bills relative to production costs. *Médecins Sans Frontières* has criticized this “corporate profiteering,” noting that GLP-1 drugs are **sold at ~40,000% above estimated manufacturing cost in the U.S.**, and are essentially **unaffordable or unavailable in many low- and middle-income countries** ([reliefweb.int](https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030)) ([www.msfaccess.org](https://www.msfaccess.org/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=...%20www.msfaccess.org%20%20GLP,)). This dynamic places pressure on healthcare systems to negotiate better pricing or await generic competition, especially as the drug class becomes a long-term therapy for chronic conditions.\n",
      "\n",
      "## Health Outcomes and Cost-Effectiveness  \n",
      "Despite the high costs, semaglutide offers significant health benefits that can translate into economic value over time. By improving glycemic control and inducing weight loss, it helps prevent downstream complications of diabetes and obesity – complications that are very costly to manage (e.g. heart attacks, strokes, renal failure, joint replacements). Health economic evaluations increasingly find that **semaglutide can be cost-effective, or even cost-saving, in certain contexts** ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses)) ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=Health,case%20net)). \n",
      "\n",
      "For instance, a 2025 systematic review in *Diabetes Care* analyzed dozens of studies and found semaglutide was **considered cost-effective in ~74% of comparisons against other glucose-lowering drugs for type 2 diabetes** ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses)). Notably, longer-term and broader-perspective analyses (accounting for lifetime health system costs) tend to favor semaglutide’s value, especially in high-income countries ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=dominant%2Fcost,pay)). The drug’s superior efficacy in reducing HbA1c, body weight, and even cardiovascular risk factors yields more quality-adjusted life years (QALYs) relative to older treatments ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=second,since%202021%2C%20necessitating%20an%20updated)). However, results can vary by assumptions – for example, industry-sponsored models universally found semaglutide cost-effective, whereas independent studies were split, reflecting different views on future cost offsets ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses)).\n",
      "\n",
      "Cost-effectiveness in **obesity treatment** is more nuanced and depends on the comparator. Semaglutide 2.4 mg produces greater weight loss and health improvements than lifestyle changes or older obesity drugs, but it also incurs much higher drug costs ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=and%20exclusion%20criteria,systematic%20review%20showed%20that%20semaglutide)). A recent systematic review of economic studies in obesity noted that **semaglutide yields more QALYs but at substantially higher lifetime costs** compared to alternatives ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=and%20exclusion%20criteria,systematic%20review%20showed%20that%20semaglutide)). In one modeling example for class I obesity (BMI ~33), total lifetime medical costs were estimated at **$370,776 with semaglutide** therapy versus roughly **$125,000–$140,000** with intensive lifestyle intervention or bariatric procedures ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=conventional%20interventions%20in%20patients%20with,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric)). Consequently, semaglutide’s **incremental cost-effectiveness ratios (ICERs)** sometimes exceed common willingness-to-pay thresholds in obesity, especially against highly effective interventions like gastric sleeve surgery ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=intervention%20,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric)) ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=the%20comprehensive%20management%20of%20type,the%20management%20and%20treatment%20of)). The review concluded that semaglutide **appears cost-effective versus lifestyle-only management and versus a daily GLP-1 like liraglutide**, but **is not cost-effective versus bariatric surgery at current prices** ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=the%20comprehensive%20management%20of%20type,the%20management%20and%20treatment%20of)). These findings underscore that the drug’s value for money is strongly tied to its price and the alternatives available – if semaglutide’s price declines (or if surgery is not accessible), its cost-effectiveness improves. Indeed, analysts note that with “substantial price reduction” semaglutide could become a dominant option for wider obesity populations ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=respectively,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric)).\n",
      "\n",
      "## Long-Term Savings Through Avoided Health Costs  \n",
      "Crucially, semaglutide’s **impact on hard outcomes** – cardiovascular events, kidney disease, etc. – may offer long-term savings to healthcare systems by reducing expensive acute care and procedures. A **landmark economic analysis** published in *Value in Health* (October 2025) modeled the effect of comprehensive semaglutide access in U.S. Medicare over 10 years. The results predicted **major health gains** for seniors: an estimated **38,950 fewer cardiovascular events** (including ~3,800 heart-related deaths), plus **2,330 fewer kidney failure deaths**, **1,820 fewer new sleep apnea cases**, and even **7,900 fewer knee replacement surgeries** compared to a scenario with no semaglutide ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,02%20billion%20while)) ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=beginning%20in%202027,The%20most%20pronounced%20cost)). These improvements stem from better weight and diabetes control across populations with obesity, type 2 diabetes, or related conditions. Importantly, the downstream cost savings from averting these events **offset the drug’s expenses** in the model. Under base-case assumptions (including a modest 10–20% price discount from forthcoming Medicare negotiations), broad semaglutide coverage in Medicare was projected to yield **net savings of about $715 million over 10 years** ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for)) ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=%5BMASH%5D,in%20savings%20with%20a%2020)). In other words, the **$4.44 billion in added treatment costs** would be outweighed by about **$5.15 billion in avoided healthcare costs** (e.g. fewer hospitalizations, dialysis, surgeries) ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=approximately%206180%20fewer%20deaths%20,02%20billion%20under%20alternative)). \n",
      "\n",
      "Even in less optimistic scenarios, the Medicare study found a **consistent trend toward cost neutrality or savings**. Across various uptake rates, net savings ranged from **$412 million up to $1.02 billion** over ten years ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=savings%20over%2010%20years,The%20findings%20contrast%20with)). With larger price concessions – e.g. a 20% price cut or eventual generic entry (anticipated by 2032) – the modeled savings rose further, reaching **$1.04–$1.71 billion** in the decade ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for)) ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=%2428%20million,exclusivity%20and%20generic%20entry%20The)). Notably, the analysis showed that covering semaglutide for **obesity alone** (in people without diabetes) might *slightly increase* short-term spending, but when accounting for the reduced incidence of diabetes and cardiovascular disease in that group, even obesity treatment **pays for itself in the long run** ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=maintaining%20major%20cardiovascular%20and%20renal,condition%20benefits.%20The%20present)) ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=billion%20in%20disease,The%20authors%20utilized)). These findings contrast with earlier projections that considered only drug costs: by integrating multi-condition benefits, semaglutide was reframed as a **“net value generator rather than a cost driver”** for insurers ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=disease%20progression%20outweighed%20treatment%20costs,Limitations)) ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=reduced%20diabetes%20incidence%20and%20comorbidity,insulin%20use%20or%20lower%20bariatric)). In summary, if health systems take a long-term view, investing in semaglutide can yield **significant clinical dividends and alleviate future healthcare expenditures** – especially for populations at high risk of expensive complications.\n",
      "\n",
      "## Global Access Disparities and Challenges  \n",
      "While semaglutide’s health-economic promise is compelling, there is a stark **global disparity in access** to this medication. High-income countries (HICs) are currently the primary consumers, whereas **lower- and middle-income countries (LMICs) have minimal access** due to cost and supply constraints ([reliefweb.int](https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030)) ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=public%20health%20interventions%20focused%20on,analysis%20suggests%20that%20over%20140)). This gap is troubling because obesity and diabetes are rising rapidly in LMICs – it’s projected that **79% of adults with obesity will live in LMICs by 2035** ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=associated%20with%20cardiovascular%20conditions%20and,taken%20seriously%3F%20In%20addition%20to)). Yet in those regions, semaglutide is often unavailable through public health systems and is **far too expensive for most patients out-of-pocket**. The **markup** issue noted earlier plays a big role here: for example, in the U.S. or Europe a monthly course costs roughly a thousand dollars, an amount utterly unfeasible in countries where health budgets and incomes are much lower. *Doctors Without Borders* reports that **GLP-1 drugs like Ozempic remain essentially absent from most low-income countries** in large part because of their price ([reliefweb.int](https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030)) ([www.msfaccess.org](https://www.msfaccess.org/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=...%20www.msfaccess.org%20%20GLP,)). This means the **majority of the world’s population** at risk of obesity-related disease is currently left behind from this pharmacological advance – a serious equity concern.\n",
      "\n",
      "Even within wealthy countries, **demand has outstripped supply**, creating **logistical and ethical challenges**. Semaglutide’s popularity led to global shortages starting in 2022–2023, as the manufacturer struggled to scale production. This has had ripple effects: a 2023 investigation in the UK uncovered **widespread black-market sales of semaglutide** (via social media and even salons), as desperate consumers sought the drug outside official channels ([www.thelancet.com](https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00376-0/fulltext#:~:text=This%20practice%2C%20which%20has%20resulted,some%20beauty%20salons%20in%20England)). Such unregulated use raises safety issues and reflects the intense pressure on formal healthcare systems to respond to demand. Meanwhile, healthcare providers must manage expectations and ensure appropriate use – reinforcing lifestyle interventions and reserving medication for those who will benefit medically. \n",
      "\n",
      "**Policymakers worldwide are grappling** with how to integrate costly anti-obesity drugs into public health strategies. Thus far, many HICs have adopted a **phased or selective approach**. The United States recently moved toward expanded coverage for weight-loss drugs in Medicare, negotiating price discounts in exchange ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,across%20utilization%20rates%20consistently%20favored)). In Europe, countries like **England and Denmark initially limit semaglutide prescriptions to specialist weight management clinics** and severe cases ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=semaglutide%20,clinical%20trial%2C%20a%20randomised%20double)) ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=list%20price%20of%20semaglutide%202,A)). Notably, the UK’s NHS made a deal with Eli Lilly to roll out tirzepatide (a similar GLP-1/GIP agonist) for up to **220,000 high-risk patients over three years** – starting with those who have a **BMI over 40 plus multiple comorbidities** ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=playbook%20for%20healthcare%20system,ensure%20the%20required%20level%20of)). This pilot aims to target those most likely to avoid expensive healthcare events, and to gather real-world evidence on outcomes and cost-benefit. Such examples serve as **emerging models for coverage**: prioritize the sickest patients first, monitor results, and gradually broaden access if proven cost-effective and if budgets allow.\n",
      "\n",
      "## Future Outlook: Balancing Cost and Benefit  \n",
      "The economic impact of semaglutide on global healthcare systems will ultimately depend on how effectively we balance its **considerable upfront costs against its downstream benefits**. In the near term, the **financial burden is significant** – payers are spending billions on these drugs, prompting concerns about sustainability. However, the evidence is growing that semaglutide can **pay for itself by preventing costly diseases**, especially when targeting populations at elevated risk (e.g. patients with diabetes or established cardiovascular disease). Health systems that invest in these treatments may see reduced expenditures on heart attacks, dialysis, orthopedic surgeries, and other complications within a decade ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,02%20billion%20while)) ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for)). From a macroeconomic perspective, widespread effective obesity treatment could also boost productivity and labor participation by improving population health (obesity-related illness costs economies in lost output as well).\n",
      "\n",
      "Key factors will shape the future impact: **pricing and competition** are foremost. As patent exclusivity lapses (semaglutide could face generic versions in some markets by 2026–2032 ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=case%20assumptions%2C%20semaglutide%20access%20would,across%20utilization%20rates%20consistently%20favored)) ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=development%20for%20the%20treatment%20of,insurance%20schemes%2C%20particularly%20when%20more))) and as new competitors (including oral GLP-1 pills and other weight-loss drugs) emerge, prices may decline. Even a 20% negotiated price reduction substantially improved the cost savings in modeling studies ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for)). Robust generic/biosimilar competition could gradually bring yearly treatment costs from five figures down to more affordable levels, enabling broader global use. Additionally, **innovative financing strategies** might mitigate the budget impact – for example, outcomes-based contracts where payers pay less if patients don’t achieve certain health targets, or government subsidy programs recognizing obesity treatment as an investment in public health.\n",
      "\n",
      "In conclusion, semaglutide represents a **paradigm shift**: a drug that can significantly reduce the burden of obesity and diabetes, potentially saving healthcare systems money in the long run, yet whose high price today poses a challenge for budgets and equitable access. The **economic impact is two-fold** – there is a **short-term cost surge** as health systems adopt this expensive therapy, but there is also the promise of **long-term economic gains** from a healthier population with fewer expensive chronic conditions. Global healthcare systems are in the process of negotiating this trade-off. With data-driven policies (like careful patient selection, price negotiations, and ongoing cost-effectiveness evaluation), many countries are finding that semaglutide can be a **high-value intervention**. However, extending those benefits worldwide will require addressing affordability for LMICs and ensuring supply meets demand. If these issues are managed, semaglutide and similar GLP-1 therapies could play a pivotal role in bending the curve of obesity- and diabetes-related costs that are projected to reach **trillions of dollars** in coming decades ([www.bmj.com](https://www.bmj.com/content/380/bmj.p523#:~:text=BMJ%20www,gross%20domestic%20product%E2%80%94annually%20by%202035)). In summary, semaglutide’s emergence is **economically impactful**: it is reshaping drug spending patterns and budget priorities, but it also offers an unprecedented opportunity to **reduce the healthcare and societal costs** of two global epidemics. The challenge for global healthcare systems is to harness its benefits in a **sustainable and equitable** way ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=public%20health%20interventions%20focused%20on,analysis%20suggests%20that%20over%20140)) ([reliefweb.int](https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030)). \n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Access and print the final report from the response\n",
    "final_report = response.output[-1].content[0].text\n",
    "print(final_report)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f2758cdc",
   "metadata": {},
   "source": [
    "# Economic Impact of Semaglutide on Global Healthcare Systems\n",
    "\n",
    "## Background: Semaglutide’s Rise and Global Health Context  \n",
    "Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes, now also approved at higher doses for obesity management. It has demonstrated unprecedented efficacy in weight loss, with clinical trials showing average body weight reductions of 12–16% over ~68 weeks ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=for%20a%20maximum%20of%20two,The%202019%20Health%20Survey%20for)) ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=with%20its%20weight,influencers%20and%20public%20figures%20touting)). This dual utility in diabetes control and obesity treatment addresses two major public health challenges. Globally, diabetes and obesity impose enormous economic burdens: annual healthcare spending on diabetes soared from **$232 billion in 2007 to $966 billion in 2021** ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=The%20economic%20burden%20of%20type,1RA%29%20semaglutide)), and the world’s economic cost of high BMI is projected to reach **$4.32 trillion per year by 2035** (nearly 3% of global GDP) if current trends continue ([www.bmj.com](https://www.bmj.com/content/380/bmj.p523#:~:text=BMJ%20www,gross%20domestic%20product%E2%80%94annually%20by%202035)). In this context, semaglutide’s notable health benefits have driven explosive demand worldwide – but also raised pressing questions about costs, affordability, and value for healthcare systems.\n",
    "\n",
    "## Surging Demand and Expenditures  \n",
    "The advent of semaglutide (branded as Ozempic for diabetes and Wegovy for obesity) has triggered a **skyrocketing surge in spending on GLP-1 drugs**. In the United States alone, spending on GLP-1 receptor agonists climbed to an estimated **$71.7 billion in 2023**, a **500% increase** since 2018 ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=medications%2C%20initially%20developed%20to%20manage,Approved)) ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=practice%20and%20consumer%20spending,levels%20with%20minimal%20side%20effects)). This surge is largely driven by semaglutide-based medications and similar agents like tirzepatide, reflecting both medical innovation and intense consumer demand (amplified by social media hype and off-label weight loss use) ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=The%20popularity%20of%20GLP,government%E2%80%99s)) ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=the%20market,1%20RAs%20and)). Ozempic’s spending grew from just **$0.4 billion in 2018 to $26.4 billion in 2023** in the U.S., while newer products like Wegovy and Mounjaro rapidly captured market share ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=Data%20from%20Symphony%20Health%2C%20analyzed,billion%2C%20as%20newer%20drugs%20dominated)). \n",
    "\n",
    "The **unit prices of semaglutide therapies are high**, contributing to this expenditure growth. Typical list prices exceed **$900–$1,300 per month** – for example, Wegovy’s list price is about **$1,349 for a 4-week supply**, and Ozempic about **$968 per pen** (one month’s dose) ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=Cost%20Barrier%20GLP,high%20costs%2C%20some%20economists%20argue)). Such costs translate to over $10,000 per patient annually at list price. Many health insurers cover semaglutide for diabetes, but coverage for obesity is inconsistent (only ~40% of U.S. private plans covered Wegovy for weight loss as of 2023) ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=supply,This%20disparity%20exacerbates%20healthcare)). Consequently, a significant share of patients pay out-of-pocket, underscoring how **semaglutide’s expense can strain personal finances and insurer budgets alike**. Even in public systems, the drug’s cost is substantial; for instance, the UK’s NHS has confidential discounted pricing for Wegovy, but its list price is ~£176 for four weekly 2.4 mg injections ([pharmaphorum.com](https://pharmaphorum.com/news/wegovy-finally-reaches-uk-limited-quantities#:~:text=Wegovy%20finally%20reaches%20the%20UK%2C,although%2C%20one)). Overall, the rapid uptake of semaglutide is **fast becoming a multi-billion-dollar line item** in health expenditures across high-income countries.\n",
    "\n",
    "## Budgetary Impact and Cost Pressures  \n",
    "Health economists warn that broad uptake of semaglutide could **strain healthcare budgets** without careful prioritization or price negotiation. The sheer number of eligible patients is enormous – more than 1 billion adults worldwide have obesity (BMI ≥30) ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=list%20of%20keyboard%20shortcuts%20Wealthier,broad%20range%20of%20cardiometabolic%20conditions)), including an estimated 42% of U.S. adults and 28% of English adults ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=less%20and%20reducing%20their%20overall,a%20new%20line%20of%20pharmaceutical)). If even a fraction of these individuals were to use costly GLP-1 therapy long-term, drug spending would balloon. One projection noted that if **about half of U.S. adults with obesity used GLP-1 medications, annual costs could reach $411 billion by 2031**, a figure that would **far exceed current Medicare or private payer drug budgets** ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=spending%20in%20sectors%20like%20fitness%2C,Challenges%20and%20Controversies)). In fact, early analyses by the U.S. Congressional Budget Office estimated that expanding Medicare coverage to anti-obesity drugs would add tens of billions in new spending over a decade ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=disease%20progression%20outweighed%20treatment%20costs,Limitations)). These forecasts have led many payers and governments to approach semaglutide coverage cautiously – targeting the highest-risk patients to maximize impact per dollar. For example, several European countries have limited reimbursement to those with severe obesity and comorbidities, and England’s NICE recommends Wegovy only for adults with **BMI ≥35 plus a weight-related illness (or ≥30 in exceptional cases), for a maximum of two years** under specialist supervision ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=semaglutide%20,clinical%20trial%2C%20a%20randomised%20double)) ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=list%20price%20of%20semaglutide%202,A)). This targeting aims to ensure that the **hefty upfront costs** are justified by substantial health gains in those patients.\n",
    "\n",
    "Another aspect of budget impact is **the markup between manufacturing cost and price**. Studies suggest semaglutide is relatively inexpensive to produce – a recent analysis in *JAMA Network Open* estimated that **a month’s supply of semaglutide could be manufactured for under $5** ([www.cnbc.com](https://www.cnbc.com/2024/03/27/novo-nordisk-ozempic-can-be-made-for-less-than-5-a-month-study.html#:~:text=Novo%20Nordisk%27s%20Ozempic%20can%20be,month%27s%20supply%20of%20the%20treatment)). Yet the U.S. list price for Ozempic is around **$935–$1,000 per month** ([www.cnbc.com](https://www.cnbc.com/2024/03/27/novo-nordisk-ozempic-can-be-made-for-less-than-5-a-month-study.html#:~:text=Novo%20Nordisk%27s%20list%20price%20for,manufactured%20for%20prices%20far%20below)), implying a **markup on the order of tens of thousands of percent**. Such pricing has made semaglutide a blockbuster revenue source for Novo Nordisk, but it also means payers are footing extremely high bills relative to production costs. *Médecins Sans Frontières* has criticized this “corporate profiteering,” noting that GLP-1 drugs are **sold at ~40,000% above estimated manufacturing cost in the U.S.**, and are essentially **unaffordable or unavailable in many low- and middle-income countries** ([reliefweb.int](https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030)) ([www.msfaccess.org](https://www.msfaccess.org/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=...%20www.msfaccess.org%20%20GLP,)). This dynamic places pressure on healthcare systems to negotiate better pricing or await generic competition, especially as the drug class becomes a long-term therapy for chronic conditions.\n",
    "\n",
    "## Health Outcomes and Cost-Effectiveness  \n",
    "Despite the high costs, semaglutide offers significant health benefits that can translate into economic value over time. By improving glycemic control and inducing weight loss, it helps prevent downstream complications of diabetes and obesity – complications that are very costly to manage (e.g. heart attacks, strokes, renal failure, joint replacements). Health economic evaluations increasingly find that **semaglutide can be cost-effective, or even cost-saving, in certain contexts** ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses)) ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=Health,case%20net)). \n",
    "\n",
    "For instance, a 2025 systematic review in *Diabetes Care* analyzed dozens of studies and found semaglutide was **considered cost-effective in ~74% of comparisons against other glucose-lowering drugs for type 2 diabetes** ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses)). Notably, longer-term and broader-perspective analyses (accounting for lifetime health system costs) tend to favor semaglutide’s value, especially in high-income countries ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=dominant%2Fcost,pay)). The drug’s superior efficacy in reducing HbA1c, body weight, and even cardiovascular risk factors yields more quality-adjusted life years (QALYs) relative to older treatments ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=second,since%202021%2C%20necessitating%20an%20updated)). However, results can vary by assumptions – for example, industry-sponsored models universally found semaglutide cost-effective, whereas independent studies were split, reflecting different views on future cost offsets ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses)).\n",
    "\n",
    "Cost-effectiveness in **obesity treatment** is more nuanced and depends on the comparator. Semaglutide 2.4 mg produces greater weight loss and health improvements than lifestyle changes or older obesity drugs, but it also incurs much higher drug costs ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=and%20exclusion%20criteria,systematic%20review%20showed%20that%20semaglutide)). A recent systematic review of economic studies in obesity noted that **semaglutide yields more QALYs but at substantially higher lifetime costs** compared to alternatives ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=and%20exclusion%20criteria,systematic%20review%20showed%20that%20semaglutide)). In one modeling example for class I obesity (BMI ~33), total lifetime medical costs were estimated at **$370,776 with semaglutide** therapy versus roughly **$125,000–$140,000** with intensive lifestyle intervention or bariatric procedures ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=conventional%20interventions%20in%20patients%20with,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric)). Consequently, semaglutide’s **incremental cost-effectiveness ratios (ICERs)** sometimes exceed common willingness-to-pay thresholds in obesity, especially against highly effective interventions like gastric sleeve surgery ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=intervention%20,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric)) ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=the%20comprehensive%20management%20of%20type,the%20management%20and%20treatment%20of)). The review concluded that semaglutide **appears cost-effective versus lifestyle-only management and versus a daily GLP-1 like liraglutide**, but **is not cost-effective versus bariatric surgery at current prices** ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=the%20comprehensive%20management%20of%20type,the%20management%20and%20treatment%20of)). These findings underscore that the drug’s value for money is strongly tied to its price and the alternatives available – if semaglutide’s price declines (or if surgery is not accessible), its cost-effectiveness improves. Indeed, analysts note that with “substantial price reduction” semaglutide could become a dominant option for wider obesity populations ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=respectively,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric)).\n",
    "\n",
    "## Long-Term Savings Through Avoided Health Costs  \n",
    "Crucially, semaglutide’s **impact on hard outcomes** – cardiovascular events, kidney disease, etc. – may offer long-term savings to healthcare systems by reducing expensive acute care and procedures. A **landmark economic analysis** published in *Value in Health* (October 2025) modeled the effect of comprehensive semaglutide access in U.S. Medicare over 10 years. The results predicted **major health gains** for seniors: an estimated **38,950 fewer cardiovascular events** (including ~3,800 heart-related deaths), plus **2,330 fewer kidney failure deaths**, **1,820 fewer new sleep apnea cases**, and even **7,900 fewer knee replacement surgeries** compared to a scenario with no semaglutide ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,02%20billion%20while)) ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=beginning%20in%202027,The%20most%20pronounced%20cost)). These improvements stem from better weight and diabetes control across populations with obesity, type 2 diabetes, or related conditions. Importantly, the downstream cost savings from averting these events **offset the drug’s expenses** in the model. Under base-case assumptions (including a modest 10–20% price discount from forthcoming Medicare negotiations), broad semaglutide coverage in Medicare was projected to yield **net savings of about $715 million over 10 years** ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for)) ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=%5BMASH%5D,in%20savings%20with%20a%2020)). In other words, the **$4.44 billion in added treatment costs** would be outweighed by about **$5.15 billion in avoided healthcare costs** (e.g. fewer hospitalizations, dialysis, surgeries) ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=approximately%206180%20fewer%20deaths%20,02%20billion%20under%20alternative)). \n",
    "\n",
    "Even in less optimistic scenarios, the Medicare study found a **consistent trend toward cost neutrality or savings**. Across various uptake rates, net savings ranged from **$412 million up to $1.02 billion** over ten years ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=savings%20over%2010%20years,The%20findings%20contrast%20with)). With larger price concessions – e.g. a 20% price cut or eventual generic entry (anticipated by 2032) – the modeled savings rose further, reaching **$1.04–$1.71 billion** in the decade ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for)) ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=%2428%20million,exclusivity%20and%20generic%20entry%20The)). Notably, the analysis showed that covering semaglutide for **obesity alone** (in people without diabetes) might *slightly increase* short-term spending, but when accounting for the reduced incidence of diabetes and cardiovascular disease in that group, even obesity treatment **pays for itself in the long run** ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=maintaining%20major%20cardiovascular%20and%20renal,condition%20benefits.%20The%20present)) ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=billion%20in%20disease,The%20authors%20utilized)). These findings contrast with earlier projections that considered only drug costs: by integrating multi-condition benefits, semaglutide was reframed as a **“net value generator rather than a cost driver”** for insurers ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=disease%20progression%20outweighed%20treatment%20costs,Limitations)) ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=reduced%20diabetes%20incidence%20and%20comorbidity,insulin%20use%20or%20lower%20bariatric)). In summary, if health systems take a long-term view, investing in semaglutide can yield **significant clinical dividends and alleviate future healthcare expenditures** – especially for populations at high risk of expensive complications.\n",
    "\n",
    "## Global Access Disparities and Challenges  \n",
    "While semaglutide’s health-economic promise is compelling, there is a stark **global disparity in access** to this medication. High-income countries (HICs) are currently the primary consumers, whereas **lower- and middle-income countries (LMICs) have minimal access** due to cost and supply constraints ([reliefweb.int](https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030)) ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=public%20health%20interventions%20focused%20on,analysis%20suggests%20that%20over%20140)). This gap is troubling because obesity and diabetes are rising rapidly in LMICs – it’s projected that **79% of adults with obesity will live in LMICs by 2035** ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=associated%20with%20cardiovascular%20conditions%20and,taken%20seriously%3F%20In%20addition%20to)). Yet in those regions, semaglutide is often unavailable through public health systems and is **far too expensive for most patients out-of-pocket**. The **markup** issue noted earlier plays a big role here: for example, in the U.S. or Europe a monthly course costs roughly a thousand dollars, an amount utterly unfeasible in countries where health budgets and incomes are much lower. *Doctors Without Borders* reports that **GLP-1 drugs like Ozempic remain essentially absent from most low-income countries** in large part because of their price ([reliefweb.int](https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030)) ([www.msfaccess.org](https://www.msfaccess.org/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=...%20www.msfaccess.org%20%20GLP,)). This means the **majority of the world’s population** at risk of obesity-related disease is currently left behind from this pharmacological advance – a serious equity concern.\n",
    "\n",
    "Even within wealthy countries, **demand has outstripped supply**, creating **logistical and ethical challenges**. Semaglutide’s popularity led to global shortages starting in 2022–2023, as the manufacturer struggled to scale production. This has had ripple effects: a 2023 investigation in the UK uncovered **widespread black-market sales of semaglutide** (via social media and even salons), as desperate consumers sought the drug outside official channels ([www.thelancet.com](https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00376-0/fulltext#:~:text=This%20practice%2C%20which%20has%20resulted,some%20beauty%20salons%20in%20England)). Such unregulated use raises safety issues and reflects the intense pressure on formal healthcare systems to respond to demand. Meanwhile, healthcare providers must manage expectations and ensure appropriate use – reinforcing lifestyle interventions and reserving medication for those who will benefit medically. \n",
    "\n",
    "**Policymakers worldwide are grappling** with how to integrate costly anti-obesity drugs into public health strategies. Thus far, many HICs have adopted a **phased or selective approach**. The United States recently moved toward expanded coverage for weight-loss drugs in Medicare, negotiating price discounts in exchange ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,across%20utilization%20rates%20consistently%20favored)). In Europe, countries like **England and Denmark initially limit semaglutide prescriptions to specialist weight management clinics** and severe cases ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=semaglutide%20,clinical%20trial%2C%20a%20randomised%20double)) ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=list%20price%20of%20semaglutide%202,A)). Notably, the UK’s NHS made a deal with Eli Lilly to roll out tirzepatide (a similar GLP-1/GIP agonist) for up to **220,000 high-risk patients over three years** – starting with those who have a **BMI over 40 plus multiple comorbidities** ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=playbook%20for%20healthcare%20system,ensure%20the%20required%20level%20of)). This pilot aims to target those most likely to avoid expensive healthcare events, and to gather real-world evidence on outcomes and cost-benefit. Such examples serve as **emerging models for coverage**: prioritize the sickest patients first, monitor results, and gradually broaden access if proven cost-effective and if budgets allow.\n",
    "\n",
    "## Future Outlook: Balancing Cost and Benefit  \n",
    "The economic impact of semaglutide on global healthcare systems will ultimately depend on how effectively we balance its **considerable upfront costs against its downstream benefits**. In the near term, the **financial burden is significant** – payers are spending billions on these drugs, prompting concerns about sustainability. However, the evidence is growing that semaglutide can **pay for itself by preventing costly diseases**, especially when targeting populations at elevated risk (e.g. patients with diabetes or established cardiovascular disease). Health systems that invest in these treatments may see reduced expenditures on heart attacks, dialysis, orthopedic surgeries, and other complications within a decade ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,02%20billion%20while)) ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for)). From a macroeconomic perspective, widespread effective obesity treatment could also boost productivity and labor participation by improving population health (obesity-related illness costs economies in lost output as well).\n",
    "\n",
    "Key factors will shape the future impact: **pricing and competition** are foremost. As patent exclusivity lapses (semaglutide could face generic versions in some markets by 2026–2032 ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=case%20assumptions%2C%20semaglutide%20access%20would,across%20utilization%20rates%20consistently%20favored)) ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=development%20for%20the%20treatment%20of,insurance%20schemes%2C%20particularly%20when%20more))) and as new competitors (including oral GLP-1 pills and other weight-loss drugs) emerge, prices may decline. Even a 20% negotiated price reduction substantially improved the cost savings in modeling studies ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for)). Robust generic/biosimilar competition could gradually bring yearly treatment costs from five figures down to more affordable levels, enabling broader global use. Additionally, **innovative financing strategies** might mitigate the budget impact – for example, outcomes-based contracts where payers pay less if patients don’t achieve certain health targets, or government subsidy programs recognizing obesity treatment as an investment in public health.\n",
    "\n",
    "In conclusion, semaglutide represents a **paradigm shift**: a drug that can significantly reduce the burden of obesity and diabetes, potentially saving healthcare systems money in the long run, yet whose high price today poses a challenge for budgets and equitable access. The **economic impact is two-fold** – there is a **short-term cost surge** as health systems adopt this expensive therapy, but there is also the promise of **long-term economic gains** from a healthier population with fewer expensive chronic conditions. Global healthcare systems are in the process of negotiating this trade-off. With data-driven policies (like careful patient selection, price negotiations, and ongoing cost-effectiveness evaluation), many countries are finding that semaglutide can be a **high-value intervention**. However, extending those benefits worldwide will require addressing affordability for LMICs and ensuring supply meets demand. If these issues are managed, semaglutide and similar GLP-1 therapies could play a pivotal role in bending the curve of obesity- and diabetes-related costs that are projected to reach **trillions of dollars** in coming decades ([www.bmj.com](https://www.bmj.com/content/380/bmj.p523#:~:text=BMJ%20www,gross%20domestic%20product%E2%80%94annually%20by%202035)). In summary, semaglutide’s emergence is **economically impactful**: it is reshaping drug spending patterns and budget priorities, but it also offers an unprecedented opportunity to **reduce the healthcare and societal costs** of two global epidemics. The challenge for global healthcare systems is to harness its benefits in a **sustainable and equitable** way ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=public%20health%20interventions%20focused%20on,analysis%20suggests%20that%20over%20140)) ([reliefweb.int](https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030)). \n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d9eef677",
   "metadata": {},
   "source": [
    "### citations"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "532f38d8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Citation 1:\n",
      " Cited Text: ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=for%20a%20maximum%20of%20two,The%202019%20Health%20Survey%20for))\n",
      " Title: NICE recommends new drug for people living with obesity\n",
      " URL: https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=for%20a%20maximum%20of%20two,The%202019%20Health%20Survey%20for\n",
      " Location: chars 435-625\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 2:\n",
      " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=with%20its%20weight,influencers%20and%20public%20figures%20touting))\n",
      " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
      " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=with%20its%20weight,influencers%20and%20public%20figures%20touting\n",
      " Location: chars 626-811\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 3:\n",
      " Cited Text: ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=The%20economic%20burden%20of%20type,1RA%29%20semaglutide))\n",
      " Title: Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering ...\n",
      " URL: https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=The%20economic%20burden%20of%20type,1RA%29%20semaglutide\n",
      " Location: chars 1084-1281\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 4:\n",
      " Cited Text: ([www.bmj.com](https://www.bmj.com/content/380/bmj.p523#:~:text=BMJ%20www,gross%20domestic%20product%E2%80%94annually%20by%202035))\n",
      " Title: Global cost of overweight and obesity will hit $4.32tn a year ... - The BMJ\n",
      " URL: https://www.bmj.com/content/380/bmj.p523#:~:text=BMJ%20www,gross%20domestic%20product%E2%80%94annually%20by%202035\n",
      " Location: chars 1436-1567\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 5:\n",
      " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=medications%2C%20initially%20developed%20to%20manage,Approved))\n",
      " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
      " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=medications%2C%20initially%20developed%20to%20manage,Approved\n",
      " Location: chars 2096-2276\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 6:\n",
      " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=practice%20and%20consumer%20spending,levels%20with%20minimal%20side%20effects))\n",
      " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
      " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=practice%20and%20consumer%20spending,levels%20with%20minimal%20side%20effects\n",
      " Location: chars 2277-2473\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 7:\n",
      " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=The%20popularity%20of%20GLP,government%E2%80%99s))\n",
      " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
      " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=The%20popularity%20of%20GLP,government%E2%80%99s\n",
      " Location: chars 2700-2867\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 8:\n",
      " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=the%20market,1%20RAs%20and))\n",
      " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
      " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=the%20market,1%20RAs%20and\n",
      " Location: chars 2868-3013\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 9:\n",
      " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=Data%20from%20Symphony%20Health%2C%20analyzed,billion%2C%20as%20newer%20drugs%20dominated))\n",
      " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
      " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=Data%20from%20Symphony%20Health%2C%20analyzed,billion%2C%20as%20newer%20drugs%20dominated\n",
      " Location: chars 3188-3396\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 10:\n",
      " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=Cost%20Barrier%20GLP,high%20costs%2C%20some%20economists%20argue))\n",
      " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
      " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=Cost%20Barrier%20GLP,high%20costs%2C%20some%20economists%20argue\n",
      " Location: chars 3679-3862\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 11:\n",
      " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=supply,This%20disparity%20exacerbates%20healthcare))\n",
      " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
      " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=supply,This%20disparity%20exacerbates%20healthcare\n",
      " Location: chars 4107-4276\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 12:\n",
      " Cited Text: ([pharmaphorum.com](https://pharmaphorum.com/news/wegovy-finally-reaches-uk-limited-quantities#:~:text=Wegovy%20finally%20reaches%20the%20UK%2C,although%2C%20one))\n",
      " Title: Wegovy finally reaches the UK, in 'limited' quantities\n",
      " URL: https://pharmaphorum.com/news/wegovy-finally-reaches-uk-limited-quantities#:~:text=Wegovy%20finally%20reaches%20the%20UK%2C,although%2C%20one\n",
      " Location: chars 4635-4798\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 13:\n",
      " Cited Text: ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=list%20of%20keyboard%20shortcuts%20Wealthier,broad%20range%20of%20cardiometabolic%20conditions))\n",
      " Title: Are lower- and middle-income countries ready for the roll-out of anti ...\n",
      " URL: https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=list%20of%20keyboard%20shortcuts%20Wealthier,broad%20range%20of%20cardiometabolic%20conditions\n",
      " Location: chars 5247-5465\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 14:\n",
      " Cited Text: ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=less%20and%20reducing%20their%20overall,a%20new%20line%20of%20pharmaceutical))\n",
      " Title: NICE recommends new drug for people living with obesity\n",
      " URL: https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=less%20and%20reducing%20their%20overall,a%20new%20line%20of%20pharmaceutical\n",
      " Location: chars 5535-5738\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 15:\n",
      " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=spending%20in%20sectors%20like%20fitness%2C,Challenges%20and%20Controversies))\n",
      " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
      " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=spending%20in%20sectors%20like%20fitness%2C,Challenges%20and%20Controversies\n",
      " Location: chars 6078-6273\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 16:\n",
      " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=disease%20progression%20outweighed%20treatment%20costs,Limitations))\n",
      " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
      " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=disease%20progression%20outweighed%20treatment%20costs,Limitations\n",
      " Location: chars 6461-6696\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 17:\n",
      " Cited Text: ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=semaglutide%20,clinical%20trial%2C%20a%20randomised%20double))\n",
      " Title: NICE recommends new drug for people living with obesity\n",
      " URL: https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=semaglutide%20,clinical%20trial%2C%20a%20randomised%20double\n",
      " Location: chars 7166-7353\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 18:\n",
      " Cited Text: ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=list%20price%20of%20semaglutide%202,A))\n",
      " Title: NICE recommends new drug for people living with obesity\n",
      " URL: https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=list%20price%20of%20semaglutide%202,A\n",
      " Location: chars 7354-7518\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 19:\n",
      " Cited Text: ([www.cnbc.com](https://www.cnbc.com/2024/03/27/novo-nordisk-ozempic-can-be-made-for-less-than-5-a-month-study.html#:~:text=Novo%20Nordisk%27s%20Ozempic%20can%20be,month%27s%20supply%20of%20the%20treatment))\n",
      " Title: Novo Nordisk's Ozempic can be made for less than $5 a month: study - CNBC\n",
      " URL: https://www.cnbc.com/2024/03/27/novo-nordisk-ozempic-can-be-made-for-less-than-5-a-month-study.html#:~:text=Novo%20Nordisk%27s%20Ozempic%20can%20be,month%27s%20supply%20of%20the%20treatment\n",
      " Location: chars 7927-8134\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 20:\n",
      " Cited Text: ([www.cnbc.com](https://www.cnbc.com/2024/03/27/novo-nordisk-ozempic-can-be-made-for-less-than-5-a-month-study.html#:~:text=Novo%20Nordisk%27s%20list%20price%20for,manufactured%20for%20prices%20far%20below))\n",
      " Title: Novo Nordisk's Ozempic can be made for less than $5 a month: study - CNBC\n",
      " URL: https://www.cnbc.com/2024/03/27/novo-nordisk-ozempic-can-be-made-for-less-than-5-a-month-study.html#:~:text=Novo%20Nordisk%27s%20list%20price%20for,manufactured%20for%20prices%20far%20below\n",
      " Location: chars 8208-8415\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 21:\n",
      " Cited Text: ([reliefweb.int](https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030))\n",
      " Title: New MSF costing study in JAMA reveals dramatic markup on prices of new ...\n",
      " URL: https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030\n",
      " Location: chars 8917-9141\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 22:\n",
      " Cited Text: ([www.msfaccess.org](https://www.msfaccess.org/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=...%20www.msfaccess.org%20%20GLP,))\n",
      " Title: New MSF costing study in JAMA reveals dramatic markup on prices of new ...\n",
      " URL: https://www.msfaccess.org/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=...%20www.msfaccess.org%20%20GLP,\n",
      " Location: chars 9142-9330\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 23:\n",
      " Cited Text: ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses))\n",
      " Title: Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering ...\n",
      " URL: https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses\n",
      " Location: chars 10054-10284\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 24:\n",
      " Cited Text: ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=Health,case%20net))\n",
      " Title: ISPOR - The Ozempic Paradox: How Spending Billions on Weight-Loss Drug ...\n",
      " URL: https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=Health,case%20net\n",
      " Location: chars 10285-10499\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 25:\n",
      " Cited Text: ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses))\n",
      " Title: Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering ...\n",
      " URL: https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses\n",
      " Location: chars 10724-10954\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 26:\n",
      " Cited Text: ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=dominant%2Fcost,pay))\n",
      " Title: Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering ...\n",
      " URL: https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=dominant%2Fcost,pay\n",
      " Location: chars 11127-11287\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 27:\n",
      " Cited Text: ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=second,since%202021%2C%20necessitating%20an%20updated))\n",
      " Title: Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering ...\n",
      " URL: https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=second,since%202021%2C%20necessitating%20an%20updated\n",
      " Location: chars 11464-11658\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 28:\n",
      " Cited Text: ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses))\n",
      " Title: Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering ...\n",
      " URL: https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses\n",
      " Location: chars 11878-12108\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 29:\n",
      " Cited Text: ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=and%20exclusion%20criteria,systematic%20review%20showed%20that%20semaglutide))\n",
      " Title: The cost-effectiveness analysis of semaglutide for the ... - Springer\n",
      " URL: https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=and%20exclusion%20criteria,systematic%20review%20showed%20that%20semaglutide\n",
      " Location: chars 12363-12531\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 30:\n",
      " Cited Text: ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=and%20exclusion%20criteria,systematic%20review%20showed%20that%20semaglutide))\n",
      " Title: The cost-effectiveness analysis of semaglutide for the ... - Springer\n",
      " URL: https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=and%20exclusion%20criteria,systematic%20review%20showed%20that%20semaglutide\n",
      " Location: chars 12704-12872\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 31:\n",
      " Cited Text: ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=conventional%20interventions%20in%20patients%20with,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric))\n",
      " Title: The cost-effectiveness analysis of semaglutide for the ... - Springer\n",
      " URL: https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=conventional%20interventions%20in%20patients%20with,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric\n",
      " Location: chars 13113-13310\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 32:\n",
      " Cited Text: ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=intervention%20,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric))\n",
      " Title: The cost-effectiveness analysis of semaglutide for the ... - Springer\n",
      " URL: https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=intervention%20,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric\n",
      " Location: chars 13534-13695\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 33:\n",
      " Cited Text: ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=the%20comprehensive%20management%20of%20type,the%20management%20and%20treatment%20of))\n",
      " Title: The cost-effectiveness analysis of semaglutide for the ... - Springer\n",
      " URL: https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=the%20comprehensive%20management%20of%20type,the%20management%20and%20treatment%20of\n",
      " Location: chars 13696-13872\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 34:\n",
      " Cited Text: ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=the%20comprehensive%20management%20of%20type,the%20management%20and%20treatment%20of))\n",
      " Title: The cost-effectiveness analysis of semaglutide for the ... - Springer\n",
      " URL: https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=the%20comprehensive%20management%20of%20type,the%20management%20and%20treatment%20of\n",
      " Location: chars 14088-14264\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 35:\n",
      " Cited Text: ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=respectively,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric))\n",
      " Title: The cost-effectiveness analysis of semaglutide for the ... - Springer\n",
      " URL: https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=respectively,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric\n",
      " Location: chars 14622-14780\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 36:\n",
      " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,02%20billion%20while))\n",
      " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
      " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,02%20billion%20while\n",
      " Location: chars 15530-15761\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 37:\n",
      " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=beginning%20in%202027,The%20most%20pronounced%20cost))\n",
      " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
      " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=beginning%20in%202027,The%20most%20pronounced%20cost\n",
      " Location: chars 15762-15983\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 38:\n",
      " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for))\n",
      " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
      " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for\n",
      " Location: chars 16460-16713\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 39:\n",
      " Cited Text: ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=%5BMASH%5D,in%20savings%20with%20a%2020))\n",
      " Title: ISPOR - The Ozempic Paradox: How Spending Billions on Weight-Loss Drug ...\n",
      " URL: https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=%5BMASH%5D,in%20savings%20with%20a%2020\n",
      " Location: chars 16714-16950\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 40:\n",
      " Cited Text: ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=approximately%206180%20fewer%20deaths%20,02%20billion%20under%20alternative))\n",
      " Title: ISPOR - The Ozempic Paradox: How Spending Billions on Weight-Loss Drug ...\n",
      " URL: https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=approximately%206180%20fewer%20deaths%20,02%20billion%20under%20alternative\n",
      " Location: chars 17141-17413\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 41:\n",
      " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=savings%20over%2010%20years,The%20findings%20contrast%20with))\n",
      " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
      " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=savings%20over%2010%20years,The%20findings%20contrast%20with\n",
      " Location: chars 17640-17869\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 42:\n",
      " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for))\n",
      " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
      " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for\n",
      " Location: chars 18055-18308\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 43:\n",
      " Cited Text: ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=%2428%20million,exclusivity%20and%20generic%20entry%20The))\n",
      " Title: ISPOR - The Ozempic Paradox: How Spending Billions on Weight-Loss Drug ...\n",
      " URL: https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=%2428%20million,exclusivity%20and%20generic%20entry%20The\n",
      " Location: chars 18309-18563\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 44:\n",
      " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=maintaining%20major%20cardiovascular%20and%20renal,condition%20benefits.%20The%20present))\n",
      " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
      " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=maintaining%20major%20cardiovascular%20and%20renal,condition%20benefits.%20The%20present\n",
      " Location: chars 18877-19134\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 45:\n",
      " Cited Text: ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=billion%20in%20disease,The%20authors%20utilized))\n",
      " Title: ISPOR - The Ozempic Paradox: How Spending Billions on Weight-Loss Drug ...\n",
      " URL: https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=billion%20in%20disease,The%20authors%20utilized\n",
      " Location: chars 19135-19379\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 46:\n",
      " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=disease%20progression%20outweighed%20treatment%20costs,Limitations))\n",
      " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
      " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=disease%20progression%20outweighed%20treatment%20costs,Limitations\n",
      " Location: chars 19599-19834\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 47:\n",
      " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=reduced%20diabetes%20incidence%20and%20comorbidity,insulin%20use%20or%20lower%20bariatric))\n",
      " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
      " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=reduced%20diabetes%20incidence%20and%20comorbidity,insulin%20use%20or%20lower%20bariatric\n",
      " Location: chars 19835-20093\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 48:\n",
      " Cited Text: ([reliefweb.int](https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030))\n",
      " Title: New MSF costing study in JAMA reveals dramatic markup on prices of new ...\n",
      " URL: https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030\n",
      " Location: chars 20683-20907\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 49:\n",
      " Cited Text: ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=public%20health%20interventions%20focused%20on,analysis%20suggests%20that%20over%20140))\n",
      " Title: Are lower- and middle-income countries ready for the roll-out of anti ...\n",
      " URL: https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=public%20health%20interventions%20focused%20on,analysis%20suggests%20that%20over%20140\n",
      " Location: chars 20908-21118\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 50:\n",
      " Cited Text: ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=associated%20with%20cardiovascular%20conditions%20and,taken%20seriously%3F%20In%20addition%20to))\n",
      " Title: Are lower- and middle-income countries ready for the roll-out of anti ...\n",
      " URL: https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=associated%20with%20cardiovascular%20conditions%20and,taken%20seriously%3F%20In%20addition%20to\n",
      " Location: chars 21279-21498\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 51:\n",
      " Cited Text: ([reliefweb.int](https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030))\n",
      " Title: New MSF costing study in JAMA reveals dramatic markup on prices of new ...\n",
      " URL: https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030\n",
      " Location: chars 22044-22268\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 52:\n",
      " Cited Text: ([www.msfaccess.org](https://www.msfaccess.org/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=...%20www.msfaccess.org%20%20GLP,))\n",
      " Title: New MSF costing study in JAMA reveals dramatic markup on prices of new ...\n",
      " URL: https://www.msfaccess.org/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=...%20www.msfaccess.org%20%20GLP,\n",
      " Location: chars 22269-22457\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 53:\n",
      " Cited Text: ([www.thelancet.com](https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00376-0/fulltext#:~:text=This%20practice%2C%20which%20has%20resulted,some%20beauty%20salons%20in%20England))\n",
      " Title: The era of GLP-1 receptor agonists: costs versus benefits\n",
      " URL: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00376-0/fulltext#:~:text=This%20practice%2C%20which%20has%20resulted,some%20beauty%20salons%20in%20England\n",
      " Location: chars 23093-23289\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 54:\n",
      " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,across%20utilization%20rates%20consistently%20favored))\n",
      " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
      " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,across%20utilization%20rates%20consistently%20favored\n",
      " Location: chars 23927-24191\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 55:\n",
      " Cited Text: ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=semaglutide%20,clinical%20trial%2C%20a%20randomised%20double))\n",
      " Title: NICE recommends new drug for people living with obesity\n",
      " URL: https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=semaglutide%20,clinical%20trial%2C%20a%20randomised%20double\n",
      " Location: chars 24342-24529\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 56:\n",
      " Cited Text: ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=list%20price%20of%20semaglutide%202,A))\n",
      " Title: NICE recommends new drug for people living with obesity\n",
      " URL: https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=list%20price%20of%20semaglutide%202,A\n",
      " Location: chars 24530-24694\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 57:\n",
      " Cited Text: ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=playbook%20for%20healthcare%20system,ensure%20the%20required%20level%20of))\n",
      " Title: Are lower- and middle-income countries ready for the roll-out of anti ...\n",
      " URL: https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=playbook%20for%20healthcare%20system,ensure%20the%20required%20level%20of\n",
      " Location: chars 24934-25131\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 58:\n",
      " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,02%20billion%20while))\n",
      " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
      " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,02%20billion%20while\n",
      " Location: chars 26242-26473\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 59:\n",
      " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for))\n",
      " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
      " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for\n",
      " Location: chars 26474-26727\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 60:\n",
      " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=case%20assumptions%2C%20semaglutide%20access%20would,across%20utilization%20rates%20consistently%20favored))\n",
      " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
      " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=case%20assumptions%2C%20semaglutide%20access%20would,across%20utilization%20rates%20consistently%20favored\n",
      " Location: chars 27137-27412\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 61:\n",
      " Cited Text: ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=development%20for%20the%20treatment%20of,insurance%20schemes%2C%20particularly%20when%20more))\n",
      " Title: Are lower- and middle-income countries ready for the roll-out of anti ...\n",
      " URL: https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=development%20for%20the%20treatment%20of,insurance%20schemes%2C%20particularly%20when%20more\n",
      " Location: chars 27413-27629\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 62:\n",
      " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for))\n",
      " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
      " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for\n",
      " Location: chars 27837-28090\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 63:\n",
      " Cited Text: ([www.bmj.com](https://www.bmj.com/content/380/bmj.p523#:~:text=BMJ%20www,gross%20domestic%20product%E2%80%94annually%20by%202035))\n",
      " Title: Global cost of overweight and obesity will hit $4.32tn a year ... - The BMJ\n",
      " URL: https://www.bmj.com/content/380/bmj.p523#:~:text=BMJ%20www,gross%20domestic%20product%E2%80%94annually%20by%202035\n",
      " Location: chars 29706-29837\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 64:\n",
      " Cited Text: ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=public%20health%20interventions%20focused%20on,analysis%20suggests%20that%20over%20140))\n",
      " Title: Are lower- and middle-income countries ready for the roll-out of anti ...\n",
      " URL: https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=public%20health%20interventions%20focused%20on,analysis%20suggests%20that%20over%20140\n",
      " Location: chars 30199-30409\n",
      "\n",
      "==================================================\n",
      "\n",
      "Citation 65:\n",
      " Cited Text: ([reliefweb.int](https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030))\n",
      " Title: New MSF costing study in JAMA reveals dramatic markup on prices of new ...\n",
      " URL: https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030\n",
      " Location: chars 30410-30634\n",
      "\n",
      "==================================================\n",
      "\n"
     ]
    }
   ],
   "source": [
    "annotations = response.output[-1].content[0].annotations\n",
    "\n",
    "if not annotations:\n",
    "    print(\"No annotations found in the response.\")\n",
    "else:\n",
    "    for i, citation in enumerate(annotations):\n",
    "        cited_text = final_report[citation.start_index:citation.end_index]\n",
    "\n",
    "        print(f\"Citation {i+1}:\")\n",
    "        print(f\" Cited Text: {cited_text}\")\n",
    "        print(f\" Title: {citation.title}\")\n",
    "        print(f\" URL: {citation.url}\")\n",
    "        print(f\" Location: chars {citation.start_index}-{citation.end_index}\")\n",
    "        print(\"\\n\" + \"=\"*50 + \"\\n\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7ca5f781",
   "metadata": {},
   "source": [
    "1. Reasoning Steps: Internal plans and summaries generated by the model."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "cecd101b",
   "metadata": {},
   "source": [
    "Citation 1:\n",
    " Cited Text: ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=for%20a%20maximum%20of%20two,The%202019%20Health%20Survey%20for))\n",
    " Title: NICE recommends new drug for people living with obesity\n",
    " URL: https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=for%20a%20maximum%20of%20two,The%202019%20Health%20Survey%20for\n",
    " Location: chars 435-625\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 2:\n",
    " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=with%20its%20weight,influencers%20and%20public%20figures%20touting))\n",
    " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
    " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=with%20its%20weight,influencers%20and%20public%20figures%20touting\n",
    " Location: chars 626-811\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 3:\n",
    " Cited Text: ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=The%20economic%20burden%20of%20type,1RA%29%20semaglutide))\n",
    " Title: Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering ...\n",
    " URL: https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=The%20economic%20burden%20of%20type,1RA%29%20semaglutide\n",
    " Location: chars 1084-1281\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 4:\n",
    " Cited Text: ([www.bmj.com](https://www.bmj.com/content/380/bmj.p523#:~:text=BMJ%20www,gross%20domestic%20product%E2%80%94annually%20by%202035))\n",
    " Title: Global cost of overweight and obesity will hit $4.32tn a year ... - The BMJ\n",
    " URL: https://www.bmj.com/content/380/bmj.p523#:~:text=BMJ%20www,gross%20domestic%20product%E2%80%94annually%20by%202035\n",
    " Location: chars 1436-1567\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 5:\n",
    " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=medications%2C%20initially%20developed%20to%20manage,Approved))\n",
    " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
    " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=medications%2C%20initially%20developed%20to%20manage,Approved\n",
    " Location: chars 2096-2276\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 6:\n",
    " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=practice%20and%20consumer%20spending,levels%20with%20minimal%20side%20effects))\n",
    " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
    " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=practice%20and%20consumer%20spending,levels%20with%20minimal%20side%20effects\n",
    " Location: chars 2277-2473\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 7:\n",
    " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=The%20popularity%20of%20GLP,government%E2%80%99s))\n",
    " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
    " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=The%20popularity%20of%20GLP,government%E2%80%99s\n",
    " Location: chars 2700-2867\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 8:\n",
    " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=the%20market,1%20RAs%20and))\n",
    " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
    " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=the%20market,1%20RAs%20and\n",
    " Location: chars 2868-3013\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 9:\n",
    " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=Data%20from%20Symphony%20Health%2C%20analyzed,billion%2C%20as%20newer%20drugs%20dominated))\n",
    " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
    " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=Data%20from%20Symphony%20Health%2C%20analyzed,billion%2C%20as%20newer%20drugs%20dominated\n",
    " Location: chars 3188-3396\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 10:\n",
    " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=Cost%20Barrier%20GLP,high%20costs%2C%20some%20economists%20argue))\n",
    " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
    " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=Cost%20Barrier%20GLP,high%20costs%2C%20some%20economists%20argue\n",
    " Location: chars 3679-3862\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 11:\n",
    " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=supply,This%20disparity%20exacerbates%20healthcare))\n",
    " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
    " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=supply,This%20disparity%20exacerbates%20healthcare\n",
    " Location: chars 4107-4276\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 12:\n",
    " Cited Text: ([pharmaphorum.com](https://pharmaphorum.com/news/wegovy-finally-reaches-uk-limited-quantities#:~:text=Wegovy%20finally%20reaches%20the%20UK%2C,although%2C%20one))\n",
    " Title: Wegovy finally reaches the UK, in 'limited' quantities\n",
    " URL: https://pharmaphorum.com/news/wegovy-finally-reaches-uk-limited-quantities#:~:text=Wegovy%20finally%20reaches%20the%20UK%2C,although%2C%20one\n",
    " Location: chars 4635-4798\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 13:\n",
    " Cited Text: ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=list%20of%20keyboard%20shortcuts%20Wealthier,broad%20range%20of%20cardiometabolic%20conditions))\n",
    " Title: Are lower- and middle-income countries ready for the roll-out of anti ...\n",
    " URL: https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=list%20of%20keyboard%20shortcuts%20Wealthier,broad%20range%20of%20cardiometabolic%20conditions\n",
    " Location: chars 5247-5465\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 14:\n",
    " Cited Text: ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=less%20and%20reducing%20their%20overall,a%20new%20line%20of%20pharmaceutical))\n",
    " Title: NICE recommends new drug for people living with obesity\n",
    " URL: https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=less%20and%20reducing%20their%20overall,a%20new%20line%20of%20pharmaceutical\n",
    " Location: chars 5535-5738\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 15:\n",
    " Cited Text: ([healthcarereaders.com](https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=spending%20in%20sectors%20like%20fitness%2C,Challenges%20and%20Controversies))\n",
    " Title: GLP-1 Drugs Surge: $71B Spent on Ozempic, Wegovy in 2023\n",
    " URL: https://healthcarereaders.com/news/americans-spent-71-billion-on-drugs-like-ozempic#:~:text=spending%20in%20sectors%20like%20fitness%2C,Challenges%20and%20Controversies\n",
    " Location: chars 6078-6273\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 16:\n",
    " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=disease%20progression%20outweighed%20treatment%20costs,Limitations))\n",
    " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
    " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=disease%20progression%20outweighed%20treatment%20costs,Limitations\n",
    " Location: chars 6461-6696\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 17:\n",
    " Cited Text: ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=semaglutide%20,clinical%20trial%2C%20a%20randomised%20double))\n",
    " Title: NICE recommends new drug for people living with obesity\n",
    " URL: https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=semaglutide%20,clinical%20trial%2C%20a%20randomised%20double\n",
    " Location: chars 7166-7353\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 18:\n",
    " Cited Text: ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=list%20price%20of%20semaglutide%202,A))\n",
    " Title: NICE recommends new drug for people living with obesity\n",
    " URL: https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=list%20price%20of%20semaglutide%202,A\n",
    " Location: chars 7354-7518\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 19:\n",
    " Cited Text: ([www.cnbc.com](https://www.cnbc.com/2024/03/27/novo-nordisk-ozempic-can-be-made-for-less-than-5-a-month-study.html#:~:text=Novo%20Nordisk%27s%20Ozempic%20can%20be,month%27s%20supply%20of%20the%20treatment))\n",
    " Title: Novo Nordisk's Ozempic can be made for less than $5 a month: study - CNBC\n",
    " URL: https://www.cnbc.com/2024/03/27/novo-nordisk-ozempic-can-be-made-for-less-than-5-a-month-study.html#:~:text=Novo%20Nordisk%27s%20Ozempic%20can%20be,month%27s%20supply%20of%20the%20treatment\n",
    " Location: chars 7927-8134\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 20:\n",
    " Cited Text: ([www.cnbc.com](https://www.cnbc.com/2024/03/27/novo-nordisk-ozempic-can-be-made-for-less-than-5-a-month-study.html#:~:text=Novo%20Nordisk%27s%20list%20price%20for,manufactured%20for%20prices%20far%20below))\n",
    " Title: Novo Nordisk's Ozempic can be made for less than $5 a month: study - CNBC\n",
    " URL: https://www.cnbc.com/2024/03/27/novo-nordisk-ozempic-can-be-made-for-less-than-5-a-month-study.html#:~:text=Novo%20Nordisk%27s%20list%20price%20for,manufactured%20for%20prices%20far%20below\n",
    " Location: chars 8208-8415\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 21:\n",
    " Cited Text: ([reliefweb.int](https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030))\n",
    " Title: New MSF costing study in JAMA reveals dramatic markup on prices of new ...\n",
    " URL: https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030\n",
    " Location: chars 8917-9141\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 22:\n",
    " Cited Text: ([www.msfaccess.org](https://www.msfaccess.org/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=...%20www.msfaccess.org%20%20GLP,))\n",
    " Title: New MSF costing study in JAMA reveals dramatic markup on prices of new ...\n",
    " URL: https://www.msfaccess.org/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=...%20www.msfaccess.org%20%20GLP,\n",
    " Location: chars 9142-9330\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 23:\n",
    " Cited Text: ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses))\n",
    " Title: Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering ...\n",
    " URL: https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses\n",
    " Location: chars 10054-10284\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 24:\n",
    " Cited Text: ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=Health,case%20net))\n",
    " Title: ISPOR - The Ozempic Paradox: How Spending Billions on Weight-Loss Drug ...\n",
    " URL: https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=Health,case%20net\n",
    " Location: chars 10285-10499\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 25:\n",
    " Cited Text: ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses))\n",
    " Title: Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering ...\n",
    " URL: https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses\n",
    " Location: chars 10724-10954\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 26:\n",
    " Cited Text: ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=dominant%2Fcost,pay))\n",
    " Title: Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering ...\n",
    " URL: https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=dominant%2Fcost,pay\n",
    " Location: chars 11127-11287\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 27:\n",
    " Cited Text: ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=second,since%202021%2C%20necessitating%20an%20updated))\n",
    " Title: Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering ...\n",
    " URL: https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=second,since%202021%2C%20necessitating%20an%20updated\n",
    " Location: chars 11464-11658\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 28:\n",
    " Cited Text: ([diabetesjournals.org](https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses))\n",
    " Title: Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering ...\n",
    " URL: https://diabetesjournals.org/care/article/48/6/1032/158296/Cost-effectiveness-of-Semaglutide-Compared-With#:~:text=reporting%20quality%20was%20high%20%2886.7,information%20for%20more%20granular%20analyses\n",
    " Location: chars 11878-12108\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 29:\n",
    " Cited Text: ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=and%20exclusion%20criteria,systematic%20review%20showed%20that%20semaglutide))\n",
    " Title: The cost-effectiveness analysis of semaglutide for the ... - Springer\n",
    " URL: https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=and%20exclusion%20criteria,systematic%20review%20showed%20that%20semaglutide\n",
    " Location: chars 12363-12531\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 30:\n",
    " Cited Text: ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=and%20exclusion%20criteria,systematic%20review%20showed%20that%20semaglutide))\n",
    " Title: The cost-effectiveness analysis of semaglutide for the ... - Springer\n",
    " URL: https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=and%20exclusion%20criteria,systematic%20review%20showed%20that%20semaglutide\n",
    " Location: chars 12704-12872\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 31:\n",
    " Cited Text: ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=conventional%20interventions%20in%20patients%20with,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric))\n",
    " Title: The cost-effectiveness analysis of semaglutide for the ... - Springer\n",
    " URL: https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=conventional%20interventions%20in%20patients%20with,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric\n",
    " Location: chars 13113-13310\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 32:\n",
    " Cited Text: ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=intervention%20,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric))\n",
    " Title: The cost-effectiveness analysis of semaglutide for the ... - Springer\n",
    " URL: https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=intervention%20,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric\n",
    " Location: chars 13534-13695\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 33:\n",
    " Cited Text: ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=the%20comprehensive%20management%20of%20type,the%20management%20and%20treatment%20of))\n",
    " Title: The cost-effectiveness analysis of semaglutide for the ... - Springer\n",
    " URL: https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=the%20comprehensive%20management%20of%20type,the%20management%20and%20treatment%20of\n",
    " Location: chars 13696-13872\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 34:\n",
    " Cited Text: ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=the%20comprehensive%20management%20of%20type,the%20management%20and%20treatment%20of))\n",
    " Title: The cost-effectiveness analysis of semaglutide for the ... - Springer\n",
    " URL: https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=the%20comprehensive%20management%20of%20type,the%20management%20and%20treatment%20of\n",
    " Location: chars 14088-14264\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 35:\n",
    " Cited Text: ([link.springer.com](https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=respectively,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric))\n",
    " Title: The cost-effectiveness analysis of semaglutide for the ... - Springer\n",
    " URL: https://link.springer.com/article/10.1007/s00228-024-03755-w#:~:text=respectively,endoscopic%20sleeve%20gastroplasty%2C%20and%20gastric\n",
    " Location: chars 14622-14780\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 36:\n",
    " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,02%20billion%20while))\n",
    " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
    " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,02%20billion%20while\n",
    " Location: chars 15530-15761\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 37:\n",
    " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=beginning%20in%202027,The%20most%20pronounced%20cost))\n",
    " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
    " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=beginning%20in%202027,The%20most%20pronounced%20cost\n",
    " Location: chars 15762-15983\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 38:\n",
    " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for))\n",
    " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
    " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for\n",
    " Location: chars 16460-16713\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 39:\n",
    " Cited Text: ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=%5BMASH%5D,in%20savings%20with%20a%2020))\n",
    " Title: ISPOR - The Ozempic Paradox: How Spending Billions on Weight-Loss Drug ...\n",
    " URL: https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=%5BMASH%5D,in%20savings%20with%20a%2020\n",
    " Location: chars 16714-16950\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 40:\n",
    " Cited Text: ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=approximately%206180%20fewer%20deaths%20,02%20billion%20under%20alternative))\n",
    " Title: ISPOR - The Ozempic Paradox: How Spending Billions on Weight-Loss Drug ...\n",
    " URL: https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=approximately%206180%20fewer%20deaths%20,02%20billion%20under%20alternative\n",
    " Location: chars 17141-17413\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 41:\n",
    " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=savings%20over%2010%20years,The%20findings%20contrast%20with))\n",
    " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
    " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=savings%20over%2010%20years,The%20findings%20contrast%20with\n",
    " Location: chars 17640-17869\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 42:\n",
    " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for))\n",
    " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
    " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for\n",
    " Location: chars 18055-18308\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 43:\n",
    " Cited Text: ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=%2428%20million,exclusivity%20and%20generic%20entry%20The))\n",
    " Title: ISPOR - The Ozempic Paradox: How Spending Billions on Weight-Loss Drug ...\n",
    " URL: https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=%2428%20million,exclusivity%20and%20generic%20entry%20The\n",
    " Location: chars 18309-18563\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 44:\n",
    " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=maintaining%20major%20cardiovascular%20and%20renal,condition%20benefits.%20The%20present))\n",
    " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
    " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=maintaining%20major%20cardiovascular%20and%20renal,condition%20benefits.%20The%20present\n",
    " Location: chars 18877-19134\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 45:\n",
    " Cited Text: ([www.ispor.org](https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=billion%20in%20disease,The%20authors%20utilized))\n",
    " Title: ISPOR - The Ozempic Paradox: How Spending Billions on Weight-Loss Drug ...\n",
    " URL: https://www.ispor.org/heor-resources/news-top/news/2025/10/14/the-ozempic-paradox--how-spending-billions-on-weight-loss-drug-would-actually-reduce-overall-medicare-costs#:~:text=billion%20in%20disease,The%20authors%20utilized\n",
    " Location: chars 19135-19379\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 46:\n",
    " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=disease%20progression%20outweighed%20treatment%20costs,Limitations))\n",
    " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
    " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=disease%20progression%20outweighed%20treatment%20costs,Limitations\n",
    " Location: chars 19599-19834\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 47:\n",
    " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=reduced%20diabetes%20incidence%20and%20comorbidity,insulin%20use%20or%20lower%20bariatric))\n",
    " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
    " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=reduced%20diabetes%20incidence%20and%20comorbidity,insulin%20use%20or%20lower%20bariatric\n",
    " Location: chars 19835-20093\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 48:\n",
    " Cited Text: ([reliefweb.int](https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030))\n",
    " Title: New MSF costing study in JAMA reveals dramatic markup on prices of new ...\n",
    " URL: https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030\n",
    " Location: chars 20683-20907\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 49:\n",
    " Cited Text: ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=public%20health%20interventions%20focused%20on,analysis%20suggests%20that%20over%20140))\n",
    " Title: Are lower- and middle-income countries ready for the roll-out of anti ...\n",
    " URL: https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=public%20health%20interventions%20focused%20on,analysis%20suggests%20that%20over%20140\n",
    " Location: chars 20908-21118\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 50:\n",
    " Cited Text: ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=associated%20with%20cardiovascular%20conditions%20and,taken%20seriously%3F%20In%20addition%20to))\n",
    " Title: Are lower- and middle-income countries ready for the roll-out of anti ...\n",
    " URL: https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=associated%20with%20cardiovascular%20conditions%20and,taken%20seriously%3F%20In%20addition%20to\n",
    " Location: chars 21279-21498\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 51:\n",
    " Cited Text: ([reliefweb.int](https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030))\n",
    " Title: New MSF costing study in JAMA reveals dramatic markup on prices of new ...\n",
    " URL: https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030\n",
    " Location: chars 22044-22268\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 52:\n",
    " Cited Text: ([www.msfaccess.org](https://www.msfaccess.org/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=...%20www.msfaccess.org%20%20GLP,))\n",
    " Title: New MSF costing study in JAMA reveals dramatic markup on prices of new ...\n",
    " URL: https://www.msfaccess.org/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=...%20www.msfaccess.org%20%20GLP,\n",
    " Location: chars 22269-22457\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 53:\n",
    " Cited Text: ([www.thelancet.com](https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00376-0/fulltext#:~:text=This%20practice%2C%20which%20has%20resulted,some%20beauty%20salons%20in%20England))\n",
    " Title: The era of GLP-1 receptor agonists: costs versus benefits\n",
    " URL: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00376-0/fulltext#:~:text=This%20practice%2C%20which%20has%20resulted,some%20beauty%20salons%20in%20England\n",
    " Location: chars 23093-23289\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 54:\n",
    " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,across%20utilization%20rates%20consistently%20favored))\n",
    " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
    " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,across%20utilization%20rates%20consistently%20favored\n",
    " Location: chars 23927-24191\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 55:\n",
    " Cited Text: ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=semaglutide%20,clinical%20trial%2C%20a%20randomised%20double))\n",
    " Title: NICE recommends new drug for people living with obesity\n",
    " URL: https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=semaglutide%20,clinical%20trial%2C%20a%20randomised%20double\n",
    " Location: chars 24342-24529\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 56:\n",
    " Cited Text: ([www.nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=list%20price%20of%20semaglutide%202,A))\n",
    " Title: NICE recommends new drug for people living with obesity\n",
    " URL: https://www.nice.org.uk/news/articles/nice-recommends-new-drug-for-people-living-with-obesity?utm#:~:text=list%20price%20of%20semaglutide%202,A\n",
    " Location: chars 24530-24694\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 57:\n",
    " Cited Text: ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=playbook%20for%20healthcare%20system,ensure%20the%20required%20level%20of))\n",
    " Title: Are lower- and middle-income countries ready for the roll-out of anti ...\n",
    " URL: https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=playbook%20for%20healthcare%20system,ensure%20the%20required%20level%20of\n",
    " Location: chars 24934-25131\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 58:\n",
    " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,02%20billion%20while))\n",
    " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
    " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=Medicare%20drug%20price%20negotiations%20,02%20billion%20while\n",
    " Location: chars 26242-26473\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 59:\n",
    " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for))\n",
    " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
    " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for\n",
    " Location: chars 26474-26727\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 60:\n",
    " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=case%20assumptions%2C%20semaglutide%20access%20would,across%20utilization%20rates%20consistently%20favored))\n",
    " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
    " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=case%20assumptions%2C%20semaglutide%20access%20would,across%20utilization%20rates%20consistently%20favored\n",
    " Location: chars 27137-27412\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 61:\n",
    " Cited Text: ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=development%20for%20the%20treatment%20of,insurance%20schemes%2C%20particularly%20when%20more))\n",
    " Title: Are lower- and middle-income countries ready for the roll-out of anti ...\n",
    " URL: https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=development%20for%20the%20treatment%20of,insurance%20schemes%2C%20particularly%20when%20more\n",
    " Location: chars 27413-27629\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 62:\n",
    " Cited Text: ([tribemd.com](https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for))\n",
    " Title: Expanding semaglutide access in Medicare: modeling shows billions in ...\n",
    " URL: https://tribemd.com/us/contents/expanding-semaglutide-access-in-medicare%3A-modeling-shows-billions-in-health-gains-and-potential-cost-savings/#:~:text=knee%20replacements%20and%20reduced%20progression,While%20coverage%20expansion%20for\n",
    " Location: chars 27837-28090\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 63:\n",
    " Cited Text: ([www.bmj.com](https://www.bmj.com/content/380/bmj.p523#:~:text=BMJ%20www,gross%20domestic%20product%E2%80%94annually%20by%202035))\n",
    " Title: Global cost of overweight and obesity will hit $4.32tn a year ... - The BMJ\n",
    " URL: https://www.bmj.com/content/380/bmj.p523#:~:text=BMJ%20www,gross%20domestic%20product%E2%80%94annually%20by%202035\n",
    " Location: chars 29706-29837\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 64:\n",
    " Cited Text: ([www.weforum.org](https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=public%20health%20interventions%20focused%20on,analysis%20suggests%20that%20over%20140))\n",
    " Title: Are lower- and middle-income countries ready for the roll-out of anti ...\n",
    " URL: https://www.weforum.org/stories/2025/01/anti-obesity-medication-lower-middle-income-countries/#:~:text=public%20health%20interventions%20focused%20on,analysis%20suggests%20that%20over%20140\n",
    " Location: chars 30199-30409\n",
    "\n",
    "==================================================\n",
    "\n",
    "Citation 65:\n",
    " Cited Text: ([reliefweb.int](https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030))\n",
    " Title: New MSF costing study in JAMA reveals dramatic markup on prices of new ...\n",
    " URL: https://reliefweb.int/report/world/new-msf-costing-study-jama-reveals-dramatic-markup-prices-new-diabetes-medicines-and-insulin-pens#:~:text=New%20MSF%20costing%20study%20in,pen%20devices%20could%20be%2030\n",
    " Location: chars 30410-30634\n",
    "\n",
    "==================================================\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "d8769f5c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "[Found a Reasoning Step]\n",
      "    - **Researching economic impact of semaglutide**\n",
      "\n",
      "The user wants to explore the economic impact of semaglutide on global healthcare systems, so I need to focus on gathering data and using reliable sources. I’ll prepare a structured report with headings and bullet points. Semaglutide is a GLP-1 analog for treating type 2 diabetes and weight management, known commercially as Ozempic and Wegovy. The user's question suggests an analysis of how this drug affects healthcare costs and systems globally, which is quite significant.\n",
      "    - **Analyzing economic impact of semaglutide**\n",
      "\n",
      "The user's question indicates that I should focus on data from reliable sources, highlighting statistics on global adoption, costs, and savings regarding semaglutide. It's a GLP-1 analog for managing type 2 diabetes and weight loss. I should consider how its costs impact healthcare systems and patient expenses, alongside possible savings from better health outcomes. Examining the drug's high costs against its potential for reducing complications could provide insights into its overall economic effect on healthcare budgets.\n"
     ]
    }
   ],
   "source": [
    "try:\n",
    "    reasoning_step = next(item for item in response.output if item.type == \"reasoning\")\n",
    "    print(\"\\n[Found a Reasoning Step]\")\n",
    "    for summary_part in reasoning_step.summary:\n",
    "        print(f\"    - {summary_part.text}\")\n",
    "except StopIteration:\n",
    "    print(\"\\nNo Reasoning Step Found]\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "60cd03f1",
   "metadata": {},
   "source": [
    "\n",
    "[Found a Reasoning Step]\n",
    "    - **Researching economic impact of semaglutide**\n",
    "\n",
    "The user wants to explore the economic impact of semaglutide on global healthcare systems, so I need to focus on gathering data and using reliable sources. I’ll prepare a structured report with headings and bullet points. Semaglutide is a GLP-1 analog for treating type 2 diabetes and weight management, known commercially as Ozempic and Wegovy. The user's question suggests an analysis of how this drug affects healthcare costs and systems globally, which is quite significant.\n",
    "    - **Analyzing economic impact of semaglutide**\n",
    "\n",
    "The user's question indicates that I should focus on data from reliable sources, highlighting statistics on global adoption, costs, and savings regarding semaglutide. It's a GLP-1 analog for managing type 2 diabetes and weight loss. I should consider how its costs impact healthcare systems and patient expenses, alongside possible savings from better health outcomes. Examining the drug's high costs against its potential for reducing complications could provide insights into its overall economic effect on healthcare budgets."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "54daa867",
   "metadata": {},
   "source": [
    "2. Web Search Calls: The exact search queries the agent executed."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "8afe5c54",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "[Found a Web Search Call]\n",
      "    Query Executed: semaglutide economic impact global healthcare cost-effectiveness\n",
      "    Status: completed \n"
     ]
    }
   ],
   "source": [
    "try:\n",
    "    search_step = next(item for item in response.output if item.type ==\"web_search_call\")\n",
    "    print(\"\\n[Found a Web Search Call]\")\n",
    "    print(f\"    Query Executed: {search_step.action.query}\")\n",
    "    print(f\"    Status: {search_step.status} \")\n",
    "except StopIteration:\n",
    "    print(\"\\nNo Web Search steps found.]\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "312d03d0",
   "metadata": {},
   "source": [
    "\n",
    "[Found a Web Search Call]\n",
    "    Query Executed: semaglutide economic impact global healthcare cost-effectiveness\n",
    "    Status: completed "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "57c5b61e",
   "metadata": {},
   "source": [
    "3. Code Execution: Any code run by the agent using the code interpreter."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "39cd3496",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "No Code Execution steps found.]\n"
     ]
    }
   ],
   "source": [
    "try:\n",
    "    code_step = next(item for item in response.output if item.type == \"code_interpreter_call\")\n",
    "    print(\"\\n[Found a Code Execution Step]\")\n",
    "    print(\"    Code Input:\")\n",
    "    print(f\" ```python\\n{code_step.input}\\n ```\")\n",
    "    print(f\"    Code Output:\")\n",
    "    print(f\"    {code_step.output}\")\n",
    "except StopIteration:\n",
    "    print(\"\\nNo Code Execution steps found.]\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4bc257c9",
   "metadata": {},
   "source": [
    "No Code Execution steps found.]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "48b01078",
   "metadata": {},
   "source": [
    "Google 쪽이 “사용자와 함께 계획을 세우는 시스템”이라면, OpenAI는 “API 레벨에서 완전히 자율적 계획 수행이 가능한 시스템”"
   ]
  },
  {
   "attachments": {
    "image.png": {
     "image/png": "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"
    }
   },
   "cell_type": "markdown",
   "id": "4fb503b8",
   "metadata": {},
   "source": [
    "# At a Glance\n",
    "\n",
    "복잡한 문제를 한 번의 행동으로 해결하기는 어렵다.  \n",
    "\n",
    "---\n",
    "\n",
    "## What (무엇을 해결하나)\n",
    "- 복잡한 목표는 보통 **여러 단계의 작업과 상호 의존 관계**로 이루어져 있다.  \n",
    "- 이런 목표를 구조화된 접근 없이 처리하면,  \n",
    "  에이전트는 **큰 목표를 세부 실행 단위로 분해하지 못하고**  \n",
    "  결과적으로 **빠진 부분이 있거나 부정확한 결과**를 낸다.  \n",
    "- 따라서 단일 행동으로는 **다단계로 얽힌 문제(multi-step task)**를 제대로 해결할 수 없다.\n",
    "\n",
    "---\n",
    "## Why (왜 필요한가)\n",
    "- **Planning 패턴**은 에이전트가 일을 시작하기 전에 먼저 **목표를 달성하기 위한 실행 계획**을 세우도록 만든다.  \n",
    "- 즉, 큰 목표를 한 번에 처리하려 하지 않고, **작은 단계(sub-goal)**로 나눈 다음  \n",
    "  이 단계를 **논리적인 순서**로 이어가며 해결한다.  \n",
    "- LLM은 학습 데이터를 기반으로 이런 과정을 스스로 설계할 수 있어,  \n",
    "  **현실적이고 효율적인 계획**을 자동으로 만들어낸다.  \n",
    "- 이렇게 계획적으로 접근하면 단순히 요청에 반응하는 것에서 벗어나,  \n",
    "  **전략적으로 사고하고 실행하는 에이전트**로 발전하게 된다.  \n",
    "  → 상황이 바뀌면 계획을 조정하면서 **유연하게 대응(adaptive behavior)**할 수도 있다.\n",
    "---\n",
    "\n",
    "## Rule of Thumb (언제 적용하나)\n",
    "> “한 번의 행동이나 도구만으로는 해결하기 어려운 복잡한 요청일 때 사용한다.”\n",
    "\n",
    "- **여러 단계를 거치는 과정**을 자동화해야 할 때 적합하다.  \n",
    "  - 예: **연구 보고서 작성**, **신규 직원 온보딩**, **경쟁사 분석**\n",
    "- 작업 단계 사이에 **의존 관계(interdependencies)**가 있는 경우 특히 효과적이다.  \n",
    "- 목표를 달성하기 위해 **순차적으로 연결된 여러 단계를 수행해야 하는 상황**에 이상적이다.\n",
    "---\n",
    "\n",
    "## Visual Summary\n",
    "![image.png](attachment:image.png)\n",
    "---\n",
    "\n",
    "## Key Takeaways\n",
    "- **Planning**은 복잡한 목표를 **실행 가능한 단계(actionable steps)**로 나누는 과정이다.  \n",
    "- 이런 접근은 **다단계 작업, 워크플로 자동화, 복잡한 문제 해결**에 필수적이다.  \n",
    "- **LLM**은 주어진 과제를 분석해 **단계별 접근(step-by-step approach)**을 스스로 설계할 수 있다.  \n",
    "- 프롬프트나 시스템을 설계할 때 **계획을 세우는 과정 자체를 명시적으로 포함**시키면,  \n",
    "  에이전트의 **계획 능력(planning behavior)**이 더 강화된다.  \n",
    "- **Google DeepResearch**는 이 패턴의 대표적인 사례로,  \n",
    "  정보를 **반영(reflect)**하고, **계획(plan)**하고, **실행(execute)**하는 과정을 통해  \n",
    "  복잡한 주제를 체계적으로 탐구한다.\n",
    "---\n",
    "\n",
    "## Conclusion\n",
    "> **Planning은 에이전트를 단순한 ‘반응형 응답자’에서 ‘전략적 목표 지향 실행자’로 발전시키는 핵심 개념이다.**\n",
    "\n",
    "- 현대 LLM은 고차원적인 목표를 **일관되고 실행 가능한 단계(coherent, actionable steps)**로 스스로 분해할 수 있다.  \n",
    "- 이 패턴은 단순한 순차 실행에 머무르지 않고, **Google DeepResearch**처럼  \n",
    "  지속적으로 정보를 갱신하며 계획을 수정하는 **동적 연구 시스템(dynamic research system)**으로 확장된다.  \n",
    "- 궁극적으로 Planning은 **인간의 의도(human intent)**와 **자동화된 실행(automated execution)** 사이를 잇는 **핵심 연결 고리**다.  \n",
    "- 문제 해결 과정을 구조화함으로써, **복잡한 목표를 더 체계적이고 신뢰성 있게 달성**할 수 있도록 만든다."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f2b89303",
   "metadata": {},
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Agentic-Design-Patterns-LanGraph",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
